Code	NCIt Preferred Name	Synonyms	Definition	Semantic Type
C957	10-Deacetyltaxol	10-DEACETYLPACLITAXEL || 10-Deacetylpaclitaxel || 10-Deacetyltaxol || 10-Deacetyltaxol || benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-	An analog of paclitaxel with antineoplastic activity.  10-Deacetyltaxol binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and apoptosis.	Organic Chemical || Pharmacologic Substance
C28780	117-126:FGF-5 Peptide	117-126:FGF-5 Peptide || Fibroblast Growth Factor-5 (117-126) Peptide	A fragment of fibroblast growth factor-5 (FGF-5). Originally isolated from a renal cell carcinoma cell line that overexpressed FGF-5, FGF-5:117-126 peptide is recognized by tumor infiltrating cytotoxic T lymphocytes. Overexpressed by several cancer cell types, this peptide is being tested as a potential target for antineoplastic immunotherapies. (NCI04)	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C49172	11C Topotecan	11C Topotecan || 11C topotecan	A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata radiolabeled with carbon 11 (11C) with antineoplastic and radiotracer properties. During the S phase of the cell cycle, topotecan inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Quantitation of 11C topotecan accumulated in tumor tissues by positron emission tomography (PET) may help predict responses to topotecan therapy.	Indicator, Reagent, or Diagnostic Aid || Pharmacologic Substance
C28781	11D10 AluGel Anti-Idiotype Monoclonal Antibody	11D10 AluGel Anti-Idiotype Monoclonal Antibody || TriAb	A monoclonal anti-idiotype antibody adsorbed to aluminum hydroxide gel (AluGel) with potential antineoplastic activity.  11D10 AluGel anti-idiotype monoclonal antibody mimics the human milk fat globule (HMFG) antigen found in breast and other cancers.  Vaccination with 11D10 AluGel anti-idiotype monoclonal antibody may induce a host antibody response against tumor cells positive for the HMFG antigen. (NCI04)	Immunologic Factor
C41441	12-Allyldeoxoartemisinin	12-Allyldeoxoartemisinin || 12-Allyldeoxoartemisinin	A semi-synthetic analogue of Artemisinin - a sesquiterpene lactone extracted from the dry leaves of Artemisia Annua (sweet wormwood) used as anti-malaria agent. Limited data is available on Artemisinin antineoplastic activity.	Pharmacologic Substance
C2494	13-Deoxydoxorubicin	13-DEOXYDOXORUBICIN || 13-Deoxydoxorubicin || GPX-100 || GPX-100 || GPX100	An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  13-Deoxydoxorubicin intercalates DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent was designed to be a non-cardiotoxic anthracycline antibiotic.	Organic Chemical || Pharmacologic Substance
C62553	14C BMS-275183	14C BMS-275183 || [14C] BMS-275183	An orally bioavailable taxane compound, a C-4 methyl carbonate analogue of paclitaxel, labeled with radioactive carbon 14, with potential antineoplastic and radioimaging activities. BMS-275183 binds to tubulin and as a result inhibits microtubule disassembly or assembly. This leads to cell cycle arrest at the G2/M phase, thereby resulting in an inhibition of cell division and ultimately cell death. BMS-275183 may be useful for treating multi-drug resistant tumors as it does not appear to be a substrate for P-glycoprotein.	Indicator, Reagent, or Diagnostic Aid || Pharmacologic Substance
C133224	17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521	(4-(2-Hydroxy-2-methylpropyl)piperidin-1-yl)(5-methoxy-1H-indol-2-yl)methanone || 17bHSD5 Inhibitor ASP9521 || 17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521 || ASP 9521 || ASP-9521 || ASP9521	A selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17bHSD5, aldo-keto reductase 1C3; AKR1C3), with potential antineoplastic activity. Upon administration, ASP9521 selectively binds to and inhibits the activity of 17bHSD5. This prevents the conversion of the adrenal androgens dehydroepiandrosterone and androstenedione into 5-androstenediol and testosterone. By blocking testosterone production, ASP9521 may inhibit the growth of testosterone-dependent cancers such as castration-resistant prostate cancer (CRPC). 17bHSD5, expressed both in normal prostate tissue and in prostate cancer (PC), plays a crucial role in persistent production of androgens despite castration; its expression is associated with increased malignancy of PC.	Pharmacologic Substance
C29796	2,6-Diaminopurine	1H-Purine-2,6-diamine || 2,6-DIAMINOPURINE || 2,6-Diaminopurine || 2,6-Diaminopurine || 9h-purine-2,6-diamine || DAP	One of a number of organic compounds that share a similar purine structure and possess antiviral and antitumor properties. 2,6-Diaminopurine nucleosides are versatile synthetic precursors for specific N-6 modifications of antiviral and antitumor agents. (NCI04)	Nucleic Acid, Nucleoside, or Nucleotide
C126754	2,6-Dimethoxyquinone	2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy- || 2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy- (9CI) || 2,6-DIMETHOXYQUINONE || 2,6-DMBQ || 2,6-Dimethoxy-1,4-Benzoquinone || 2,6-Dimethoxy-p-Benzoquinone || 2,6-Dimethoxy-p-Quinone || 2,6-Dimethoxybenzoquinone || 2,6-Dimethoxycyclohexa-2,5-Diene-1,4-Dione || 2,6-Dimethoxyquinone || 2,6-Dimethoxyquinone || p-Benzoquinone, 2,6-Dimethoxy-	A methoxy-substituted benzoquinone and bioactive compound found in fermented wheat germ extracts, with potential antineoplastic and immune-enhancing activity. 2,6-Dimethoxyquinone (2,6-DMBQ) inhibits anaerobic glycolysis thereby preventing cellular metabolism and inducing apoptosis. As cancer cells use the anaerobic glycolysis pathway to metabolize glucose and cancer cells proliferate at an increased rate as compared to normal, healthy cells, this agent is specifically cytotoxic towards cancer cells. In addition, 2,6-DMBQ exerts immune-enhancing effects by increasing natural killer (NK) cell and T-cell activity against cancer cells.	Organic Chemical
C116618	2-Deoxy-D-glucose	2-DEOXYGLUCOSE || 2-DG || 2-Deoxy-D-glucose || 2-Deoxy-D-glucose || Deoxyglucose	A non-metabolizable glucose analog in which the hydroxyl group at position 2 of glucose is replaced by hydrogen, with potential glycolysis inhibiting and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration of 2-deoxy-D-glucose (2-DG), this agent competes with glucose for uptake by proliferating cells, such as tumor cells. 2-DG inhibits the first step of glycolysis and therefore prevents cellular energy production, which may result in decreased tumor cell proliferation.	Pharmacologic Substance
C1165	2-Ethylhydrazide	2-Ethylhydrazide	A podophyllic acid derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, 2-ethylhydrazide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.	Organic Chemical || Pharmacologic Substance
C80036	2'-F-ara-deoxyuridine	1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) Uracil || 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) uracil || 1-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)URACIL || 2'-F-ara-deoxyuridine || 2'-F-ara-deoxyuridine || FAU || FAU	A deoxyuridine prodrug with potential antineoplastic activity. Upon cellular uptake, 2'-F-ara-deoxyuridine (FAU) is phosphorylated by thymidine kinase to FAU monophosphate and subsequently methylated in the 5'-position by thymidylate synthase (TS) to its activated form, 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) 5-methyluracil monophosphate (FMAUMP). FMAUMP is incorporated into DNA leading to an inhibition of DNA synthesis and so cell growth. The catalytic activity of TS is critical to activation of FAU and subsequent incorporation into DNA. FAU may be beneficial in the case of tumors with high TS activity that are resistant to TS inhibitors.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C29794	2-Fluoroadenine	1H-Purin-6-amine, 2-fluoro- (9CI) || 2-FLUOROADENINE || 2-Fad || 2-Fluoro-1H-purin-6-amine || 2-Fluoroadenine || Adenine, 2-fluoro- || BRN 0610958 || Purine, 6-amino-2-fluoro- || SRI 774	A fluorinated heterocyclic 2-ring compound. 2-fluoroadenine is the base moiety for many carbocyclic and acyclic nucleoside analogues, which may be used in antineoplastic studies.	Hazardous or Poisonous Substance
C131289	2-Fluorofucose	2-FF Containing SGN-2FF || 2-FLUOROFUCOSE || 2-Fluorofucose || 2-Fluorofucose || 2FF-containing SGN-2FF || SGN-2FF	An orally bioavailable fluorinated analog of fucose that is a protein fucosylation inhibitor, with potential antineoplastic and immunomodulating activities. Upon administration, 2-fluorofucose (2-FF) mimics fucose and is converted to guanosine diphosphate (GDP)-2FF, which prevents the formation of the fucosylation substrate GDP-fucose, and the incorporation of fucose into glycoproteins by fucosyltransferase. As fucosylation of glycoproteins plays a key role in many biological processes, such as protein function, receptor binding, cell signaling and cellular adhesion, and is essential for tumor progression, blocking fucosylation decreases tumor cell growth. In addition, blocking fucosylation of monoclonal antibodies generates fucose-deficient antibodies that exert enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).	Organic Chemical || Pharmacologic Substance
C82408	2G-1 TCR Retroviral Vector-Transduced Lymphocytes	2G-1 TCR Retroviral Vector-Transduced Lymphocytes || PG13-A(F/K)-F-SGSG-T2a-B(opt)(2G-1 TCR) Retroviral Vector-Transduced Lymphocytes	A preparation of autologous human T-lymphocytes isolated from renal cell cancer (RCC) patient and transduced with 2G-1 TCR, a retroviral vector encoding the alpha and beta chains of a T-cell receptor that recognizes TNF-related apoptosis inducing ligand (TRAIL) bound to death receptor 4 (DR4), with potential immunostimulating and antineoplastic activities. After transduction, expansion in culture, and introduction into the RCC patient, 2G-1 TCR retroviral vector-transduced lymphocytes may stimulate a cytotoxic T lymphocyte (CTL) response against RCC cells with TRAIL bound to DR4 on their surfaces. TRAIL, a member of the TNF superfamily, is a homotrimeric type II membrane protein that rapidly induces oligomerization of receptor intracellular death domains and apoptosis in a variety of tumor cells when bound to its receptors; DR4 (TRAIL receptor 1), a member of the TNF receptor family, is overexpressed by a variety of malignant cell types.	Cell || Pharmacologic Substance
C120474	2-Hydroxyestradiol	(17beta)-Estra-1,3,5(10)-Triene-2,3,17-Triol || 2-HYDROXYESTRADIOL || 2-Hydroxy-17beta-Estradiol || 2-Hydroxyestradiol || 2-Hydroxyestradiol || 2-Hydroxyestradiol-17beta || 2-OH-E2 || 2-OH-Estradiol || 2-OHE2	A metabolite formed during the metabolism of 17beta-estradiol by hydroxylation of the carbon at position 2 by the CYP450 enzymes 1A1/1A2. Theoretically, 2-hydroxyestradiol (2-OHE2) is able to undergo redox cycling, which generates active radicals and induces DNA damage; however, this estradiol metabolite is very unstable in vivo and is quickly inactivated by catechol-O-methyltransferase (COMT)-mediated O-methylation and converted to 2-methoxyestradiol (2-MeE2). 2-MeE2 exerts antineoplastic activities through its estrogen receptor antagonistic effect and the induction of apoptosis in susceptible cancer cells.	Organic Chemical || Pharmacologic Substance
C63947	2-Hydroxyestrone	1,3,5(10)-Estratrien-2,3-diol-17-one || 2-HYDROXYESTRONE || 2-Hydroxyestrone || 2-Hydroxyestrone || 2-Hydroxyestrone || 2-OHE(1) || 2-OHE1 || Catecholestrone || Estra-1,3,5(1)-Trien-17-One, 2,3-Dihydroxy-	A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 2 by cytochrome P450 (CYP) enzymes, including CYP1A1 and 1A2, with potential anticarcinogenic activity. The mechanism of action for the antitumor activity of 2-hydroxyestrone is not known but this metabolic product has minimal estrogenic activity compared to the parent compound and other estrone metabolites. Additionally, O-methylation of this compound produces 2-methoxyestradiol (2-MeOE2), which is a potent inhibitor of both cell proliferation and angiogenesis.	Organic Chemical || Pharmacologic Substance
C85482	2-Hydroxyflutamide Depot	2-Hydroxyflutamide Controlled-Release Formulation || 2-Hydroxyflutamide Depot || Liproca	A depot formulation containing a bioresorbable, controlled-release, calcium sulphate-based paste of the nonsteroidal antiandrogen 2-hydroxyflutamide (2-HOF) with potential antineoplastic activity. Upon injection into the tumor site in the prostate, 2-hydroxyflutamide depot slowly releases 2-HOF, which competitively binds to androgen receptors (ARs), blocking the binding of dihydrotestosterone (DHT). This may inhibit androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest and decreased cellular proliferation. In addition, 2-HOF inhibits nuclear uptake of androgen in androgen-responsive tissues.	Pharmacologic Substance
C965	2-Methoxyestradiol	(17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol || 2-METHOXYESTRADIOL || 2-MeE2 || 2-MeOE2 || 2-Methoxy Estradiol || 2-Methoxyestradiol || 2-Methoxyestradiol || 2-Methoxyestradiol || 2-methoxyestradiol || 2ME2 || Panzem	An orally bioavailable estradiol metabolite with potential antineoplastic activity.  2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis.  This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis. (NCI04)	Pharmacologic Substance || Organic Chemical
C62603	2-Methoxyestradiol Nanocrystal Colloidal Dispersion	2-Methoxyestradiol Nanocrystal Colloidal Dispersion || 2-Methoxyestradiol Nanocrystal Colloidal Dispersion || Panzem NCD	An orally bioavailable liquid formulation containing the small molecule 2-methoxyestradiol with potential antineoplastic activity. 2-Methoxyestradiol, a naturally occurring estradiol metabolite, exerts its antitumor effect by inhibiting endothelial cells as well as tumor cells through multiple mechanisms. This agent binds to tubulin and disrupts microtubule formation, thereby preventing mitosis and subsequent cellular proliferation. In addition, 2-methoxyestradiol induces caspase activation, resulting in cell cycle arrest in G2 phase and apoptosis in due course. This agent also down-regulates hypoxia inducible factor-one alpha (HIF-1a). The nanocrystal colloidal dispersion increases the absorption of 2-methoxyestradiol, thereby improving its bioavailability, which results in enhanced drug plasma levels.	Organic Chemical || Pharmacologic Substance
C120472	2-Methoxyestrone	2-METHOXYESTRONE || 2-MeE1 || 2-MeOE1 || 2-Methoxyestrone || 2-Methoxyestrone || 2-OMeE1 || 3-Hydroxy-2-Methoxyestra-1,3,5(10)-Trien-17-One	A metabolite formed during the methylation of 2-hydroxyestrone (2-OHE1) by catechol-O-methyltransferase (COMT), with potential anticarcinogenic and minimal estrogen activities. The mechanism of action for the antitumor activity of 2-methoxyestrone (2-OMeE1) is not known. A high 2-methoxyestrone (2-OMeE1)/2-OHE1 ratio indicates higher methylation efficiency and correlates with a lower cancer risk.	Organic Chemical || Pharmacologic Substance
C29475	3'-C-ethynylcytidine	1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine || 3'-C-Ethynylcytidine || 3'-C-ethynylcytidine || 3'-C-ethynylcytidine || 3'-C-ethynylcytidine || ECdy || ECyd || TAS-106 || TAS-106	A synthetic cytidine nucleoside containing a covalently bound ethynyl group with potential antineoplastic and radiosensitizing activities. 3'-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C171381	3'-dA Phosphoramidate NUC-7738	3'-dA Phosphoramidate NUC-7738 || NUC 7738 || NUC-7738 || NUC7738 || Nucleoside Analog NUC-7738	A phosphoramidate derivative of the monophosphate form of cordycepin (3'-deoxyadenosine; 3'-dA), an adenosine derivative first isolated from Cordyceps sinensis, with potential antineoplastic, antioxidant, and anti-inflammatory activities. Upon administration and cellular uptake of NUC-7738 by passive diffusion, cordycepin monophosphate (3'-dAMP) is converted into its active anti-cancer metabolite 3'-deoxyadenosine triphosphate (3'-dATP). 3'-dATP functions as a ribonucleoside analogue and competes with ATP during transcription. Therefore, this agent causes RNA synthesis inhibition, inhibits cellular proliferation, and induces apoptosis. Also, 3'-dAMP activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling. This prevents the hyperphosphorylation of the translation repressor protein 4E-BP1. This results in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers. Compared to cordycepin alone, the addition of the phosphoramidate moiety may overcome cancer resistance and allow for greater cytotoxicity as NUC-7738 does not require a nucleoside transporter for cellular uptake, is independent of  enzymatic activation by adenosine kinase (AK) and is not susceptible to enzymatic degradation by adenosine deaminase (ADA). Altogether, this may help overcome cancer resistance to cordycepin.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C123823	4H11-28z/fIL-12/EGFRt-expressing Autologous T-lymphocytes	4H11-28z/fIL-12/EGFRt+ Genetically-modified T Cells || 4H11-28z/fIL-12/EGFRt+ T Cells || 4H11-28z/fIL-12/EGFRt-expressing Autologous T-lymphocytes || 4H11-28z/fIL-12/EGFRt-expressing Autologous T-lymphocytes || Autologous 4H11-28z/fIL-12/EGFRt+ Genetically-modified T Cells || Autologous MUC16ecto-targeting EGFR-secreting T Lymphocytes	A preparation of genetically modified autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) MUC16ecto and encoding the human pro-inflammatory cytokine interleukin-12 (IL-12), fused to the signaling domain of the zeta chain of the TCR/CD3 complex (28z), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, 4H11-28z/fIL-12/EGFRt-expressing autologous T-lymphocytes are directed to and induce selective toxicity in MUC16-expressing tumor cells. In addition, the T-cells secrete IL-12 which induces secretion of interferon-gamma, promotes the activation of natural killer cells (NKs), and induces cytotoxic T-cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. MUC16, a transmembrane protein and glycosylated mucin, is overexpressed on the cell surface of the majority of ovarian cancer cells but not on healthy cells. MUC16ecto is the extracellular portion of MUC-16 and is the part that is retained by cells after cleavage of CA-125.	Cell || Pharmacologic Substance
C971	4'-Iodo-4'-Deoxydoxorubicin	4'-Deoxy-4'-Iododoxorubicin || 4'-Iodo-4'-Deoxydoxorubicin || 4'-Iodo-4'-Deoxydoxorubicin || IDOX || IODODOXORUBICIN || Iodo-Doxorubicin || Iododoxorubicin || iododoxorubicin	An iodinated doxorubicin analogue with antiamyloid activity. 4'-Iodo-4'-deoxydoxorubicin (IDOX) binds with high affinity to five types of natural amyloid fibrils including immunoglobulin light chains, amyloid A, transthyretin (methionine-30 variant), beta-protein (Alzheimer), and beta2-microglobulin. This agent may inhibit fibril growth, increasing the solubility of amyloid tissue deposits and facilitating their clearance. IDOX has also been shown to insulin amyloid fibrillogenesis in vitro.	Pharmacologic Substance || Antibiotic || Organic Chemical
C977	4-Nitroestrone 3-Methyl Ether	3-METHOXY-4-NITRO-ESTRA-1,3,5(10)-TRIEN-17-ONE || 3-Methoxy-4-nitro-estra-1,3,5(10)-trien-17-one || 4-Nitroestrone || 4-Nitroestrone 3-Methyl Ether || 4-Nitroestrone 3-methyl ether	A synthetic derivative of estradiol. 4-nitroestrone 3-methyl ether inhibits estrogen sulfotransferase (EST), a progesterone-induced secretory endometrial enzyme which affects estrogen receptor levels.  This agent has been shown to be an effective growth inhibitor of some chemically induced animal mammary tumors. (NCI04)	Organic Chemical || Pharmacologic Substance
C91722	4-Peptide Melanoma Vaccine	4-Peptide Melanoma Vaccine || 4-Peptide Melanoma Vaccine	An emulsion of 4 melanoma peptides with potential immunomodulating and antineoplastic activities. Upon vaccination, 4-peptide melanoma vaccine may stimulate an immune response against 4 different melanoma associated antigens. This may lead to a reduction in tumor cell proliferation of cancer cells expressing these antigens.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C121828	4-Thio-2-deoxycytidine	4'-THIO-2'-DEOXYCYTIDINE || 4'-Thio-2'-deoxycytidine || 4-Thio-2-deoxycytidine || 4-Thio-2-deoxycytidine || T-dCyd || TdCyd	An orally bioavailable 4-thio modified 2-deoxycytidine analog, with potential antineoplastic activity. Upon administration of 4-thio-2-deoxycytidine (TdCyd), this cytidine analog gets incorporated into DNA during replication and inhibits the activity of DNA methyltransferase 1 (DNMT1), which blocks DNA hypermethylation. This results in DNMT1 depletion, hypomethylation of DNA, and the reactivation of tumor suppressor genes that were silenced by hypermethylation; this results in antitumor activity and an inhibition of tumor cell proliferation.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C153479	5-Aza-4'-thio-2'-deoxycytidine	5-AZA-4'-THIO-2'-DEOXYCYTIDINE || 5-Aza-4'-thio-2'-deoxycytidine || 5-Aza-4'-thio-2'-deoxycytidine || 5-Aza-4-thio-2-deoxycytidine || 5-Aza-TdCyd || Aza-TdC || Aza-TdCyd	An orally bioavailable, nucleoside analog and DNA methyltransferase I (DNMT1) inhibitor, with potential DNA hypomethylating and antineoplastic activities. Upon administration, 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) gets incorporated into DNA, where it binds to the active site of DNMT1, a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. The formation of covalent DNMT1-DNA complexes inhibits DNMT1, prevents DNA methylation of CpG sites, causes CpG demethylation, and results in the re-expression and re-activation of silenced tumor suppressor genes. This inhibits tumor cell proliferation. DNMT1, overactivated in tumor cells, plays a key role in tumor cell proliferation.	Pharmacologic Substance
C62785	5-Fluoro-2-Deoxycytidine	5-FLUORO-2'-DEOXYCYTIDINE || 5-Fluoro-2-Deoxycytidine || 5-Fluoro-2-Deoxycytidine || 5-fluoro-2-deoxycytidine || Cytidine, 2'-deoxy-5-fluoro- || FdCyd || FdCyd || Ro 5-1090	An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted by intracellular deaminases to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate, which leads to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand thus leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C153515	6 Melanoma Helper Peptide Vaccine	6 Melanoma Helper Peptide Vaccine || 6 Melanoma Helper Peptide Vaccine || 6MHP || 6MHP Vaccine	A multi-epitope vaccine containing the following six class II MHC-restricted peptides: gp100, MelanA/MART-1, two tyrosinase peptides, and the cancer/testis antigens MAGE-A3 and MAGE-A1,2,3,6, with potential antineoplastic activity. Upon administration, melanoma helper peptides induce an antigen-specific, Th1-dominant, CD4+ T-cell response, potentially augmenting cytotoxic T-cell (CTL) responses and maintaining immunologic memory against tumor cells expressing melanoma-specific antigens. The 6MHP vaccine may also induce a CD8+ T-cell response through epitope spreading, potentially priming subsequent immune responses against tumor cells.	Immunologic Factor || Pharmacologic Substance
C113787	6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158	6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158 || ACT-PFK-158 || PFK-158 || PFKFB3 Inhibitor PFK-158	An inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) and derivative of 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth. PFKFB3, an enzyme that catalyzes the conversion of fructose-6-phosphate to fructose-2,6-bisphosphate, is highly expressed and active in human cancer cells; it plays a key role in increasing both glycolytic flux in and proliferation of cancer cells.	Pharmacologic Substance
C1611	7-Cyanoquinocarcinol	(+)-DX 52-1 || 7-Cyanoquinocarcinol || DX 52-1 || DX-52-1 || DX-52-1 || DX-52-1	A semisynthetic analogue of the Streptomyces melanovinaceus-derived tetracyclic antitumor antibiotic quinocarmycin with potential antineoplastic activity. Quinocarmycin belongs to the naphthyridinomycin/saframycin class of antitumor antibiotics. These antibiotics appear to act through DNA alkylation.	Antibiotic || Organic Chemical
C61618	7-Ethyl-10-Hydroxycamptothecin	7-ETHYL-10-HYDROXYCAMPTOTHECIN || 7-Ethyl-10-Hydroxycamptothecin || 7-Ethyl-10-hydroxy-20(S)-camptothecin || SN 38 || SN-38		Pharmacologic Substance
C1271	7-Hydroxystaurosporine	(+)-UCN-01 || 2,3,9,10,11,12-Hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)-8,12-epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)triinden-1-one || 7-HYDROXYSTAUROSPORINE || 7-Hydroxy-staurosporine || 7-Hydroxystaurosporine || 7-Hydroxystaurosporine || 7-Hydroxystaurosporine || 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo[a, g]cyclonona[cde] Trinden-1-one, 2,3,9,10,11, 12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino) || UCN-01 || UCN-01 || UCN-01	A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis. (NCI04)	Organic Chemical || Pharmacologic Substance
C28788	8-Azaguanine	5-Amino-1,4-dihydro-7H-1,2,3-triazolo(4,5-d)pyrimidin-7-one || 5-Amino-1H-v-triazolo(d)pyrimidin-7-ol || 5-Amino-7-hydroxy-1H-v-triazolo(d)pyrimidine || 8 AG || 8-AZAGUANINE || 8-Azaguanine || Guanazolo || Pathocidin || SF-337 || SK 1150 || Triazologuanine	A purine analogue with potential antineoplastic activity.  8-Azaguanine interferes with the modification of transfer ribonucleic acid (tRNA) by competing with guanine for incorporation into tRNA catalyzed by the enzyme tRNA-guanine ribosyltransferase (tRNA-guanine transglycosylase).  Altered guanine modification of tRNA has been implicated in cellular differentiation and neoplastic transformation.  8-Azaguanine also inhibits the formation of 43S and 80S initiation complexes, thereby interfering with initiation of translation and inhibiting protein synthesis.  This agent inhibits tumor cell growth and stimulates cell differentiation. (NCI04)	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C124047	8-Chloroadenosine	8-CHLOROADENOSINE || 8-Chloro-adenosine || 8-Chloroadenosine || 8-Chloroadenosine || 8-Cl-Ado || 8-Cl-adenosine || Adenosine, 8-Chloro-	An antimetabolite and a chlorine derivative of the purine nucleoside adenosine, with potential antineoplastic activity. Upon administration, 8-chloro-adenosine is phosphorylated to form 8-chloro-adenosine triphosphate (8-chloro-ATP), which functions as a ribonucleoside analogue and competes with ATP during transcription. Therefore, this agent causes RNA synthesis inhibition, inhibits cellular proliferation, and induces apoptosis.	Pharmacologic Substance
C28789	9-Ethyl 6-Mercaptopurine	9-Ethyl 6-MP || 9-Ethyl 6-Mercaptopurine	A synthetic alkyl derivative prodrug of the antineoplastic agent 6-mercaptopurine (6-MP).  In vivo, 9-ethyl 6-mercaptopurine appears to be converted to 6-MP, which substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. (NCI04)	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C28793	9H-Purine-6Thio-98D	9H-Purine-6Thio-98D	An antimetabolite analogue of purine with antineoplastic and immuno-suppressant properties.  9H-Purine-6Thio-98D substitutes for the normal nucleoside and fraudulently incorporates into DNA and inhibits de novo purine synthesis, thereby inducing cell death. In vivo, this agent, also known as 6MP-arabinoside, may occur as a metabolite of the antineoplastic agent mercaptopurine. (NCI04)	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C178440	A2A/A2B Adenosine Receptor Antagonist INCB106385	A2A/A2B Adenosine Receptor Antagonist INCB106385 || A2A/A2B Adenosine Receptor Antagonist INCB106385 || A2AR/A2BR Antagonist INCB106385 || INCB 106385 || INCB-106385 || INCB106385	An orally bioavailable antagonist of both the immunomodulatory checkpoint molecules adenosine A2A receptor (A2AR; ADORA2A) and A2B receptor (A2BR; ADORA2B), with potential immunomodulating and antineoplastic activities. Upon oral administration, A2A/A2B adenosine receptor antagonist INCB106385 competes with tumor-released adenosine for binding to A2AR and A2BR expressed on numerous intra-tumoral immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages and T-lymphocytes. The binding of INCB106385 to A2AR and A2BR inhibits A2AR/A2BR activity and prevents adenosine-A2AR/A2BR-mediated signaling. A2AR/A2BR inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing. A2AR and A2BR, G protein-coupled signaling receptors, are expressed on the cell surfaces of numerous immune cells. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation.	Pharmacologic Substance
C179629	A2AR Antagonist EXS21546	A2AR Antagonist EXS21546 || A2AR Antagonist EXS21546 || EXS 21546 || EXS-21546 || EXS21546	An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon oral administration, A2AR antagonist EXS21546 selectively targets, binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression in the tumor microenvironment (TME). EXS21546 does not penetrate the central nervous system (CNS).	Pharmacologic Substance
C2048	A-65	A-65	An amide analogue of Trichostatin A studied for potential antineoplastic activity.  A-65 inhibits zinc-dependent histone deacetylase, inducing terminal cell differentiation and anti-angiogenic activity. (NCI04)	Pharmacologic Substance
C26449	Abagovomab	ABAGOVOMAB || Abagovomab || Abagovomab || Monoclonal Antibody ACA125 Anti-Idiotype Vaccine || VaccinOvar	A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.	Immunologic Factor || Pharmacologic Substance
C2015	Abarelix	ABARELIX || Abarelix || Abarelix || PPI-149 || Plenaxis || Plenaxis || R-3827 || abarelix	A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone.  As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C97660	Abemaciclib	2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl) || ABEMACICLIB || Abemaciclib || LY-2835219 || LY2835219 || Verzenio	An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.	Pharmacologic Substance
C162507	Abemaciclib Mesylate	ABEMACICLIB MESYLATE || Abemaciclib Mesylate || LY-2835219 Methanesulfonate || LY-2835219 methanesulfonate	The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.	Pharmacologic Substance
C131910	Abequolixron	ABEQUOLIXRON || Abequolixron || LXR-b Agonist RGX-104 || Liver X Receptor beta Agonist RGX-104 || RGX 104 || RGX-104 || RGX104 || SB-742881	An orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, abequolixron selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels.	Pharmacologic Substance
C68920	Abexinostat	2-benzofurancarboxamide, 3-((dimethylamino)methyl)-n-(2-(4-((hydroxyamino)carbonyl)phenoxy)ethyl)- || 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)-1-benzofuran-2-carboxamide || ABEXINOSTAT || Abexinostat || Abexinostat || CRA-024781 || CRA-024781 || HDAC Inhibitor PCI-24781 || PCI-24781	An orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.	Organic Chemical || Pharmacologic Substance
C160889	Abexinostat Tosylate	1H-Pyrrolo(2,3-C)pyridine-2-carboxamide, N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl)-6,7-dihydro-6-methyl-7-oxo- || ABEXINOSTAT TOSYLATE || Abexinostat Tosylate || Abexinostat Tosylate || PCI-24781 Tosylate	The tosylate salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.	Pharmacologic Substance
C77333	Abiraterone	17-(3-Pyridyl)androsta-5,16-dien-3beta-ol || ABIRATERONE || Abiraterone || Abiraterone || CB 7598	A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.	Pharmacologic Substance
C68845	Abiraterone Acetate	17-(3-Pyridyl)-5,16-androstadien-3beta-acetate || ABIRATERONE ACETATE || Abiraterone Acetate || Abiraterone Acetate || Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3beta)- || BR9004 || BR9004-1 || CB7630 || JNJ-212082 || Yonsa || Zytiga || abiraterone acetate	An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.	Organic Chemical || Pharmacologic Substance
C175940	Abiraterone Amorphous Solid Dispersion Formulation DST-2970	Abiraterone Amorphous Solid Dispersion Formulation DST-2970 || Abiraterone KinetiSol Formulation DST-2970 || DST 2970 || DST-2970 || DST2970	An orally bioavailable, amorphous solid dispersion formulation of the steroidal compound abiraterone, with potential antiandrogen activity. Upon oral administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This may suppress testosterone production by both the testes and the adrenals to castrate-range levels.	Pharmacologic Substance
C184796	Abiraterone Decanoate	ABIRATERONE DECANOATE || Abiraterone Decanoate	The decanoate form of abiraterone, a steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.	Pharmacologic Substance
C179617	Abiraterone Decanoate Depot	Abiraterone Decanoate Depot || PRL 02 || PRL-02 || PRL-02 Depot || PRL02	A depot formulation containing the decanoate ester of abiraterone, a steroidal compound with antiandrogen activity. Upon administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This suppresses testosterone production by both the testes and the adrenals to castrate-range levels. This may decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells.	Pharmacologic Substance
C82422	Abituzumab	ABITUZUMAB || Abituzumab || Abituzumab || EMD 525797	A humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities. Abituzumab, a chimeric antibody which includes the antigen binding sites of the anti-integrin mouse antibody 17E6, binds to and inhibits the activity of alphaVbeta3 integrin (vitronectin receptor); this may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in alphavbeta3-expressing tumor cells. AlphaVbeta3 integrin, a cell adhesion and signaling receptor, is expressed on the surface of tumor vessel endothelial cells and plays a crucial role in endothelial cell adhesion and migration.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C99901	Acai Berry Juice	Acai Berry Juice || Acai Juice || Açai Berry Juice || Açai Juice	A juice product obtained from the fruit of the acai palm tree (Euterpe oleracea) with anti-inflammatory, antioxidant and potential chemopreventive activities. Besides high amounts of vitamins, minerals and fatty acids, acai berry is rich in phytonutrients such as anthocyanins and flavones which are potent scavengers of reactive oxygen species. The fruit also contains high amounts of the flavone velutin which exhibits potent anti-inflammatory properties. Velutin is able to inhibit the degradation of the inhibitor of nuclear factor kappa-B (NF-kB), thereby blocking the activation of NF-kB, as well as inhibiting phosphorylation of mitogen-activated protein kinase p38 and JNK. Inhibition of these processes results in suppression of the production of proinflammatory cytokines, such as tumor necrosis factor alpha and interleukin 6.	Pharmacologic Substance
C113442	Acalabrutinib	ACALABRUTINIB || ACP-196 || Acalabrutinib || Acalabrutinib || Benzamide, 4-(8-Amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl- || Bruton Tyrosine Kinase Inhibitor ACP-196 || Calquence	An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.	Pharmacologic Substance
C103277	Acalisib	6-Fluoro-3-phenyl-2-((1S)-1-(7H-purin-6-ylamino)ethyl)quinazolin-4(3H)-one || ACALISIB || Acalisib || CAL-120 || GS-9820	An inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. Acalisib inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.	Pharmacologic Substance
C984	Aceglatone	ACEGLATONE || Aceglatone || Glucaron	A derivative of D-glucaro-1, 4-lactone with chemopreventive and anti-tumor activities. One of the key processes in which human body eliminates toxic chemicals as well as hormones (such as estrogen) is by glucuronidation. When beta-glucuronidase deconjugates these glucuronides, it prolongs the stay of the hormone or toxic chemical in the body. Elevated beta-glucuronidase activity has been implicated to be associated with an increased risk for hormone-dependent cancers like breast, prostate, and colon cancers. Thereby, aceglatone may suppress the developments of hormone-dependent cancers mediated through beta-glucuronidase inhibition.	Organic Chemical || Pharmacologic Substance
C200	Acetylcysteine	ACETYLCYSTEINE || Acetadote || Acetylcysteine || Acetylcysteine || Acetylcysteine || Airbron || Airbron || Broncholysin || Broncholysin || Brunac || Fabrol || Fluatox || Fluimucetin || Fluimucetin || Fluimucil || Fluimucil || Fluprowit || L-Alpha-acetamido-beta-mercaptopropionic Acid || Muco Sanigen || Mucocedyl || Mucolator || Mucolyticum || Mucomyst || Mucomyst || Mucosolvin || Mucosolvin || Mucret || N-Acetyl Cysteine || N-Acetyl-L-cysteine || N-Acetylcysteine || N-Acetylcysteine || N-acetyl-3-mercaptoalanine || N-acetyl-L-cysteine || N-acetyl-L-cysteine || N-acetylcysteine || NAC || Neo-Fluimucil || Parvolex || Parvolex || Respaire || Respaire || Tixair || acetylcysteine	A synthetic N-acetyl derivative and prodrug of the endogenous amino acid L-cysteine, a precursor of the antioxidant glutathione (GSH), with mucolytic, antioxidant, and potential cytoprotective, cancer-preventive, and anti-inflammatory activities.  Upon administration, acetylcysteine exerts its mucolytic activity by reducing disulfide bonds in mucoproteins, resulting in liquification of mucus and reducing its viscosity. It is also used for the treatment of acetaminophen overdose as it can restore the depleted GSH reserves in the hepatocytes during the process of detoxification.  The antioxidant activity is attributed to the ability of GSH to scavenge reactive oxygen species (ROS), thereby preventing ROS-mediated cell damage, decreasing oxidative stress, protecting cells against the damaging effects of free radicals and preventing apoptosis in these cells. In addition, this may inhibit tumor cell proliferation, progression and survival, in susceptible tumor cells that rely on ROS-mediated signaling for their proliferation and malignant behavior. Under certain circumstances, acetylcysteine is able to induce apoptosis in susceptible cells, including certain tumor cells, via the intrinsic mitochondria-dependent pathway but not involving endoplasmic reticulum stress. Also, acetylcysteine may also be able to degrade Notch2, thereby preventing proliferation, migration, and invasion in Notch2-overexpressing glioblastoma cells. In addition, acetylcysteine may inhibit viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. Acetylcysteine also possesses anti-inflammatory activity through modulation of the nuclear factor-kappa B (NF-kB) pathway and the modulation of cytokine synthesis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C985	Acitretin	(All-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid || ACITRETIN || Acitretin || Acitretin || Etretin || Neotigason || Ro 10-1670 || Ro-10-1670 || Soriatane || Trimethylmethoxyphenyl-retinoic acid || acitretin	An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties.  Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  This agent may also inhibit tumor angiogenesis. (NCI04)	Organic Chemical || Pharmacologic Substance
C986	Acivicin	(S-(R*,R*))-4,5-Dihydro-alpha-amino-3-chloro-5-isoxazoleacetic Acid || ACIVICIN || AT-125 || Acivicin || Acivicin || U-42126	A modified amino acid and structural analog of glutamine.  Acivicin inhibits glutamine amidotransferases in the purine and pyrimidine biosynthetic pathways, thereby inhibiting tumor growth in cell lines dependent on glutamine metabolism. (NCI04)	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C1861	Aclacinomycin B	1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexapyranosyl)oxy)-, methyl ester,(1R-(1-alpha,2-beta,4-beta))- || ACLACINOMYCIN B || Aclacinomycin B || Aclacinomycin B || Aclarubicin B || Antibiotic MA 144B1	An antineoplastic oligosaccharide anthracycline antibiotic isolated from the bacterium Streptomyces galilaeus.  Aclacinomycin B intercalates into DNA and inhibits both the topoisomerase I and II enzymes, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.	Antibiotic || Organic Chemical || Pharmacologic Substance
C202	Aclarubicin	(1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-1-naphthacenecarboxylic acid methyl ester || 1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1alpha,2beta,4beta))-(9CI) || ACLARUBICIN || ACM-A || Aclacinomycin || Aclacinomycin A || Aclacinomycin A || Aclacinomycin-A || Aclarubicin || Antibiotic MA144-A1 || MA144-A1	An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.	Pharmacologic Substance || Antibiotic || Organic Chemical
C988	Acodazole	1H-imidazo[4,5-f]quinoline, acetamide deriv || ACODAZOLE || Acodazole || Acodazole || acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4, 5-f]quinolin-9-yl)amino]phenyl]-	A synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity. (NCI04)	Organic Chemical || Pharmacologic Substance
C71627	Acodazole Hydrochloride	ACODAZOLE HYDROCHLORIDE || Acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4, 5-f]quinolin-9-yl)amino]phenyl]-, monohydrochloride (9CI) || Acodazole Hydrochloride || acetamide, N-methyl-N-[4-[(7-methyl-1H-imidazo[4, 5-f]quinolin-9-yl)amino]phenyl]-, monohydrochloride (9CI)	The hydrochloride salt of acodazole, a synthetic imidazoquinoline with antineoplastic activity. Acodazole intercalates into DNA, resulting in disruption of DNA replication.  Use of this agent has been associated with significant cardiotoxicity.	Organic Chemical || Pharmacologic Substance
C65213	Acolbifene Hydrochloride	ACOLBIFENE HYDROCHLORIDE || Acolbifene Hydrochloride || Acolbifene Hydrochloride || acolbifene hydrochloride	The hydrochloride salt form of acolbifene, a fourth-generation estrogen receptor modulator (SERM) with potential lipid lowering and antineoplastic activity. Acolbifene specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. Acolbifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the effects of estrogen in these tissues. This may inhibit tumor cell proliferation in ER-positive tumor cells. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In bone, it decreases bone resorption and bone turnover and increases bone mineral density.	Pharmacologic Substance
C203	Acridine	ACRIDINE || Acridine	A polycyclic aromatic dye with antineoplastic, antimicrobial and imaging activities. Acridine and its derivatives intercalate within DNA and RNA by forming hydrogen-bonds and stacking between base pairs resulting in DNA crosslinks and strand breaks. In addition, acridine and its derivatives are a potent inhibitor of topoisomerase II enzyme. This results in the inhibition of DNA and RNA synthesis, predominantly occurring during S phase of the cell cycle and ultimately leads to cell death.	Organic Chemical || Pharmacologic Substance
C2203	Acridine Carboxamide	ACRIDINE CARBOXAMIDE || Acridine Carboxamide || DACA || DACA || N-(2-(Dimehtylamino)ethyl)acridine-4-carboxamide || SN 22995 || XR5000 || acridine carboxamide	A tricyclic acridine-based (or carboxamide-based) drug with dual topoisomerase inhibitor and potential antineoplastic activities. Acridine carboxamide inhibits both topoisomerases I and II and intercalates into DNA, resulting in DNA damage, the disruption of DNA repair and replication, the inhibition of RNA and protein synthesis, and cell death.	Organic Chemical || Pharmacologic Substance
C75297	Acronine	ACRONINE || Acronine || Acronycine	A natural alkaloid with an acridine structure isolated from the bark of the plant Acronychia baueri (Australian scrub ash) with antineoplastic properties.  Acronycine appears to alkylate DNA and interfere with DNA replication. (NCI04)	Pharmacologic Substance
C181770	ACSS2 Inhibitor MTB-9655	ACSS2 Inhibitor MTB-9655 || Acetyl-CoA Synthetase 2 Inhibitor MTB-9655 || MTB 9655 || MTB-9655 || MTB9655	An orally bioavailable small molecule inhibitor of the enzyme human acetyl coenzyme A synthetase short chain family member 2 (ACSS2; acetyl CoA synthetase 2), with potential antineoplastic activity. Upon oral administration, the ACSS2 inhibitor MTB-9655 selectively targets, binds to and inhibits the activity of ACSS2. This prevents acetate metabolism to acetyl-CoA which may lead to an inhibition of tumor cell proliferation. ACSS2, an enzyme that converts acetate to acetyl-CoA, is upregulated in cancer cells in response to low nutrient availability and hypoxia. Stressed cancer cells utilize acetate as an alternative nutrient source for cell growth.	Pharmacologic Substance
C82414	Actinium Ac 225 Lintuzumab	225Ac-HuM195 || Actinium (225Ac) Lintuzumab Satetraxetan || Actinium Ac 225 Lintuzumab || Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195 || LINTUZUMAB SATETRAXETAN AC-225 || SGN-33 AC-225	A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C187702	Actinium Ac 225 Vofatamab	225Ac-FPI-1966 || 225Ac-Vofatamab || Actinium Ac 225 Vofatamab || Actinium-225 Vofatamab || [225Ac]-FPI-1966 || [225Ac]-Vofatamab	A radioimmunoconjugate containing vofatamab, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the fibroblast growth factor receptor type 3 (FGFR3) labeled, via a chelating agent, with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225 vofatamab, the vofatamab moiety specifically targets and binds to FGFR3. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C185145	Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A	225Ac-DOTA-M5A Humanized Anti-CEA Antibody || 225Ac-DOTA-anti-CEA Monoclonal Antibody M5A || Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A || Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A	A radioimmunoconjugate comprised of M5A, a humanized monoclonal antibody directed against carcinoembryonic antigen-related cell adhesion molecule 5 (CEA or CEACAM5), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of actinium Ac 225-DOTA-anti-CEA monoclonal antibody M5A specifically targets and binds to CEA, thereby delivering a cytotoxic dose of alpha radiation to CEA-expressing tumor cells. CEA, a tumor-associated antigen (TAA) and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion and cell adhesion, and is overexpressed by a variety of cancer types.	Pharmacologic Substance
C186744	Actinium Ac 225-DOTA-Daratumumab	225Ac-DOTA-Daratumumab || Actinium Ac 225-DOTA-Daratumumab || Actinium Ac 225-DOTA-Daratumumab || [225Ac]-DOTA-Daratumumab	A radioimmunoconjugate containing daratumumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, conjugated to the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-DOTA-daratumumab, the monoclonal antibody moiety specifically targets and binds to cell surface antigen CD38. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to CD38-expressing tumor cells. CD38, a cell surface glycoprotein, is expressed on various hematopoietic cells and is overexpressed on multiple myeloma (MM) cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C176627	Actinium Ac 225-DOTA-h11B6 JNJ-69086420	225Ac-h11B6 JNJ-69086420 || Actinium Ac 225-DOTA-h11B6 JNJ-69086420 || Actinium Ac 225-DOTA-h11B6 JNJ-69086420 || Actinium-225-labeled Anti-kallikrein-2 h11B6 JNJ-69086420 || Actinium-225-labeled h11B6 JNJ-69086420 || JNJ 69086420 || JNJ-69086420 || JNJ69086420 || [225Ac]-DOTA-h11B6	A radioimmunoconjugate containing h11B6, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets human kallikrein-2 (hK2), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-DOTA-h11B6 JNJ-69086420, the monoclonal antibody moiety of JNJ-69086420 targets and binds to hK2, thereby delivering a cytotoxic dose of alpha radiation to hK2-expressing tumor cells. hK2 is overexpressed on a variety of cancer cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C158815	Actinium Ac 225-FPI-1434	225Ac-FPI-1434 || Actinium Ac 225-FPI-1397-FPI-1175 || Actinium Ac 225-FPI-1434 || Actinium Ac 225-FPI-1434 || Actinium Ac 225-labeled FPI-1434 || FPX 01 || FPX-01 || FPX01 || [225Ac]-FPI-1434 || [Ac-225]-FPI-1434	A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.	Pharmacologic Substance || Amino Acid, Peptide, or Protein
C153159	Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591	225Ac-J591 || Ac 225 MOAB J591 || Ac 225 Monoclonal Antibody J591 || Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591 || Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591 || Actinium Ac-225 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591	A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac-225 anti-PSMA monoclonal antibody J591 binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C95198	Actinomycin C2	ACTINOMYCIN C2 || Actinomycin C2 || Actinomycin D, 2a-D-Alloisoleucine-	A natural analogue of actinomycin, a chromopeptide antineoplastic antibiotic isolated from the bacterial genus Streptomyces. Actinomycin C2 inhibits DNA replication as well as RNA and protein synthesis by various mechanisms including, intercalating into the minor groove of DNA and interfering with the function of topoisomerase II. In addition, actinomycin C2 appears to block the interaction between the SH2 domain of growth factor receptor-bound protein-2 (GRB2) and the Src homology 2 domain containing transforming protein 1 adaptor protein SHC, which plays a key role in the Ras signaling pathway thereby halting cellular differentiation and proliferation.	Amino Acid, Peptide, or Protein || Antibiotic || Pharmacologic Substance
C99564	Actinomycin C3	2104-L-I || ACTINOMYCIN C3 || AY 3 || Actinomycin AY1 || Actinomycin C3 || Actinomycin I3 || Actinomycin VII || Aurathin-A3	A natural analogue of actinomycin, a chromopeptide antineoplastic antibiotic isolated from the bacterial genus Streptomyces. Actinomycin C3 inhibits DNA replication as well as RNA and protein synthesis by various mechanisms such as intercalating into the minor groove of DNA and interfering with the function of topoisomerase II.	Amino Acid, Peptide, or Protein || Antibiotic || Pharmacologic Substance
C2844	Actinomycin F1	ACTINOMYCIN F1 || Actinomycin F1 || Actinomycin KS4 || KS4	A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces chrysomallus.  Actinomycin F1 intercalates into the minor groove of DNA and binds to topoisomerase II, leading to the inhibition of DNA replication and RNA and protein synthesis. (NCI04)	Amino Acid, Peptide, or Protein || Antibiotic || Pharmacologic Substance
C111759	Activated Marrow Infiltrating Lymphocytes	Activated Marrow Infiltrating Lymphocytes || Activated Marrow Infiltrating Lymphocytes || aMIL	A preparation of cells, which consists of autologous marrow infiltrating lymphocytes (MILs), that are manipulated in vitro, with potential antitumor and immune stimulating activities. MILs are harvested from autologous bone marrow from multiple myeloma patients and, in vitro, are exposed to and activated by anti-CD3/anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads. After removal of the beads and expansion of the cells in culture, the activated MILs (aMILs) are re-introduced into the patient. The aMILs possess enhanced myeloma specificity, and are able to infiltrate the tumor microenvironment and initiate tumor cell lysis. CD3 and CD28, co-stimulatory molecules expressed on the surface of T-lymphocytes, play a key role in the activation of T-cells.	Pharmacologic Substance
C118625	Activin Type 2B Receptor Fc Fusion Protein STM 434	Activin Inhibitor STM 434 || Activin Type 2B Receptor Fc Fusion Protein STM 434 || Activin Type 2B Receptor Fc Fusion Protein STM 434 || STM 434 || STM-434	A soluble fusion protein containing the extracellular domain of the activin receptor type 2B (ACVR2B or ActRIIB) fused to a human Fc domain, with potential antineoplastic activity. Upon intravenous administration, STM 434 selectively binds to the growth factor activin A, thereby preventing its binding to and the activation of endogenous ActRIIB. This prevents activin A/ActRIIB-mediated signaling and inhibits the proliferation of activin A-overexpressing tumor cells. Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, is overexpressed in a variety of cancers and plays a key role in promoting cancer cell proliferation, migration, and survival.	Pharmacologic Substance
C151941	Acyclic Nucleoside Phosphonate Prodrug ABI-1968	ABI-1968 || ABI1968 || Acyclic Nucleoside Phosphonate Prodrug ABI-1968 || HTI 1968	A prodrug of an acyclic nucleoside phosphonate, with potential anti-viral and antineoplastic activities. Upon administration, acyclic nucleoside phosphonate prodrug ABI-1968 is taken up by viral-infected cells and converted to its active metabolite. The metabolite is incorporated into DNA chains by DNA polymerases, which results in the termination of DNA synthesis, inhibits viral replication and induces apoptosis and inhibits the proliferation of susceptible virally-infected tumor cells.	Pharmacologic Substance
C88261	Ad5.SSTR/TK.RGD	Ad5.SSTR/TK.RGD || Ad5.SSTR/TK.RGD || RGD-Modified Adenoviral Vector Encoding SSTR/TK	An RGD-4C-modified, infectivity-enhanced, bicistronic type 5 adenovirus expressing herpes simplex virus thymidine kinase (HSV-tk) gene, a therapeutic suicide gene, and the somatostatin receptor type 2 (SSTR2) gene with potential antineoplastic activity. Modification with the double cyclic peptide RGD-4C allows the virus to bind to cellular integrins, frequently expressed on the surfaces of ovarian cancer cells, instead of the coxsackie and adenovirus (CAR) receptor, which is often nonfunctional in ovarian cancer cells. Upon intratumoral administration, Ad5.SSTR/TK.RGD transfects tumor cells and expresses the HSV-tk gene. After subsequent administration of a synthetic acyclic guanosine analogue prodrug like ganciclovir (GCV), expressed HSV-tk phosphorylates and activates the prodrug, which may result in inhibition of DNA synthesis and apoptosis in HSV-tk-expressing cancer cells. Additionally, as a bystander effect, adjacent non-transfected cells may be killed by the activated antiviral drug. SSTR2 expression allows imaging of gene transfer into tumor cells using a radiolabeled somatostatin analogue.	Pharmacologic Substance
C79800	Ad5-CMV-NIS	Ad5-CMV-NIS || Ad5-CMV-NIS	A recombinant type 5 adenovirus (Ad5), encoding the gene for the human sodium-iodide symporter (NIS) linked to the cytomegalovirus (CMV) promoter, with potential gene transfection activity. Upon intratumoral injection, Ad5-CMV-NIS is taken up by tumor cells, resulting in the cellular expression of NIS. Subsequently, orally administered iodine 131 is taken up by NIS-expressing tumor cells, which may result in the selective accumulation of a cytotoxic dose of beta and gamma radiation in non-thyroidal tumor cells, sparing adjacent normal tissue. NIS, an intrinsic membrane glycoprotein, is an ion pump that actively transports iodide into cells which concentrate iodine; in addition to thyroid epithelial cells, it is found in non-thyroidal tissues including the salivary glands, the gastric mucosa, and lactating mammary glands.	Pharmacologic Substance || Virus
C73995	Ad5F35-LMP1/LMP2-Transduced Autologous Dendritic Cells	Ad5F35-LMP1/LMP2-Transduced Autologous Dendritic Cells	Autologous dendritic cells (DCs) transduced with the replication-deficient adenoviral vector Ad5F53 encoding the Epstein-Barr virus (EBV) transmembrane latent membrane proteins 1 and 2 (LMP1/LMP2) with potential immunostimulatory activity. Vaccination with Ad5F35-LMP1/LMP2-transduced autologous dendritic cells may stimulate a specific cytotoxic T-lymphocyte (CTL) response against LMP1- and LMP2-expressing tumor positive cells, resulting in tumor cell lysis and inhibition of tumor cell proliferation. LMP1 and LMP2 are expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkins disease.	Pharmacologic Substance
C94205	Ad5-SGE-REIC/Dkk-3 MTG-201	Ad5-SGE-REIC/Dkk-3 MTG-201 || Ad5-SGE-REIC/Dkk-3 MTG-201 || Ad5-SGE-REIC/Dkk3 || MTG 201 || MTG-201 || MTG201	A replication incompetent adenoviral vector type 5 (Ad5) encoding the tumor suppressor gene dickkopf-3 (DKK3; reduced expression in immortalized cells; REIC; Dickkopf WNT signaling pathway inhibitor 3), and containing the super gene expression (SGE) system, composed of the triple tandem enhancer sequences of human telomerase reverse transcriptase (hTERT), simian virus 40 (SV40) and cytomegalovirus (CMV), with potential immunostimulating and antineoplastic activities. Upon intratumoral (IT) injection and transfection of Ad5-SGE-REIC/Dkk-3 MTG-201, tumor cells express REIC/DKK3 protein. This may result in the activation of c-Jun-NH2-kinase (JNK) and ultimately lead to apoptosis via B-cell lymphoma-2 (Bcl2) suppression and caspase-3 activation. Increased expression of REIC/DKK3 in cancer cells may lead to an induction of tumor cell apoptosis and a reduction in tumor cell growth, while sparing normal, healthy cells expressing endogenous REIC/DKK3. In addition, the tumor cell killing promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response, thereby further killing any remaining REIC-deficient, untransfected tumor cells. The SGE system, also called C-TSC (CMV promoter driving the triple tandem enhancer sequences of hTERT, SV40 and CMV), enhances gene expression compared to more conventional adenoviral vectors. REIC/DKK3 is expressed by healthy cells, but expression is reduced or absent in many cancer cells due to REIC/DKK3 gene defects. As REIC/DKK3 plays a key role in tumor cell apoptosis, the absence of the REIC protein in tumor cells prevents tumor cell apoptosis.	Pharmacologic Substance || Virus
C128860	Ad5-survivin-transduced Autologous Dendritic Cell Vaccine	Ad5-survivin-transduced Autologous DC Vaccine || Ad5-survivin-transduced Autologous Dendritic Cell Vaccine || Ad5-survivin-transduced Autologous Dendritic Cell Vaccine || Autologous DC:AdmS || Autologous Dendritic Cell Adenovirus Type 5-Survivin Vaccine	A cell-based cancer vaccine containing autologous dendritic cells (DCs) that are transduced with a replication-deficient adenovirus type 5 vector (Ad5) encoding a mutated form of the tumor-associated antigen (TAA) survivin, with potential immunostimulatory and antineoplastic activities. Upon administration, Ad5-survivin-transduced autologous DC vaccine may elicit an immune response against cancer cells expressing survivin by activating cytotoxic T-cells (CTLs). This leads to an induction of cell death in survivin-positive tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and plays a key role in tumor cell growth and survival.	Cell || Pharmacologic Substance
C88330	Ad5-yCD/mutTK(SR39)rep-ADP	Ad5-yCD/mutTK(SR39)rep-ADP || Ad5-yCD/mutTK(SR39)rep-ADP	A second generation, replication-competent adenovirus type 5 containing a yeast cytosine deaminase(yCD)/mutant sr39 herpes simplex virus thymidine kinase fusion (yCD/mutTKsr39) gene and the 11.6 kDa adenovirus death protein (ADP) gene with potential oncolytic activity. Upon intratumoral administration and transduction of Ad5-yCD/mutTK(SR39)rep-ADP into tumor cells and subsequent expression of cytosine deaminase and viral thymidine kinase, administered prodrugs 5-fluorocytosine (5-FC) and ganciclovir are converted into their respective metabolites 5-fluorouracil (5-FU) and ganciclovir-5-monophosphate (ganciclovir-MP); 5-FU is subsequently metabolized to cytotoxic active metabolites 5-fluoroxyuridine monophosphate (F-UMP) and 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP); ganciclovir-TP subsequently is converted by mammalian thymidine kinase to cytotoxic ganciclovir-triphosphate (ganciclovir -TP). Tumor cells adjacent to tumor cells transduced with this agent may be killed through a 'bystander effect'. ADP may enhance spread and oncolytic activity of replication-competent adenoviruses. In addition to its oncolytic activity, Ad5-yCD/mutTK(SR39)rep-ADP may exhibit radiosensitizing activity.	Pharmacologic Substance
C123930	Ad5-yCD/mutTKSR39rep-hIL12	Ad5-yCD/mutTKSR39rep-hIL12 || Oncolytic Adenovirus Ad5-yCD/mutTKSR39rep-hIL12	A replication-competent oncolytic adenovirus encoding the murine pro-inflammatory cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, a yeast cytosine deaminase (yCD) and a mutant form of herpes simplex virus type 1 thymidine kinase (HSV-1 TKSR39), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of Ad5-yCD/mutTKSR39rep-hIL12, the adenovirus selectively infects and replicates in tumor cells, which results in direct tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL) responses against tumor cells, which may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. In addition, Ad5-yCD/mutTKSR39rep-hIL12-infected cancer cells express yCD and TKSR39; upon administration of the prodrugs 5-fluorocytosine (5-FC) and valganciclovir (vGCV), the yCD and HSV-1 TKSR39 activate these prodrugs to form 5-fluorouracil (5-FU) and ganciclovir, respectively. 5-FU gets converted to 5-fluoro-uridine monophosphate (5-FUMP) and subsequently to 5-fluoro-deoxyuridine monophosphate (5-FdUMP); 5-FdUMP irreversible inhibits thymidylate synthase, inhibits deoxythymidine triphosphate (dTTP) formation and halts DNA synthesis. Once phosphorylated intracellularly, ganciclovir triphosphate competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis.	Pharmacologic Substance
C99766	Adagloxad Simolenin	ADAGLOXAD SIMOLENIN || Adagloxad Simolenin || Adagloxad Simolenin || OBI 822 || OBI-822 || OBI822	A carbohydrate-based immunostimulant comprised of the Globo H hexasaccharide 1 (Globo H) epitope linked to the immunostimulant carrier protein keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Upon administration of adagloxad simolenin, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. Globo H is a tumor associated antigen (TAA) commonly found on a variety of tumor cells including breast cancer cells. KLH improves antigenic immune recognition and T-cell responses.	Pharmacologic Substance
C157493	Adagrasib	ADAGRASIB || Adagrasib || Adagrasib || KRAS G12C Inhibitor MRTX849 || MRTX 849 || MRTX-849 || MRTX849	An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	Pharmacologic Substance
C91725	Adavosertib	2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one || ADAVOSERTIB || AZD-1775 || AZD1775 || Adavosertib || Adavosertib || MK-1775 || MK1775	A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. Adavosertib selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53 deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53 deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect.	Pharmacologic Substance
C181900	AdC68 Expressing PSA/PSMA/PSCA Vaccine PF-06755992	AdC68 Expressing PSA/PSMA/PSCA Vaccine PF-06755992 || AdC68 Expressing PSA/PSMA/PSCA Vaccine PF-06755992 || Chimpanzee Adenovirus Serotype-68 Expressing PSA/PSMA/PSCA Priming Vaccine PF-06755992 || PF 06755992 || PF-06755992 || PF06755992	A prime cancer vaccine comprised of a genetically engineered, replication-deficient chimpanzee adenovirus serotype-68 (AdC68) encoding the tumor-associated antigens (TAAs) human prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA) and prostate stem cell antigen (PSCA), with potential immunostimulating and antineoplastic activities. Upon administration of AdC68 expressing PSA/PSMA/PSCA priming vaccine PF-06755992, the adenovirus infects and expresses PSA, PSMA and PSCA. The expressed proteins may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing PSA, PSMA and PSCA, thereby inducing tumor cell lysis. PSA, PSMA and PSCA are overexpressed on a variety of cancer cell types.	Pharmacologic Substance
C148535	Adebrelimab	ADEBRELIMAB || Adebrelimab || HTI-1088 || SHR-1316	An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Pharmacologic Substance
C82358	Adecatumumab	ADECATUMUMAB || Adecatumumab || Anti-EpCAM Monoclonal Antibody MT201 || MT201	A recombinant human IgG1 monoclonal antibody (MoAb) directed against the tumor associated antigen (TAA) epithelial cell adhesion molecule (EpCAM) with potential antitumor activity. Adecatumumab binds to EpCAM, which may result in antibody-dependent cellular cytotoxicity (ADCC) directed against EpCAM-expressing tumor cells. EpCAM (CD326), a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells; for some cancers, overexpression has been correlated with decreased survival.	Pharmacologic Substance
C175468	Adenosine A2A Receptor Antagonist CS3005	A2AR Antagonist CS3005 || Adenosine A2A Receptor Antagonist CS3005 || CS 3005 || CS-3005 || CS3005	An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist CS3005 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.	Pharmacologic Substance
C178569	Adenosine A2A Receptor Antagonist DZD2269	A2AR Antagonist DZD2269 || Adenosine A2A Receptor Antagonist DZD2269 || Adenosine A2A Receptor Antagonist DZD2269 || DZD 2269 || DZD-2269 || DZD2269	An immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist DZD2269 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.	Pharmacologic Substance
C187102	Adenosine A2A Receptor Antagonist ILB2109	A2AR Antagonist ILB2109 || Adenosine A2A Receptor Antagonist ILB2109 || ILB 2109 || ILB-2109 || ILB2109	An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon oral administration, A2AR antagonist ILB2109 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.	Pharmacologic Substance
C142374	Adenosine A2A Receptor Antagonist NIR178	A2AR Antagonist NIR178 || Adenosine A2A Receptor Antagonist NIR178 || Adenosine A2A Receptor Antagonist NIR178 || NIR 178	An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist NIR178 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.	Pharmacologic Substance
C181753	Adenosine A2A Receptor Antagonist TT-10	A2AR Inhibitor TT-10 || Adenosine A2A Receptor Antagonist TT-10 || TT 10 || TT-10 || TT10	An immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist TT-10 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.	Pharmacologic Substance
C157489	Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999	A2A/PDE-10A Inhibitor PBF-999 || Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999 || PBF 999 || PBF-999 || PBF-999 || PBF999	An orally bioavailable inhibitor of both the adenosine A2A receptor (A2AR; ADORA2A) and phosphodiesterase 10A (PDE-10A), with potential immunomodulating and antineoplastic activities. Upon administration, A2A/PDE-10A inhibitor PBF-999 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression. In addition, PBF-999 binds to and inhibits the activity of PDE-10A, thereby preventing the degradation of cyclic guanosine monophosphate (cGMP) and activates cGMP/cGMP-dependent protein kinase G (PKG) signaling. This induces beta-catenin degradation and thereby prevents the translocation of beta-catenin into the nucleus, and the beta-catenin-mediated induction of transcription of survival proteins, such as cyclin D1 and survivin. It also suppresses RAS/RAF/mitogen-activated protein kinase (MAPK) signaling. This induces apoptosis and inhibits the growth of tumor cells in which PDE-10A is overexpressed. PDE-10A is a cGMP-degrading PDE isozyme that is highly expressed in the brain and overexpressed in certain types of tumor cells. Elevation of intracellular cGMP is known to inhibit tumor proliferation and induce apoptosis. cGMP levels are low in cancer cells resulting from the overexpression PDE-10A.	Pharmacologic Substance
C148435	Adenosine A2B Receptor Antagonist PBF-1129	A2BR Antagonist PBF-1129 || Adenosine A2B Receptor Antagonist PBF-1129 || Adenosine A2B Receptor Antagonist PBF-1129 || PBF 1129 || PBF-1129 || PBF1129	An orally bioavailable antagonist of the immunomodulatory checkpoint molecule adenosine A2B receptor (A2BR; ADORA2B), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, A2BR antagonist PBF-1129 competes with adenosine for binding to A2BR expressed on various cancer cell types and numerous immune cells, such as dendritic cells (DCs), mast cells, macrophages and lymphocytes. This inhibits A2BR activity and prevents adenosine/A2BR-mediated signaling. The inhibition of A2BR in cancer cells prevents activation of downstream oncogenic pathways, which leads to an inhibition of cell proliferation and metastasis. A2BR inhibition also prevents the release of various growth factors, cytokines and chemokines, such as vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin-2 (Ang2) from immune cells, which may abrogate the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activate the immune system to exert anti-tumor immune responses against cancer cells leading to tumor cell killing. In addition, under non-cancerous inflammatory conditions, inhibition of A2BR leads to reduced activation and proliferation of various immune cells, which results in decreased pro-inflammatory cytokine production and may prevent inflammation. A2BR, a G protein-coupled signaling receptor, is expressed on the cell surfaces of numerous immune cells and is often overexpressed on a variety of cancer cell types; it plays a key role in their proliferation, progression and metastasis. Adenosine is overproduced under inflammatory conditions and plays a key role in pro-inflammatory actions. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation. The pro- and anti-inflammatory effects of adenosine and A2BR are cell type-specific and dependent on the extracellular microenvironment.	Pharmacologic Substance
C181756	Adenosine A2B Receptor Antagonist TT-4	A2BR Inhibitor TT-4 || Adenosine A2B Receptor Antagonist TT-4 || TT 4 || TT-4 || TT4	An orally bioavailable antagonist of the immunomodulatory checkpoint molecule adenosine A2B receptor (A2BR; ADORA2B), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon oral administration, A2BR antagonist TT-4 competes with adenosine for binding to A2BR expressed on various cancer cell types and numerous immune cells, such as dendritic cells (DCs), mast cells, macrophages and lymphocytes. This inhibits A2BR activity and prevents adenosine/A2BR-mediated signaling. The inhibition of A2BR in cancer cells prevents activation of downstream oncogenic pathways, which leads to an inhibition of cell proliferation and metastasis. A2BR inhibition also prevents the release of various growth factors, cytokines and chemokines, such as vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin-2 (Ang2) from immune cells, which may abrogate the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activate the immune system to exert anti-tumor immune responses against cancer cells leading to tumor cell killing. In addition, under non-cancerous inflammatory conditions, inhibition of A2BR leads to reduced activation and proliferation of various immune cells, which results in decreased pro-inflammatory cytokine production and may prevent inflammation. A2BR, a G protein-coupled signaling receptor, is expressed on the cell surfaces of numerous immune cells and is often overexpressed on a variety of cancer cell types; it plays a key role in their proliferation, progression and metastasis. Adenosine is overproduced under inflammatory conditions and plays a key role in pro-inflammatory actions. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation. The pro- and anti-inflammatory effects of adenosine and A2BR are cell type-specific and dependent on the extracellular microenvironment.	Pharmacologic Substance
C187108	Adenosine A2B Receptor Antagonist TT-702	A2B Receptor Antagonist TT-702 || A2BR Antagonist TT-702 || Adenosine A2B Receptor Antagonist TT-702 || TT 702 || TT-702 || TT702	An orally bioavailable prodrug and selective antagonist of the immunomodulatory checkpoint molecule adenosine A2B receptor (A2BR; ADORA2B), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon oral administration, A2BR antagonist TT-702 is converted to its active metabolite TT-478. TT-478 selectively binds to and blocks A2BR expressed on various cancer cell types and numerous immune cells, such as dendritic cells (DCs), mast cells, macrophages and lymphocytes. This prevents the binding of adenosine to A2BR, inhibits A2BR activity and prevents adenosine/A2BR-mediated signaling. This abrogates adenosine/A2BR-mediated immunosuppression, activates immune stimulatory cell, such as DCs and cytotoxic T-lymphocytes (CTLs), and reduces immunosuppressive cells myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). This suppresses cancer cell growth, which leads to an inhibition of cell proliferation and metastasis. A2BR inhibition also prevents the release of various growth factors, cytokines and chemokines, which may further abrogate the adenosine-mediated immunosuppression in the tumor microenvironment (TME). This further activates the immune system to exert anti-tumor immune responses against tumor cells leading to tumor cell killing. In addition, under non-cancerous inflammatory conditions, inhibition of A2BR leads to reduced activation and proliferation of various immune cells, which results in decreased pro-inflammatory cytokine production and may prevent inflammation. A2BR, a G protein-coupled signaling receptor, is expressed on the cell surfaces of numerous immune cells and is often overexpressed on a variety of cancer cell types, especially under hypoxic conditions; it plays a key role in their proliferation, progression and metastasis. Adenosine is overproduced under inflammatory conditions and plays a key role in pro-inflammatory actions. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation. The pro- and anti-inflammatory effects of adenosine and A2BR are cell type-specific and dependent on the extracellular microenvironment.	Pharmacologic Substance
C186671	Adenosine Receptor A2A/A2B Antagonist M1069	A2A/A2B Adenosine Receptor Antagonist M1069 || A2AR/A2BR Antagonist M1069 || Adenosine Receptor A2A/A2B Antagonist M1069 || Dual Adenosine Receptor Antagonist M1069 || M 1069 || M-1069 || M1069	An orally bioavailable antagonist of both the immunomodulatory checkpoint molecules adenosine A2A receptor (A2AR; ADORA2A) and A2B receptor (A2BR; ADORA2B), with potential immunomodulating and antineoplastic activities. Upon oral administration, adenosine A2A/A2B receptor antagonist M1069 competes with tumor-released adenosine for binding to A2AR and A2BR expressed on numerous intratumoral immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages and T-lymphocytes. The binding of M1069 to A2AR and A2BR inhibits A2AR/A2BR activity and prevents adenosine-A2AR/A2BR-mediated signaling. A2AR/A2BR inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing. A2AR and A2BR, G protein-coupled signaling receptors, are expressed on the cell surfaces of numerous immune cells. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation.	Pharmacologic Substance
C48368	Adenovector Encoding MDA7	Ad-MDA-7 || Adenovector Encoding MDA7 || INGN241	A nonreplicating adenoviral vector (adenovector) encoding the melanoma differentiation-associated 7 gene (MDA7) with potential antineoplastic activity. After intratumoral injection and adenovector-mediated gene transfer of MDA7 into tumor cells, the expressed MDA7 transgene may inhibit tumor cell proliferation and induce tumor cell apoptosis.	Pharmacologic Substance
C106242	Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201	Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201 || Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201 || Adenovector-transduced AP1903-inducible iMC-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201 || BPX-201	A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling.	Cell || Pharmacologic Substance
C143034	Adenoviral Brachyury Vaccine ETBX-051	Adenoviral Brachyury Vaccine ETBX-051 || Adenoviral Brachyury Vaccine ETBX-051 || ETBX 051 || ETBX-051 || ETBX-051	A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.	Immunologic Factor || Pharmacologic Substance
C156015	Adenoviral Cancer Vaccine PF-06936308	Adenoviral Cancer Vaccine PF-06936308 || Adenoviral Cancer Vaccine PF-06936308 || PF 06936308 || PF-06936308 || PF06936308	A cancer vaccine composed of a replication-defective E1-deleted adenovirus vector based on chimpanzee adenovirus serotype 68 (AdC68) expressing three not yet disclosed tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral cancer vaccine PF-06936308, the adenovirus infects cells and expresses the TAAs. In turn, the TAAs activate the immune system to produce a cytotoxic T-lymphocyte (CTL) response against cells expressing the TAAs.	Pharmacologic Substance
C143035	Adenoviral MUC1 Vaccine ETBX-061	Adenoviral MUC1 Vaccine ETBX-061 || Adenoviral MUC1 Vaccine ETBX-061 || ETBX 061 || ETBX-061 || ETBX-061	A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.	Immunologic Factor || Pharmacologic Substance
C101789	Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001	Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001 || Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001 || DC-RTS-IL-12 || INXN-3001/1001	Autologous dendritic cells tranduced with a replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-3001) in combination with the proprietary orally bioavailable, small molecule activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer INXN-1001. Upon intratumoral injection of INXN-3001 and subsequent oral administration of activator ligand, INXN-1001 is able to induce expression of IL-12 in INXN-3001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells, inducing the secretion of interferon-gamma and inducing a cytotoxic T lymphocyte response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. As INXN-1001 regulates both the timing and the levels of IL-12 expression, IL-12 toxicity can be reduced.	Pharmacologic Substance
C162805	Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP	Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP || Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP || GAd-209-FSP || GAd20-209-FSP || Great Ape Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP	An off-the-shelf neoantigen priming vaccine comprised of a great ape adenovirus (GAd) encoding tumor-specific neoantigens (TSNAs) derived from as of yet undisclosed frameshift peptides (FSPs) with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA priming vaccine GAd-209-FSP is followed by boosting with a vaccine that encodes the same target TSNAs.	Immunologic Factor || Pharmacologic Substance
C156925	Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901	Adenoviral TSNA Priming Vaccine GRT-C901 || Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901 || Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901 || GRT C901 || GRT-C901 || GRTC901 || Priming Cancer Vaccine GRT-C901	A personalized cancer vaccine comprised of a chimpanzee adenovirus vector (ChAdV) encoding twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral-TSNA priming vaccine GRT-C901, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA vaccine GRT-C901 is followed by monthly boosting with a self-amplifying mRNA (SAM) boosting vaccine that encodes the same 20 target TSNAs. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.	Immunologic Factor || Pharmacologic Substance
C91373	Adenoviral Vector Ad5-CEA(6D) Vaccine	Ad5 CEA Vaccine || Adenoviral Vector Ad5-CEA(6D) Vaccine || Adenoviral Vector Ad5-CEA(6D) Vaccine || ETBX-011 || ETBX-011	A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses.	Pharmacologic Substance || Virus
C162634	Adenoviral Vector Encoding VEGF-C LX-1101	AdAptVEGF-C Adenoviral Vector LX-1101 || Adenoviral Vector Encoding VEGF-C LX-1101 || LX 1101 || LX-1101 || LX1101 || Lymfactin || VEGFC-expressing Gene Therapeutic LX-1101	A genetically engineered, replication-deficient adenovirus carrying the gene encoding for the human vascular endothelial growth factor C (VEGFC; VEGF-C; Flt4 ligand), with potential pro-angiogenic activity. Upon perinodal administration of the AdAptVEGF-C adenoviral vector LX-1101, the adenovirus infects cells and promotes expression of VEGF-C. In turn, VEGF-C induces vascular and lymphatic endothelial cell proliferation locally, and may help re-grow the lymphatic system and improve symptoms associated with lymphedema (LE). VEGF-C, a lymphatic growth factor, plays a key role in (lymph)angiogenesis and the functioning of the lymphatic system.	Pharmacologic Substance
C173640	Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE	Ad5.F35-hGCC-PADRE || Ad5/F35-hGCC-PADRE || Adenovirus 5/F35-HGCC-PADRE || Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE || Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE	A recombinant adenoviral serotype 5 (Ad5) in which the Ad5-based vector fiber is replaced by the fiber from the human B adenovirus serotype 35 (F35), encoding for the human guanylyl cyclase C (hGCC), and fused to the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration of the Ad5/F35-hGCC-PADRE, the Ad5/F35 targets CD46, which is expressed widely on most tumor cells, and the virus is taken up by cells. Once inside the cells, the virus expresses hGCC. The expressed hGCC induces both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated killing of tumor cells. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response. The inclusion of the chimeric Ad5/F35 fiber increases viral uptake in cells through CD46.	Pharmacologic Substance
C112005	Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine	Ad5-hGCC-PADRE Vaccine || Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine || Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine	A replication-defective, recombinant adenoviral serotype 5 (Ad5) encoding human guanylyl cyclase C (hGCC) and the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the Ad5-hGCC-PADRE vaccine expresses hGCC, which may induce both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response.	Pharmacologic Substance
C2204	Adenovirus B7-1	Adenovirus B7-1	A gene-viral vector complex comprised of an adenovirus vector and B7-1 gene targeting the CD80 antigen.  Adenovirus B7-1 is used as a component in antineoplastic vaccines to elicit a cytotoxic T-cell response. (NCI04)	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C62527	Adenovirus Encoding Rat HER-2/neu	Adenovirus Encoding Rat HER-2/neu	A replication-defective oncolytic adenovirus, encoding rat Her-2/neu (ErbB-2), with potential antineoplastic activity. Upon administration, adenovirus encoding rat HER-2/neu may induce an immune response against tumor cells expressing the HER-2/neu antigen, which may result in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. Her-2/neu, a tumor-associated antigen and member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types.	Pharmacologic Substance
C61492	Adenovirus Encoding Recombinant Human Endostatin	Ad-rhENDO || Adenovirus Encoding Recombinant Human Endostatin || Adenovirus Encoding Recombinant Human Endostatin || E10A	A replication-defective, recombinant oncolytic adenovirus encoding human endostatin with potential antineoplastic activity. Endostatin, a 20 kDa C-terminal proteolytic fragment of collagen XVIII, is an important angiogenesis inhibitor. Upon intratumoral administration, the adenovirus infects and replicates in tumor cells. The expressed endostatin may inhibit endothelial cell proliferation and angiogenesis which may result in a reduction of tumor growth.	Pharmacologic Substance
C102753	Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine	AdVTMM2-transduced Dendritic Cell Vaccine || Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine || Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy.	Pharmacologic Substance
C157777	Adenovirus Expressing Mutant HPV E6/E7	Ad-E6/E7 || Ad-E6E7 || Adenoviral-HPV E6E7 Vaccine || Adenoviral-expressing Mutant HPV E6/E7 || Adenovirus Expressing Mutant HPV E6/E7 || Adenovirus Expressing Mutant HPV E6/E7 || Adenovirus Vaccine Expressing Mutant HPV E6 and E7	A cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of adenovirus expressing mutant HPV E6/E7, the adenovirus infects and expresses the E6 and E7 proteins. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.	Pharmacologic Substance
C61098	Adenovirus HER2-Transduced Autologous Dendritic Cell Vaccine	AdHer2/DC || Adenovirus HER2-Transduced Autologous Dendritic Cell Vaccine || Adenovirus HER2-Transduced Autologous Dendritic Cell Vaccine || Autologous Dendritic Cell-Adenovirus HER2 Vaccine || HER-2 pulsed DC vaccine || autologous dendritic cell/adenovirus HER-2 vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a replication-deficient adenovirus vector encoding HER-2 with potential antineoplastic activity. Upon administration, adenovirus HER2-transduced autologous dendritic cell vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by some breast, ovarian, and gastric cancers.	Immunologic Factor || Pharmacologic Substance
C167360	Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918	Ad26-expressing HPV16 Vaccine JNJ-63682918 || Ad26.HPV16 JNJ-63682918 || Adenovirus Serotype 26-Human Papillomavirus 16 JNJ-63682918 || Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918 || Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918 || JNJ 63682918 || JNJ-63682918 || JNJ63682918 || Monovalent HPV16 Ad26-vectored Vaccine JNJ-63682918	A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 16 (HPV16), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV16 vaccine JNJ-63682918, the adenovirus infects and expresses HPV16. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 antigens, thereby inducing tumor cell lysis. HPV16 infection plays a key role in the development of a variety of cancers.	Immunologic Factor || Pharmacologic Substance
C167361	Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931	Ad26-expressing HPV18 Vaccine JNJ-63682931 || Ad26.HPV18 JNJ-63682931 || Adenovirus Serotype 26-Human Papillomavirus 18 JNJ-63682931 || Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931 || Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931 || JNJ 63682931 || JNJ-63682931 || JNJ63682931 || Monovalent HPV18 Ad26-vectored Vaccine JNJ-63682931	A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV18 vaccine JNJ-63682931, the adenovirus infects and expresses HPV18. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV18 antigens, thereby inducing tumor cell lysis. HPV18 infection plays a key role in the development of a variety of cancers.	Immunologic Factor || Pharmacologic Substance
C96221	Adenovirus-Encoding E.coli PNP	Ad/PNP || Adenovirus Encoding Purine Nucleoside Phosphorylase || Adenovirus-Encoding E.coli PNP || Adenovirus-Encoding E.coli PNP	A replication-incompetent adenovirus encoding E. coli purine nucleoside phosphorylase (Ad/PNP) used as a prodrug activating agent. Administered intratumorally, Ad/PNP expresses the enzyme PNP, which may catalyze systematically administrated fludarabine phosphate prodrug into its active form 2-fluoroadenine (F-Ade). F-Ade inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. Localized prodrug activation provides targeted chemotherapy, thereby potentially reducing systemic side effects.	Pharmacologic Substance
C131825	Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3	Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3 || M-VM3 || Mobilan	A nanoparticle-based formulation containing a recombinant non-replicating adenovirus (Ad) encoding toll-like receptor 5 (TLR5) and its specific ligand protein 502S, with potential antineoplastic and immunomodulating activities. Upon administration, the Ad preferentially and specifically infects cells expressing the Coxsackievirus and adenovirus receptor (CAR), which is highly expressed in certain human tumors, and expresses both TLR5 and a specific agonistic ligand in the same cell. 502S binds to and activates TLR5, thereby allowing for continuous TLR5 signaling. This stimulates dendritic cells (DCs), monocytes, macrophages and the nuclear factor-kappa B (NF-kappaB) signaling cascade. This activation results in the production of pro-inflammatory cytokines, including interferon alpha, tumor necrosis factor-alpha and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and activate a cytotoxic T-lymphocyte (CTL) response against tumor associated antigens (TAAs). TLR5, a member of the TLR family, plays a key role in the activation of innate immunity.	Pharmacologic Substance
C37515	Adenovirus-mediated Human Interleukin-12	Ad.hIL-12 || Adenovirus-interleukin-12 || Adenovirus-mediated Human Interleukin-12	A replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (Ad.hIL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.	Therapeutic or Preventive Procedure
C97959	Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001	Ad-RTS-IL-12 Plus AL || Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001 || Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001 || INXN-2001/1001 || ZIN ATI-001	A replication incompetent adenovirus encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-2001) in combination with the proprietary activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer. Upon intratumoral administration of INXN-2001 and oral administration of INXN-1001, INXN-1001 is able to induce expression of IL-12 from INXN-2001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.	Pharmacologic Substance
C90542	Adenovirus-p53 Transduced Dendritic Cell Vaccine	Adenovirus-p53 Transduced Dendritic Cell Vaccine || Adenovirus-p53 Transduced Dendritic Cell Vaccine || Dendritic Cell-P53	A cancer vaccine consisting of autologous dendritic cells (DCs) transduced with a recombinant adenovirus encoding p53 peptide, with potential immunomodulating activity. Intradermal vaccination with adenoviral-p53 transduced dendritic cell vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.	Immunologic Factor || Pharmacologic Substance
C102541	Adenovirus-PSA Prostate Cancer Vaccine	Ad/PSA Vaccine || Adenovirus-PSA Prostate Cancer Vaccine || Adenovirus-PSA Prostate Cancer Vaccine || Adenovirus/PSA Vaccine	A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer.	Pharmacologic Substance
C76115	Aderbasib	5-Azaspiro(2.5)octane-5-carboxylic Acid, 7-((Hydroxyamino)carbonyl)-6-((4-phenyl-1-piperazinyl)carbonyl)-, Methyl Ester, (6S,7S)- || ADERBASIB || Aderbasib || Aderbasib || INCB007839 || INCB7839 || Methyl (6S,7S)-7-(Hhydroxyamino)carbonyl)-6-((4-phenylpiperazin-1-yl)carbonyl)-5-azaspiro(2.5)octane-5-carboxylate	An orally bioavailable inhibitor of the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins with potential antineoplastic activity. Aderbasib represses the metalloproteinase 'sheddase' activities of ADAM10 and ADAM17, which may result in the inhibition of tumor cell proliferation. The metalloproteinase domains of ADAMs cleave cell surface proteins at extracellular sites proximal to the cell membrane, releasing or ""shedding"" soluble protein etcodomains from the cell surface; the disintegrin domains of these multifunctional proteins interact with various components of the extracellular matrix (ECM). ADAM10 processes particular epithelial growth factor receptor (EGFR) ligands and appears to regulate Notch signaling through the cleavage of Notch and its related ligand delta-like ligand-1 (Dll-1). ADAM17 (also known as Tumor necrosis factor-Converting Enzyme or TACE) is involved in processing tumor necrosis factor (TNF) from its membrane bound precursor to its soluble circulating form and in processing ligands for the epidermal growth factor receptor (EGFR) family.	Pharmacologic Substance
C105809	AdGMCAIX-transduced Autologous Dendritic Cells	AdGMCAIX-transduced Autologous Dendritic Cells || AdGMCAIX-transduced Autologous Dendritic Cells || DC-AdGMCAIX || DCs expressing CMCA9 Gene	Autologous dendritic cells (DCs) transduced with a recombinant, replication-defective adenoviral vector expressing the fusion gene granulocyte-macrophage colony-stimulating factor (GM-CSF) and carbonic anhydrase IX (CA-IX or CA9) (GMCA-9), with potential immunomodulating activity. The autologous DCs are transduced ex vivo and express the GMCA-9 fusion protein on the cell surface. Upon intradermal administration of the AdGMCAIX-transduced autologous DCs back into the patient, the DCs activate the immune system to both mount a cytotoxic T lymphocyte-mediated response against tumor cells positive for the CA9 antigen, and generate memory T cells. This may result in decreased tumor growth. CA9, also known as G250, is a renal cell carcinoma (RCC)-associated antigen and a member of the carbonic anhydrase family that contains a human leukocyte antigen (HLA)-A2.1-restricted epitope; it is found in a majority of renal cell carcinomas while absent in most normal tissues. The cytokine GM-CSF enhances the immunogenicity of CA9-based DC vaccines.	Pharmacologic Substance
C53399	ADH-1	ADH-1 || ADH-1 || ADH-1 || Exherin	A small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell-cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels.	Organic Chemical || Pharmacologic Substance
C105813	Ad-hCMV-Flt3L	Ad-hCMV-Flt3L || Ad-hCMV-Flt3L	A human serotype 5, replication-defective, first generation adenoviral vector, with the viral E1a and E3 protein encoding regions deleted, which is engineered to express the soluble, immune-mediated stimulatory gene human fms-like tyrosine kinase 3 ligand (Flt3L), under the transcriptional control of the CMV promoter, with potential immunostimulating activity. Upon administration, Ad-hCMV-Flt3L is transduced into tumor cells and Flt3L is expressed. Flt3L stimulates both the proliferation of dendritic cells (DCs) and their migration to the tumor site. Upon exposure to the tumor-associated antigens (TAA) released from dying glioma cells, which were killed by thymidine kinase-mediated valacyclovir-induced tumor cell death, the DCs initiate a specific immune response against any remaining TAA-expressing tumor cells. Flt3L is a hematopoietic growth factor and ligand for the Flt3 tyrosine kinase receptor.	Pharmacologic Substance
C105811	Ad-hCMV-TK	Ad-hCMV-TK || Ad-hCMV-TK	A human serotype 5, replication-defective, first generation adenoviral vector, with the viral E1a and E3 protein encoding regions deleted, which is engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene under the transcriptional control of the CMV promoter. This agent, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Upon administration into the peritumoral region after tumor resection, adenoviral vector encoding HSV thymidine kinase is transduced into tumor cells, and HSV-tk is expressed. Tumor cells expressing HSV-tk are sensitive to synthetic acyclic guanosine analogues. Subsequent administration of a synthetic acyclic guanosine analogue, such as valacyclovir (VCV) or ganciclovir (GCV), kills the tumor cells expressing HSV-tk. The release of tumor-associated antigens (TAA) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response, directed aganst any remaining tumor cells.	Pharmacologic Substance
C127154	Ad-ISF35	Ad-CD154 ISF35 || Ad-CD40L ISF35 || Ad-ISF35	A replication-defective adenovirus vector (Ad-ISF35), which encodes a membrane-stabilized, chimeric human-mouse CD40 binding protein (CD40 ligand; CD40L; CD154), with potential immunomodulatory and antineoplastic activities. Upon intratumoral administration, Ad-ISF135 preferentially transduces tumor cells and immunoregulatory cells in the tumor microenvironment. This increases the expression of CD154 in tumor cells, activates CD40 and stimulates signaling and immunoactivation, which are both mediated by CD40. This increases the expression of co-stimulatory molecules on these cells, which enhances their ability to function as antigen presenting cells (APCs) and increases their apoptotic potential. This leads to an increase in the infiltration of macrophages and neutrophils, which promote direct cytotoxicity, enhances the production of pro-inflammatory cytokines in the tumor microenvironment, and induces a specific cytotoxic T-lymphocyte (CTL) response against the tumor cells. In addition, transduction with Ad-ISF35 induces direct tumor cell death, probably through an anti-viral immune response. Ad-ISF35 also exerts a strong bystander effect in non-transduced cells thereby further inducing tumor cell death. Altogether, this will eradicate tumor cells. CD154, the main ligand for CD40, plays a key role in the activation of APCs, promotes immunoactivation, and increases apoptotic potential. The protein encoded by Ad-ISF35 does not contain the mouse antibody binding domains and does not induce human neutralizing antibodies. The metalloprotease cleavage site is deleted in this chimeric CD154 and thus it resists cleavage; the encoded protein also contains amino acid substitutions within the carboxy-terminal. Both sets of engineered mutations promote cell surface expression.	Amino Acid, Peptide, or Protein || Immunologic Factor
C143953	Ad-RTS-hIL-12	Ad-RTS-hIL-12 || Ad-RTS-hIL-12 || Adenoviral- RheoSwitch Therapeutic System-Human Interleukin 12 || INXN 2001 || INXN-2001	An inducible adenoviral vector encoding human pro-inflammatory cytokine interleukin-12 (IL-12; IL12), which is under the transcriptional control of the RheoSwitch Therapeutic System (RTS) (Ad-RTS-hIL-12), with potential immunomodulating and antineoplastic activities. RTS consists of two fusion proteins: Gal4-EcR, which contains a modified ecdysone receptor (EcR) fused with the DNA binding domain of the yeast Gal4 transcription factor, and VP16-RXR, which contains a chimeric retinoid X receptor (RXR) fused with the transcription activation domain of the viral protein VP16 of herpes simplex virus type 1 (HSV1). Upon intratumoral administration of Ad-RTS-hIL-12, given in combination with the proprietary, diacylhydrazine-based activator ligand veledimex (INXN-1001), veledimex binds specifically to the EcR part of the RTS and stabilizes heterodimerization between the two fusion proteins, forming an active transcription factor, which induces the transcription of IL-12 under the control of an inducible promoter containing Gal4-binding sites. The expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL)-mediated responses against tumor cells, which may result in immune-mediated tumor cell lysis and inhibition of tumor cell proliferation. In the presence of veledimex, the protein heterodimer changes to a stable conformation and can bind to the inducible promoter, while without veledimex the two fusion proteins form unstable heterodimers; this allows the controlled, regulated intratumoral expression of the IL-12 gene.	Pharmacologic Substance
C64785	AdRTVP-1-Transduced Prostate Cancer Cell-Based Vaccine	AdRTVP-1-Transduced Prostate Cancer Cell-Based Vaccine || AdRTVP-1-Transduced Prostate Cancer Cell-Based Vaccine || Adenoviral Vector-Mediated RTVP-1 Gene-modified Prostate Cancer Cell-based Vaccine	A cell-based vaccine comprised of prostate cancer cells transduced with an adenoviral vector encoding human RTVP-1 (AdRTVP-1), with potential antineoplastic and immunostimulating activities. RTVP-1, also referred to as glioma pathogenesis-related protein 1 (GLIP1), is down-regulated in prostate tumors. Regulated by tumor suppressor p53, the expression of RTVP-1 functions as a tumor suppressor, and is abundant in normal human prostate epithelial cells as well as in differentiated macrophages. Administration of this vaccine leads to an induction of apoptosis through the expression of RTVP-1 and results in a reduction in cellular proliferation in prostate cancer cells. In addition, this cancer-cell based vaccine may induce a cytotoxic T lymphocyte (CTL) response against prostate specific tumor associated antigens, resulting in an immune-mediated prostate cancer cell death. Furthermore, RTVP-1 stimulates CTL and natural killer (NK) cell activities.	Immunologic Factor || Pharmacologic Substance
C77910	Ad-sig-hMUC-1/ecdCD40L Vaccine	Ad-sig-hMUC-1/ecdCD40L Adenoviral Vector Vaccine || Ad-sig-hMUC-1/ecdCD40L Vaccine	A cancer vaccine consisting of a recombinant adenoviral vector encoding the tumor-associated antigen (TAA) human MUC-1 (hMUC-1) linked to the extracellular domain (ecd) of the co-stimulatory molecule CD40 ligand (CD40L) and an adenovirus signal sequence that encodes a secretory signal peptide (Ad-sig) with potential immunostimulating and antineoplastic activities. Due to the presence of the secretory signal peptide expressed by Ad-sig in the vaccine construct, transfected cells may secrete a fusion protein composed of hMUC-1 and the CD40L ecd. The CD40L moiety part of the fusion protein binds to CD40 receptors on dendritic cells (DCs). Subsequently, DCs may be activated and migrate, T-cells may expand, and a cytotoxic T lymphocyte (CTL) response against tumor cells that overexpress hMUC-1 may follow. MUC-1 is a hypoglycosylated TAA overexpressed by epithelial cancer cells.	Amino Acid, Peptide, or Protein || Immunologic Factor
C91719	AE37 Peptide/GM-CSF Vaccine	AE-37 Peptide/GM-CSF Vaccine || AE37 Peptide/GM-CSF Vaccine || AE37 Peptide/GM-CSF Vaccine	A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.	Immunologic Factor || Pharmacologic Substance
C153133	Aerosol Gemcitabine	Aerosol Gemcitabine || Aerosol Gemcitabine || Aerosolized GCB || Aerosolized Gemcitabine	An aerosol inhalation formulation containing gemcitabine (GCB), a broad-spectrum antimetabolite and deoxycytidine analogue, with potential antineoplastic activity. Upon inhalation via a nebulizer, GCB is converted intracellularly by deoxycytidine kinase to its active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase (RNR), thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in DNA strand termination and the induction of apoptosis of lung tumor cells. GCB administration directly into the lungs via aerosol yields higher concentrations of GCB locally than can be achieved by systemic GCB administration, potentially reducing systemic toxicity.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C101794	Aerosolized Aldesleukin	Aerosolized Aldesleukin || Aerosolized Aldesleukin || Aerosolized Recombinant IL-2	An aerosol formulation of aldesleukin, a recombinant form of interleukin-2 (IL-2), with potential immunostimulating activity. Upon IL-2 inhalation, this cytokine activates lymphokine-activated killer cells and natural killer cells, and induces expression of cytotoxic cytokines, such as interferon-gamma and transforming growth factor-beta. This may eventually halt tumor cell growth. Localized administration of IL-2 may decrease toxicity and increase efficacy.	Amino Acid, Peptide, or Protein || Immunologic Factor
C61071	Aerosolized Liposomal Rubitecan	Aerosolized Liposomal Rubitecan || Aerosolized liposomal 9-nitro-20(S)-camptothecin	An aerosolized liposomal preparation of rubitecan, a water-insoluble derivative of camptothecin with potential antineoplastic activity. Rubitecan (or 9-nitro-20 (S)-camptothecin) and its active metabolite 9-aminocamptothecin (9-AC) selectively stabilize topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. This agent is formulated with dilauroylphosphatidylcholine and nebulized in particle sizes of 1.2-1.6 micrometer mass median aerodynamic diameter.	Pharmacologic Substance
C66940	Afatinib	(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide || AFATINIB || Afatinib || Afatinib || BIBW 2992 || BIBW2992	An orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.	Pharmacologic Substance
C97273	Afatinib Dimaleate	(2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate) || 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-,(2E)-, (2Z)-2-Butenedioate (1:2) || AFATINIB DIMALEATE || Afatinib Dimaleate || Afatinib Dimaleate || BIBW 2992MA2 || BIBW2992 MA2 || Gilotrif	The dimaleate salt form of afatinib, an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity. Upon administration, afatinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4), and certain EGFR mutants, including those caused by EGFR exon 19 deletion mutations or exon 21 (L858R) mutations. This may result in the inhibition of tumor growth and angiogenesis in tumor cells overexpressing these RTKs. Additionally, afatinib inhibits the EGFR T790M gatekeeper mutation which is resistant to treatment with first-generation EGFR inhibitors. EGFR, HER2 and HER4 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.	Pharmacologic Substance
C1886	Afeletecan Hydrochloride	AFELETECAN HYDROCHLORIDE || Afeletecan Hydrochloride || BAY 38-3441 || BAY 56-3722 || BAY 56-3722 || BAY56-3722 || Camptothecin Glycoconjugate BAY 38-3441	The hydrochloride salt form of afeletecan, a water-soluble camptothecin derivative conjugated to a carbohydrate moiety exhibiting antineoplastic activity. Afeletecan stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. The peptide carbohydrate moiety of this agent stabilizes the lactone form of camptothecin in blood.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C975	Afimoxifene	4-(1-(4-(2-(Dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol || 4-Hydroxy-Tamoxifen || 4-Hydroxytamoxifen || 4-Hydroxytamoxifen || 4-OHT || 4-hydroxytamoxifen || AFIMOXIFENE || Afimoxifene || Afimoxifene	A tamoxifen metabolite with both estrogenic and anti-estrogenic effects.  Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.	Organic Chemical || Pharmacologic Substance
C2512	AFP Gene Hepatocellular Carcinoma Vaccine	AFP Gene Hepatocellular Carcinoma Vaccine || vaccine, AFP gene hepatocellular carcinoma	A cancer vaccine composed of naked plasmid DNA of the gene for the tumor-associated antigen alpha-fetoprotein (AFP), a macromolecule that acts as a specific immunologic target for hepatocellular carcinoma. This agent exerts an antitumor effect by inducing cytotoxic T-lymphocytes to attack AFP-expressing tumor cells. (NCI04)	Immunologic Factor || Pharmacologic Substance
C82390	Afuresertib	2-Thiophenecarboxamide, N-((1S)-2-amino-1-((3-fluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)- || AFURESERTIB || Afuresertib || Afuresertib || GSK2110183	An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.	Pharmacologic Substance
C88268	Agaricus blazei Murill Extract	Agaricus blazei Murill Extract	A dietary supplement containing an extract of the Basidiomycete fungus Agaricus blazei Murill with potential chemopreventive, antineoplastic and immunopotentiating activities. Agaricus blazei Murill extract contains high levels of phytochemicals, especially beta-D-glucans. Beta-D-glucans may promote dendritic cell (DC) maturation; increase interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha) and immunoglobulin levels; and may enhance natural killer (NK) cell activity, potentially boosting anti-tumor host immune responses.	Pharmacologic Substance
C28580	Agatolimod Sodium	(3'-5')d(P-thio)(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T) Tricosasodium Salt || AGATOLIMOD SODIUM || Agatolimod Sodium || Agatolimod Sodium || CpG 7909 || CpG 7909 || PF-3512676 || PF-3512676 || ProMune || ProMune	The tricosasodium salt of a synthetic 24-mer oligonucleotide containing 3 CpG motifs with potential antineoplastic and immunostimulatory activity. Agatolimod selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C107245	Agerafenib	1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride || AC013773 || AGERAFENIB || Agerafenib || Agerafenib || CEP-32496 || RXDX-105	An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. Agerafenib specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.	Pharmacologic Substance
C73996	Aglatimagene Besadenovec	ADV-tk || AGLATIMAGENE BESADENOVEC || Aglatimagene Besadenovec || Aglatimagene Besadenovec || GliAtak || ProstAtak || Virafir	An adenoviral vector engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene, which, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Aglatimagene besadenovec is transduced into tumor cells, sensitizing tumor cells that overexpress HSV-tk to synthetic acyclic guanosine analogues. Subsequently, a low dose of a synthetic acyclic guanosine analogue such as valacyclovir (VCV) or ganciclovir (GCV) is given, which may preferentially kill tumor cells containing the adenoviral vector and overexpressing HSV-tk. Release of tumor-associated antigens (TAAs) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response.	Pharmacologic Substance
C129967	Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949	Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 || Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949 || Anti-OX40 Agonist Antibody INCAGN01949 || Anti-OX40 Monoclonal Antibody INCAGN0194 || INCAGN 1949 || INCAGN-1949 || INCAGN1949 || Monoclonal Antibody INCAGN01949 || NCAGN01949	An agonistic human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, agonistic anti-OX40 monoclonal antibody INCAGN01949 selectively binds to and activates OX40 on activated T-cells, thereby potentiating T-cell receptor (TCR) signaling. OX40 activation inhibits regulatory T-cell (Treg)-mediated suppression of effector T-cells, induces the proliferation of memory and effector T-lymphocytes and modulates cytokine production. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. In addition, the IgG1 Fc region of INCAGN01949 binds to and co-engages with the IgG Fc-gamma receptor III (FcgammaRIII; CD16) expressed by immune effector cells; thus, binding activates FcgammaRIII-mediated signaling and facilitates the selective depletion of intratumoral Tregs, thereby further enhancing the cytotoxic T-lymphocyte (CTL)-mediated tumor cell response. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells; OX40 stimulation abrogates the immunosuppressive tumor microenvironment.	Amino Acid, Peptide, or Protein || Immunologic Factor
C117293	Agonistic Anti-OX40 Monoclonal Antibody MEDI6469	Agonistic Anti-CD134 Monoclonal Antibody MEDI6469 || Agonistic Anti-OX40 Monoclonal Antibody MEDI6469 || MEDI-6469 || MEDI6469	An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-OX40 monoclonal antibody MEDI6469 selectively binds to and activates OX40. OX40 activation induces proliferation of effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.	Pharmacologic Substance
C99129	AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine	AIM2(-1)/HT001(-1)/TAF1B(-1) FSP Vaccine || AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine	A cancer vaccine containing the three frame shift peptides (FSP) AIM2(-1), HT001(-1) and TAF1B(-1), with potential immunomodulating activity. Upon administration, the AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine may induce an immune response against microsatellite instability (MSI) colorectal cancer-associated antigens. Frame shift mutations of AIM2 (absent in melanoma 2, an interferon-inducible protein), HT001 (asteroid homolog 1 or ASTE1, with an unknown function) and TAF1B (TATA box-binding protein-associated RNA polymerase I B, a transcription factor) are seen in MSI-positive colorectal cancers and may be associated with malignant transformation, tumor progression and the presence of tumor-infiltrating lymphocytes. These FSPs all have one-base deletions.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C156414	AKR1C3-activated Prodrug OBI-3424	AKR1C3-activated Prodrug OBI-3424 || AKR1C3-activated Prodrug OBI-3424 || AKR1C3-activated Prodrug TH-3424 || Aldo-keto Reductase 1c3-activated Prodrug OBI-3424 || OBI 3424 || OBI-3424 || OBI-3424 || OBI3424 || TH 3424 || TH-3424 || TH3424	A small-molecule nitro-benzene, aldo-keto reductase 1C3 (AKR1C3)-activated prodrug of N,N'-bisethylenephosphoramidate, a DNA bis-alkylating agent, with potential antineoplastic activity. Upon intravenous administration, AKR1C3-activated prodrug OBI-3424 is converted to its active form by AKR1C3, which is upregulated in certain tumor cell types while not expressed in normal healthy cells. The active metabolite selectively binds to and alkylates DNA in AKR1C3-overexpressing tumor cells, resulting in DNA base pair mismatching, interstrand crosslinking and inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. As the expression of AKR1C3 is restricted to tumors, OBI-3424 is selectively converted to its active metabolite in tumor cells only while its conversion in normal, healthy tissue is absent; this allows for an increased cytotoxic effect of the alkylating agent in tumor cells while decreasing its toxicity.	Pharmacologic Substance || Organic Chemical
C111575	AKT 1/2 Inhibitor BAY1125976	AKT 1/2 Inhibitor BAY1125976 || AKT 1/2 Inhibitor BAY1125976 || BAY-1125976 || BAY1125976	An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) isoforms 1 and 2 (AKT1/2) with potential antineoplastic activity. AKT1/2 inhibitor BAY1125976 selectively binds to and inhibits the phosphorylation and activity of AKT1/2 in a non-ATP competitive manner, which may result in the inhibition of the phosphatidylinositol 3 (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. This may lead to both the reduction of cell proliferation and the induction of cell apoptosis in AKT-overexpressing tumor cells. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.	Organic Chemical || Pharmacologic Substance
C95737	Akt Inhibitor LY2780301	Akt Inhibitor LY2780301 || LY2780301	An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor LY2780301 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway, thereby leading to inhibition of cell proliferation and the induction of apoptosis in tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.	Pharmacologic Substance
C90581	Akt Inhibitor MK2206	1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl- || Akt Inhibitor MK2206 || Akt Inhibitor MK2206 || Akt inhibitor MK2206 || MK 2206 || MK-2206 || MK-2206 FREE BASE || MK2206 || MK2206	An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.	Pharmacologic Substance
C85448	Akt Inhibitor SR13668	Akt Inhibitor SR13668 || Akt Inhibitor SR13668 || SRI13668	An orally bioavailable indole-3-carbinol (I3C) analogue inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic and antiangiogenic activities. Akt inhibitor SR13668 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation, and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.	Pharmacologic Substance
C178300	Akt Inhibitor TAS-117	Akt Inhibitor TAS-117 || Akt Inhibitor TAS-117 || TAS 117 || TAS-117 || TAS-117 || TAS117	An orally bioavailable allosteric and selective pan-inhibitor of the serine/threonine protein kinase Akt (protein kinase B; v-akt murine thymoma viral oncogene homolog 1), with potential antineoplastic activity. Upon oral administration, Akt inhibitor TAS-117 targets, binds to and inhibits the activity of Akt, which may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt-mediated signaling. This may inhibit proliferation and induce apoptosis of tumor cells in which Akt is overexpressed. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.	Pharmacologic Substance
C113792	Akt/ERK Inhibitor ONC201	Akt/ERK Inhibitor ONC201 || ONC-201 || ONC201 || TIC10	A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon administration, Akt/ERK inhibitor ONC201 binds to and inhibits the activity of Akt and ERK, which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL death receptor type 5 (DR5) signaling in AKT/ERK-overexpressing tumor cells. The PI3K/Akt signaling pathway and MAPK/ERK pathway are upregulated in a variety of tumor cell types and play a key role in tumor cell proliferation, differentiation and survival by inhibiting apoptosis. In addition, ONC201 is able to cross the blood-brain barrier.	Pharmacologic Substance
C175557	AKT/RSK/S6K Inhibitor TAS0612	AKT/RSK/S6K Inhibitor TAS0612 || AKT/RSK/S6K Inhibitor TAS0612 || AKT/p90RSK/p70S6K Inhibitor TAS0612 || TAS 0612 || TAS-0612 || TAS0612	An orally bioavailable inhibitor of the serine/threonine kinases AKT (protein kinase B), 90S ribosome S6 kinase (p90RSK; RSK) and 70S ribosome S6 kinase (p70S6K; S6K), with potential antineoplastic activity. Upon oral administration, AKT/RSK/S6K inhibitor TAS0612 targets, binds to, and inhibits the activity of AKT, p90RSK and p70S6K. This inhibits both the AKT/mTOR/p70S6K and RAS/RAF/MEK/p90RSK signaling pathways and prevents the phosphorylation, nuclear translocation, and activation of the transcription factor Y-box-binding protein 1 (YBX1; YB-1). This may lead to cell cycle arrest, an induction of apoptosis, and an inhibition of tumor cell proliferation in tumor cells that have overactivated AKT/mTOR/p70S6K and RAS/RAF/MEK/p90RSK signaling pathways. Nuclear expression of YBX1 is associated with drug resistance such as antiestrogen resistance. AKT, RSK and S6K play key roles in tumor cell proliferation, differentiation, survival, and metastasis.	Pharmacologic Substance
C187033	Akt-1 Antisense Oligonucleotide WGI-0301	Akt-1 AS ODN WGI-0301 || Akt-1 Antisense ODN WGI-0301 || Akt-1 Antisense Oligonucleotide WGI-0301 || WGI 0301 || WGI-0301 || WGI0301	A lipid nanoparticle preparation of archexin, a 20-mer antisense (AS) oligodeoxynucleotide (ODN) against the proto-oncogene Akt, with potential antineoplastic activity. Upon administration of AS ODN WGI-0301, archexin binds to Akt-1 mRNA, inhibiting translation of the transcript. Suppression of Akt-1 expression may result in the inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt-mediated signaling. This may inhibit proliferation and induce apoptosis of tumor cells in which Akt-1 is overexpressed. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.	Pharmacologic Substance
C123720	Akt-1/2 Inhibitor-treated Tumor Infiltrating Lymphocytes	AKTi-treated TIL || AKTi-treated TILs || Akt-1/2 Inhibitor-treated Tumor Infiltrating Lymphocytes || Akt-1/2 Inhibitor-treated Tumor Infiltrating Lymphocytes || Akti-1/2-treated Tumor Infiltrating Lymphocytes	Autologous tumor infiltrating lymphocytes (TILs) harvested directly from the infiltrate of a patient's tumor and treated with an inhibitor of the serine/threonine kinases Akt-1 and -2 (Akti-1/2) during ex vivo expansion, with potential antineoplastic activity. Upon reintroduction into the patient, the Akti-1/2-treated TILs recognize and kill cancer cells. Akt inhibition promotes the immunologic memory of the TILs and enhances their expansion, in vivo long-term persistence and antitumor activity.	Cell || Pharmacologic Substance
C61438	Alacizumab Pegol	ALACIZUMAB PEGOL || Alacizumab Pegol || CDP-791	A pegylated, cross-linked, humanized divalent-Fab' antibody fragment directed against vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antiangiogenic and antitumor activities. Alacizumab pegol binds to and inhibits VEGFR-2, which may inhibit angiogenesis and tumor cell proliferation. Multivalent Fab' antibody fragments may exhibit improved retention and internalization properties compared to their parent IgGs.	Pharmacologic Substance
C994	Alanosine	3-(Hydroxynitrosoamino)-L-alanine || ALANOSINE || ALANOSINE || Alanosine || Alanosine || L-2-Amino-3-(hydroxynitrosoamino)propionic Acid || L-2-Amino-3-[(N-nitroso)hydroxylamino]propionic Acid || L-2-Amino-3-[(N-nitroso)hydroxylamino]propionic acid || L-Alanosine || L-Alanosine Sodium || SDX-102 || alanosine	An amino acid analogue and antibiotic derived from the bacterium Streptomyces alanosinicus with antimetabolite and potential antineoplastic activities. L-alanosine inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate, an intermediate in purine metabolism. L-alanosine-induced disruption of de novo purine biosynthesis is potentiated by methylthioadenosine phosphorylase (MTAP) deficiency. The clinical use of this agent may be limited by its toxicity profile. MTAP is a key enzyme in the adenine and methionine salvage pathways.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C131607	Albumin-binding Cisplatin Prodrug BTP-114	Albumin-binding Cisplatin Prodrug BTP-114 || Albumin-binding Cisplatin Prodrug BTP-114 || Albumin-conjugating Platinum-prodrug BTP-114 || BTP 114 || BTP-114 || Cisplatin Prodrug BTP-114 || Cisplatin/Maleimide-based Complex BTP-114 || Platinum-Prodrug BTP-114 || Prodrug BTP 114	A proprietary, albumin-binding platinum (Pt)-based complex containing a prodrug form of the platinum compound cisplatin and a maleimide moiety, with an ability to strongly and selectively bind human serum albumin (HSA), and with potential antineoplastic activity.  Upon intravenous administration, the maleimide group of BTP-114 rapidly conjugates with HSA in the bloodstream; this prolongs the blood circulation, enhances the half-life, and alters the biodistribution of BTP-114, as compared to cisplatin alone. Thus, BTP-114 demonstrates enhanced extravasation to the tumor, an increased accumulation in the tumor tissue and enhanced uptake by cancer cells. The prodrug form is reduced in the hypoxic tumor cell environment, which releases the highly cytotoxic active metabolite cisplatin. Once inside the tumor cell, cisplatin binds to nucleophilic groups, such as GC-rich sites, in DNA and induces intrastrand and interstrand DNA cross-links, resulting in apoptosis and cell growth inhibition. Compared to cisplatin alone, BTP-114 has improved selectivity towards tumor tissue, thereby enhancing efficacy while reducing systemic toxicities.	Pharmacologic Substance
C1498	Aldesleukin	125-L-Serine-2-133-interleukin 2 || ALDESLEUKIN || Aldesleukin || Aldesleukin || Proleukin || Proleukin || Recombinant Human IL-2 || Recombinant Human Interleukin-2 || aldesleukin || r-serHuIL-2 || recombinant human interleukin-2	A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.	Pharmacologic Substance || Organic Chemical
C175595	ALDH Inhibitor NYH817G and Mitochondrial Complex 1 Inhibitor NYH100P	ALDH Inhibitor NYH817G and Mitochondrial Complex 1 Inhibitor NYH100P || NYH817100 || NYH817G Plus NYH100P || NYH817G and NYH100P || NYH817G/NYH100P || Starvanip	An orally bioavailable combination agent composed of the aldehyde dehydrogenase (ALDH) inhibitor NYH817G and the mitochondrial complex 1 (NADH-ubiquinone oxidoreductase) inhibitor NYH100P, with potential antineoplastic activity. Upon oral administration of ALDH inhibitor NYH817G and mitochondrial complex 1 inhibitor NYH100P, NYH817G targets and binds to ALDH, and prevents the formation of NADH. It also inhibits lactate dehydrogenase A (LDH-A), thereby preventing lactate formation from pyruvate. NYH100P targets and binds to MC1. This all blocks the cancer cell energy production pathway, deprives tumor cells of nutrients, and energy, and inhibits nucleotide and amino acid production, which induces autophagy, causes tumor cell death and inhibits cell proliferation.	Pharmacologic Substance
C68921	Aldoxorubicin	ALDOXORUBICIN || Aldoxorubicin || Aldoxorubicin || DOXO-EMCH || Doxorubicin-EMCH || INNO-206	A 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, aldoxorubicin binds selectively to the cysteine-34 position of albumin via its maleimide moiety. Doxorubicin is released from the albumin carrier after cleavage of the acid-sensitive hydrazone linker within the acidic environment of tumors and, once located intracellularly, intercalates DNA, inhibits DNA synthesis, and induces apoptosis. Albumin tends to accumulate in solid tumors as a result of high metabolic turnover, rapid angiogenesis, hypervasculature, and impaired lymphatic drainage. Because of passive accumulation within tumors, this agent may improve the therapeutic effects of doxorubicin while minimizing systemic toxicity.	Pharmacologic Substance
C101790	Alectinib	5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo- || AF-802 || AF802 || ALECTINIB || ALK Inhibitor RO5424802 || Alecensa || Alecensa || Alectinib || Alectinib || CH5424802 || RG7853 || RO5424802	An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.	Pharmacologic Substance
C65220	Alefacept	ALEFACEPT || Alefacept || Alefacept || Amevive || Amevive || LFA3TIP || alefacept	A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3; CD58) linked to the Fc portion of human immunoglobulin G1 (IgG1) with potential immunosuppressive activity. Alefacept binds to the CD2 receptor expressed on the majority of T lymphocytes, blocking the binding of endogenous LFA-3, located on antigen-presenting cells (APCs), to the CD2 receptor; the activation and proliferation of T lymphocytes in response to LFA-3 binding is thus inhibited. In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes.	Pharmacologic Substance
C1681	Alemtuzumab	ALEMTUZUMAB || Alemtuzumab || Alemtuzumab || Anti-CD52 Monoclonal Antibody || Campath || Campath-1H || Campath-1H || LDP-03 || Lemtrada || MabCampath || Monoclonal Antibody Campath-1H || alemtuzumab	A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)	Amino Acid, Peptide, or Protein || Pharmacologic Substance || Immunologic Factor
C77370	Alestramustine	ALESTRAMUSTINE || Alestramustine	The l-alanine ester form of estramustine, a combination of the nitrogen mustard normustine coupled via a carbamate to estradiol, with antineoplastic activity. Upon conversion of alestramustine to estramustine, estramustine binds to microtubule-associated proteins (MAPs) and beta tubulin, thereby interfering with microtubule dynamics and leading to microtubule disassembly and cell cycle arrest. Due to the estrogen moiety, this agent is able to selectively bind to and be taken up by estrogen receptor-positive cells.	Pharmacologic Substance
C180535	Alflutinib	2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-6-(2,2,2-trifluoroethoxy)-3-pyridinyl)- || AST 2818 || AST-2818 || AST2818 || Alflutinib || FURMONERTINIB || Furmonertinib	An orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, alflutinib specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may have therapeutic benefits in tumors with T790M-mediated drug resistance.	Pharmacologic Substance
C133719	Alflutinib Mesylate	ASK120067 || AST 2818 Mesylate || AST2818 Mesylate || Alflutinib Mesylate || FURMONERTINIB MESILATE || Furmonertinib Mesylate	The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, alflutinib specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may have therapeutic benefits in tumors with T790M-mediated drug resistance.	Pharmacologic Substance
C61082	Algenpantucel-L	ALGENPANTUCEL-L || Algenpantucel-L || Algenpantucel-L || Alpha (1,3) Galactosyltransferase Tumor Vaccine || Alpha-1,3-Galactosyltransferase-expressing Allogeneic Pancreatic Tumor Cell Vaccine || HAPa || HyperAcute-Pancreas Immunotherapy || Hyperacute Pancreatic Cancer Vaccine	A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells.	Pharmacologic Substance
C71717	Alisertib	ALISERTIB || Alisertib || Alisertib || Aurora A Kinase Inhibitor MLN8237 || Benzoic Acid, 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Pyrimido(5,4-d)(2)Benzazepin-2-yl)Amino)-2-Methoxy- || MLN-8237 || MLN8237	A second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Alisertib binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers.	Pharmacologic Substance
C1574	Alitretinoin	3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-trans-4-trans-6-cis-8-trans-nonatetraenoic Acid || 9-Cis-Retinoic Acid || 9-cRA || 9-cis Retinoic Acid || 9-cis retinoic acid || 9-cis-RA || 9-cis-Retinoic Acid || ALITRETINOIN || ALRT1057 || Alitretinoin || Alitretinoin || LGD1057 || Panretin || Panretyn || Panrexin || Retinoicacid-9-cis	An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.	Organic Chemical || Pharmacologic Substance
C116727	ALK Inhibitor ASP3026	ALK Inhibitor ASP3026 || ALK Inhibitor ASP3026 || ASP-3026 || ASP-3026 || ASP3026 || N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine	An orally available, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ASP3026 binds to and inhibits ALK tyrosine kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.	Pharmacologic Substance
C188054	ALK Inhibitor NVL-655	ALK Inhibitor NUV-655 || ALK Inhibitor NVL-655 || NUV 655 || NUV-655 || NUV655 || NVL 655 || NVL-655 || NVL655	An orally bioavailable, brain-penetrant, selective small molecule inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ALK inhibitor NVL-655 specifically targets, binds to and inhibits ALK fusion proteins and activating mutations, including the acquired resistance mutations solvent front mutation (SFM) G1202R and the compound mutations G1202R/L1196M and G1202R/G1269A. The inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types. NVL-655 is able to penetrate the blood-brain-barrier (BBB) and may therefore exert its activity against EGFR-driven central nervous system (CNS) primary tumors and CNS metastases.	Pharmacologic Substance
C148533	ALK Inhibitor PLB 1003	ALK Inhibitor PLB 1003 || PLB 1003 || PLB-1003 || PLB1003	An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, PLB1003 selectively binds to and inhibits wild-type ALK, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.	Pharmacologic Substance
C187034	ALK Inhibitor SY-3505	ALK Inhibitor SY-3505 || ALK TKI SY-3505 || CT 3505 || CT-3505 || CT3505 || SY 3505 || SY-3505 || SY3505	An orally bioavailable, third-generation inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ALK inhibitor SY-3505 binds to and inhibits ALK wild-type tyrosine kinase and numerous ALK mutations, including acquired resistance mutations. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.	Pharmacologic Substance
C171615	ALK Inhibitor TAE684	5-Chloro-n4-(2-(isopropylsulfonyl)phenyl)-n2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine || ALK Inhibitor TAE684 || NPM-ALK Inhibitor TAE684 || NVP-TAE684 || TAE 684 || TAE-684 || TAE-684 || TAE684	A small molecule inhibitor of the receptor tyrosine kinases (RTKs) anaplastic lymphoma kinase (ALK) and nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), with potential antineoplastic activity. Upon administration, TAE684 binds to and inhibits ALK and NPM-ALK tyrosine kinases, which leads to a disruption of ALK- and NPM-ALK mediated signaling and eventually inhibits tumor cell growth in ALK- and NPM-ALK overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. NPM-ALK is an oncogenic fusion protein associated with ALK-positive anaplastic large cell lymphoma. ALK mutations are also associated with acquired resistance to small molecule tyrosine kinase inhibitors.	Pharmacologic Substance
C180420	ALK Inhibitor TPX-0131	ALK Inhibitor TPX-0131 || ALK Inhibitor TPX-0131 || TPX 0131 || TPX-0131 || TPX-0131 || TPX0131	An orally available, compact macrocyclic structure-based inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ALK inhibitor TPX-0131 binds within the ATP binding boundary and inhibits ALK wild-type tyrosine kinase, ALK fusion proteins and numerous ALK point mutations, including acquired resistance mutations, such as the solvent front mutation (SFM) G1202R and compound mutations L1196M/G1202R, L1198F/G1202R, L1196M/L1198F, and C1156Y/G1202R. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types. Compared to other ALK inhibitors, TPX-0131 is able to inhibit ALK resistance mutations associated with acquired resistance to other ALK inhibitors.	Pharmacologic Substance
C154279	ALK Inhibitor WX-0593	ALK Inhibitor WX-0593 || FL 006 || FL-006 || FL006 || WX 0593 || WX-0593 || WX0593	An orally available, small molecule inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, WX-0593 binds to and inhibits ALK tyrosine kinase, ALK fusion proteins, ALK point mutation variants ALK L1196M, ALK C1156Y, and EGFR L858R/T790M. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.	Pharmacologic Substance
C148513	ALK/c-Met Inhibitor  TQ-B3139	ALK/c-Met Inhibitor  TQ-B3139 || TQ B3139 || TQ-B3139	An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.	Pharmacologic Substance
C126648	ALK/FAK/Pyk2 Inhibitor CT-707	ALK/FAK/Pyk2 Inhibitor CT-707 || CT 707 || CT-707	An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), with potential antineoplastic activity. Upon administration, ALK/FAK/Pyk2 inhibitor CT-707 selectively binds to and inhibits ALK , FAK and Pyk2. The inhibition leads to disruption of ALK- , FAK- and Pyk2-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and Pyk2-overexpressing tumor cells. Expression of these tyrosine kinases is dysregulated in various tumor types; they play a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.	Pharmacologic Substance
C184737	ALK/ROS1 Inhibitor XZP-3621	ALK/ROS1 Dual Inhibitor XZP-3621 || ALK/ROS1 Inhibitor XZP-3621 || XZP 3621 || XZP-3621 || XZP3621	An orally bioavailable inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, ALK/ROS1 inhibitor XZP-3621 targets, binds to and inhibits the activity of ALK and ROS1, which leads to the disruption of ALK- and ROS1-mediated signaling and the inhibition of cell growth in ALK- and ROS1-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types. XZP-3621 may be able to inhibit ALK resistance mutations associated with other ALK inhibitors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.	Pharmacologic Substance
C173430	ALK/ROS1/Met Inhibitor TQ-B3101	ALK/ROS1/Met Inhibitor TQ-B3101 || TQB 3101 || TQB-3101 || TQB3101	An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK), C-ros oncogene 1 (ROS1) and Met (hepatocyte growth factor receptor; HGFR; c-Met), with potential antineoplastic activity. Upon oral administration, TQ-B3101 targets, binds to and inhibits the activity of ALK, ROS1 and c-Met, which leads to the disruption of ALK-, ROS1- and c-Met-mediated signaling and the inhibition of cell growth in ALK-, ROS1- and c-Met-expressing tumor cells. ALK, ROS1 and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.	Pharmacologic Substance
C114287	ALK/TRK Inhibitor TSR-011	ALK/TRK Inhibitor TSR-011 || TSR-011	An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. TRK, a family of receptor tyrosine kinases activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.	Pharmacologic Substance
C175551	ALK2 Inhibitor INCB000928	ALK2 Inhibitor INCB000928 || ALK2 Inhibitor INCB000928 || INCB 000928 || INCB-000928 || INCB000928	An inhibitor of activin A receptor type 1 (activin receptor-like kinase 2; ALK2; ALK-2; ACVR1; ACTR-I), with potential anti-anemic and ossification suppressive activities. Upon administration, ALK2 inhibitor INCB000928 targets, binds to and inhibits the activity of ALK-2. This prevents ALK2-mediated signaling and ALK2-mediated excessive bone morphogenetic protein (BMP) signaling. This may suppress heterotopic ossification (HO). As ALK-2 enhances the secretion of hepcidin, a peptide liver hormone and a key modulator of iron homeostasis, INCB000928 is able to decrease hepcidin expression in the liver, thereby increasing and restoring plasma iron levels, enhancing erythropoiesis, and correcting anemia of chronic disease (ACD). ALK2, a serine/threonine receptor kinase and type I cell surface receptor for BMPs, is constitutively activated due to activating mutations in inflammatory conditions, various types of cancer, and in fibrodysplasia ossificans progressiva (FOP). Elevated serum hepcidin levels enhance storage of iron, reduce iron availability and causes iron deficiency anemia.	Pharmacologic Substance
C111685	ALK-FAK Inhibitor CEP-37440	ALK-FAK Inhibitor CEP-37440 || ALK-FAK Inhibitor CEP-37440 || CEP-37440 || CEP-37440	An orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon administration, ALK-FAK inhibitor CEP-37440 selectively binds to and inhibits ALK kinase and FAK kinase. The inhibition leads to disruption of ALK- and FAK-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK- and FAK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.	Pharmacologic Substance
C165556	Alkotinib	Alkotinib || ZG 0418 || ZG-0418 || ZG0418	An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, alkotinib binds to and inhibits the wild-type, point mutations and fusion proteins of ALK and ROS1. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of proliferation in tumor cells which these kinases are overexpressed, rearranged or mutated.	Pharmacologic Substance
C156175	Alkylglycerol/Rosemary Capsules	Alkylglycerol and Rosemary Capsules || Alkylglycerol/Rosemary Capsules || Rosemary/Alkylglycerol Dietary Supplement	An orally available capsule containing alkylglycerols and Rosmarinus officinalis extracts standardized to diterpenes, including carnosic acid and carnosol, with potential antineoplastic and anti-inflammatory activities. Upon administration, carnosic acid and carnosol may induce apoptosis by decreasing apoptosis regulator B-cell lymphoma 2 (Bcl-2) expression, decrease tumor cell growth through inhibition of mammalian target of rapamycin (mTOR) phosphorylation, and inhibit metastatic activity by preventing the adhesion of tumor cells to type I collagen and fibronectin. Additionally, these diterpenes may decrease inflammation by downregulating cyclooxygenase (COX) type 2 (COX-2) protein synthesis. Alkylglycerols (alkyl-Gro) are bioactive ether lipids that may, through a not yet fully elucidated mechanism, inhibit tumor cell growth and metastases.	Pharmacologic Substance
C179280	Allitinib	ALLITINIB || ALS 1306 || ALS-1306 || ALS1306 || AST 1306 || AST-1306 || AST1306 || Allitinib || N-(4-(4-(3-Fluorobenzyloxy)-3-chlorophenylamino)quinazolin-6-yl) Acrylamide || N-[4-[3-Chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]prop-2-enamide	An orally bioavailable and irreversible inhibitor of the receptor tyrosine kinases (RTKs) epidermal growth factor receptors 1 (EGFR; ErbB1) and 2 (ErbB2; HER2; HER-2), with potential antineoplastic activity. Upon oral administration, allitinib selectively and irreversibly binds to and inhibits the activity of both EGFR and HER2, which prevents signaling mediated by EGFR and HER2. This may inhibit tumor growth and angiogenesis in tumor cells overexpressing these RTKs. EGFR and HER2 are RTKs that belong to the EGFR superfamily; they play major roles in both tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types.	Pharmacologic Substance
C123911	Allodepleted T Cell Immunotherapeutic ATIR101	ATIR101 || Allodepleted T Cell Immunotherapeutic ATIR101 || Allodepleted T Cell Immunotherapeutic ATIR101 || Allodepleted T-cell ImmunotheRapeutics || Theralux-ATIR	A cell-based immunotherapeutic product containing T-lymphocyte-enriched leukocytes that are devoid of alloreactive T-lymphocytes, that can potentially be used to restore lymphocyte levels after stem cell transplantations and are derived from partially matched (haploidentical) family donors for blood cancer patients who do not have a matching stem cell donor available. Host alloreactive T-cells, which can cause graft-versus-host disease (GVHD), are eliminated from the donor lymphocytes ex vivo using photodynamic therapy. After allogeneic hematopoietic stem cell transplantation (HSCT), allodepleted T cell immunotherapeutic ATIR101 is administered. This maintains a T-cell-mediated immune response against tumor cells and the donor T-cells can prevent opportunistic infections. ATIR101 does not cause severe, acute GVHD. In addition, administration of ATIR101 eliminates the need for immunosuppressants.	Cell || Pharmacologic Substance
C97265	Allogeneic AML Antigen-expressing Dendritic Cell Vaccine	Allogeneic AML Antigen-expressing Dendritic Cell Vaccine || Allogeneic AML Antigen-expressing Dendritic Cell Vaccine || Allogeneic Acute Myeloid Leukemia Antigen-expressing Dendritic Cell Vaccine || DCOne || DCP-001	A cancer vaccine consisting of allogeneic, immortalized dendritic precursor cells derived from a patient with acute myelogenous leukemia (AML), with potential immunostimulatory and antineoplastic activities. Upon ex vivo stimulation and expansion of the precursor cells into mature, fully functional dendritic cells (DCs) and subsequent administration, the allogeneic AML antigen-expressing DC vaccine may elicit a potent cytotoxic T-cell (CTL) and antibody response against AML antigen-expressing cells, resulting in tumor cell death.	Pharmacologic Substance
C182066	Allogeneic Anti-BCMA CAR T Cells ALLO-605	ALLO 605 || ALLO-605 || ALLO605 || Allogeneic Anti-BCMA CAR T Cells ALLO-605 || Allogeneic Anti-BCMA CAR T Cells ALLO-605 || Allogeneic Anti-BCMA CAR-T Cells ALLO-605 || Allogeneic Anti-BCMA TRAC/CD52-edited CAR T Cells ALLO-605 || Allogeneic BCMA TurboCAR T Cells ALLO-605	A preparation of allogeneic, transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and engineered to express a constitutively active chimeric cytokine receptor (CACCR), with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and CD52 genes are inactivated. Upon administration, the allogeneic anti-BCMA CAR T Cells ALLO-605 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. Inactivation of the CD52 gene makes the modified donor T-cells resistant to an anti-CD52 monoclonal antibody treatment, that is used during lymphodepletion. The knockout of TRAC eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The expression of CACCR allows for intracellular cytokine activation signaling, which may enhance expansion and persistence of the CAR T cells, thereby improving long-term anti-tumor activity. In addition, the incorporated CD20-based off-switch of ALLO-605 permits selective depletion of the ALLO-605 cells when the anti-CD20 monoclonal antibody rituximab is administered. ALLO-605 can also be inactivated with dasatinib.	Pharmacologic Substance
C181747	Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1	Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1 || Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1 || Allogeneic Anti-BCMA-CAR-expressing Tscm P-BCMA-ALLO1 || Allogeneic Tscm-rich Anti-BCMA CAR T Cells P-BCMA-ALLO1 || P-BCMA-ALLO 1 || P-BCMA-ALLO-1 || P-BCMA-ALLO1	An off-the-shelf (OTS) preparation composed of human allogeneic T-cells and containing primarily stem cell memory T-cells (Tscm) that are transfected by electroporation with a proprietary transposon-based DNA plasmid vector (PiggyBac; PB) encoding for an undisclosed drug selection gene encoding for a selectable marker to generate close to 100% CAR-based product, a caspase-based safety switch to reduce or eliminate the product in vivo if needed, and a B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17)-specific single domain variable heavy chain (VH) chimeric antigen receptor (CAR) (VCAR), with potential immunostimulating and antineoplastic activities. The CAR T-cells are also site specifically gene-edited with Cas-CLOVER (CC) to eliminate surface expression of both T-cell receptor (TCR) and beta-2 microglobulin (beta 2M) to decrease major histocompatibility complex (MHC) class I expression and further selected, by depletion of residual CD3-positive/TCR-positive cells, and expanded to yield Tscm enriched allogeneic transposed CAR-T cells. Upon administration, allogeneic anti-BCMA CAR T cells P-BCMA-ALLO1 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a member of the tumor necrosis factor receptor superfamily (TNFRSF) that binds to both a proliferation-inducing ligand (APRIL; TNFSF13) and B-cell activating factor (BAFF; TNFSF13B), plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.	Cell || Pharmacologic Substance
C165779	Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715	ALLO 715 || ALLO-715 || ALLO-715 || ALLO-715 Cells || ALLO715 || ALLOCar T ALLO-715 || Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715 || Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715 || BCMA Allogeneic CAR T Cells ALLO-715	A preparation of allogeneic, 'off-the-shelf' (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and CD52 genes are deleted from the CAR T-cells. Upon administration, the allogeneic anti-BCMA CAR-transduced T-cells ALLO-715 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. Deletion of the CD52 gene makes the modified donor T-cells resistant to an anti-CD52 monoclonal antibody treatment, that is used during lymphodepletion. The knockout of TRAC eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The donor-derived, gene-edited CAR T cells have reduced production times and have increased availability when compared to autologous CAR-T cells, which use the patient's own cells and are produced on an individual basis. In addition, if the ALLO-715 cells cause unacceptable side effects, the incorporated CD20-based off-switch permits selective depletion of the ALLO-715 cells when the anti-CD20 monoclonal antibody rituximab is administered.	Cell || Pharmacologic Substance
C173967	Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells	Allogeneic Anti-BCMA/CS1 Bispecific CAR T-cells || Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells || Allogeneic Anti-BCMA/SLAMF7 Bispecific CAR-T Cells || Allogeneic BCMA/CS1 Bispecific CAR-T Cells || Allogeneic BCMA/SLAMF7 Bispecific CAR-T Cells	A preparation of allogeneic T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting both the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; TNFRSF17) and human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-BCMA/CS1 bispecific CAR-T cells target and bind to tumor cells expressing BCMA and/or CS1 and induce selective cytotoxicity in those cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells. Targeting the two different TAAs highly expressed on malignant plasma cells may improve coverage and protect against antigen escape and resistance as tumor cells would need to lose both antigens. 	Pharmacologic Substance
C171066	Allogeneic Anti-BCMA-CAR T-cells PBCAR269A	Allogeneic Anti-BCMA-CAR T-cells PBCAR269A || Allogeneic Anti-BCMA-CAR T-cells PBCAR269A	A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-BCMA-CAR T-cells PBCAR269A specifically recognize and kill BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival.	Cell || Pharmacologic Substance
C176850	Allogeneic Anti-CD19 1XX-CAR T-cells FT819	Allogeneic Anti-CD19 1XX-CAR T-cells FT819 || Allogeneic Anti-CD19 1XX-CAR T-cells FT819 || Allogeneic Anti-CD19 CAR T-cells FT819 || CAR19-T Cells FT819 || FT 819 || FT-819 || FT819 || TCR-Less Trac-1XX CAR-T Cells FT819	A preparation of off-the-shelf (OTS) T-lymphocytes, generated from an induced pluripotent stem cell (iPSC) line, that have been genetically modified to express a CD19 1XX chimeric antigen receptor (CAR) that targets the tumor-associated antigen (TAA) CD19, linked to the co-stimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR (T-cell receptor)/CD3 complex (CD3-zeta) (CD28zeta; CD28z), and inserted into the T-cell receptor alpha constant (TRAC) locus and edited for elimination of TCR expression, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19 1XX-CAR T-cells FT819 specifically recognize and bind to CD19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells. The CD19 1XX CAR T-cells include a 1928zeta mutant, 1XX, which contains one instead of all three immunoreceptor tyrosine-based activation motifs (iTAMs). This may help prevent counterproductive T-cell differentiation and exhaustion, and may enhance the anti-tumor activity of the CAR T-cells. By nullifying the TCR, the possibility of graft versus host disease (GvHD) is eliminated.	Pharmacologic Substance
C172708	Allogeneic Anti-CD19 CAR T-cells ALLO-501A	ALLO 501A || ALLO-501A || ALLO501A || Allogeneic Anti-CD19 CAR T-cells ALLO-501A || Allogeneic Anti-CD19 CAR T-cells ALLO-501A || Allogeneic Anti-CD19 CAR T-lymphocytes ALLO-501A || Allogeneic Anti-CD19 CAR-T Cells ALLO-501A || Allogeneic CD19-specific CAR T-cells ALLO-501A	A preparation of allogeneic, frozen, 'off-the-shelf', universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon administration, allogeneic anti-CD19 CAR T-cells ALLO-501A specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. ALLO-501A lacks the rituximab recognition domains of ALLO-501.	Pharmacologic Substance
C179301	Allogeneic Anti-CD19 CAR T-cells PBCAR19B	Allogeneic Anti-CD19 CAR T Cells PBCAR19B || Allogeneic Anti-CD19 CAR T-cells PBCAR19B || Allogeneic Anti-CD19 CAR T-cells PBCAR19B || Allogeneic CD19 CAR T-cells PBCAR19B || Allogeneic CD19-targeting CAR-T Cells PBCAR19B || PBCAR19B	A preparation of allogeneic T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19), a single short hairpin RNA (shRNA) that disrupts the expression of beta-2 microglobulin (B2M) component of the class 1 major histocompatibility complex (MHC) molecules, and a HLA-E gene, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19 CAR T-cells PBCAR19B specifically recognize and bind to CD19-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-expressing tumor cells. The downregulation of the expression of the class 1 MHC molecule component B2M by shRNA and the HLA-E gene decrease the number of CAR T-cells that are rejected and killed by natural killer (NK) and cytotoxic T-cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.	Pharmacologic Substance
C188046	Allogeneic Anti-CD19 CAR-NK Cells QN-019a	Allogeneic Anti-CD19 CAR-NK Cells QN-019a || Allogeneic CD19-targeting CAR-NK Cells QN-019a || QN 019a || QN-019a || QN019a	A preparation of allogeneic natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-CD19 CAR-NK cells QN-019a recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.	Pharmacologic Substance
C173959	Allogeneic Anti-CD19 Universal CAR-T Cells CTA101	Allogeneic Anti-CD19 UCAR-T Cells CTA101 || Allogeneic Anti-CD19 Universal CAR-T Cells CTA101 || CTA 101 || CTA-101 || CTA101 || Universal CD19-directed CAR-T Cells CTA101	A preparation of allogeneic, off-the-shelf (OTS), universal, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 universal CAR-T cells CTA101 specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. CTA101 is genetically engineered to prevent graft-versus-host disease (GvHD) by the donor T-cells. OTS CAR-T cells require reduced production times when compared to autologous CAR-T cells.	Pharmacologic Substance
C177533	Allogeneic Anti-CD19-CAR-CD28-IL-15-expressing Natural Killer T-cells	Allogeneic Anti-CD19 CAR/IL-15-expressing Natural Killer T-cells || Allogeneic Anti-CD19-CAR-CD28-IL-15-expressing NKTs || Allogeneic Anti-CD19-CAR-CD28-IL-15-expressing Natural Killer T-cells || Allogeneic Anti-CD19-CAR-CD28-IL-15-expressing Natural Killer T-cells || Allogeneic Anti-CD19-CAR-IL-15-expressing Natural Killer T-cells || CD19.CAR Allogeneic NKT Cells || CD19.CAR-aNKT Cells || CD19.CAR-aNKTs	A preparation of allogeneic natural killer T-lymphocytes (NKTs) that have been engineered to express a chimeric antigen receptor (CAR) specific for the human tumor associated antigen (TAA) CD19, interleukin 15 (IL-15) and the costimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD19-CAR-CD28-IL-15-expressing NKTs target, bind to, and induce selective toxicity in CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. CD28 costimulatory molecule enhances activation and signaling after recognition of CD19, and may increase proliferation of T-cells and antitumor activity. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.	Pharmacologic Substance
C174397	Allogeneic Anti-CD20 CAR T-cells LUCAR-20S	Allogeneic Anti-CD20 CAR T-cells LUCAR-20S || LUCAR 20S || LUCAR-20S || LUCAR-20S CAR-T Cells || LUCAR20S	A preparation of donor-derived T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T-cells LUCAR-20S specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.	Pharmacologic Substance
C168570	Allogeneic Anti-CD20-CAR T-cells PBCAR20A	Allogeneic Anti-CD20 CAR T-lymphocytes PBCAR20A || Allogeneic Anti-CD20-CAR T-cells PBCAR20A || Allogeneic Anti-CD20-CAR T-cells PBCAR20A || PBCAR 20A || PBCAR-20A || PBCAR20A	A preparation of allogeneic, off-the-shelf (OTS), T-lymphocytes, derived from healthy donors, that have been genetically modified using a proprietary synthetic endonuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20-CAR T-cells PBCAR20A specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.	Cell || Pharmacologic Substance
C175980	Allogeneic Anti-CD30 CAR-Epstein-Barr Virus-specific T-lymphocytes	Allogeneic Anti-CD30 CAR EBV-specific T Lymphocytes || Allogeneic Anti-CD30 CAR-EBVSTs || Allogeneic Anti-CD30 CAR-Epstein-Barr Virus-specific T-lymphocytes || Allogeneic Anti-CD30 CAR-Epstein-Barr Virus-specific T-lymphocytes || Allogeneic CD30.CAR-EBVSTs	A preparation of allogeneic human Epstein-Barr virus (EBV)-specific T-lymphocytes (EBVSTs) that have been genetically modified to express a chimeric antigen receptor (CAR) recognizing the tumor-associated antigen (TAA) cluster of differentiation 30 (CD30), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD30 CAR-EBVSTs specifically recognize and bind to CD30-expressing EBV-infected tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies. EBV, a ubiquitous human herpes virus, is associated with various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.	Cell || Pharmacologic Substance
C183523	Allogeneic Anti-CD33 CAR NK Cells	Allogeneic Anti-CD33 CAR NK Cells || Allogeneic Anti-CD33 Chimeric Antigen Receptor-Natural Killer Cells	A preparation of off-the-shelf natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the cluster of differentiation 33 (CD33) antigen, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-CD33 CAR NK cells target and bind to CD33 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and on myeloid leukemia cells.	Pharmacologic Substance
C182613	Allogeneic Anti-CD38 DAR-T Cells STI-1492	Allogeneic Anti-CD38 A2 KOKI DAR T-cells STI-1492 || Allogeneic Anti-CD38 DAR-T Cells STI-1492 || Allogeneic Anti-CD38 DAR-T Cells STI-1492 || Allogeneic Anti-CD38 Dimeric Antigen Receptor-expressing T-lymphocytes STI-1492 || Allogeneic Second Generation Anti-CD38 Knock-out Knock-in Dimeric Antigen Receptor-4-1BB-CD3zeta-expressing T-cells STI-1492 || Anti-CD38 A2 KOKI DAR Allogeneic T Cells STI-1492 || STI 1492 || STI-1492 || STI1492	A preparation of human allogeneic T-lymphocytes that are gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt the expression of endogenous T-cell receptor (TCR) alpha and to express a dimeric antigen receptor (DAR) composed of a fragment antigen-binding variable region (Fab) recognizing the tumor-associated antigen (TAA) cluster of differentiation 38 (CD38), linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, allogeneic anti-CD38 DAR-T cells STI-1492 are directed to and induce selective toxicity in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. The disruption of endogenous TCR alpha prevents graft-versus-host disease (GvHD).	Pharmacologic Substance
C184378	Allogeneic Anti-CD5 CAR T Cells	Allogeneic Anti-CD5 CAR T Cells || Allogeneic Anti-CD5 CAR-T Cells || Allogeneic CD5-targeting CAR T-cells || Donor-derived Anti-CD5 CAR T Cells || Donor-derived CD5 CAR T Cells	A preparation of allogeneic T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for CD5, with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-CD5 CAR T cells target and bind to CD5-expressing tumor cells, thereby inducing selective cytotoxicity in CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T-cells and overexpressed on various B- and T-cell malignancies.	Pharmacologic Substance
C178587	Allogeneic Anti-CD5-IL-15/IL-15sushi-safety Switch CAR T Cells	Allogeneic Anti-CD5-IL-15/IL-15sushi-safety Switch CAR T Cells || Allogeneic CD5-IL-15/IL-15sushi-CAR T-cells || Allogeneic CD5-IL-15/IL-15sushi-safety Switch CAR T Cells || Allogeneic CD5-IL-15/IL-15sushi-safety Switch CAR-T Cells || Anti-CD5 CAR T Cells	A preparation of allogeneic T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a humanized anti-CD5 single chain variable fragment (scFv) domain linked to a interleukin (IL)-15/IL-15sushi domain and a safety switch, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-CD5-IL-15/IL-15sushi-safety switch CAR T cells target and bind to CD5-expressing tumor cells, thereby inducing selective cytotoxicity in CD5-expressing tumor cells. The IL-15/IL-15sushi domain activates and increases the levels of natural killer (NK) cells and memory CD8+ T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. The pro-survival cytokine IL-15 regulates CD8+ T and NK cell development, activation and proliferation. The safety switch, composed of two rituximab (RTX)-binding epitope sites, allows for the selective elimination of the CAR-T cells through the administration of RTX. CD5, a T-cell associated antigen, is expressed in many T-cell lymphomas and leukemias.	Pharmacologic Substance
C179630	Allogeneic Anti-CD7 CAR T Cells	Allogeneic Anti-CD7 CAR T Cells || Donor Anti-CD7 CAR T Cells || Donor-Derived CD7 CAR T Cells	A preparation of donor-derived T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the allogeneic anti-CD7 CAR T cells specifically recognize and bind to CD7-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD7 is a transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.	Cell || Pharmacologic Substance
C182072	Allogeneic Anti-CD7 CAR-T Cells WU-CART-007	Allogeneic Anti-CD7 CAR-T Cells WU-CART-007 || Allogeneic Anti-CD7 CAR-T Cells WU-CART-007 || WU-CART 007 || WU-CART-007 || WU-CART007	A preparation of off-the-shelf (OTS) donor-derived T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the allogeneic anti-CD7 CAR-T cells WU-CART-007 specifically recognize and bind to CD7-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD7 is a transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.	Cell || Pharmacologic Substance
C177917	Allogeneic Anti-CD70-CAR T-cells ALLO-316	ALLO 316 || ALLO-316 || ALLO316 || AlloCAR T (TM) ALLO-316 || Allogeneic Anti-CD70-CAR T-cells ALLO-316 || Allogeneic Anti-CD70-CAR T-cells ALLO-316 || Allogeneic TALEN-edited Anti-CD70-CAR T-cells ALLO-316 || Anti-CD70 AlloCAR T-cells ALLO-316	An off-the-shelf (OTS) preparation of human allogeneic T-lymphocytes obtained from healthy donors that are engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70) and gene-edited with transcription activator-like effector nuclease (TALEN) to inactivate the endogenous T-cell receptor alpha constant (TRAC) and CD52 loci, with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic anti-CD70-CAR T-cells ALLO-316 recognize and bind to CD70-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD70-positive tumor cells. CD70, a type II transmembrane glycoprotein and member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. Deletion of the CD52 gene makes the modified donor T-cells resistant to anti-CD52 monoclonal antibodies, which can be used during lymphodepletion. The deletion of the TRAC gene abrogates the potential induction of graft-versus-host disease (GvHD) by the donor T-cells.	Cell || Pharmacologic Substance
C183511	Allogeneic Anti-CD70-CAR-IL-15-transduced Cord Blood-derived Natural Killer Cells	Allogeneic Anti-CD70-CAR-IL-15-expressing CB-NK Cells || Allogeneic Anti-CD70-CAR-IL-15-transduced CB-derived NK Cells || Allogeneic Anti-CD70-CAR-IL-15-transduced Cord Blood-derived Natural Killer Cells || Allogeneic Anti-CD70-CAR-IL-15-transduced Cord Blood-derived Natural Killer Cells || CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells || CAR.70/IL15-transduced CB-NK Cells	A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells (NKs) that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70) and interleukin-15 (IL-15), with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic anti-CD70-CAR-IL-15-transduced CB-derived NK cells target, bind to and induce selective cytotoxicity in CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27, is overexpressed on the surfaces of various cancer cell types. IL-15 is a pro-survival cytokine that promotes persistence of multiple lymphocyte lineages and potentiates the immune response against tumor cells.	Pharmacologic Substance
C107681	Allogeneic Autophagosome-enriched Vaccine DPV-001	Allogeneic Autophagosome-enriched Vaccine DPV-001 || Allogeneic Autophagosome-enriched Vaccine DPV-001 || Allogeneic DRibble Vaccine DPV-001 || DPV 001 || DPV-001 || DPV-001 Vaccine || DPV001 || DRiPs and SLiPs-containing Blebs Vaccine DPV-001 || DRibble Vaccine DPV-001 || Dribble Cancer Vaccine DPV-001 || Dribbles Vaccine DPV-001 || Tumor-derived Autophagosomes Vaccine DPV-001 || Vaccine DPV-001	An off-the-shelf (OTS) autophagosome-enriched tumor vaccine composed of dendritic cell (DC)-targeting microvesicles containing short lived proteins (SLiPs) and defective ribosomal products (DRiPs) derived from tumor cells, with potential immunostimulating and antineoplastic activities. The DriPs- and SLiPs-filled autophagosome microvesicles are made by treating two human non-small cell lung cancer (NSCLC) cell lines, UbiLT3 (non-specific histopathology) and UbiLT6 (adenocarcinoma-like) with both a proteasome inhibitor, to prevent protein degradation, and an autophagy inducer. DPV-001 contains a wide variety of NSCLC-derived TAAs, many as immunogenic altered-peptide ligands (APL), and numerous damage-associated molecular pattern molecules (DAMPs) with Toll-like receptor (TLR) 2, 3, 4, 7 and 9 agonist activities. Upon administration of allogeneic autophagosome-enriched vaccine DPV-001, the proteins in the vaccine target DCs and may stimulate the immune system to mount cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte responses against the TAAs. The TAAs are overexpressed in a variety of cancer cell types other than NSCLC. The tumor-associated SLiPS and DRiPs are highly unstable and normally degraded by tumor cell proteasomes. They are typically not processed and cross-presented by antigen-presenting cells (APCs).	Immunologic Factor || Pharmacologic Substance
C70985	Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine	Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine	An allogeneic whole cell vaccine, derived from irradiated allogenic tumor cells manipulated to express human B7.1 (CD80 antigen) and human leukocyte antigen (HLA) A1, with potential antitumor activity. Vaccination with allogeneic B7.1/HLA-A1 transfected tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor cell proliferation.	Pharmacologic Substance
C125420	Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes	Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes || Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes || Allogeneic CD123R(EQ)28zeta/EGFRt+ T Cells	A preparation of genetically modified allogeneic T-cells transduced with a replication-incompetent, self-inactivating lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR), comprised of a CD28 co-stimulatory signaling domain fused to CD3 zeta, the single-chain variable fragment of CD123 antigen (interleukin-3 receptor alpha chain or IL3RA), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes are directed to and induce selective toxicity in CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents recognition of the CAR by Fc receptors (FcRs).	Pharmacologic Substance
C146806	Allogeneic CD123-specific Universal CAR123-expressing T-lymphocytes	Allogeneic CD123-specific Universal CAR123-expressing T-lymphocytes || Allogeneic CD123-specific Universal CAR123-expressing T-lymphocytes || Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor || UCART123 || UCART123 T Cells || Universal Chimeric Antigen Receptor T-cell 123 || Universal Chimeric Antigen Receptor T-cells targeting CD123 || Universal TALEN Gene-edited CART123 Cells	Allogeneic, off-the-shelf, universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human interleukin-3 receptor alpha chain (IL3RA; cluster of differentiation 123; CD123), with potential immunomodulating and antineoplastic activities.  Upon transfusion of allogeneic CD123-specific universal CAR123-expressing T-lymphocytes (UCART123), these cells target and bind to cancer cells expressing CD123. This induces selective toxicity in and causes lysis of CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with both increased leukemic cell proliferation and aggressiveness. Using TALEN technology, the UCART123 cells no longer express the endogenous T-cell receptor (TCR) thereby abrogating the potential induction of graft-versus-host disease (GvHD) by the donor T-cells.	Pharmacologic Substance
C186655	Allogeneic CD16-expressing Natural Killer Cells CYNK-101	Allogeneic CD16-expressing NK Cells CYNK-101 || Allogeneic CD16-expressing Natural Killer Cells CYNK-101 || Allogeneic CD34-positive Human Placental Hematopoietic Stem Cell-derived CD16-expressing Natural Killer Cells CYNK-101 || CYNK 101 || CYNK-101 || CYNK101 || Human Placental CD34+ HSC-derived CD16-expressing NKs CYNK-101 || Natural Killer Cells CYNK-101 (SY); Allogeneic Human HSC-derived CD16-expressing Natural Killer Cells CYNK-101	A population of cryopreserved, off-the-shelf (OTS) allogeneic natural killer (NK) cells derived from human placental hematopoietic stem cells (HSCs) expressing the CD34 surface antigen, and engineered to express a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, with potential antineoplastic and immunostimulatory activities. Upon infusion of CYNK-101, the allogeneic CD16-expressing NK cells bind to the Fc portion of tumor cell-bound monoclonal antibodies that were administered as induction therapy. This enhances NK cell activation, cytokine secretion, and antibody-dependent cellular cytotoxicity (ADCC) in the presence of certain antibody therapeutics. CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response. CYNK-101 NK cells' hnCD16 Fc receptor prevents downregulation and optimizes binding to tumor-targeting antibodies for enhanced ADCC.	Pharmacologic Substance || Cell
C179501	Allogeneic CD19-CAR CD45RA-negative T-cells	Allogeneic Anti-CD19-CAR-4-1BBz CD45RA-negative T-cells || Allogeneic CD19-CAR CD45RA-negative T-cells || Allogeneic CD19-CAR CD45RA-negative T-cells || Allogeneic CD19-CAR Memory T-cells || Allogeneic CD19-CAR(Mem)T-cells || Allogeneic CD45RA-negative T-cells-expressing CD19-specific CAR 41BBz	A preparation of allogeneic T-lymphocytes, depleted of CD45RA-positive cells, that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain (4-1BBz), with potential immunostimulating and antineoplastic activities. CD45RA depletion results in a cellular product that contains a high amount of memory T-cells (Tm). Upon administration, the allogeneic CD19-CAR CD45RA-negative T-cells specifically recognize and bind to CD19-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. CD45RA is expressed on naive T-cells (Tn), whereas Tm cells are CD45RA-negative. The depletion of the CD45RA-positive cells reduces the risk of graft-versus-host disease (GvHD) upon infusion. Tn cells have the potential to induce more severe graft-versus-host disease (GvHD) than Tm cells.	Pharmacologic Substance
C178433	Allogeneic CD19CAR-CD28-CD3-zeta-expressing T-lymphocytes	Allogeneic 19-28z CAR T-cells || Allogeneic 19-28z CAR-T Cells || Allogeneic CD19-28z CAR T Cells || Allogeneic CD19CAR-CD28-CD3-zeta-expressing T-lymphocytes	A preparation of allogeneic, donor-derived T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment), fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (19-28z), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic CD19CAR-CD28-CD3-zeta-expressing T-lymphocytes are directed to CD19-expressing tumor cells, which induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.	Pharmacologic Substance
C154284	Allogeneic CD19CAR-transfected Cytokine-induced Killer Cells	Allogeneic CARCIK-CD19 (SY) || Allogeneic CARCIK-CD19 Cells || Allogeneic CD19CAR-transfected Cytokine-induced Killer Cells || Transposon-manipulated Allogeneic CARCIK-CD19 Cells	A preparation of allogeneic cytokine-induced killer (CIK) cells derived from peripheral blood mononuclear cells (PBMCs) transfected with the Sleeping Beauty (SB) transposon, CD19CAR (CARCIK-CD19), with potential immunomodulatory and antineoplastic activities. CIK cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T-lymphocytes. Upon infusion following an allogeneic stem cell transplantation, the CARCIK-CD19 cells bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CIK cells may have enhanced cytotoxic activity compared to lymphokine-activated killer (LAK) cells. CD19 is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Cell || Pharmacologic Substance
C181804	Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019	Allogeneic Anti-CD-19 CAR NK Cells NKX019 || Allogeneic Anti-CD-19 CAR-NKs NKX019 || Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NK Cells NKX019 || Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NKs NKX019 || Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019 || Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019 || NKX 019 || NKX-019 || NKX019	A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 that is coupled to the co-stimulatory domain of OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NK cells NKX019, these cells specifically target and bind to tumor cells expressing CD19. This induces secretion of pro-inflammatory cytokines and results in the lysis of CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that potentiates the immune response against tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Pharmacologic Substance
C99215	Allogeneic CD19-specific CAR-modified CD8 Plus Central Memory-derived Virus-specific T Cells	Allogeneic CD19-specific CAR-modified CD8 Plus Central Memory-derived Virus-specific T Cells || Allogeneic CD19CAR-TCM Cells	A preparation of allogeneic Epstein-Barr virus (EBV)- and human cytomegalovirus (CMV)-specific CD8+ central memory-derived T effector-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) anti-CD19/CD3 zeta chain fusion protein coupled to the intracellular signal domain of CD28 antigen, with potential immunostimulating, anti-viral and antineoplastic activities. Upon infusion, allogeneic CD19-specific CAR-modified CD8+ central memory-derived virus-specific T cells directs the T-lymphocytes to CD19-expressing tumor cells, stimulating a selective toxicity to tumor cells which may eventually result in tumor cell lysis. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The viral specific T-cells exert antiviral immunity.	Pharmacologic Substance
C137819	Allogeneic CD19-specific Universal CAR19-expressing T-lymphocytes	ALLO-501 || Allogeneic CD19-specific Universal CAR19-expressing T-lymphocytes || Allogeneic CD19-specific Universal CAR19-expressing T-lymphocytes || S68587 || TCR/CD52-deficient RQR8+ CD19-CAR+ T-cells || UCART 19 || UCART19 Cells || Universal Chimeric Antigen Receptor T-cell 19 || Universal TALEN Gene-edited CART19 Cells	A preparation of allogeneic, frozen, 'off-the-shelf', universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, and containing a RQR8 transgene, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon infusion, allogeneic universal CD19-specific CAR-modified T cells (UCART19) specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The gene-edited allogeneic, frozen UCART19 have reduced production times and provide off-the-shelf CAR-T cells when compared to autologous CAR-T cells, which use the patient's own cells and are produced on an individual basis. The protein expressed by the RQR8 transgene contains epitopes from CD34 and CD20, which allows tracking of the UCART19 cells with a clinically-approved anti-CD34 antibody. Additionally if the UCART19 cells cause unacceptable side effects, the CD20 portion of the protein permits selective depletion of the UCART19 cells when the anti-CD20 monoclonal antibody rituximab is administered.	Pharmacologic Substance
C178424	Allogeneic CD20 CAR-grafted Gamma Delta T-cells ADI-001	ADI 001 || ADI-001 || ADI001 || Allogeneic Anti-CD20 CAR-engineered Gamma Delta T Cells ADI-001 || Allogeneic Anti-CD20-CAR Gamma Delta T-lymphocytes ADI-001 || Allogeneic CD20 CAR-grafted Gamma Delta T-cells ADI-001 || Allogeneic CD20 CAR-grafted Gamma Delta T-cells ADI-001	A preparation of a subset of allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) and that are engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic CD20 CAR-grafted gamma delta T-cells ADI-001 specifically target and bind to tumor cells expressing CD20. This induces secretion of pro-inflammatory cytokines and results in the lysis of CD20-expressing tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.	Pharmacologic Substance
C165696	Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22	Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22 || Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22 || Allogeneic Gene-edited CAR T-Cells UCART22 || Allogeneic TALEN Gene-edited CAR T-Cells UCART22 || Allogenic Engineered T-cells Expressing Anti- CD22 CAR UCART22 || UCART 22 || UCART-22 || UCART22 || UCART22 Cells	A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CD22 with potential immunomodulating and antineoplastic activities. Upon transfusion, allogeneic CD22-specific universal CAR-expressing T-lymphocytes UCART22 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.	Cell || Pharmacologic Substance
C137863	Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100	Adaptive Memory NKs Cells FATE-NK100 || Adaptive Memory Natural Killer Cells FATE-NK100 || Adaptive NKs Cells FATE-NK100 || Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100 || Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100 || FATE NK100 || FATE-NK100	A preparation of pharmacologically-enriched, allogeneic natural killer (NK) cells derived from a related but not completely matched human leukocyte antigen (HLA)-haploidentical donor that is seropositive for cytomegalovirus (CMV+), with potential cytolytic and antineoplastic activities. Upon leukapheresis, the donor peripheral blood mononuclear cells (PBMCs) are treated to remove T-lymphocytes (CD3+) and B-lymphocytes (CD19+). The remaining leukocytes are cultured for 7 days with the cytokine interleukin-15 (IL-15) and a small molecule inhibitor of glycogen synthase kinase 3-beta (GSK3beta) to generate the adaptive, CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100 ex vivo. Upon infusion of the allogeneic CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100, these cells selectively recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis. Exposure to CMV induces the expression of the memory-like activating receptor NKG2C and the maturation marker CD57 in the isolated NK cells, making them more potent than those not pre-exposed to CMV. CD57 both enhances the effector function of NK cells and stimulates CD16-dependent signaling. Treatment with IL-15 enhances NK cell proliferation and survival. The GSK3beta inhibitor induces preferential expansion of CD57+ NK cells that exhibit enhanced interferon (IFN)-gamma production.	Cell || Pharmacologic Substance
C121445	Allogeneic CD3- CD19- Selected Natural Killer Cells	Allogeneic CD3- CD19- Selected Natural Killer Cells || Allogeneic CD3- CD19- Selected Natural Killer Cells || Allogeneic CD3-/CD19- NK Cell Product || Allogeneic CD3-/CD19- NK Cells || Allogeneic CD3-/CD19- Natural Killer Cells || CD3/CD19-depleted Donor NK Cells	Human leukocyte antigen (HLA)-haploidentical donor-derived natural killer (NK) cells that are activated with the cytokine interleukin-15 (IL-15), with immunomodulating and antineoplastic activities. Upon leukapheresis, the HLA-haploidentical donor peripheral blood mononuclear cells (PBMCs) are treated to remove T-lymphocytes (CD3+) and B-lymphocytes (CD19+) cells. In turn, NK cells are expanded and activated with IL-15. Upon infusion of the allogeneic CD3- CD19- selected NK cells, these cells recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis.	Cell || Pharmacologic Substance
C153885	Allogeneic CD34-positive E-rosetted T-cell Depleted Peripheral Blood Stem Cells	Allogeneic CD34-positive E-rosetted T-cell Depleted Peripheral Blood Stem Cells || Allogeneic CD34-positive E-rosetted T-cell Depleted Peripheral Blood Stem Cells	A preparation of CD34+ selected peripheral blood stem cells (PBSCs) that are depleted of T-cells via erythrocyte rosetting (E-rosetting) and intended for allogeneic stem cell transplant. Administration of this particular preparation of CD34+E- T-cell depleted PBSCs may potentially reduce the occurrence of graft-versus-host disease (GvHD) without increasing the risk of graft failure or poor graft function	Cell || Pharmacologic Substance
C71540	Allogeneic CD4+ Memory Th1-like T Cells/Microparticle-bound Anti-CD3/anti-CD28	AlloStim || Allogeneic CD4+ Memory Th1-like T Cells/Microparticle-bound Anti-CD3/anti-CD28	A preparation consisting of allogeneic, differentiated Th1-like T cells bound to T cell-stimulating monoclonal antibodies with potential antitumor activity. More specifically, allogeneic CD4+ memory Th1-like T cells/microparticle-bound anti-CD3/anti-CD28 are composed of a proprietary preparation of mismatched, allogeneic differentiated CD4+ memory Th1-like T cells bound to paramagnetic, epoxy-covered 4.5 micron microparticles with covalently bound anti-CD3/anti-CD28 monoclonal antibodies at a 2:1 bead:cell ratio. The CD4+ memory Th1-like T cells are derived from precursors found in the circulation of a normal donor. Stimulated by the microparticle-bound monoclonal antibodies, the infused T cells produce pro-inflammatory, anti-tumor cytokines such as like IFN-gamma, TNF-beta, and IL-2, disabling tumor immune avoidance mechanisms and stimulating the host immune system to both reject the infused T cells and kill tumor cells.	Cell || Pharmacologic Substance
C96741	Allogeneic CD56-positive CD3-negative Natural Killer Cells	Allogeneic CD56-positive CD3-negative Natural Killer Cells || Allogeneic CD56-positive CD3-negative Natural Killer Cells	A population of allogeneic lymphocytes expressing the CD56 surface antigen and exhibiting a lack of CD3, with immunomodulating activity. Upon infusion of allogeneic CD56-positive CD3-negative natural killer (NK) cells, these cells are able to secrete cytokines and recognize and kill tumor cells as well as virally-infected cells. CD56 is a transmembrane glycoprotein also known as NCAM (Neural Cell Adhesion Molecule).	Cell || Pharmacologic Substance
C170887	Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001	Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001 || Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001 || NEXI 001 || NEXI-001 || NEXI001	A preparation of allogeneic CD8+ T cells targeting multiple undisclosed leukemia-associated antigens, with potential immunomodulating and antineoplastic activities. Following peripheral blood mononuclear cell (PBMC) collection from the original stem cell donor and ex vivo priming and expansion, the allogeneic CD8+ leukemia-associated antigens specific T cells NEXI-001 are re-introduced into the leukemia patient, where they target and kill tumor cells expressing these leukemia-associated antigens.	Cell || Pharmacologic Substance
C119759	Allogeneic Cellular Vaccine 1650-G	1650-G || 1650-G Vaccine || 1650G || Allogeneic Cellular Vaccine 1650-G || Allogeneic Cellular Vaccine 1650-G	A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs.	Immunologic Factor || Pharmacologic Substance
C157340	Allogeneic CMV Antigen-specific CD4+/CD8+ T-lymphocytes	Allogeneic CMV Antigen-specific CD4+/CD8+ T-lymphocytes || Allogeneic CMV Antigen-specific CD4+/CD8+ T-lymphocytes || Allogeneic CMV-specific Antigen-selected T-cells || Allogeneic Cytomegalovirus-specific CD4+ and CD8+ T-cells || Allogeneic Cytomegalovirus-specific CD4+ and CD8+ T-lymphocytes	A population of allogeneic T-lymphocytes specifically reactive to cytomegalovirus (CMV) with potential antiviral activity. Allogeneic CMV antigen-specific T-cells are prepared via ex vivo stimulation of donor-derived peripheral blood mononuclear cells (PBMCs) with major cytomegalovirus structural protein, pp65 (ppUL83). T-cells that secrete interferon (IFN)-gamma in response to pp65 antigen exposure are selected and expanded for administration. Administration of the CMV antigen-specific CD4+ and CD8+T-lymphocytes into hematopoietic stem cell transplant (HSCT) or immunocompromised patients infected with CMV may potentially reconstitute virus-specific responses, thereby controlling CMV infections.	Cell || Pharmacologic Substance
C172741	Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120	Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120 || Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120 || CRISPR/Cas9 Gene-edited Allogeneic Anti-BCMA CAR-T Cells CTX120 || CTX 120 || CTX-120 || CTX120	A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-BCMA CAR T-cells CTX120 recognize and bind to BCMA-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of BCMA-positive tumor cells. BCMA, a receptor for proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. The disruption of endogenous TCR prevents graft-versus-host disease (GvHD). The disruption of MHC class I molecules increases the persistence of the CAR T-cells.	Cell || Pharmacologic Substance
C165492	Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T Cells CTX110	Allogeneic Anti-CD19 CAR CRISPR-edited T Cells CTX110 || Allogeneic Anti-CD19 CAR-T Cells CTX110 || Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T Cells CTX110 || Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T Cells CTX110 || Allogeneic CRISPR-Cas9 Gene-edited CD19-directed CAR T-cells CTX110 || Allogeneic CRISPR-Cas9-Engineered Anti-CD19 CAR T Cells CTX110 || CTX 110 || CTX-110 || CTX101 || CTX110	A preparation of human allogeneic T-lymphocytes transduced with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to eliminate endogenous TCR, with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-CD19 CAR T-cells CTX110 recognize and bind to CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. Removal of endogenous TCR reduces the risk of graft-versus-host disease (GvHD). CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Pharmacologic Substance || Cell
C173153	Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130	Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130 || Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130 || Allogeneic CRISPR-Cas9-engineered T Cells CTX130 || CRISPR/Cas9 Gene-edited Allogeneic Anti-CD70 CAR-T Cells CTX130 || CTX 130 || CTX-130 || CTX130 || Donor-derived Gene-edited Allogeneic CAR-T Cells CTX130	A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-CD70 CAR T-cells CTX130 recognize and bind to CD70-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD70-positive tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. Disruption of endogenous TCR prevents graft-versus-host disease (GvHD); the disruption of MHC class I molecules increases the persistence of the CAR T-cells.	Cell || Pharmacologic Substance
C184372	Allogeneic CRISPR-edited Anti-CD19 CAR T Cells PACE CART19	Allogeneic Anti-CD19 CAR T Cells PACE CART19 || Allogeneic Anti-CD19 CAR T-cells PACE CART19 || Allogeneic Anti-CD19 CAR-T Cells PACE CART19 || Allogeneic CRISPR-edited Anti-CD19 CAR T Cells PACE CART19 || PACE CART19 || PACE CART19 Cells	An off-the-shelf (OTS) preparation of human allogeneic T-lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), and electroporated with clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to eliminate the expression of endogenous TCR, HLA class I and HLA class II molecules, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic CRISPR-edited anti-CD19 CAR T cells PACE CART19 recognize and bind to CD19-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-expressing tumor cells. The removal of endogenous TCR, HLA class I and HLA class II molecules prevents allogeneic immune responses and reduces the risk of graft-versus-host disease (GvHD). The tumor-associated antigen (TAA) CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.	Pharmacologic Substance
C178434	Allogeneic CRISPR-edited Anti-CD19 CAR T Cells PBLTT52CAR19	Allogeneic CRISPR-edited Anti-CD19 CAR T Cells PBLTT52CAR19 || Allogeneic CRISPR-edited Anti-CD19 CAR T-cells PBLTT52CAR19 || Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells PBLTT52CAR19 || PBLTT52 CAR19 || PBLTT52-CAR19 || PBLTT52CAR19	A preparation of allogeneic T-lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with genetic modification of CD52 and T-cell receptor alpha constant (TRAC) loci via clustered regularly interspaced short palindromic repeats (CRISPR), with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic CRISPR-edited anti-CD19 CAR T cells PBLTT52CAR19 recognize and bind to CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The editing of the CD52 gene may make the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The editing of the TRAC may eliminate TCR expression, which may abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells, and may also result in uniform CAR expression and enhanced T-cell potency.	Pharmacologic Substance
C179255	Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010	Allogeneic CRISPR-edited Anti-CD19 CAR T-cells CB-010 || Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010 || Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010 || Allogeneic CRISPR-edited CD19-targeted CAR T Cells CB-010 || CB 010 || CB-010 || CB010	A preparation of allogeneic, off-the-shelf T-lymphocytes genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, and clustered regularly interspaced short palindromic repeats (CRISPR)-edited to eliminate endogenous T-cell receptor (TCR) and programmed death 1 (PD-1; PDCD1; CD279; programmed cell death-1) expression, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic CRISPR-edited anti-CD19 CAR-T cells CB-010 recognize and bind to CD19-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. PD-1, an immune checkpoint receptor expressed on T-cells, plays a key role in tumor immune evasion by binding to its ligand programmed death ligand 1 (PD-L1; cluster of differentiation 274; CD274; programmed cell death-1 ligand 1) expressed on tumor cells. By removing PD-1 from T-cells, PD-1-mediated signaling is halted which may decrease T-cell exhaustion and may enhance T-cell activity against the CD19-expressing tumor cells. The endogenous TCR is removed to prevent graft-versus-host disease (GvHD). CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.	Pharmacologic Substance
C165661	Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A	Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A || Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A || Allogeneic Gene-edited CAR T-Cells UCARTCS1A || Allogeneic TALEN Gene-edited CAR T-Cells UCARTCS1A || Allogenic Engineered T-cells Expressing Anti- CS1 CAR UCARTCS1A || UCART CS1A || UCART-CS1A || UCARTCS1A || UCARTCS1A Cells	A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon transfusion of allogeneic CS1-specific universal CAR-expressing T-lymphocytes UCARTCS1A, these cells target and bind to cancer cells expressing CS1. This induces selective toxicity in and causes lysis of CS1-expressing tumor cells. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells.	Pharmacologic Substance
C180829	Allogeneic Cytokine-induced Memory-like NK Cells WU-NK-101	Allogeneic CIML NKs WU-NK-101 || Allogeneic Cytokine-induced Memory-like NK Cells WU-NK-101 || WU-NK 101	A population of off-the-shelf (OTS) donor-derived cytokine-induced, memory-like, cytotoxic natural killer (NK) cells (CIML NKs) containing NK cell-activating surface receptors, with potential immunomodulating and antineoplastic activities. The allogeneic NK cells are pre-activated ex vivo using the human-derived cytokines interleukin (IL)-12, IL-15, and IL-18, which induces the differentiation of the NK cells into CIML NK cells, which contain more NK cell-activating surface receptors. The pretreated NK cells exhibit enhanced activation and increased production of the cytokine interferon-gamma (IFN-g), and may exert enhanced cytotoxicity against tumor cells, including enhanced antibody-dependent cellular cytotoxicity (ADCC). Upon administration, the CIML NKs WU-NK-101 may induce an anti-tumor immune response and kill tumor cells.	Pharmacologic Substance
C61434	Allogeneic Dendritic Cell-Myeloma Idiotype Vaccine	Allogeneic Dendritic Cell-Myeloma Idiotype Vaccine	A cell-based vaccine composed of allogeneic dendritic cells pulsed ex-vivo with an autologous myeloma idiotype with potential antineoplastic activity. Upon administration, allogeneic dendritic cell-myeloma idiotype vaccine may stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against myeloma cells, resulting in cell lysis.	Cell || Pharmacologic Substance
C187122	Allogeneic Dendritic Secretomes	Allogeneic DC Secretomes || Allogeneic Dendritic Secretomes	A preparation of allogeneic dendritic cell (DC) secretomes, with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic DC secretomes may help activate an anti-tumor immune response.	Organic Chemical || Pharmacologic Substance
C62769	Allogeneic Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes	Allogeneic EBV-Specific CTL || Allogeneic Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes || Allogeneic Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes	A preparation of allogeneic Epstein-Barr virus (EBV) specific cytotoxic T-lymphocytes (CTL) with potential antineoplastic activity. Upon administration, the allogeneic EBV-specific CTLs are either harvested from a donor with an EBV-positive tumor or are donor CTLs activated against EBV-specific antigens ex vivo. Administration into a patient exerts a CTL response against EBV-positive tumor cells or EBV-infected cells. This results in cell lysis and inhibition of cancer cell proliferation. EBV, a ubiquitous human herpes virus, is associated with various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.	Cell || Pharmacologic Substance
C187650	Allogeneic Gamma-delta T-lymphocytes TCB-008	Allogeneic Gamma-delta T Lymphocytes TCB-008 || Allogeneic Gamma-delta T-cells TCB-008 || Allogeneic Gamma-delta T-lymphocytes TCB-008 || TCB 008 || TCB-008 || TCB008	A preparation of ex vivo-expanded, allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs), with potential immunomodulating and antineoplastic activities. Upon administration of the allogeneic gamma-delta T-lymphocytes TCB-008, these cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma-delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect.	Pharmacologic Substance
C113296	Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine	Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from an allogeneic glioblastoma (GBM) stem-like cell line, with potential immunostimulatory and antineoplastic activities. Upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to GBM stem cell antigens, which may result in cytotoxic T lymphocyte (CTL) and antibody responses against GBM cells. This leads to GBM cell lysis. GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.	Cell || Pharmacologic Substance
C90540	Allogeneic GM-CSF-Based Myeloma Cell Vaccine	Allogeneic GM-CSF-Based Myeloma Cell Vaccine || Allogeneic GM-CSF-Based Myeloma Cell Vaccine || Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Based Myeloma Cellular Vaccine	An allogeneic tumor cell vaccine containing myeloma cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, allogeneic GM-CSF-based myeloma cellular vaccine secretes GM-CSF, which may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against myeloma cancer cell-associated antigens.	Immunologic Factor || Pharmacologic Substance
C48371	Allogeneic GM-CSF-Secreting Breast Cancer Vaccine	Allogeneic GM-CSF-Secreting Breast Cancer Vaccine || Allogeneic GM-CSF-Secreting Breast Cancer Vaccine || GM-CSF BREAST VAC || GM-CSF-secreting breast tumor vaccine	An allogenic vaccine consisting of irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene. Upon vaccination, the genetically modified cells secrete GM-CSF, thereby potentiating a tumor-specific T cell response against breast cancer cell-asociated antigens.	Pharmacologic Substance
C146711	Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM	Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM || Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM || Breast Cancer Vaccine SV-BR-1-GM || Bria-IMT || GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM || SV-BR-1 Breast Cancer Cell Line Vaccine || SV-BR-1-GM || SV-BR-1-GM Vaccine	A vaccine consisting of irradiated allogeneic breast cancer cells, derived from the breast cancer cell line SV-BR-1 that are transfected with the immunostimulant granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) gene, with potential immunostimulating and antineoplastic activities. Upon intradermal administration of the allogeneic GM-CSF-secreting breast cancer vaccine SV-BR-1-GM, the genetically-modified cells secrete GM-CSF. This potentiates a tumor-specific cytotoxic T-lymphocyte (CTL) immune response against breast cancer cells.	Immunologic Factor
C153334	Allogeneic GM-CSF-secreting Lethally Irradiated Pancreatic Tumor Cell Vaccine	Allogeneic GM-CSF-secreting Lethally Irradiated Pancreatic Tumor Cell Vaccine || Allogeneic GM-CSF-secreting Lethally Irradiated Pancreatic Tumor Cell Vaccine || GVAX Allogeneic Irradiated Pancreatic Tumor Cell Vaccine || Irradiated Allogeneic GM-CSF-secreting Pancreatic Tumor Cell Vaccine	An allogeneic tumor vaccine composed of lethally irradiated allogeneic pancreatic tumor cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, allogeneic GM-CSF-secreting lethally irradiated pancreatic tumor cell vaccine secretes GM-CSF at the injection site. In turn, GM-CSF may stimulate the body's immune system against tumor cells by attracting and enhancing the activation of antigen-presenting cells (APCs), such as dendritic cells (DCs). This promotes antigen presentation to T-lymphocytes and induces a cytotoxic T-lymphocyte (CTL) response against the pancreatic tumor cells expressing the pancreatic tumor-associated antigens (TAAs).	Immunologic Factor || Pharmacologic Substance
C2525	Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine	Allogeneic GM-CSF Prostate Cancer Vaccine || Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine || Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine || Allogeneic Prostate Cancer Vaccine, GM- CSF Gene Transduced || Allogenic Prostate GVAX || GM-CSF Gene Transduced Allogeneic Prostate Cancer Vaccine || GVAX Allogeneic Prostate Cancer Vaccine || GVAX Allogenic Prostate Cancer Vaccine || GVAX Prostate || GVAX Prostate Cancer Vaccine || Prostate Cancer Vaccine, GM-CSF Gene Transduced || Prostate Cancer Vaccine, GVAX	An allogeneic whole cell vaccine expressing human granulocyte macrophage-colony stimulating factor (GM-CSF) with potential antineoplastic activity. Tumor cells from prostate cancer patients are harvested and then genetically modified to secrete GM-CSF, an immune stimulatory growth factor that plays a key role in stimulating the body's immune responses against tumor cells. Because the vaccine is derived from allogenic cells, it has demonstrated a favorable side effect profile than other approaches of delivering long-lasting GM-CSF.	Immunologic Factor || Pharmacologic Substance
C98282	Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine	Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine || Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine || GVAX Melanoma Vaccine	An allogeneic cancer vaccine composed of lethally irradiated whole melanoma cancer cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic GM-CSF-secreting lethally irradiated whole melanoma cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the body's immune system against tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.	Pharmacologic Substance
C161652	Allogeneic GM-CSF-secreting Myeloma Vaccine 	Allogeneic GM-CSF-secreting Multiple Myeloma Vaccine || Allogeneic GM-CSF-secreting Myeloma Vaccine || Allogeneic GM-CSF-secreting Myeloma Vaccine || Allogeneic GM-CSF-secreting Myeloma Vaccine  || Allogeneic GVAX Myeloma Vaccine || Allogeneic Myeloma Vaccine with GM-CSF-secreting K562 Cells || GVAX Allogeneic Myeloma Vaccine	An allogeneic plasma cell myeloma vaccine consisting two multiple myeloma cell lines, H929 and U266, admixed with GM-CSF-secreting K562 cells, with potential antineoplastic and immunopotentiating activities. Upon administration, the secreted GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells, with some specificity towards stimulation of leukocyte production, and may reverse treatment-induced neutropenia. This agent also promotes antigen presentation, upregulates antibody-dependent cellular cytotoxicity (ADCC), increases interleukin-2-mediated lymphokine-activated killer cell (LAK) function and may augment host antitumoral immunity. For safety, the myeloma cells are irradiated prior to vaccination.	Immunologic Factor || Pharmacologic Substance
C101892	Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo	Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo || PANC 10.05 pcDNA-1/GM-Neo	An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line.	Cell || Pharmacologic Substance
C101891	Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo	Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo || PANC 6.03 pcDNA-1/GM-Neo	An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line.	Cell || Pharmacologic Substance
C157341	Allogeneic HAdV Antigen-specific T-lymphocytes	Allogeneic HAdV Antigen-selected T-cells || Allogeneic HAdV Antigen-selected T-lymphocytes || Allogeneic HAdV Antigen-specific T-cells || Allogeneic HAdV Antigen-specific T-lymphocytes || Allogeneic HAdV Antigen-specific T-lymphocytes || Allogeneic Human Adenovirus-specific T-lymphocytes	A population of allogeneic T-lymphocytes specifically reactive to human adenovirus (HAdV) with potential antiviral activity. Allogeneic HAdV antigen-specific T-cells are prepared via ex vivo stimulation of donor-derived peripheral blood mononuclear cells (PBMCs) with HAdV hexon protein. T-cells that secrete interferon (IFN)-gamma in response to HAdV antigen exposure are selected and expanded for administration. Infusion of the HAdV antigen-specific T-lymphocytes into hematopoietic stem cell transplant (HSCT) patients infected with HAdV may potentially reconstitute virus-specific responses, thereby controlling HAdV infections.	Cell || Pharmacologic Substance
C107169	Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine	Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine	An allogeneic melanoma cell vaccine derived from a cell line with high expression of melanoma associated antigens and genetically modified to express both HLA-A2 and 4-1BB ligand, with potential immunostimulating and antineoplastic activities. Upon administration, the 4-1BB ligand of the allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine binds to 4-1BB on activated T-lymphocytes, which induces a strong immune response against HLA-A2 positive melanoma cells.	Cell || Pharmacologic Substance
C155881	Allogeneic HPV-specific Cytotoxic T Lymphocytes	Allogeneic HPV Specific Immune Lymphocytes || Allogeneic HPV-CTLs || Allogeneic HPV-specific Cytotoxic T Lymphocytes	A population of allogeneic cytotoxic T-lymphocytes (CTLs) that are specifically reactive to human papillomavirus (HPV), with potential antiviral and antineoplastic activities. Upon infusion of the allogeneic HPV-specific CTLs, these CTLs induce selective toxicity in HPV-positive cancer cells and other HPV-infected cells. HPV is associated with various cancer cell types.	Cell || Pharmacologic Substance
C148215	Allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced Cord Blood-derived Natural Killer Cells TAK-007	Allogeneic iC9/CAR19/IL15-transduced CB-NK Cells || Allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced Cord Blood-derived Natural Killer Cells TAK-007 || Allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced Cord Blood-derived Natural Killer Cells TAK-007 || CAR-CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK Cells || TAK 007 || TAK-007 || TAK007 || UCB-derived CAR-CD19-CD28-zeta-2A-iCasp9-IL15 Engineered NK Cells || iC9/CAR-CD19-CD28-zeta-2A/IL-15 CB-NK Cells || iC9/CAR.19/IL15-transduced CB-NK Cells || iC9/CAR19/IL15-transduced CB-NKs	A preparation of allogeneic, umbilical cord blood (CB)-derived natural killer cells (NKs) transduced with a retroviral vector expressing interleukin-15 (IL-15) and encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 that is coupled to the co-stimulatory domains of CD28 and to the zeta chain of the TCR/CD3 complex (CD3-zeta), and is linked to the suicide gene inducible caspase 9 (iCasp9; iC9), with potential immunomodulating and antineoplastic activities. Upon transfusion, the allogeneic iC9/CD19-CAR-CD28-zeta-2A-IL15-transduced CB-NKs TAK-007 recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered NK cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered; AP1903 binds to the FKBP12-F36V drug-binding domain, activates caspase 9, and results in apoptosis of the administered NK cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. IL-15 enhances the cytotoxic effect of the NK cells.	Cell || Pharmacologic Substance
C90577	Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2	Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2 || GRm13Z40-2	A preparation of glucocorticoid receptor (GR) negative, allogeneic cytotoxic T-lymphocytes (CTLs) expressing a membrane-tethered interleukin 13 (IL13) cytokine chimeric T-cell antigen receptor (zetakine), with potential antineoplastic activity. Upon transfection of donor T-lymphocytes with a plasmid encoding a fusion protein of the IL13-zetakine and the selection-suicide expression enzyme HyTK, these modified CTLs are expanded and introduced into a patient with glioblastoma multiforme (GBM). This agent specifically targets IL13 receptor alpha2, a glioma-restricted cell-surface epitope; the CTLs exert their cytolytic effect thereby killing IL13Ra2-expressing glioma cells. In addition, IL13-zetakine redirected CTLs induce production of certain cytokines. Furthermore, due to the fact that these CTLs are GR negative, they can be used concomitantly with glucocorticoid therapy. The IL13-zetakine consists of an extracellular IL-13 E13Y mutein-human IgG4 hinge-Fc chimera fused to human cytoplasmic CD3-zeta via the transmembrane domain of human CD4.	Cell || Pharmacologic Substance
C178501	Allogeneic Invariant Natural Killer T-cells agenT-797	AGENT 797 || AGENT-797 || AgenT-797 || Allogeneic Invariant Natural Killer T-cells agenT-797 || Allogeneic Invariant Natural Killer T-cells agenT-797 || Allogeneic iNKT agenT-797 || agenT797	A preparation of allogeneic, off-the shelf, natural killer T-cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic iNKT agenT-797, the invariant T-cell receptor (TCR) and natural-killer group 2, member D receptor (NKG2D; KLRK1; natural killer cell activating receptor group 2D) expressed by these cells recognize CD1d-restricted lipid ligands and stress ligands, which are expressed on certain tumor cells. These receptor-ligand interactions may induce the secretion of large amounts of various pro-inflammatory cytokines, including interferon gamma (IFN-g), and activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells.	Pharmacologic Substance
C187301	Allogeneic iPSC-derived Anti-CD19-CAR/IL-15-expressing NK Cells CNTY-101	Allogeneic Anti-CD19-CAR-iNK Cells CNTY-101 || Allogeneic Anti-CD19-CAR-iPSC-derived Natural Killer Cells CNTY-101 || Allogeneic iPSC-derived Anti-CD19-CAR-CD28-CD3zeta-IL-15-expressing NK Cells CNTY-101 || Allogeneic iPSC-derived Anti-CD19-CAR/IL-15-expressing NK Cells CNTY-101 || Allogeneic iPSC-derived Anti-CD19-CAR/IL-15-expressing Natural Killer Cells CNTY-101 || CNTY 101 || CNTY-101 || CNTY101	A preparation of allogeneic natural killer (NK) cells derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) derived from the anti-CD19 monoclonal antibody FMC63 and coupled to the CD28 and zeta chain of the TCR/CD3 complex (CD3-zeta) costimulatory signaling domains, and interleukin 15 (IL-15), with potential immunostimulatory and antineoplastic activities. Upon administration, allogeneic iPSC-derived anti-CD19-CAR/IL-15-expressing NK cells CNTY-101 recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. The human tumor associated antigen (TAA) CD19 is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CNTY-101 is also engineered with a safety switch composed of a shorter version of the extracellular domain of human epidermal growth factor receptor (EGFR). This allows the elimination of CNTY-101 upon the administration of anti-EGFR antibodies such as cetuximab. In addition, CNTY-101 is gene-edited to prevent its elimination by the patient's NK cells, CD4 and CD8 T-cells.	Pharmacologic Substance || Cell
C103862	Allogeneic Irradiated Melanoma Cell Vaccine CSF470	Allogeneic Irradiated Melanoma Cell Vaccine CSF470 || CSF 470 Vaccine || CSF470 Vaccine	An allogeneic cancer vaccine composed of a mixture of lethally irradiated whole melanoma cancer cells obtained from four different melanoma cell lines, with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic irradiated melanoma cell vaccine may stimulate the body's immune system to exert a cytotoxic T-lymphocyte response and antibody-dependent cellular cytotoxicity (ADCC) against the melanoma cancer cells.	Pharmacologic Substance
C79799	Allogeneic Large Multivalent Immunogen Breast Cancer Vaccine	Allogeneic LMI Breast Cancer Vaccine || Allogeneic Large Multivalent Immunogen Breast Cancer Vaccine || Allogeneic Large Multivalent Immunogen Breast Cancer Vaccine	A cancer vaccine, containing human-specific large multivalent immunogens (LMIs) isolated from the membrane fraction of cells from a breast cancer cell line, with potential immunostimulatory and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen breast cancer vaccine may stimulate a cytotoxic T lymphocyte (CTL) immune response against tumor cells that express the breast cancer cell-specific LMIs.	Immunologic Factor || Pharmacologic Substance
C78862	Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307	Allogeneic LMI Melanoma Vaccine LP2307 || Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307 || Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307 || LP2307	A cancer vaccine, containing human-specific large multivalent immunogen (LMI) isolated from plasma membrane fractions of the melanoma cell lines MSM-M1 and MSM-M2, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen melanoma vaccine LP2307 may stimulate a CD8+ cytotoxic T lymphocyte (CTL) response against melanoma tumor cells that express melanoma-specific LMI.	Immunologic Factor || Pharmacologic Substance
C78201	Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes	Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes || Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes	A preparation of cytotoxic T-lymphocytes (CTL), specifically reactive to the Epstein-Barr virus (EBV) latent membrane proteins (LMP) 1 and 2, with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMC) are collected from a donor and are exposed ex vivo to dendritic cells (DCs) transfected with a replication-deficient adenovirus encoding EBV LMP1/2 to generate LMP1/2-specific CTL which are subsequently expanded. Administration of allogeneic LMP1-/LMP2- specific CTL to patients with LMP1/2-positive tumors may result in a specific CTL response against tumor cells expressing LMP1 and LMP2, resulting in cell lysis and inhibition of tumor cell proliferation. As tumor associated antigens (TAAs), LMP1 and LMP2 are expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.	Cell || Pharmacologic Substance
C78861	Allogeneic Melanoma Vaccine AGI-101H	AGI-101H || Allogeneic Melanoma Vaccine AGI-101H	A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative. Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells.	Immunologic Factor || Pharmacologic Substance
C121640	Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine	Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous DC Vaccine || Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine || MesoCancerVac	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a mixture of lysates from five allogeneic mesothelioma tumor cell lines, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic mesothelioma tumor cell lysates. Upon re-administration of the allogeneic mesothelioma tumor lysate-pulsed autologous DC vaccine, the immune system is exposed to an undefined amount of mesothelioma-associated antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against mesothelioma tumor cells and leads to tumor cell lysis.	Cell || Pharmacologic Substance
C187029	Allogeneic MUC1-C-specific CAR-T Cells P-MUC1C-ALLO1	Allogeneic Anti-MUC1-C CAR T Cells P-MUC1C-ALLO1 || Allogeneic MUC1-C-specific CAR-T Cells P-MUC1C-ALLO1 || P-MUC1C-ALLO 1 || P-MUC1C-ALLO-1 || P-MUC1C-ALLO1 || P-MUC1C-ALLO1 CAR-T Cells	An off-the-shelf (OTS) preparation of human allogeneic T-lymphocytes containing primarily stem cell memory T-cells (Tscm) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the C-terminal subunit of the tumor-associated antigen (TAA) mucin-1 (MUC1-C) and gene-edited to knockout both the T-cell receptor (TCR) and major histocompatibility complex (MHC) class I proteins, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic MUC1-C-specific CAR-T cells P-MUC1C-ALLO1 specifically recognize and induce selective toxicity in MUC1-C-expressing tumor cells. MUC1, a glycoprotein normally expressed on epithelial cells and overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation. The proteolytic cleavage of MUC1 in the tumor microenvironment (TME) leads to the overexpression of MUC1-C in the TME.	Cell || Pharmacologic Substance
C94209	Allogeneic Natural Killer Cell Line MG4101	Allogeneic NK Cell Line MG4101 || Allogeneic Natural Killer Cell Line MG4101 || MG-4101 || MG4101	A population of allogeneic, cytotoxic natural killer (NK) cells with potential antitumor activity. Allogeneic natural killer cell line MG4101 is derived from cells of a normal, healthy donor upon leukapheresis and activation.	Cell || Pharmacologic Substance
C117231	Allogeneic Natural Killer Cell Line NK-92	Allogeneic Natural Killer Cell Line NK-92 || Allogeneic Natural Killer Cell Line NK-92 || HUMAN NATURAL KILLER CELL LINE NK-92 || NK-92 || NK-92 Cells || haNK	A proprietary, human cytotoxic cell line composed of allogeneic, activated, interleukin-2 (IL-2) dependent-natural killer cells derived from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma, with potential antineoplastic activity. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells. Upon infusion of the allogeneic NK cell line NK-92, the NKs recognize and bind to tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in cancer cell lysis and apoptosis. In addition, NK-92 cells express high affinity Fc receptors, which bind to therapeutic antibodies; therefore, this agent can enhance antibody dependent cellular cytotoxicity (ADCC) of co-administered therapeutic antibodies.	Cell || Pharmacologic Substance
C178455	Allogeneic Natural Killer Cells PB103	Allogeneic NK Cells PB103 || Allogeneic NKs PB103 || Allogeneic Natural Killer Cells PB103 || PB 103 || PB-103 || PB103	A preparation of allogeneic, natural killer (NK) cells, with potential cytolytic and antineoplastic activities. Upon administration, allogeneic NK cells PB103 may lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate an anti-tumor immune response.	Pharmacologic Substance
C143157	Allogeneic Nicotinamide-expanded Natural Killer Cells	Allogeneic NAM NK Cells || Allogeneic NAM NKs || Allogeneic Nicotinamide-expanded Natural Killer Cells || Donor Nicotinamide expanded-Natural Killer Cells	Allogeneic, nicotinamide (NAM)-expanded natural killer (NK) cells, with potential cytolytic and antineoplastic activities. Upon administration, the allogeneic NAM-expanded NK cells may lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate an anti-tumor immune response. Ex-vivo treatment with the vitamin B3 derivative NAM increases the in-vivo homing, retention and proliferation potential of the NK cells.	Cell || Pharmacologic Substance
C187130	Allogeneic Nicotinamide-expanded Natural Killer Cells GDA-201	Allogeneic NAM-expanded NK Cells GDA-201 || Allogeneic Nicotinamide-expanded Natural Killer Cells GDA-201 || GDA 201 || GDA-201 || GDA201 || NAM NKs GDA-201 || NAM-expanded Allogeneic NK Cells GDA-201	A preparation of allogeneic, nicotinamide (NAM)-expanded natural killer (NK) cells, with potential cytolytic and antineoplastic activities. Upon administration, the allogeneic NAM-expanded NK cells GDA-201 may lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate an anti-tumor immune response. Ex-vivo treatment with the vitamin B3 derivative NAM increases the in-vivo homing, retention and proliferation potential of the NK cells.	Pharmacologic Substance
C167220	Allogeneic NKG2DL-targeting CAR-grafted Gamma Delta T Cells	Allogeneic NKG2DL-targeting CAR-gd T-cells || Allogeneic NKG2DL-targeting CAR-grafted Gamma Delta T Cells || CTM-N2D	A preparation of a subset of allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) and that are engineered to express a chimeric antigen receptor (CAR) encoding for human natural-killer group 2, member D receptor protein (NKG2D or KLRK1; natural killer cell activating receptor group 2D), with potential immunomodulating and antineoplastic activities. Upon administration of the NKG2DL-targeting CAR-grafted gamma delta T cells, these cells specifically target and bind to tumor cells expressing NKG2D ligands (NKG2DL). This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2DL-expressing tumor cells. In addition, these cells target, bind to and kill NKG2DL-expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. Gamma/delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells.	Pharmacologic Substance
C176027	Allogeneic NKG2D-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX101	Allogeneic NKG2D-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX101 || Allogeneic NKG2D-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX101 || Allogeneic mbIL-15/NKG2D-OX40-CD3zeta-CAR Expressing NKs NKX101 || IL-15-armored NKG2D Ligands-targeting NKX101 || NKX 101 || NKX-101 || NKX101	A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) encoding for human natural-killer group 2, member D receptor protein (NKG2D; KLRK1; natural killer cell activating receptor group 2D) that is coupled to the co-stimulatory domain of OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon transfusion of the allogeneic NKG2D-OX40-CD3zeta-CAR-mbIL-15-expressing NKs NKX101, these cells specifically target and bind to tumor cells expressing NKG2D ligands (NKG2DL). This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2DL-expressing tumor cells. In addition, these cells target, bind to and kill NKG2DL-expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. IL-15 is a pro-survival cytokine that potentiates the immune response against tumor cells. NKG2D ligands are overexpressed in a variety of cancer cells.	Cell || Pharmacologic Substance
C185594	Allogeneic NK-like Cells GAIA-102	Allogeneic NK-like Cells GAIA-102 || GAIA 102 || GAIA-102 || GAIA102	A preparation of allogeneic, off-the-shelf (OTS), ex-vivo activated and expanded natural killer (NK)-like cells, with a CD3-negative/CD56bright/CD57-negative immature phenotype, with potential cytolytic and antineoplastic activities. Upon infusion, allogeneic NK-like cells GAIA-102 may lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate anti-tumor immune responses.	Cell || Pharmacologic Substance
C174011	Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells	Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells || Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells || Allogeneic PD-L1 t-haNK || Allogeneic PD-L1-t-haNK || Allogeneic PD-L1-targeting High-affinity NKs	A preparation of natural killer (NK) cells that are derived from NK-92 cells, a human cytotoxic cell line composed of allogeneic NK cells derived from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma (NHL), that are genetically engineered to express the high-affinity CD16/FcgammaRIIIa (158V) allele, endoplasmic reticulum (ER)-retained interleukin (IL)-2 and a chimeric antigen receptor (CAR) specific for programmed death-ligand 1 (PD-L1), with potential immunomodulating, cytolytic and antineoplastic activities. Upon infusion of the PD-L1 tumor-targeted high-affinity (ha) NK cells, the NK cells recognize and bind to tumor cells, preferentially to PD-L1-expressing tumor cells and human peripheral myeloid-derived suppressor cells (MDSCs). This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, and results in cancer cell lysis and apoptosis. In addition, the incorporation of the high-affinity CD16 allele allows the NK cells to lyse tumor cells via antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by tumor-antigen-specific immunoglobulin G1 (IgG1) antibodies through binding of CD16 with the Fc region of human IgG1 antibodies. IL-2 replenishes the granular stock of NK cells, leading to enhanced perforin- and granzyme-mediated lysis of tumor cells.	Cell || Pharmacologic Substance
C173427	Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01	Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01 || Allogeneic pDCs- expressing Lung Tumor Antigens PDC*lung01 || PDC*lung01 || PDClung01 || Therapeutic Cancer Vaccine PDC*lung01	An off-the-shelf (OTS) preparation composed of irradiated allogeneic plasmacytoid dendritic cells (pDCs) loaded with seven immunogenic, human leukocyte antigen (HLA)-A*02:01 serotype-restricted peptides derived from the lung tumor antigens cancer/testis antigen 1 (NY-ESO-1), melanoma antigen A3 (MAGE-A3), MAGE-A4, multi-MAGE, a peptide shared by multiple MAGE-A proteins, survivin, mucin1 (MUC1) and melanoma antigen recognized by T-cells 1 (Mart-1; Melan-A), with potential immunostimulating and antineoplastic activities. Upon administration of the allogeneic pDCs expressing lung tumor antigens PDC*lung01, the pDCs may activate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against HLA-A*0201 positive lung cancer cells expressing the TAAs NY-ESO-1, MAGE-A3, MAGEA4, multi-MAGE, survivin, MUC1 and melan-A. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.	Immunologic Factor || Pharmacologic Substance
C95213	Allogeneic Renal Cell Carcinoma Vaccine MGN1601	Allogeneic Renal Cell Carcinoma Vaccine MGN1601 || IL-7/GM-CSF/CD80/CD154-encoding Synthetic dSLIM-30L1 Allogeneic Renal Cell Carcinoma Vaccine MGN1601 || MGN1601	A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist.. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.	Cell || Pharmacologic Substance
C176885	Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211	Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211 || Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211 || Allogeneic shRNA-based Anti-BCMA CAR-T Cells CYAD-211 || CYAD 211 || CYAD-211 || CYAD211	A preparation of human allogeneic, 'off-the-shelf' (OTS), non-gene edited T-lymphocytes that are engineered to co-express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and a single short hairpin RNA (shRNA) that disrupts the expression of the CD3zeta component of the T-cell receptor (TCR), with potential immunostimulating and antineoplastic activities. Upon administration, the allogeneic shRNA-based anti-BCMA CAR T-cells CYAD-211 recognize and bind to BCMA-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. The downregulation of the expression of the TCR CD3zeta subunit by shRNA prevents the potential induction of graft-versus-host disease (GvHD) by the donor T-cells.	Pharmacologic Substance
C148149	Allogeneic TCR alpha/beta-positive T-lymphocyte-depleted Peripheral Blood Stem Cells	Allogeneic TCR a/b T cell-depleted PBSCs || Allogeneic TCR alpha/beta T Cell-depleted PBSCs || Allogeneic TCR alpha/beta-positive T-lymphocyte-depleted Peripheral Blood Stem Cells	A preparation of allogeneic T-cell receptor (TCR) alpha/beta-positive T cell-depleted peripheral blood stem cells (PBSCs), that can potentially be used for hematopoietic stem cell transplantation (HSCT). Allogeneic PBMCs are processed, using the proprietary CliniMACS device, to remove TCRalpha/beta T-cells, while retaining other cells, such as donor-derived natural killer (NK) cells and gamma/delta T-cells. As TCR alpha/beta-positive T-cells appear to be related to the development of graft versus host disease (GvHD), depletion of these cells may lower the risk of the recipient developing GvHD. Upon infusion of the TCR alpha/beta-positive T-cell-depleted PBSCs for allogeneic stem cell transplantation (allo SCT), the alpha/beta-positive T-cell depletion as well as the presence of allogeneic NK cells, and other cells, may facilitate engraftment, exert graft-versus-leukemia effects, enhance post-transplant immune recovery, and reduce the risk of infections and GvHD.	Cell || Pharmacologic Substance
C174401	Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19	Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19 || CTL 19 || CTL-19 || CTL19	A preparation of allogeneic, third-party, CD4+ T-lymphocytes that specifically recognizes the human leukocyte antigen (HLA)-DPB1*0401 and transduced with a suicide gene, with potential antineoplastic activity. Upon administration, allogeneic third-party suicide gene-transduced anti-HLA-DPB1*0401 CD4+ T-cells CTL 19 specifically target and kill HLA-DPB1*0401-positive leukemic cells. The suicide gene causes the destruction of the T-cell clone upon the administration and presence of ganciclovir, which enhances the safety of the agent. HLA-DP is expressed by many leukemic cells.	Pharmacologic Substance
C150511	Allogeneic T-lymphocytes Expressing NY-ESO-1-C259-specific TCR	Allogeneic NY-ESO-1-C259 T-cells || Allogeneic T-lymphocytes Expressing NY-ESO-1-C259-specific TCR || NY-ESO-1 c259 T Cells	Genetically engineered human allogeneic T-lymphocytes that are transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer/testis antigen NY-ESO-1, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and introduction into the patient, the allogeneic T-lymphocytes expressing NY-ESO-1-C259-specific TCR specifically target and bind to NY-ESO-1-overexpressing tumor cells. This may result in the specific cytotoxic T-lymphocyte (CTL) killing of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is expressed in normal testis and on the surface of various tumor cell types.	Cell || Pharmacologic Substance
C157484	Allogeneic Tri-functional Anti-CD19 CAR-NK Cells	Allogeneic CD19-TriCAR SILK Cells || Allogeneic CD19-TriCAR-T/SILK || Allogeneic CD19-TriCAR-T/SILK Cells || Allogeneic Tri-functional Anti-CD19 CAR-NK Cells	A preparation of allogeneic natural killer (NK) cells transduced with a retroviral vector expressing the immunostimulatory cytokine interleukin-15 (IL-15) and encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) that is coupled to the co-stimulatory domains cluster of differentiation 28 (CD28, T-cell-specific surface glycoprotein CD28), cluster of differentiation 137 (CD137; 4-1BB), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (TCRzeta; CD247; CD3zeta); and a blocker for the inhibitory T-cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immunomodulating and antineoplastic activities. Upon transfusion, the allogeneic tri-functional anti-CD19 CAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15 enhances the cytotoxic effect of the NK cells and the activated anti-tumor T-cells. The PD-1 inhibitory domain targets and binds to programmed cell death-1 ligand 1 (PD-L1) expressed on tumor cells, thereby preventing the binding of the PD-1 on T-lymphocytes to its ligand, PD-L1 on tumor cells. This prevents PD-1/PD-L1-mediated inhibition of T-lymphocytes and leads to the activation and expansion of T-cells resulting in a cytotoxic T-lymphocyte (CTL) response against tumor cells, thereby enhancing the elimination of tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The co-stimulatory signaling domains enhance both proliferation of T-cells and anti-tumor activity.	Cell || Pharmacologic Substance
C1983	Allogeneic Tumor Cell Vaccine	Allogeneic Tumor Cell Vaccine || Allogeneic Tumor Cell Vaccine || allogenic cell vaccine	A vaccine composed of tumor cells isolated from the tumor of one patient, killed and processed, and administered to another patient to stimulate cytotoxic immune responses to a similar tumor cell type. The cells found in this type of whole-cell vaccine express many cell-surface tumor-associated antigens. This vaccine is frequently administered with an adjuvant immunostimulant. (NCI04)	Immunologic Factor || Pharmacologic Substance
C182633	Allogeneic Variable Delta 1 Gamma-delta T-lymphocytes GDX012	Allogeneic Variable Delta 1 Gamma-delta T-cells GDX012 || Allogeneic Variable Delta 1 Gamma-delta T-lymphocytes GDX012 || Allogeneic Variable Delta 1 Gamma-delta T-lymphocytes GDX012 || Allogeneic Vd1 gd T-cells GDX012 || Allogeneic Vd1 gd T-lymphocytes GDX012 || Allogeneic gd T-cells GDX012 || GDX 012 || GDX-012 || GDX012 || Gamma-delta T-cells GDX012	An off-the-shelf (OTS) preparation of allogeneic variable delta 1 (Vd1) gamma-delta (gd) T-lymphocytes, with potential immunomodulating and antineoplastic activities. Upon administration of the allogeneic Vd1 gd T-lymphocytes GDX012, these cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. Vd1 gd T-cells, a subset of gamma delta T-cells, recognize and are activated by cancer cells, and may therefore have a stronger association with antitumor immune responses compared with other gamma delta T-cell subtypes.	Pharmacologic Substance || Cell
C1649	Allovectin-7	Allovectin-7 || Allovectin-7 || Allovectin-7 || HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex || HLA-B7/Beta2M DNA Lipid Complex || HLA-B7/Beta2M Plasmid DNA/DMRIE/DOPE Lipid Complex || HLA-B7/Beta2M Plasmid DNA/Lipid Complex || HLA-B7/Beta2Microglobulin DNA-Liposome Complex		Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C81667	Almurtide	2-Acetamido-3-O-((((1S)-1-(((1R)-1-carbamoyl-3- carboxypropyl)carbamoyl)ethyl)carbamoyl)methyl)-2-deoxy-D- glucopyranose || ALMURTIDE || Almurtide || Cgp-11637 || N-Acetyl-nor-muramyl-L-alanyl-D-isoglutamine || nor-MDP || norMDP	A synthetic muramyl dipeptide (MDP) analogue with potential immunostimulating and antineoplastic activity. As a derivative of the mycobacterial cell wall component MDP, almurtide activates both monocytes and macrophages. This results in the secretion of cytokines and induces the recruitment and activation of other immune cells, which may result in indirect tumoricidal or cytostatic effects.	Pharmacologic Substance
C126640	Alobresib	(2-Cyclopropyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1hbenzimidazol-4-yl)(dipyridin-2-yl)methanol || ALOBRESIB || Alobresib || Alobresib || GS 5829 || GS-5829 || GS5829	An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, alobresib binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.	Pharmacologic Substance
C170744	Alofanib	ALOFANIB || Alofanib || Benzoic Acid, 3-(((4-Methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)- || ES000835 || RPT 835 || RPT-835 || RPT835	An inhibitor of the fibroblast growth factor receptor (FGFR) type 2 (FGFR2), with potential antineoplastic and anti-angiogenic activities. Upon administration, alofanib targets, allosterically binds to the extracellular domain of FGFR2 and inhibits the activity of FGFR2, which may result in the inhibition of basic FGF (bFGF)/FGFR2-related signal transduction pathways. This inhibits FGF-induced endothelial cell proliferation and migration, and inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.	Pharmacologic Substance
C162521	Alomfilimab	ALOMFILIMAB || Alomfilimab || Alomfilimab || Anti-ICOS Monoclonal Antibody KY1044 || KY 1044 || KY-1044 || KY1044	A human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, alomfilimab selectively binds to dimeric ICOS expressed on certain T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Additionally, KY1044 may eliminate ICOS-positive T-cells via antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C94214	Alpelisib	ALPELISIB || Alpelisib || Alpelisib || BYL719 || Phosphoinositide 3-kinase Inhibitor BYL719 || Piqray || VIJOICE	An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.	Pharmacologic Substance
C48372	Alpha Fetoprotein Adenoviral Vector Vaccine	AdVhAFP || Alpha Fetoprotein Adenoviral Vector Vaccine || Alpha Fetoprotein Adenoviral Vector Vaccine	A vaccine consisting of a recombinant adenoviral vector encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. (NCI05)	Pharmacologic Substance
C48373	Alpha Fetoprotein Plasmid DNA Vaccine	Alpha Fetoprotein Plasmid DNA Vaccine || phAFP	A vaccine consisting of plasmid DNA encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. (NCI05)	Pharmacologic Substance
C1720	Alpha Galactosylceramide	ALPHA-GALACTOSYLCERAMIDE || Alpha Galactosylceramide || Alpha Galactosylceramide || KRN-7000 || KRN7000 || KRN7000 || a-GalCer	A potent alpha galactosylceramide modified from marine-sponge that stimulates the immune system to exhibit antitumor activity.	Organic Chemical || Pharmacologic Substance
C52185	Alpha V Beta 1 Inhibitor ATN-161	ATN-161 || ATN-161 || ATN-161 || Alpha V Beta 1 Inhibitor ATN-161	A small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for integrin alpha5beta1, thereby preventing integrin alpha5beta1 binding. This receptor blockade may result in inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, angiogenesis, and tumor progression. Integrin alpha5beta1 is expressed on endothelial cells and plays a crucial role in endothelial cell adhesion and migration.	Pharmacologic Substance
C172097	Alpha V Beta 8 Antagonist PF-06940434	Alpha V Beta 8 Antagonist PF-06940434 || Alpha V Beta 8 Antagonist PF-06940434 || Alpha V Beta 8 Inhibitor PF-06940434 || PF 06940434 || PF-06940434 || PF06940434	An antagonist of integrin alpha v beta 8, with potential antineoplastic activity. Upon administration, PF-06940434 selectively binds to and blocks the receptor for integrin alpha v beta 8, thereby preventing integrin alpha v beta 8 binding. This may result in the inhibition of cell adhesion in the tumor microenvironment (TME) and blocks the activation of the cytokine transforming growth factor-beta 1 (TGF-b1), preventing TGF-b1-mediated signal transduction. This abrogates TGF-b1-mediated immunosuppression, enhances anti-tumor immunity in the TME and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGF-b1-dependent proliferation of cancer cells. Alpha v beta 8 integrin plays a key role in tumor initiation, growth, and progression through TGF-b1 activation. It is expressed in a variety of tumor cell types and is associated with poor prognosis.	Pharmacologic Substance
C113647	Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine	Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine || HAR || HyperAcute Renal	An allogeneic renal cell cancer (RCC) vaccine composed of cell line-derived RCCs that are genetically engineered to express the murine alpha-1,3-galactosyltransferase (GalT), with potential immunostimulatory and antineoplastic activities. Not naturally occurring in humans, GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes on the cell membranes of the allogeneic RCCs present in the vaccine. This induces a hyperacute rejection reaction involving pre-existing human anti-alpha-gal antibodies, which bind to the foreign alpha-gal epitopes expressed by the allogeneic RCCs. This results in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous RCCs with unmodified carbohydrate epitopes.	Cell || Pharmacologic Substance
C82258	Alpha-1-Proteinase Inhibitor Human	.ALPHA.1-PROTEINASE INHIBITOR HUMAN || A1AT || A1PI || AAT || Alpha 1 Antitrypsin || Alpha-1 Antitrypsin || Alpha-1-Antiproteinase || Alpha-1-Proteinase Inhibitor Human || Alpha-1-Proteinase Inhibitor Human || Aralast || Prolastin-C	Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.	Pharmacologic Substance
C91378	Alpha-fetoprotein Peptide-Pulsed Autologous Dendritic Cell Vaccine	Alpha-fetoprotein Peptide-Pulsed Autologous Dendritic Cell Vaccine	A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with four alpha-fetoprotein (AFP) peptides, with potential immunostimulatory and antineoplastic activities. Upon administration, AFP peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against AFP-expressing cancer cells, resulting in tumor cell lysis. AFP is overexpressed in a variety of cancer cells.	Immunologic Factor || Pharmacologic Substance
C165548	Alpha-Gal AGI-134	AGI 134 || AGI-134 || AGI-134 || AGI134 || Alpha-Gal AGI-134 || Anti-alpha Gal Immunotherapeutic AGI-134 || aGal AGI-134	A synthetic alpha Gal (aGal) molecule, with potential immunomodulating and antineoplastic activities. Upon intratumoral injection of aGal AGI-134, aGal coats the cancer cell membranes and triggers an anti-aGal antibody-mediated immune response leading to an initial complement-dependent and antibody-dependent cellular cytotoxicity (ADCC). This cytotoxicity causes release from tumor cells and subsequent uptake of released tumor-associated antigens (TAAs) by antigen-presenting cells (APCs). This may activate a systemic immune response against the TAAs and may eradicate cancer cells. aGal is a cell-surface carbohydrate antigen not expressed by humans while being expressed by all other mammals and bacteria. Anti-aGal antibodies are continuously and abundantly produced by humans due to exposure to aGal present on intestinal bacteria in the digestive system.	Pharmacologic Substance
C78200	Alpha-Gal Glycosphingolipids	Alpha-Gal Glycosphingolipids || GSL alpha-GAL || Galactose(alpha1,3,)galactose Glycosphingolipids	A preparation of glycosphingolipids (GSL), containing the disaccharide epitope galactose-alpha-1,3-galactose (alpha-Gal), with potential antineoplastic activity. Upon intratumoral injection, alpha-Gal glycosphingolipids may stimulate the immune system to mount complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) responses against alpha-Gal GSL, which may result in tumor cell death; these responses involve natural anti-alpha-Gal immunoglobulins (Igs).  As antibodies that occur naturally due to sensitization to alpha-Gal present on symbiotic bacterial flora, anti-alpha-Gal Igs are present in unusually high amounts in human sera.  GSL represent a glycolipid subtype containing the amino alcohol sphingosine; tumor-associated GSL antigens contain various oligosaccharide residues.	Organic Chemical || Pharmacologic Substance
C78489	Alpha-Galactosylceramide-Pulsed Autologous Dendritic Cells	Alpha-Galactosylceramide-Pulsed Autologous Dendritic Cells || DC-KRN7000 || KRN7000-Pulsed Autologous Dendritic Cells	A cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with the marine sponge glycolipid alpha-galactosylceramide (alpha-GalCer) with potential immunostimulatory and antimetastatic activities. Upon administration, alpha-galactosylceramide-pulsed autologous dendritic cells may result in the activation and proliferation of a subset of endogenous natural killer T (NKT) cells, B cells, and CD4+ and CD8+ T cells, and the production of interferon-gamma and interleukin-12; these cascade events may result in a T helper-1 cell-biased proinflammatory antitumor immune response. The NKT cell ligand alpha-GalCer was originally isolated from the marine sponge Agelas mauritianusis.	Cell || Pharmacologic Substance
C183167	Alpha-lactalbumin Breast Cancer Vaccine	Alpha-lactalbumin Breast Cancer Vaccine || Alpha-lactalbumin Breast Cancer Vaccine || Alpha-lactalbumin Protein Vaccine || Alpha-lactalbumin Vaccine || a-Lactalbumin Vaccine || aLA Breast Cancer Vaccine	A breast cancer vaccine consisting of recombinant human alpha-lactalbumin (aLA), with potential immunostimulatory and antineoplastic activities. Upon administration, aLA breast cancer vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that express the aLA protein, resulting in tumor cell lysis. aLA is expressed in many types of breast cancer, including triple negative breast cancer (TNBC), while normally present in healthy breast tissues only during lactation.	Pharmacologic Substance
C159497	Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H	Alpha 1H || Alpha-1H || Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H || Alpha-lactalbumin-derived Synthetic Proteolipid Complex Alpha1H || Alpha1H	A synthetic proteolipid complex comprised of the alpha-1 domain of alpha-lactalbumin (lactose synthase B protein) and oleic acid, with potential antineoplastic activity. Upon intravesical instillation, alpha1H selectively accumulates in the nuclei of tumor cells and binds to histones H3, H4, and H2B. By binding to histones, alpha1H disrupts chromatin assembly and interferes with intact chromatin, thereby preventing tumor cell transcription and replication. Additionally, alpha1H inhibits the phosphorylation of multiple kinases involved in cancer-associated pathways including the Ras/Raf/ERK, PI3K/AKT, p38 MAPK and JNK signaling pathways. This may inhibit tumor cell proliferation and induce apoptosis in tumor cells that are driven by the dysregulation of certain kinases and oncogenic GTPases.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C106371	Alpha-lipoic Acid-Palladium/Vitamin/Mineral Supplement	Alpha-lipoic Acid-Palladium/Vitamin/Mineral Supplement || LAPd || Palladium Lipoic Complex || PolyMVA	A proprietary water- and lipid-soluble polymer-based nutritional supplement composed of a complex mixture of alpha-lipoic acid bound to palladium (Palladium Lipoic Acid Complex (PdLA)) and other minerals, vitamins and amino acids, including vitamins B1, B2 and B12, formylmethionine, acetyl cysteine, and trace amounts of molybdinum, rhodium, and ruthenium, with potential anti-oxidant and cytoprotective activities. Upon oral administration, the alpha-lipoic acid-palladium/vitamin/mineral supplement acts as a free radical scavenger, crosses the cell membrane and is able to transfer electrons from fatty acids to DNA via the electron transport chain in mitochondria, which protects against DNA damage. This could protect non-cancerous cells from the oxidative damage caused by radiation and chemotherapy. In addition, in the hypoxic conditions found within tumors, the excess electrons can generate free radicals within mitochondria and could induce both cytochrome c release and apoptosis.	Pharmacologic Substance
C28795	Alpha-Thioguanine Deoxyriboside	6H-Purine-6-thione, 2-amino-9-(2-deoxy-alpha-D-erythro-pentofuranosyl)-1,9-dihydro- (9CI) || 9H-Purine-6-thiol, 2-amino-9-(2-deoxy-alpha-D-erythro-pentofuranosyl)- || A-TGDR || Alpha-Thioguanine Deoxyriboside || Thioguanine 9-alpha-D-2'-deoxyriboside || alpha-2'-Deoxy-6-thioguanosine || alpha-2'-Deoxythioguanosine || alpha-Thiodeoxyguanosine	A purine analog with potential antineoplastic activity. (NCI04)	Pharmacologic Substance || Amino Acid, Peptide, or Protein
C117234	Alpha-tocopheryloxyacetic Acid	.ALPHA.-TOCOPHERYLOXYACETIC ACID || 2,5,7,8-Tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) Acetic Acid || Alpha-tocopheryloxyacetic Acid || a-TEA || alpha-TEA	An orally bioavailable vitamin E derivative with potential antineoplastic and immunostimulating activities. Upon administration, alpha-tocopheryloxyacetic acid (alpha-TEA) induces tumor autophagy; the autophagosomes formed, which carry tumor associated antigens (TAAs), allow for increased cross-presentation of TAAs by professional antigen-presenting cells (APCs). This activates a T cell-mediated T helper type 1 (TH1) response, generates a cytotoxic T-lymphocyte (CTL) response against cancer cells, and reduces the frequency of regulatory T-cell (Treg) differentiation. In addition, alpha-TEA modulates the release of various cytokines and chemokines and induces tumor cell apoptosis. Altogether, this results in decreased tumor cell proliferation.	Pharmacologic Substance
C64846	Alpha-type-1 Polarized Dendritic Cells	Alpha-type-1 Polarized Dendritic Cells || Alpha-type-1 Polarized Dendritic Cells || alphaDC1	A mature polarized dendritic cell with potent immunostimulating activity. Treating dendritic cells (DCs) with interferon-alpha (IFN-a) and polyinosinic:polycytidylic acid (p-I:C) in addition to a cytokine cocktail (tumor necrosis factor alpha/Interleukin-1beta/IFN-gamma) produces mature but not exhausted alpha type-1 polarized DCs (alphaDC1) that are capable of: 1) high responsiveness to other lymphoid chemokines, and 2) producing high level of interleukin-12p70 (IL-12p70). Therefore, alphaDC1 has a much more significant capability of inducing helper T cell (CD4+ T-cell) responses in comparison with the "gold standard" DCs. When pulsed with specific tumor associated antigens (TAAs), alphaDC1 is able to induce a potent cytotoxic T lymphocyte (CTL) response against TAAs; as a result it can be used as a cancer vaccine.	Cell || Pharmacologic Substance
C132991	Alrizomadlin	AA-115 || ALRIZOMADLIN || APG 115 || APG-115 || Alrizomadlin || MDM2-p53 Inhibitor APG-115 || p53-HDM2 Protein-protein Interaction Inhibitor APG-115	An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.	Pharmacologic Substance
C155967	Alsevalimab	ALSEVALIMAB || Alsevalimab || Alsevalimab || Anti-B7-H4 Monoclonal Antibody FPA150 || FPA 150 || FPA-150 || FPA150	A fully human, glycoengineered monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) with potential antineoplastic and immune checkpoint inhibitory activities. Upon intravenous administration, alsevalimab binds to B7-H4 on the surface of tumor cells, thereby preventing B7-H4 binding to T-cells and abrogating the B7-H4-mediated negative regulation of T-cell activation. This increases a cytotoxic T-lymphocyte (CTL)-mediated immune response against B7-H4-expressing tumor cells. In addition, the afucosylated Fc region of the anti-B7-H4 monoclonal antibody FPA150 enhances its binding affinity for human FcgammaRIIIa receptors (CD16) on natural killer (NK) cells, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.	Immunologic Factor || Pharmacologic Substance
C118290	Altiratinib	1,1-Cyclopropanedicarboxamide, N-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)- || ALTIRATINIB || Altiratinib || DCC-2701	An orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities. Upon administration, altiratinib selectively binds to c-Met, VEGFR2, Tie2 and Trk tyrosine kinases, which may lead to the inhibition of endothelial cell migration, proliferation and survival. This also results in both an inhibition of tumor cell proliferation and increased tumor cell death in c-Met/VEGFR2/Tie2/Trk-expressing cells. These receptor tyrosine kinases (RTKs), frequently overexpressed or mutated by a variety of tumor cell types, play crucial roles in the regulation of angiogenesis, tumor cell growth and survival.	Pharmacologic Substance
C544	Altretamine	2,4,6-Tris(dimethylamino)-s-triazine || 2,4,6-tris(dimethylamino)-s-triazine || ALTRETAMINE || Altretamine || Altretamine || ENT 50852 || ENT-50852 || HMM || HXM || Hemel || Hemel || Hexalen || Hexaloids || Hexamethylamine || Hexamethylmelamine || Hexamethylmelamine || Hexastat || Hexastat || Hexinawas || N,N,N',N',N",N"-hexamethyl-1,3,5-triazine-2,4,6-triamine || N,n,n',N"N"-hexamethyl-1,3,5,-triazine-2,4,6,-triamine || RB-1515 || WR-95704 || altretamine || s-Triazine, 2,4,6-tris(dimethylamino)-	A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)	Organic Chemical || Pharmacologic Substance
C85447	Alunacedase Alfa	ALUNACEDASE ALFA || APN01 || Alunacedase Alfa || rhACE2 APN01	A recombinant, soluble glycosylated form of human angiotensin converting enzyme 2 (rhACE2) with antihypertensive and potential antineoplastic activities. Alunacedase Alfa may normalize ACE2 levels, cleaving angiotensin II to create angiotensin-(1-7) and restoring the function of the renin-angiotensin system (RAS). ACE2, a homolog of ACE1, appears to function as a negative regulator of the RAS system by converting angiotensin II to angiotensin-(1-7), a peptide with actions that counteract the cardiovascular actions of angiotensin II. In addition, angiotensin-(1-7) may inhibit cyclooxygenase 2 (COX-2) and the production of proinflammatory prostaglandins and may activate the angiotensin-(1-7) G protein-coupled receptor Mas, resulting in diminished tumor cell proliferation. ACE2 levels may be reduced in malignancy and diabetes and in liver, cardiovascular and lung diseases.	Pharmacologic Substance
C180518	ALVAC gp100 Vaccine	ALVAC gp-100 Vaccine || ALVAC gp100 Vaccine || ALVAC gp100 Vaccine || gp100 ALVAC Vaccine	A vaccine composed of the replication-defective plaque purified recombinant canarypox virus (ALVAC) that encodes the glycoprotein 100 (gp100) gene, with potential antineoplastic activity.  Vaccination with ALVAC gp100 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 melanoma antigen, resulting in decreased tumor growth.	Pharmacologic Substance
C73998	ALVAC(2) Melanoma Multi-antigen Vaccine	ALVAC(2) Melanoma Multi-antigen Vaccine || ALVAC(2) Melanoma Multi-antigen Vaccine	A therapeutic cancer vaccine, based on a replication-defective recombinant canarypox virus (ALVAC) encoding multiple melanoma antigens, with potential immunostimulatory and antineoplastic activities. Vaccination with ALVAC(2) melanoma multi-antigen therapeutic vaccine may stimulate the host immune system to mount an immune response against antigen-expressing melanoma cells, resulting in inhibition of tumor growth and/or metastasis.	Pharmacologic Substance
C79832	ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine	ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine || ALVAC(2)-NY-ESO-1 (M)/TRICOM Vaccine || vCP2292	A cancer vaccine consisting of a replication-defective recombinant canarypox virus [ALVAC(2)] encoding the cancer-testis antigen NY-ESO and the TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; also called TRICOM), with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC(2)/NY-ESO (M)/TRICOM vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells, including bladder, breast, hepatocellular, melanoma, and prostate tumor cells. TRICOM may enhance antigen presentation and activate cytotoxic T-cells. In addition, ALVAC(2) encodes the vaccinia virus (vv) E3L ad K3L genes, which may potentiate the translation of the NY-ESO and TRICOM genes.	Pharmacologic Substance
C1977	ALVAC-CEA B7.1 Vaccine	ALVAC CEA B7.1 Vaccine || ALVAC-CEA B7.1 Vaccine	A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It causes infected cells to temporarily display CEA and activates the immune system to attack the tumor cells.	Immunologic Factor || Pharmacologic Substance
C1648	ALVAC-CEA Vaccine	ALVAC-CEA || ALVAC-CEA Vaccine || ALVAC-CEA vaccine	A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types.	Immunologic Factor || Pharmacologic Substance
C90558	ALVAC-ESO-1 Vaccine	ALVAC-ESO-1 Vaccine	A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC-ESO-1 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-1-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells.	Immunologic Factor || Pharmacologic Substance
C2485	ALVAC-hB7.1	ALVAC-hB7.1 || ALVAC-hB7.1	A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine.  Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient. (NCI04)	Immunologic Factor || Pharmacologic Substance
C73999	ALVAC-MART-1 Vaccine	ALVAC-MART-1 Vaccine	A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential immunostimulatory and antineoplastic activities. Upon administration, the MART-1 epitope is expressed by the ALVAC vector in ALVAC-MART-1 vaccine; a host cytotoxic T lymphocyte (CTL) response against MART-1-expressing tumor cells may follow, resulting in tumor cell lysis and decreased tumor cell proliferation.	Pharmacologic Substance
C38142	Alvespimycin	17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin || 17-DMAG || 17-dimethylaminoethylamino-17-demethoxygeldanamycin || ALVESPIMYCIN || Alvespimycin || Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-	An analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.	Antibiotic || Organic Chemical || Pharmacologic Substance
C76665	Alvespimycin Hydrochloride	17-DMAG HCl || ALVESPIMYCIN HYDROCHLORIDE || Alvespimycin Hydrochloride || Alvespimycin Hydrochloride || BMS-826476 || Geldanamycin,17-demethoxy-17-((2-(dimethylamino)ethyl)amino)-, Monohydrochloride || KOS-1022	The hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.	Pharmacologic Substance
C74940	Alvocidib	(-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one || ALVOCIDIB || Alvocidib || Alvocidib || Alvocidib || Alvocidib Freebase || Flavopiridol || alvocidib || flavopiridol	The free base form of a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.	Organic Chemical || Pharmacologic Substance
C1571	Alvocidib Hydrochloride	(-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one Hydrochloride || 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5, 7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, hydrochloride, (-)-cis- || ALVOCIDIB HYDROCHLORIDE || Alvocidib Hydrochloride || Alvocidib Hydrochloride || Flavopiridol Hydrochloride || HL-275 || HMR 1275 || HMR 1275 || L-86-8275 || L-868275 || MDL 107,826A || MDL-107826A	A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.	Pharmacologic Substance
C165555	Alvocidib Prodrug TP-1287	Alvocidib Phosphate || Alvocidib Phosphate TP-1287 || Alvocidib Prodrug TP-1287 || Alvocidib Prodrug TP-1287 || TP 1287 || TP-1287 || TP-1287 || TP1287	An orally bioavailable, highly soluble phosphate prodrug of alvocidib, a potent inhibitor of cyclin-dependent kinase-9 (CDK9), with potential antineoplastic activity. Upon administration of the phosphate prodrug TP-1287, the prodrug is enzymatically cleaved at the tumor site and the active moiety alvocidib is released. Alvocidib targets and binds to CDK9, thereby reducing the expression of CDK9 target genes such as the anti-apoptotic protein MCL-1, and inducing G1 cell cycle arrest and apoptosis in CDK9-overexpressing cancer cells.	Pharmacologic Substance
C62483	Amatuximab	AMATUXIMAB || Amatuximab || Amatuximab || Anti-Mesothelin Monoclonal Antibody MORAb-009 || Immunoglobulin G1, Anti-(mesothelin) (Human-Mouse Monoclonal MORAb-009 Heavy Chain), Disulfide with Human-Mouse Monoclonal MORAb-009 Kappa-Chain, Dimer || MORAb-009 || MORAb-009 || anti-mesothelin monoclonal antibody MORAb-009	A chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed on many epithelial-derived cancer cells. Upon binding to the mesothelin antigen, amatuximab triggers an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing cells, resulting in cell lysis.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C73320	Ambamustine	AMBAMUSTINE || Ambamustine || N-(3-(m-(Bis(2-chloroethyl)amino)phenyl)-N-(3-(p-fluorophenyl)-L-alanyl)-L-alanyl)-L-methionine, Ethyl Ester || PTT-119	A tripeptidic nitrogen mustard compound and bifunctional alkylating agent with antineoplastic activity.	Pharmacologic Substance
C72627	Ambazone	AMBAZONE || Ambazone || Faringosept || p-Benzoquinone Amidinohydrazone Thiosemicarbazone	An antiseptic agent with potential antibacterial and antileukemic activity. Although the exact mechanism of action remains to be fully elucidated, ambazone appears to interfere with the membrane-bound nucleotide system by increasing the intracellular concentration of cAMP in leukemia cells and macrophages, which potentially contributes to this agent's antineoplastic activity. Furthermore, this agent's affinity for various cellular targets, i.e. membranes, nucleic acids and proteins, may contribute to the overall antibacterial effect.	Pharmacologic Substance
C148521	Amblyomin-X	Amblyomin-X	A recombinant form of a toxic protein derived from the salivary glands of the Amblyomma cajennense tick that inhibits Factor Xa and induces apoptosis, with potential antithrombotic and antineoplastic activities.  Upon administration, amblyomin-X promotes endoplasmic reticulum (ER) stress, mitochondrial dysfunction, cytochrome-c release, poly(ADP-ribose) polymerase (PARP) cleavage, and activation of caspase. Additionally, this agent selectively induces apoptosis in tumor cells. It also affects endothelial cell functions, such as adhesion, and may inhibit angiogenesis. Amblyomin-X targets and binds to factor Xa, inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development. As cancer is associated with thrombosis, amblyomin-X could potentially exert its antineoplastic and antithrombotic effects in the cancer patient at the same time.	Pharmacologic Substance
C104745	Amcasertib	AMCASERTIB || Amcasertib || Amcasertib || BBI503	An orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity. Even though the exact target has not been fully elucidated, amcasertib targets and inhibits one or more pathways involved in cancer stem cell survival. As a result, cancer stem cell (CSC) growth as well as heterogeneous cancer cell growth is inhibited. CSCs, self-replicating cells able to differentiate into heterogeneous cancer cells, appear to be responsible for both tumor relapse and metastasis.	Organic Chemical || Pharmacologic Substance
C174915	Amcenestrant	AMCENESTRANT || Amcenestrant || Amcenestrant || SAR 439859 || SAR-439859 || SAR439859 || Selective Estrogen Receptor Degrader SAR439859 || Selective Estrogen Receptor Downregulator SAR439859	An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, amcenestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.	Pharmacologic Substance
C148532	Amdizalisib	AMDIZALISIB || Amdizalisib || Amdizalisib || HMPL 689 || HMPL-689 || HMPL689 || PI3K-d Inhibitor HMPL 689 || PI3K-delta Inhibitor HMPL 689	An orally bioavailable selective inhibitor of the delta isoform of phosphatidylinositide 3-kinase (phosphoinositide 3'-kinase delta; PI3Kd; PI3K-d), with potential antineoplastic activity. Upon oral administration, amdizalisib selectively binds to and inhibits PI3Kd, and prevents the activation of the PI3Kd/AKT signaling pathway, and B-cell activation. This both decreases proliferation and induces cell death in PI3Kd-overexpressing tumor cells. PI3Kd plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of hematologic cancer cells. The targeted inhibition of PI3Kd is designed to preserve PI3K signaling in normal, non-neoplastic cells and thereby to minimize serious side effects. PI3Kd, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.	Pharmacologic Substance
C1342	Ametantrone	1,4-bis[[2-[(2-Hydroxyethyl)amino]ethyl]amino]9,10-anthracenedione || 9, 10-Anthracenedione, 1, 4-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- || AMETANTRONE || Ametantrone || Ametantrone	A topoisomerase II inhibitor of the anthrapyrazole family that causes covalent cross-links in DNA of tumor cells.	Organic Chemical || Pharmacologic Substance
C488	Amifostine	2-[(3-Aminopropyl)amino]ethanethiol Dihydrogen Phosphate Ester Trihydrate || AMIFOSTINE || APAETP || Amifostine || Amifostine || Amifostine || Amifostine || Amifostine Trihydrate || Aminopropylaminoethylthiophosphoric Acid Trihydrate || Cytofos || Ethiofos || Ethyol || Gammaphos || Gammaphos || S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid Trihydrate || S-2-(3-Aminopropylamino)ethylphosphorothioic Acid Trihydrate || WR 2721 || WR-2721 || WR2721 || YM-08310	The trihydrate form of a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues.	Organic Chemical || Pharmacologic Substance
C1488	Aminocamptothecin	9-AC || 9-AC || 9-AMINOCAMPTOTHECIN || 9-Amino-20-(S)-camptothecin || 9-amino-20(S)-camptothecin || 9-amino-20-camptothecin || 9-amino-CPT || 9-amino-camptothecin || 9-aminocamptothecin || Aminocamptothecin || aminocamptothecin	A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)	Organic Chemical || Pharmacologic Substance
C2452	Aminocamptothecin Colloidal Dispersion	9-aminocamptothecin colloidal dispersion || 9AC colloidal dispersion || Aminocamptothecin Colloidal Dispersion	A colloidal dispersion formulation of 9-Aminocamptothecin, a water-insoluble camptothecin derivative. Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages. Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity.	Pharmacologic Substance
C48370	Aminoflavone Prodrug AFP464	AFP-464 || AFP464 || AFP464 || Aminoflavone Prodrug AFP464	A synthetic lysyl prodrug of the amino-substituted flavone derivate aminoflavone with antiproliferative and antineoplastic activities. AFP464 is rapidly converted to aminoflavone in plasma. Aminoflavone activates the aryl hydrocarbon receptor (AhR) signaling pathway leading to an increase in cytochrome P450 1A1 (CYP1A1) and cytochrome P450 1A2 (CYP1A2) expression and, to a lesser extent, an increase in cytochrome P450 1B1 (CYP1B1) expression. Subsequently, aminoflavone is metabolized to toxic metabolites by the cytochromome P450 enzymes that it induces; these toxic metabolites covalently bind to DNA, resulting in the phosphorylation of p53, the induction of the p53 downstream target p21Waf1/Cip1, and apoptosis. Pulmonary toxicity may be dose-limiting.	Pharmacologic Substance
C235	Aminopterin	4-Amino-PGA || 4-Aminofolic Acid || 4-Aminofolic acid || 4-Aminopteroylglutamic Acid || 4-Aminopteroylglutamic acid || AMINOPTERIN || APGA || APGA || Aminopterin || Aminopterin || Aminopterin || Aminopteroylglutamic Acid || aminopterin	A synthetic derivative of pterins with antineoplastic and immunosuppressive properties.  As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. (NCI04)	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C74554	Aminopterin Sodium	AMINOPTERIN SODIUM || Aminopterin Sodium || Aminopterin Sodium || Sodium Aminopterin	The sodium salt of a pterin derivative with antineoplastic and immunosuppressive properties.  As a folate analogue, aminopterin competes for the folate binding site of the enzyme dihydrofolate reductase, thereby blocking tetrahydrofolate synthesis, and resulting in depletion of nucleotide precursors and inhibition of DNA, RNA and protein synthesis. (NCI04)	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C124993	Amivantamab	AMIVANTAMAB || Amivantamab || Amivantamab || Amivantamab-vmjw || Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372 || CNTO-4424 || JNJ-611 || JNJ-61186372 || JNJ61186372 || Rybrevant	A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity. Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.	Immunologic Factor || Pharmacologic Substance || Amino Acid, Peptide, or Protein
C74000	AML mRNA Positive Lysate Loaded Autologous Dendritic Cell Vaccine	AML mRNA Positive Lysate Loaded Autologous Dendritic Cell Vaccine || Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Autologous Dendritic Cell Vaccine	A cancer vaccine consisting of autologous dendritic cells loaded with separate preparations of acute myelogenous leukemia (AML) cell lysate and AML-specific messenger RNA (mRNA) with potential immunostimulatory and antineoplastic activities. Upon administration, AML mRNA plus lysate loaded autologous dendritic cell vaccine may elicit a potent cytotoxic T-cell (CTL) response against AML cells, resulting in tumor cell death. Autologous dendritic cells doubly-loaded with AML cell lysate and AML-specific mRNA may elicit superior primary, recall, and effector lytic immune responses compared to autologous dendritic cells loaded with tumor lysate or tumor mRNA alone.	Pharmacologic Substance
C90592	Amolimogene Bepiplasmid	AMOLIMOGENE BEPIPLASMID || Amolimogene || Amolimogene Bepiplasmid || Amolimogene Bepiplasmid || Bacterially Derived DNA and Microparticles Made of Poly(D,L-lactide-co-glydolide) || DNA (synthetic Plasmid p3kDRalphaHPV16-18) || ZYC101a	A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer.	Pharmacologic Substance
C61306	Amonafide L-Malate	5-amino-2-[2-(dimethylamino)ethyl]-1H-benz[de]isoquinoline-1,3(2H)-dione (2S)-2-ydroxybutanedioate || AMONAFIDE L-MALATE || AS1413 || Amonafide L-Malate || Amonafide L-Malate || Butanedioic Acid, 2-hydroxy-, (2S)-, compd. with 5-amino-2-(2-(dimethylamino)ethyl)-1h-benz[de]isoquinoline-1,3(2h)-dione (1:1) || XAN-02 || Xanafide	The malate salt of amonafide, an imide derivative of naphthalic acid, with potential antineoplastic activity. Amonafide intercalates into DNA and inhibits topoisomerase II, resulting in DNA double-strand breaks (DSB) and inhibition of DNA replication and RNA synthesis.	Pharmacologic Substance
C179231	AMP KRAS Vaccine ELI-002	AMP KRAS Vaccine ELI-002 || AMP KRAS Vaccine ELI-002 || Amphiphile mKRAS Peptides/Amp CpG-7909 ELI-002 || ELI 002 || ELI-002 || ELI002 || Vaccine ELI-002 || mKRAS Vaccine ELI-002	A peptide-based cancer vaccine composed of the adjuvant Amphiphile (Amph; AMP)-CpG-7909, which is a lipid-conjugated immune-stimulatory oligonucleotide, admixed with Amph modified Kirsten Rat Sarcoma (KRAS) mutated peptides, which contain a mixture of lipid-conjugated peptide-based antigens, with potential immunostimulatory and antitumor activities. Upon subcutaneous administration of the AMP KRAS vaccine ELI-002, the lipid moieties bind to tissue albumin and the complex is delivered to and accumulates in the lymph nodes where it is taken up by antigen presenting cells (APCs), primarily dendritic cells (DCs). This may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against KRAS/neuroblastoma ras viral oncogene homolog (NRAS)-expressing tumor cells. KRAS and NRAS, tumor-associated antigens (TAAs) that are involved in the RAS/mitogen-activated protein kinase (MAPK) signaling pathway, are overexpressed on a variety of tumor cell types and play key role in tumor cell proliferation. The CpG-based adjuvant may enhance the mutated KRAS T cell-specific immune response.  ELI-002 2P contains two KRAS mutated Amph-peptides, including Amph-G12D and Amph-G12R. ELI-002 (ELI-002 7P) contains seven KRAS mutated Amph-peptides (Amph-Peptide 7), including G12D, G12R, G12V, G12A, G12C, G12S and G13D.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C80089	Amrubicin	(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione || AMRUBICIN || Amrubicin || amrubicin	A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.	Antibiotic || Organic Chemical || Pharmacologic Substance
C47948	Amrubicin Hydrochloride	(+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride || AMRUBICIN HYDROCHLORIDE || Amrubicin Hydrochloride || Amrubicin Hydrochloride || Calsed || SM-5887 || SMP-5887	The hydrochloride salt of a third-generation synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication, and RNA and protein synthesis, followed by cell growth inhibition and cell death. This agent has demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds.	Pharmacologic Substance || Antibiotic || Organic Chemical
C240	Amsacrine	4'-(9-Acridinylamino)methane-sulfon-m-anisidide || AMSA || AMSACRINE || Acridinyl Anisidide || Amekrin || Amsa P-D || Amsacrine || Amsacrine || Amsacrine || Amsidine || Amsidine || Amsidyl || CI-880 || Cain's Acridine || Lamasine || N-[4-(9-Acridinylamino)-3-methoxyphenyl]methanesulfonamide || SN 11841 || SN-11841 || SN-21429 || amsacrine || m-AMSA || m-AMSA	An aminoacridine derivative with potential antineoplastic activity. Although its mechanism of action is incompletely defined, amsacrine may intercalate into DNA and inhibit topoisomerase II, resulting in DNA double-strand breaks, arrest of the S/G2 phase of the cell cycle, and cell death. This agent's cytotoxicity is maximal during the S phase of the cell cycle when topoisomerase levels are greatest. In addition, amsacrine may induce transcription of tumor promoter p53 protein and block p53 ubiquitination and proteasomal degradation, resulting in p53-dependent tumor cell apoptosis.	Pharmacologic Substance || Organic Chemical
C96771	Amsacrine Lactate	AMSACRINE LACTATE || Amsacrine Lactate || Methanesulfon-m-anisidide, 4'-(9-acridinylamino)-, compd. with Lactic Acid || N-(4-(9-Acridinylamino)-3-methoxyphenyl)methanesulfonamide compd. with Lactic Acid || m-AMSA lactate	The lactate form of amsacrine, an aminoacridine analog and topoisomerase II inhibitor, with antineoplastic activity. Although the exact relationship between DNA binding and its activity has yet to be fully elucidated, amsacrine intercalates DNA through its acridine moiety, and its nonintercalative headgroup impedes topoisomerase II activity, augmenting enzyme-mediated DNA cleavage and resulting in DNA double-strand breaks. This ultimately induces programmed cell death.	Organic Chemical || Pharmacologic Substance
C38684	Amsilarotene	AMSILAROTENE || Amsilarotene || TAC 101 || TAC-101 || TAC-101	A retinobenzoic acid with potential antineoplastic activity. Amsilarotene inhibits retinoblastoma-gene product (RB) phosphorylation and increases the presence of 2 cyclin-dependent kinase (CDK) inhibitors, resulting in cell cycle arrest.  This agent also causes a cytotoxic decline in cyclin A and thymidylate synthase expression.	Pharmacologic Substance
C75926	Amustaline	(N,N-bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionate || AMUSTALINE || Amustaline || S-303	A quinacrine mustard compound with potential antineoplastic activity. Amustaline binds to, intercalates and crosslinks DNA and RNA. This agent is mainly used for ex vivo purposes, specifically for the inactivation of pathogens such as viruses, protozoa and bacteria in red blood cells (RBCs).	Pharmacologic Substance
C75035	Amustaline Dihydrochloride	AMUSTALINE DIHYDROCHLORIDE || Amustaline Dihydrochloride	The hydrochloride salt form of amustaline, a quinacrine mustard compound with potential antineoplastic activity. Amustaline binds to, intercalates and crosslinks DNA and RNA. This agent is mainly used for ex vivo purposes, specifically for the inactivation of pathogens such as viruses, protozoa and bacteria in red blood cells (RBCs).	Pharmacologic Substance
C71750	Amuvatinib	AMUVATINIB || Amuvatinib || Amuvatinib || HPK56 || MP470 || MP470 || Receptor Tyrosine Kinase Inhibitor MP470	An orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.	Pharmacologic Substance
C95776	Amuvatinib Hydrochloride	1-Piperazinecarbothioamide, N-(1,3-Benzodioxol-5-Ylmethyl)-4-Benzofuro(3,2-D)Pyrimidin-4-Yl-, Hydrochloride (1:1) || AMUVATINIB HYDROCHLORIDE || Amuvatinib Hydrochloride || HPK56 HCl || MP-470 HCI || MP470 HCl || N-(1,3-Benzodioxol-5-Ylmethyl)-4-(Benzofuro(3,2-D)Pyrimidin-4-Yl)Piperazine-1- Carbothioamide Monohydrochloride	The hydrochloride salt of an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance.	Pharmacologic Substance
C38717	Anakinra	ANAKINRA || Anakinra || Anakinra || Kinaret || Kineret || anakinra || rIL-1ra || rIL1RN	A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)	Pharmacologic Substance
C1607	Anastrozole	2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile) || ANASTROZOLE || Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile || Anastrazole || Anastrozole || Anastrozole || Anastrozole || Anastrozole || Arimidex || ICI D1033 || ICI-D1033 || ZD-1033 || anastrozole	A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)	Organic Chemical || Pharmacologic Substance
C950	Anaxirone	1,2,4-triglycidylurazol || ANAXIRONE || Anaxirone || TGU || Triglycidylurazol	A synthetic triepoxide alkylating agent with potential antineoplastic activity. Anaxirone alkylates DNA via actual or derived epoxide groups, resulting in inhibition of DNA synthesis. This agent has been shown to exhibit a broad spectrum of antineoplastic activity against experimental tumors, including those resistant to other alkylating agents.	Organic Chemical || Pharmacologic Substance
C162577	Anbenitamab	ANBENITAMAB || Anbenitamab || Anbenitamab || Anti-HER-2 Bispecific Antibody KN026 || Anti-HER2 Heterodimeric Antibody KN026 || HER2 Bispecific Antibody KN026 || KN 026 || KN-026 || KN026	An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, anbenitamab simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2, thereby inhibiting HER-2 heterodimerization and prevents the activation of HER-2 signaling pathways. By binding to HER-2, KN026 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in proliferation, differentiation and survival.	Pharmacologic Substance
C80636	Ancitabine	ANCITABINE || Ancitabine	A cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine, which is converted to the active triphosphate form and competes with deoxycytidine triphosphate for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA and RNA polymerases, resulting in a decrease in cell growth. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.	Pharmacologic Substance
C403	Ancitabine Hydrochloride	6H-furo(2',3':4,5)oxazolo(3,2-a)pyrimidine-2-methanol,2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-,(2R(2alpha,3beta,3a beta,9a beta)) || ANCITABINE HYDROCHLORIDE || Ancid || Ancitabine Hydrochloride || Ancitabine hydrochloride || Ancytabine Hydrochloride || CycloCMP Hydrochloride || CycloCMP hydrochloride || Cyclocytidine || Cyclocytidine || Cyclocytidine HCL || Cyclocytidine Hydrochloride || Cyclocytidine hydrochloride || U-33, 624A	The hydrochloride salt of a cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine. Subsequently, cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. Cytarabine agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.	Pharmacologic Substance || Nucleic Acid, Nucleoside, or Nucleotide
C105803	Andecaliximab	ANDECALIXIMAB || Andecaliximab || Andecaliximab || GS-5745	A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), with potential antineoplastic activity. Upon administration, andecaliximab binds to MMP-9 and inhibits its enzymatic activity. This results in an inhibition of extracellular matrix protein degradation and, potentially, the inhibition of angiogenesis, tumor growth, invasion, and metastasis. MMP-9, a protein belonging to the MMP family, plays a key role in the degradation of collagens and proteoglycans; increased activity of MMP-9 has been associated with increased invasion and metastasis of cancer.	Pharmacologic Substance
C98290	Androgen Antagonist APC-100	APC-100 || Androgen Antagonist APC-100 || Androgen Antagonist APC-100 || CHROMANOL	An orally available, vitamin E derivative and androgen receptor (AR) antagonist with potential anti-oxidant, chemopreventative and antineoplastic activity. APC-100 binds to ARs in target tissues thereby inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. By inhibiting the formation of the complex between androgen activated AR- and the AP1 transcription factor JunD, the expression of androgen-responsive genes are blocked. One of such gene is spermidine/spermine N1-acetyl transferase gene (SSAT) that is responsible for the breakdown of polyamines, which are produced in high levels by prostatic epithelial cells, into reactive oxygen species (ROS) that cause cellular damage. APC-100 may ultimately lead to an inhibition of growth in both AR-dependent and AR-independent prostate tumor cells.	Pharmacologic Substance
C148520	Androgen Receptor Antagonist BAY 1161116	AR Antagonist BAY 1161116 || Androgen Receptor Antagonist BAY 1161116 || BAY 1161116 || BAY-1161116 || BAY1161116	An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist BAY 1161116 specifically binds to AR, inhibits AR activation, and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.	Pharmacologic Substance
C126335	Androgen Receptor Antagonist SHR3680	Androgen Receptor Antagonist SHR3680 || SHR 3680 || SHR3680	An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon administration, SHR3680 competitively binds to AR in target tissues, which both prevents androgen-induced receptor activation and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of cell growth of AR-expressing tumor cells. ARs are overexpressed in prostate cancer and play a key role in prostate cancer cell proliferation.	Pharmacologic Substance
C137818	Androgen Receptor Antagonist TAS3681	AR Antagonist TAS3681 || Androgen Receptor Antagonist TAS3681 || Androgen Receptor Inhibitor TAS3681 || TAS 3681 || TAS3681	An orally bioavailable inhibitor of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor TAS3681 specifically binds to AR. This prevents AR activation, downregulates AR and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.	Pharmacologic Substance
C180680	Androgen Receptor Antagonist TQB3720	AR Antagonist TQB3720 || Androgen Receptor Antagonist TQB3720 || TQB 3720 || TQB-3720 || TQB3720	An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist TQB3720 specifically targets and binds to the AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells.	Pharmacologic Substance
C131874	Androgen Receptor Antagonist TRC253	AR Antagonist TRC253 || Androgen Receptor Antagonist TRC253 || Androgen Receptor Antagonist TRC253 || JNJ 63576253 || JNJ-63576253 || JNJ63576253 || TRC 253 || TRC-253 || TRC253	An orally bioavailable androgen receptor (AR) antagonist, with potential antineoplastic activity. Upon oral administration, AR antagonist TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of growth of tumor cells in which AR is overexpressed and/or mutated. AR is often overexpressed and/or mutated in prostate cancers and plays a key role in proliferation, survival and chemoresistance of tumor cells.	Pharmacologic Substance
C116326	Androgen Receptor Antisense Oligonucleotide AZD5312	AZD-5312 || AZD5312 || Androgen Receptor Antisense Oligonucleotide AZD5312 || Androgen Receptor Antisense Oligonucleotide AZD5312 || ISIS-ARRx || ISIS-AZ1Rx	An antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon intravenous administration, AZD5312 hybridizes with AR mRNA, which blocks translation of the AR protein. This both inhibits AR-induced tumor cell growth and promotes apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C96742	Androgen Receptor Antisense Oligonucleotide EZN-4176	Androgen Receptor Antisense Oligonucleotide EZN-4176 || EZN-4176	A locked nucleic acid (LNA)-based antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon administration, EZN-4176 is hybridized and releases the complementary sequences of AR mRNA, thereby blocking translation of the AR protein and inhibiting AR-induced tumor cell growth and promoting tumor cell apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival. LNAs contain a methylene bridge linking 2'-oxygen and 4'-carbon of ribose sugar rings, thereby increasing their thermal stability and decreasing degradation.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C183151	Androgen Receptor Degrader ARV-766	AR Degrader ARV-766 || AR PROTAC ARV-766 || AR-targeted PROTAC Protein Degrader ARV-766 || ARV 766 || ARV-766 || ARV766 || Androgen Receptor Degrader ARV-766 || Androgen Receptor Degrader ARV-766 || Androgen Receptor PROTAC Degrader ARV-766	An orally bioavailable androgen receptor (AR)-targeted protein degrader, composed of an AR ligand attached to an E3 ligase recognition moiety and utilizing the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Upon oral administration, AR degrader ARV-766 targets and binds to the AR ligand binding domain on the AR. E3 ligase is then recruited to the AR by the E3 ligase recognition moiety of ARV-766 and the AR is tagged by ubiquitin. This causes ubiquitination and degradation of AR by the proteasome, and prevents the expression of AR target genes and halts AR-mediated signaling. This inhibits the proliferation of AR-overexpressing tumor cells. In addition, the degradation of the AR releases ARV-766, allowing it to bind to additional AR. AR plays a key role in the proliferation of castration-resistant prostate cancer cells (CRPC). ARV-766 may degrade resistance-driving point mutations of AR, including the L702H mutation associated with treatments including abiraterone.	Pharmacologic Substance
C173364	Androgen Receptor Degrader CC-94676	AR Degrader CC-94676 || Androgen Receptor Degrader CC-94676 || Androgen Receptor Degrader CC-94676 || CC 94676 || CC-94676 || CC-94676 || CC94676	An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, AR degrader CC-94676 causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).	Pharmacologic Substance
C116726	Androgen Receptor Downregulator AZD3514	AZD3514 || Androgen Receptor Downregulator AZD3514 || Androgen Receptor Downregulator AZD3514 || SARD AZD3514	An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514 binds to the AR ligand binding domain and inhibits the binding of androgen, thereby preventing androgen-dependent AR signaling. AZD3514 also causes downregulation of AR expression, which further prevents AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. AR plays a key role in the proliferation of castration-resistant prostate cancer cells.	Pharmacologic Substance
C173374	Androgen Receptor Inhibitor EPI-7386	AR Inhibitor EPI-7386 || Androgen Receptor Inhibitor EPI-7386 || Androgen Receptor Inhibitor EPI-7386 || EPI 7386 || EPI-7386 || EPI7386	An orally bioavailable, second-generation inhibitor of the N-terminal domain (NTD) of androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor EPI-7386 specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells. EPI-7386 may be more active and metabolically stable than first-generation AR NTD inhibitors.	Pharmacologic Substance
C121777	Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118	AR LBD-encoding Plasmid DNA Vaccine MVI-118 || Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118 || MVI-118 || pTVG-AR || pTVG-AR Vaccine	A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis.	Pharmacologic Substance
C172104	Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10	AR/GR Antagonist CB-03-10 || Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10 || CB 03 10 || CB-03-10 || CB0310 || Cortexolone 17alpha-Valerate-21-propionate	An orally bioavailable steroidal cortexolone derivative and antagonist of the androgen receptor (AR) and glucocorticoid receptor (GR), with potential antineoplastic activity. Upon oral administration, AR/GR antagonist CB-03-10 specifically binds to AR and GR, inhibits AR and GR activation, and prevents AR- and GR-mediated signaling. This leads to an induction of both extrinsic and intrinsic apoptotic pathways and inhibits cell growth in AR- and GR-overexpressing tumor cells. AR and GR are overexpressed in certain types of cancer cells and are involved in proliferation, survival and chemoresistance of tumor cells.	Pharmacologic Substance
C61637	Andrographolide	(1R-(1-alpha(E(S)),4a-beta,5alpha,6alpha,8a-alpha))-3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-2(3H)-furanone || (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one || (3E,4S)-4-hydroxy-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidenedecahydronaphthalen-1-yl]ethylidene}dihydrofuran-2(3H)-one || 2(3H)-Furanone, 3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-, (1R-(1-alpha(E(S*)),4a-beta,5-alpha,6-alpha,8a-alpha))- || 3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one || 3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone || ANDROGRAPHOLIDE || Andrographis || Andrographolide	A labdane diterpenoid that is produced by the Andrographis paniculata plant, which has a broad range of therapeutic applications including anti-inflammatory and anti-platelet aggregation activities and potential antineoplastic properties. Since andrographolide has multiple therapeutic activities there are several proposed mechanisms of action for this agent. The anti-inflammatory effects of this agent appear to be related to the inhibition of nitric oxide (NO) production by macrophages. This agent may activate the NO/cyclic GMP pathway and inhibit both the phospholipase C gamma 2 (PLC gamma2)/protein kinase C (PKC) and PI3K/AKT-MAPK signaling pathways in activated platelets to inhibit platelet aggregation. In activated platelets, these three signaling pathways are downstream of integrin activation mediated by collagen binding and influence the association of fibrinogen with its receptors. Additionally, andrographolide may exert its anti-cancer activity through the induction of cell cycle arrest at G0/G1 phase and the stimulation of lymphocyte proliferation and activation. These processes could result in decreased proliferation of and increased immunocytotoxicity against tumor cells.	Pharmacologic Substance
C78831	Androstane Steroid HE3235	17Alpha-ethynyl-5alpha-androstane-3alpha, 17Beta-diol || APOPTONE || APOPTONE || Androstane Steroid HE3235 || Androstane Steroid HE3235 || HE3235	An orally bioavailable adrenal steroid analogue with potential antineoplastic activity. Androstane steroid HE3235 appears to bind the androgen receptor (AR), down-regulating anti-apoptotic genes, such as Bcl-2, while increasing the expression of pro-apoptotic genes, such as caspases. In vitro and in vivo studies indicate that this agent inhibits androstenediol-dependent LNCaP cell tumor growth. In addition, HE3235 may potentiate chemotherapeutic agents by down-regulating ABCG2, the gene encoding the multi-drug resistant (MDR) protein MDR2.	Pharmacologic Substance
C98293	Anetumab Ravtansine	ANETUMAB RAVTANSINE || Anetumab Ravtansine || Anetumab Ravtansine || BAY 94-9343	A fully human IgG1 monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to the maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody moiety of anetumab ravtansine targets and binds to the tumor associated antigen mesothelin; upon internalization, the DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of mesothelin-expressing tumor cells. Mesothelin is overexpressed on all mesotheliomas as well as many ovarian and pancreatic cancers while minimally expressed on normal tissue.	Pharmacologic Substance
C88301	Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241	Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241 || Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241 || CVX-241 || CVX-241 || PF-05057459	A fusion protein containing angiopoietin-2 (Ang2) and vascular endothelial growth factor (VEGF) derived peptides covalently attached, via a proprietary diketone linker, to a proprietary humanized catalytic aldolase monoclonal antibody, with potential antiangiogenic and antineoplastic activities. The Ang2/VEGF peptide moieties of Ang2/VEGF-binding peptides-antibody fusion protein CVX-241 bind to Ang2 and VEGF receptors, which may inhibit tumor angiogenesis and tumor cell proliferation. The proprietary humanized catalytic IgG1 monoclonal aldolase antibody contains reactive lysine residues in its binding sites, which react covalently with compounds having a diketone function; the Ang2 and VEGFR peptide moieties are then covalently attached to the diketone linkers via a proprietary spacer. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. This agent possesses an enhanced half-life compared to the naked peptides.	Pharmacologic Substance
C60817	Angelica sinensis Root Extract	Angelica Root || Angelica root || Angelica sinensis Root Extract || Angelicae sinensis Radix Extract || Chinese Angelica || Dang qui || Dong quai || Female Ginseng || Tanggwi || Toki || dong quai	An herbal extract derived from the root of the plant Angelica sinensis with possible antiinflammatory, antispasmodic, vasodilatory, estrogenic, and antitumor activities. Angelica sinensis contains volatile oils, including safrole, isosafrole, and n-butylphthalide; coumarin derivatives, including psoralens, bergapten, osthol, imperatorin, and oxypeucedanin; and ferulic acid. The coumarin derivatives in this agent may vasodilate and relax smooth muscle and may exhibit additive anticoagulant effects. Ferulic acid, a phenolic phytochemical present in plant cell walls, may neutralize free radicals such as reactive oxygen species. In addition, Angelica sinensis extract has been shown to inhibit the growth and induce apoptosis of glioblastoma mutltiforme brain tumor cells through p53-dependent and p53-independent pathways.	Pharmacologic Substance || Plant
C82413	Angiogenesis Inhibitor JI-101	Angiogenesis Inhibitor JI-101 || Angiogenesis Inhibitor JI-101 || JI-101 || JI-101	An orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRb), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities. Angiogenesis inhibitor JI-101 binds to and inhibits VEGFR2, PDGFRb and EphB4, which may inhibit tumor angiogenesis and, so, cellular proliferation in tumor cells overexpressing VEGFR2, PDGFRb and EphB4. The receptor tyrosine kinases VEGFR2, PDGFRb and EphB4 may be overexpressed in a number of different cancer cell types and may play crucial roles in tumor angiogenesis.	Pharmacologic Substance
C116625	Angiopoietin-2-specific Fusion Protein PF-04856884	Angiopoietin-2-specific Fusion Protein PF-04856884 || Angiopoietin-2-specific Fusion Protein PF-04856884 || CVX-060 || CVX-060 || PF-04856884	A humanized monoclonal antibody fused to two peptides that bind to angiopoietin 2 (Ang2; ANGPT2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous administration, Ang2-targeting PF-04856884 CovX body specifically binds to Ang2 and prevents the binding of Ang2 to its receptor Tie2 expressed on endothelial cells. This inhibits Tie2-mediated signaling, prevents angiogenesis and inhibits tumor cell proliferation.  Ang2, a proangiogenic cytokine and ligand for the Tie2 receptor, plays a key role in the regulation of tumor angiogenesis and tumor cell proliferation; its expression is upregulated by tumor endothelial cells.	Pharmacologic Substance
C168687	Anhydrous Enol-oxaloacetate	AEO || Anhydrous Enol-oxaloacetate || Anhydrous Enol-oxaloacetate || OXALOACETIC ACID	The anhydrous form of enol-oxaloacetate, a small molecule blood glutamate scavenger, that can be used to lower glutamate plasma levels, and has potential neuroprotective activity. Upon administration, enol-oxaloacetate targets and binds to glutamate in the bloodstream. This lowers glutamate plasma levels and lowers the free glutamate available to be picked up by cells, such as tumor brain cells, thereby preventing glutamate metabolism and glutamate-mediated signaling. This prevents the proliferation of rapidly growing cells, such as brain tumor cells. And by lowering glutamate plasma levels, a molecular imbalance is formed and glutamate is excreted across the blood-brain barrier, resulting in lower free brain glutamate.  This may help protect the brain from excitotoxicity in conditions where there is a surge of glutamate production, such as traumatic brain injury, thereby protecting neuronal cells. Glutamate, a non-essential amino acid and the major excitatory neurotransmitter in the central nervous system (CNS), provides energy and generates building blocks for the production of macromolecules, which are needed for cellular growth and survival.	Pharmacologic Substance
C2526	Anhydrovinblastine	ANHYDROVINBLASTINE || AVLB || Anhydrovinblastine || anhydrovinblastine	A semisynthetic derivative of the vinca alkaloid vinblastine, with potential antineoplastic activity. Like vinblastine, anhydrovinblastine targets and binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and causing tumor cell cycle arrest in the M phase.	Organic Chemical || Pharmacologic Substance
C249	Aniline Mustard	.beta.,.beta.'-Dichlorodiethylaniline || A 14489 || A 14489 || Aniline Mustard || Aniline mustard || Benzenamine, N, N-bis(2-chloroethyl)- (9CI) || Benzenamine, N, N-bis(2-chloroethyl)-(9CI) || CB 1074 || CB 1074 || Lymphochin || Lymphochin || Lymphocin || Lymphocin || Lymphoquin || Lymphoquin || Mesylerythrol || N, N-Bis(2-chloroethyl)aniline || N,N-BIS(2-CHLOROETHYL)ANILINE || N,N-bis(2-chloroethyl)aniline || N,N-bis(2-chloroethyl)benzenamine || Phenylbis(2-chloroethylamine) || SK 592 || SK 592 || TL 476 || TL 476 || beta, beta'-dichlorodiethylaniline || mesylerythrol || phenylbis[2-chloroethylamine]	An alkylating mustard with antineoplastic activity. Aniline mustard forms covalent linkages with nucleophilic centers, resulting in depurination, base miscoding and strand scission, and crosslinking of DNA strands, all of which contribute to its cytotoxicity. (NCI04)	Organic Chemical || Pharmacologic Substance
C106428	Anlotinib Hydrochloride	1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolyl)oxymethyl)cyclopropanamine, Dihydrochloride || ALTN HCl || Anlotinib Hydrochloride || Anlotinib Hydrochloride || CATEQUENTINIB DIHYDROCHLORIDE || Cyclopropanamine, 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-, Hydrochloride (1:2)	The hydrochloride salt form of anlotinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.	Pharmacologic Substance
C2632	Annamycin	2'-iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin || 5,12-naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-l-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)- || ANNAMYCIN || Annamycin || annamycin	A lipophilic, anthracycline antineoplastic antibiotic. Annamycin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as inhibiting RNA and protein synthesis.  This agent appears to not be a substrate for the p-glycoprotein associated multidrug-resistance (MDR) transporter; therefore, overcoming the resistance pattern seen with other anthracycline compounds.	Antibiotic || Organic Chemical || Pharmacologic Substance
C25838	Annamycin Liposomal	Annamycin Liposomal || Annamycin Liposomal	A liposome-encapsulated form of the semi-synthetic doxorubicin analogue annamycin with antineoplastic activity. Annamycin intercalates into DNA and inhibits topoisomerase II, resulting in the inhibition of DNA replication and repair and RNA and protein synthesis. This agent circumvents multidrug-resistance (MDR) transporters, including P-glycoprotein (P-gp). Liposomal annamycin is less toxic and shows improved antitumor activity compared to annamycin.	Antibiotic || Organic Chemical
C118972	Annonaceous Acetogenins	Acetogenins || Annonaceous Acetogenins	A family of naturally occurring polyketides that consist of C32 or C34 long chain fatty acids and combined with a propan-2-ol unit at C-2 to form a gamma-lactone, which are isolated from various species of the plant family Annonaceae, with potential antineoplastic and antimicrobial activity. Annonaceous acetogenins bind to the ubiquinone catalytic site(s) within the mitochondrial NADH:ubiquinone oxidoreductase (complex I), and block the electron transport chain in mitochondria. In addition, the acetogenins bind to and block the activity of ubiquinone-linked NADH oxidase, an enzyme overexpressed in the plasma membranes of cancer cells. This inhibits adenosine triphosphate (ATP) production, decreases intracellular ATP levels, and induces tumor cell apoptosis. Compared to normal cells, cancer cells have higher ATP demands. The Annonaceous acetogenins also inhibit microbial glucose dehydrogenase 6.	Organic Chemical || Pharmacologic Substance
C97710	Ansamitomicin P-3	ANSAMITOMICIN P-3 || Ansamitomicin P-3 || Maytansine, 3-o-de(2-(acetylmethylamino)-1-oxopropyl)-3-o-(1-oxobutyl)-	An ansamacrolide and maytansine analogue originally isolated from the Ethiopian shrub Maytenus serrata with antineoplastic activity. Ansamitomicin P-3 binds to tubulin at the maytansine-binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis.	Pharmacologic Substance
C117239	Anthocyanin-rich Corn Extract	Anthocyanin-rich Corn Extract	A corn-based, water-soluble extract rich in the polyphenol anthocyanin, with potential antioxidant, anti-inflammatory and chemoprotective activities. Upon administration of the anthocyanin-rich corn extract, the anthocyanins scavenge reactive oxygen species (ROS), which protects healthy cells from radiation-induced oxidative stress and DNA damage. In addition, anthocyanins modulate the expression of various genes and proteins involved in inflammation, tumor cell proliferation, angiogenesis, tumor cell invasion and differentiation. This agent also chelates metals and induces the expression of enzymes involved in Phase II antioxidant and detoxification pathways, which may further protect cells against oxidative stress induced by toxins and carcinogens.	Pharmacologic Substance
C252	Anthramycin	3-(5,10,11,11a-tetrahydro-9,11-dihydroxy-8-methyl-5-oxo-1h-pyrrolo(2,1-c)(1,4)benzodiazepin-2-yl)-2-propenamide || ANTHRAMYCIN || Anthramycin || Anthramycin	A pyrrolo(1,4)benzodiazepine antineoplastic antibiotic isolated from the bacterium Streptomyces refuineus var. thermotolerans.  Anthramycin binds covalently to guanine in the minor groove of DNA, thereby inhibiting DNA replication and RNA and protein synthesis. (NCI04)	Antibiotic || Organic Chemical || Pharmacologic Substance
C2706	Anthrapyrazole	Anthra[1, 9-cd]pyrazol-6(2H)-one, 7, 10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino )ethyl]amino]-acetate (salt) hydrobromide (10:5:21) || Anthra[1, 9-cd]pyrazol-6(2H)-one, 7, 10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino )ethyl]amino]-acetate (salt) hydrobromide(10:5:21) || Anthra[1,9-cd]pyrazol-6(2H)-one, 7, 10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino )ethyl]amino]-, acetate (salt) hydrobromide (10:5:21) || Anthra[1,9-cd]pyrazol-6(2H)-one, 7, 10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-(methylamino )ethyl]amino]-, acetate (salt) hydrobromide(10:5:21) || Anthrapyrazole	An antineoplastic antibiotic that intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Anthrapyrazoles may also block cell cycle division.  In the presence of electron donors, some anthrapyrazole antibiotics cause single-strand breaks in DNA via photosensitization by visible light.  These agents are less cardiotoxic than doxorubicin. (NCI04)	Organic Chemical || Pharmacologic Substance
C117735	Anti c-KIT Antibody-drug Conjugate LOP628	Anti c-KIT ADC LOP628 || Anti c-KIT Antibody-drug Conjugate LOP628 || LOP628	An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) and conjugated, via a non-cleavable linker, to the cytotoxic agent maytansine, with potential antineoplastic activity. The monoclonal antibody moiety of anti c-KIT ADC LOP628 targets and binds to the cell surface antigen c-Kit. After antibody-antigen interaction followed by internalization, the maytansine moiety binds to tubulin, inhibits microtubule assembly, and induces microtubule disassembly. This leads to a disruption of mitosis and the inhibition of cell proliferation in cancer cells expressing c-Kit. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.	Pharmacologic Substance
C173556	Anti-5T4 Antibody-drug Conjugate ASN004	5T4-ADC ASN004 || 5T4-targeted Antibody-drug Conjugate ASN004 || 5T4-targeted Dolaflexin ADC ASN004 || ASN 004 || ASN-004 || ASN004 || Anti-5T4 ADC ASN004 || Anti-5T4 Antibody-drug Conjugate ASN004	An antibody-drug conjugate (ADC) composed of an antibody directed against 5T4 and conjugated, via a non-cleavable linker, to a proprietary polymer carrying multiple auristatin analog molecules via a cleavable linker, with potential antineoplastic activity. Upon administration, the antibody moiety of ASN004 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and cleavage within the tumor cell cytosol, free auristatin analog molecules binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.	Pharmacologic Substance
C107388	Anti-5T4 Antibody-Drug Conjugate PF-06263507	Anti-5T4 Antibody-Drug Conjugate PF-06263507 || Anti-5T4 Antibody-Drug Conjugate PF-06263507 || PF-06263507 || PF-06263507	An antibody-drug conjugate composed of an antibody directed against 5T4 and conjugated, via the stable linker maleimidocaproyl (mc), to the microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration, the antibody moiety of PF-06263507 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.	Pharmacologic Substance
C175444	Anti-5T4 Antibody-drug Conjugate SYD1875	ADC SYD1875 || Anti-5T4 ADC SYD1875 || Anti-5T4 Antibody-drug Conjugate SYD1875 || Antibody-drug Conjugate SYD1875 || SYD 1875 || SYD-1875 || SYD1875	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the oncofetal antigen 5T4 and site-specifically conjugated to a duocarmycin-based linker-drug valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA), with potential antineoplastic activity. Upon administration, the antibody moiety of SYD1875 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and cleavage within the tumor cell by proteases, the free and activated duocarmycin payload binds to the minor groove of DNA and alkylates adenine at the N3 position, which eventually leads to tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.	Pharmacologic Substance
C186665	Anti-5T4 CAR-NK Cells	Anti-5T4 CAR Natural Killer Cells || Anti-5T4 CAR-NK Cells || Anti-5T4 CAR-NKs || Anti-5T4 CAR-redirected Natural Killer Cells	A preparation of allogeneic natural killer cells (NKs) expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) oncofetal trophoblast glycoprotein (5T4; TPBG; Wnt-activated inhibitory factor 1 or WAIF1), with potential immunomodulating and antineoplastic activities. Upon transfusion, the anti-5T4 CAR-NK cells recognize, bind to and induce selective cytotoxicity in 5T4-expressing tumor cells. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.	Pharmacologic Substance
C90583	Anti-A33 Monoclonal Antibody KRN330	Anti-A33 Monoclonal Antibody KRN330 || Anti-A33 Monoclonal Antibody KRN330 || KRN-330 || KRN330	A recombinant fully human monoclonal antibody directed against the human A33 antigen, with potential immunomodulatory and antineoplastic activity. Anti-A33 monoclonal antibody KRN330 recognizes and binds to the human A33 antigen, which may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against A33-positive colorectal cancers. A33 antigen, a 43 kDa transmembrane glycoprotein of the immunoglobulin superfamily, is highly and homogenously expressed in 95% of colorectal cancer cancers with only restricted expression in normal colonic mucosa and small bowel epithelia.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C85478	Anti-A5B1 Integrin Monoclonal Antibody PF-04605412	Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 || Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 || Anti-alpha5beta1 Integrin Monoclonal Antibody PF-04605412 || PF-04605412	A monoclonal antibody directed against the human alpha5beta1 integrin with potential antiangiogenic and antineoplastic activities. Anti-alpha5beta1 integrin monoclonal antibody PF-04605412 selectively binds to alpha5beta1 integrin, preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in alpha5beta1-expressing tumor cells. Alpha5beta1 integrin, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in endothelial cell adhesion and migration.	Pharmacologic Substance
C129715	Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087	ACTR-087 || ACTR087 || Anti-ACTR Viral Vector-transduced Autologous T-lymphocytes ACTR087 || Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087 || Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087 || CD16-41BB-CD3zeta ACTR Autologous T-cells || Virally-delivered Antibody-coupled TCR ACTR087	Autologous T-lymphocytes that are genetically modified and transfected with a viral vector expressing the ACTR gene, a proprietary gene encoding for an antibody-coupled T-cell receptor (ATCR), with potential antineoplastic activity. The ACTR contains the extracellular Fc receptor CD16 domain, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-immunostimulatory signaling domain 4-1BB, normally expressed on T-cells, and linked to the intracellular CD3 zeta domain (CD3z), which is needed for TCR signaling. Upon reintroduction into the patient and co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, this induces the activation of the ACTR087 cells and destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; b) targeting and killing adjacent tumor cells that are not bound to the antibody; c) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it enhances the survival and persistence of T-lymphocytes. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of the TAA.	Cell || Pharmacologic Substance
C179286	Anti-ADAM9 ADC IMGC936	ADAM9-targeting Antibody-drug Conjugate IMGC936 || Anti-ADAM9 ADC IMGC936 || Anti-ADAM9 Antibody Drug Conjugate IMGC936 || Anti-ADAM9/DM21 ADC IMGC936 || IMGC 936 || IMGC-936 || IMGC936	An immunoconjugate consisting of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) that is site-specifically conjugated, via a stable tri-peptide cleavable linker, to DM21, a cytotoxic maytansinoid microtubule-disrupting payload, with potential antineoplastic activity. Upon administration of anti-ADAM9 ADC IMGC936, the anti-ADAM9 monoclonal antibody moiety targets and binds to ADAM9 on tumor cells. Upon internalization, the maytansinoid moiety is released, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in the inhibition of cell division and cell growth of tumor cells. ADAM9, belonging to the a disintegrin and metalloproteinase (ADAM) family of proteases, plays a key role in cytokine and growth factor shedding and cell migration. It is overexpressed on multiple solid tumors while minimally expressed on normal tissue. Dysregulation of ADAM9 has been implicated in tumor progression, migration and metastasis. Its expression is correlated with poor prognosis. The antibody is engineered to include a YTE mutation to improve pharmacokinetics.	Pharmacologic Substance
C133818	Anti-AG7 Antibody Drug Conjugate AbGn-107	ADC AbGn-107 || Ab1-18Hr1 || AbGn-107 || AbGn107 || Anti-AG7 ADC AbGn-107 || Anti-AG7 Antibody Drug Conjugate AbGn-107 || Anti-AG7 Antibody Drug Conjugate AbGn-107	An antibody drug conjugate (ADC) composed of a monoclonal antibody that targets the tumor-associated antigen (TAA) AG7 and is linked, through a hydrophilic, self-immolative linker, to a proprietary cytotoxic payload, with potential antineoplastic activity. Upon administration of AbGn-107 the antibody moiety targets and binds to the AG7 antigen expressed on a variety of cancer cells. Upon binding and internalization, the linker is cleaved and the payload is released, binds to tubulin, inhibits tubulin polymerization and kills the AG7-expressing tumor cells.	Pharmacologic Substance
C82685	Anti-AGS-16 Monoclonal Antibody AGS-16M18	AGS-16M18 || Anti-AGS-16 Monoclonal Antibody AGS-16M18 || Anti-AGS-16 Monoclonal Antibody AGS-16M18	A humanized monoclonal antibody directed against the activator of g-proteins signaling (AGS) cell surface protein AGS-16 with potential antineoplastic activity. Anti-AGS-16 monoclonal antibody AGS-16M18 selectively binds to AGS-16, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells expressing AGS-16. While normally expressed at low levels in the proximal tubules of the kidney, AGS-16 has been found to be overexpressed in more than 95% of kidney and 40% of liver neoplasms.	Amino Acid, Peptide, or Protein || Immunologic Factor
C92590	Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME	ASG-5ME || Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME || Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME	An antibody drug conjugate (ADC) containing the fully human IgG2k monoclonal antibody targeting an epitope of SLC44A4 (AGS-5) linked, via a valine-citrulline (vc) maleimidocaproyl (mc) linker, to the antimicrotubulin drug monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of ASG-5ME selectively binds to AGS-5. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis. SLC44A4, potentially a sodium-dependent transmembrane transport protein, is overexpressed on more than 80 percent of samples derived from patients with pancreatic, prostate and gastric cancers.	Pharmacologic Substance
C82686	Anti-AGS-8 Monoclonal Antibody AGS-8M4	AGS-8M4 || Anti-AGS-8 Monoclonal Antibody AGS-8M4 || Anti-AGS-8 Monoclonal Antibody AGS-8M4	A humanized monoclonal antibody directed against the activator of g-proteins signaling (AGS) cell surface protein AGS-8 with potential antineoplastic activity. Anti-AGS-8 monoclonal antibody AGS-8M4 selectively binds to AGS-8, triggering complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity in tumor cells expressing AGS-8. While normally expressed at low levels in the heart in response to ischemia, AGS-8 has been found to be expressed in more than 70% of ovarian neoplasms.	Amino Acid, Peptide, or Protein || Immunologic Factor
C181755	Anti-ALK-1 Monoclonal Antibody GT90001	Anti-ALK-1 Monoclonal Antibody GT90001 || Anti-ALK-1 Monoclonal Antibody GT90001 || Anti-Activin Receptor-like Kinase-1 Monoclonal Antibody GT90001 || GT 90001 || GT-90001 || GT90001	A human immunoglobulin G2 (IgG2) monoclonal antibody against activin receptor-like kinase-1 (ALK-1; ALK1), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-ALK-1 monoclonal antibody GT90001 targets and binds to ALK-1, and prevents ALK-1 activation by its ligands bone morphogenetic protein 9 (BMP) 9 and BMP10. This prevents ALK-1-mediated endothelial cell signaling and the activation of transforming growth factor-beta (TGF-beta)/TGF-beta receptor I (ALK-5) signaling. This inhibits tumor blood vessel growth, reduces blood flow and angiogenesis and leads to an inhibition of tumor cell proliferation and modulation of the tumor microenvironment (TME). ALK-1 is a type I cell surface receptor and plays a key role in angiogenesis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C164668	Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B	Anti-BCMA x aCD3 T-BsAb TNB-383B || Anti-BCMA x aCD3 T-cell Engaging Bispecific Antibody TNB-383B || Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B || Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B || TNB 383B || TNB-383B || TNB383B	A T-cell engaging bispecific antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human alpha B-cell maturation antigen (aBCMA) and against the alphaCD3 (aCD3) antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. TNB-383B is composed of two aBCMA moieties in sequence on one arm, a single aCD3 arm, and a silenced IgG4 Fc. Upon administration of anti-aBCMA/aCD3 T-cell engaging bispecific antibody TNB-383B, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Binding to aCD3 preferentially activates effector over regulatory T-cells and stimulates minimal cytokine release.	Pharmacologic Substance
C116865	Anti-alpha5beta1 Integrin Antibody MINT1526A	Anti-a5b1 Antibody MINT1526A || Anti-alpha5beta1 Integrin Antibody MINT1526A || Anti-alpha5beta1 Integrin Antibody MINT1526A || MINT-1526A || MINT1526A || RG-7594	An antibody directed against the human alpha5beta1 integrin (a5b1) with potential antiangiogenic and antineoplastic activities. Anti-a5b1 antibody MINT1526A selectively binds to a5b1, thereby preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in a5b1-expressing tumor cells. a5b1, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in both endothelial cell adhesion and migration.	Pharmacologic Substance
C95704	Anti-ANG2 Monoclonal Antibody MEDI-3617	Anti-ANG2 MoAb MEDI-3617 || Anti-ANG2 Monoclonal Antibody MEDI-3617 || Anti-ANG2 Monoclonal Antibody MEDI-3617 || MEDI-3617 || MEDI-3617	A fully human IgG1 monoclonal antibody against angiopoietin 2 (ANG2), with potential antiangiogenic activity. Anti-ANG2 monoclonal antibody MEDI-3617 binds to Ang2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinase (Tie2), thereby resulting in the disruption of vascular remodeling. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.	Immunologic Factor || Pharmacologic Substance
C99761	Antiangiogenic Drug Combination TL-118	Antiangiogenic Drug Combination TL-118 || Hamsa-1 || TL-118	A proprietary, oral suspension containing a combination of agents comprised of a nonsteroidal anti-inflammatory agent, an alkylating agent, a histamine H2 antagonist and a sulfonamide with potential anti-angiogenic and antineoplastic activities. Antiangiogenic drug combination TL-118 is administrated as a specific dosing regimen and may result in a synergistic effect and reduce angiogenesis and inhibit tumor cell proliferation.	Pharmacologic Substance
C116627	Anti-angiopoietin Monoclonal Antibody AMG 780	AMG 780 || AMG-780 || Anti-angiopoietin Monoclonal Antibody AMG 780 || Anti-angiopoietin Monoclonal Antibody AMG 780	An immunoglobulin (Ig) G2 monoclonal antibody targeting the proangiogenic cytokines angiopoietin 1 (Ang1) and 2 (Ang2), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-angiopoietin monoclonal antibody AMG 780 binds to Ang1 and Ang2. This prevents the binding of the angiopoietin ligands to their receptor Tie2 (TEK), an endothelial cell-specific receptor tyrosine kinase. This prevents Tie2-mediated signaling and results in an inhibition of Tie2-expressing, tumor-stimulated endothelial cell proliferation, which prevents angiogenesis and inhibits tumor cell proliferation.	Pharmacologic Substance
C142822	Anti-APRIL Monoclonal Antibody BION-1301	Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody BION-1301 || Anti-APRIL Monoclonal Antibody BION-1301 || Anti-APRIL Monoclonal Antibody BION-1301 || Anti-TNFSF13 Monoclonal Antibody BION-1301 || BION-1301	A humanized monoclonal antibody targeting a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), with potential antineoplastic and immune checkpoint inhibitory activities. Following administration, anti-APRIL monoclonal antibody BION-1301 binds to APRIL and inhibits its binding to both of its receptors, B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and transmembrane activator and CAML Interactor (TACI; tumor necrosis factor receptor superfamily member 13B; TNFRSF13B). This inhibits the activation of both BCMA and TACI, and their downstream signaling pathways, which prevents tumor growth, tumor cell adhesion to bone marrow cells and immune suppression. Additionally, BION-1301 may reduce APRIL-induced drug resistance which occurs in some tumors. APRIL, an extracellular protein and member of the tumor necrosis factor ligand superfamily (TNFSF), is expressed by bone marrow plasma cells and myeloid cells, and overexpressed in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and colorectal carcinoma. APRIL induces immune suppression and tumor progression through the activation of BCMA- and TACI-dependent signaling pathways.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C122924	Anti-B7-H3 Antibody DS-5573a	Anti-B7-H3 Antibody DS-5573a || DS-5573a	An antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-B7-H3 antibody DS-5573a binds to the cell surface antigen B7-H3, thereby blocking B7-H3-mediated signaling. This abrogates the inhibitory effect on T-cell activation and may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C187121	Anti-B7-H3 Antibody-drug Conjugate HS-20093	Anti-B7-H3 ADC HS-20093 || Anti-B7-H3 Antibody-drug Conjugate HS-20093 || Anti-B7H3 ADC HS-20093 || HS 20093 || HS-20093 || HS20093	An antibody-drug conjugate (ADC) composed of a human immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-homologue 3 (B7-H3, CD276) linked to an as of yet undefined cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-B7-H3 ADC HS-20093, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding, internalization and linker cleavage, the cytotoxic agent is release and induces apoptosis specifically in B7-H3-expressing tumor cells through an as of yet undefined mechanism of action (MoA). B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is an immunoregulatory protein overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.	Pharmacologic Substance
C186668	Anti-B7-H3 CAR T Cells TAA06	Anti-B7-H3 CAR T Cells TAA06 || Anti-B7-H3 CAR T-cells TAA06 || Anti-CD276 CAR T Cells TAA06 || TAA 06 || TAA-06 || TAA06	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon administration, anti-B7-H3 CAR T-cells TAA06 target and bind to B7-H3-expressing tumor cells, thereby inducing selective toxicity in B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.	Cell || Pharmacologic Substance
C165844	Anti-B7-H3 CAR T-cells	Anti-B7-H3 CAR T-cells || Anti-B7-H3 CAR T-cells || CARB7H3	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, anti-B7-H3 CAR T-cells target and bind to B7-H3-expressing tumor cells, thereby inducing selective toxicity in B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.	Cell || Pharmacologic Substance
C171577	Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a	Anti-B7-H3/DXd ADC DS-7300a || Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a || Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a || Anti-B7H3/DXd Antibody-drug Conjugate DS-7300a || DS 7300 || DS 7300a || DS-7300 || DS-7300a || DS7300 || DS7300a	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-B7-H3/DXd ADC DS-7300a, the anti-B7-H3 antibody targets and binds to B7-H3-expressing tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.	Pharmacologic Substance
C186669	Anti-B7-H4 Antibody-drug Conjugate SGN-B7H4V	Anti-B7-H4 ADC SGN-B7H4V || Anti-B7-H4 Antibody-drug Conjugate SGN-B7H4V || Anti-B7-H4 Antibody-drug Conjugate SGN-B7H4V || SGN B7H4V || SGN-B7H4V || SGNB7H4V	An antibody-drug conjugate (ADC) composed of a human immunoglobulin (Ig) G1 monoclonal antibody directed against the T-cell checkpoint ligand B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) linked to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a protease-cleavable peptide linker, with potential antineoplastic activity. Upon administration of anti-B7-H4 ADC SGN-B7H4V, the anti-B7-H4 monoclonal antibody moiety targets and binds to B7-H4 expressed on tumor cells. Upon binding, internalization and linker cleavage, MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and apoptosis specifically in B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and tumor-associated macrophages (TAMs). It negatively regulates T-cell immune responses. In addition, SGN-B7H4V may also kill B7-H4-expressing tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).	Pharmacologic Substance
C180679	Anti-B7-H4 Monoclonal Antibody NC762	Anti-B7-H4 Monoclonal Antibody NC762 || Anti-B7-H4 Monoclonal Antibody NC762 || NC 762 || NC-762 || NC762	A humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-B7-H4 monoclonal antibody NC762 binds to B7-H4 on the surface of tumor cells. This may induce antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells, which leads to the inhibition of tumor cell proliferation. In addition, the Fc region of NC762 contains three point mutations. This enhances its binding affinity for human FcgammaRIIIa receptors (CD16a) on natural killer (NK) cells, resulting in enhanced ADCC against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses. However, the anti-tumor activity of NC762 is not dependent upon T-cells.	Pharmacologic Substance
C185401	Anti-B7-H4/ TOP1i Antibody-drug Conjugate AZD8205	ADC AZD8205 || AZD 8205 || AZD-8205 || AZD8205 || Anti-B7-H4/ TOP1i Antibody-drug Conjugate AZD8205 || Anti-B7-H4/ TOP1i Antibody-drug Conjugate AZD8205 || Anti-B7-H4/TOP1i ADC AZD8205 || Anti-B7-H4/Topoisomerase I Inhibitor ADC AZD8205 || Antibody-drug Conjugate AZD8205 || B7-H4 TOP1i ADC AZD8205	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) linked to a topoisomerase-1 inhibitor (TOP1i; TOP-Ii), with potential antineoplastic activity. Upon administration, the anti-B7-H4 monoclonal antibody moiety of ADC AZD8205 targets and binds to B7-H4 expressed on tumor cells. Upon binding and internalization, the TOP1i moiety is released, binds to TOP1 and stabilizes cleaved DNA-TOP1 complexes. This prevents DNA re-ligation, induces irreversible DNA strand breaks, prevents DNA repair, and leads to cycle arrest and apoptosis specifically in tumor cells expressing B7-H4. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and tumor-associated macrophages. It negatively regulates T-cell immune responses.	Pharmacologic Substance
C185128	Anti-B7-H4/Anti-CD3 Bispecific Antibody PF-07260437	Anti-B7-H4/Anti-CD3 Bispecific Antibody PF-07260437 || Anti-B7-H4/Anti-CD3 Bispecific Antibody PF-07260437 || Anti-B7-H4/CD3 Bispecific Antibody PF-07260437 || Anti-CD3/Anti-B7-H4 Bispecific Antibody PF-07260437 || B7-H4 x CD3 Bispecific Antibody PF-07260437 || PF 07260437 || PF-07260437 || PF07260437	A bispecific monoclonal antibody against both B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-B7-H4/anti-CD3 bispecific antibody PF-07260437 targets and binds to both B7-H4 on the surface of tumor cells and CD3 on T-cells. This results in the cross-linking of tumor cells and T-cells, and induces a cytotoxic T-lymphocyte (CTL) response against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.	Pharmacologic Substance
C188024	Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049	Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049 || Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049 || Anti-B7-H6/CD3 Bispecific Antibody BI 765049 || B7-H6 x CD3 Bispecific Antibody BI 765049 || B7-H6/CD3 T-cell Engager BI 765049 || BI 765049 || BI-765049 || BI765049	An immunoglobulin G (IgG)-like bispecific T-cell engaging antibody directed against both natural cytotoxicity triggering receptor 3 ligand 1 (NCR3LG1; B7-H6) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-B7-H6/anti-CD3 bispecific antibody BI 765049 targets and binds to both B7-H6 on tumor cells and CD3 on T-cells. This results in the cross-linking of B7-H6-expressing tumor cells and T-cells, redirects cytotoxic T-lymphocytes (CTLs) to B7-H6-expressing tumor cells, which leads to the CTL-mediated cell death of B7-H6-expressing tumor cells. B7-H6, a member of the B7 family of immune modulators, is expressed in a variety of tumor cell types while minimally or not expressed in normal tissues. It is a specific ligand for the natural killer (NK) cell activating receptor NKp30, and may modulate NK cell function in certain cancers.	Pharmacologic Substance
C187117	Anti-BAFFR Monoclonal Antibody ESG206	Anti-BAFFR Monoclonal Antibody ESG206 || ESG 206 || ESG-206 || ESG206	A monoclonal antibody that is directed against the tumor-associated antigen (TAA) B-cell activating factor receptor (BAFFR; tumor necrosis factor receptor superfamily member 13C; TNFRSF13C; BLyS receptor 3; BR3), with potential antineoplastic activity. Upon administration, anti-BAFFR monoclonal antibody ESG206 binds to and blocks BAFFR. This prevents BAFFR-mediated signaling and may kill BAFFR-expressing tumor cells. BAFFR, a protein belonging to the TNF receptor superfamily, is expressed on the surface of certain types of cancer cells, including B-cell acute lymphoblastic leukemia. It plays a key role in the regulation of peripheral B-cell survival.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C148176	Anti-BCMA Antibody SEA-BCMA	Anti-BCMA Afucosylated Monoclonal Antibody SEA-BCMA || Anti-BCMA Antibody SEA-BCMA || Anti-BCMA Antibody SEA-BCMA || SEA-BCMA || SEA-BCMA	A humanized, afucosylated monoclonal antibody created using the proprietary, sugar-engineered antibody (SEA) platform and directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), with potential immunoadjuvant activity. Upon administration, the anti-BCMA antibody SEA-BCMA targets and binds to BCMA expressed on tumor cells.  When administered with antibody-coupled T-cell receptor (ACTR)-expressing T-cells, the ACTR-expressing T-cells bind, with high affinity, to the anti-BCMA antibody SEA-BCMA. This activates the ACTR T-cells and the T-cells induce specific cytotoxic T-lymphocyte (CTL)-mediated cytotoxicity toward BCMA-expressing tumor cells. BCMA, a cell surface protein and member of the tumor necrosis factor (TNF) receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C162528	Anti-BCMA Antibody-drug Conjugate AMG 224	AMG 224 || AMG-224 || AMG-224 || AMG224 || Anti-BCMA Antibody-drug Conjugate AMG 224 || Anti-BCMA Antibody-drug Conjugate AMG 224	An antibody-drug conjugate (ADC) comprised of an anti-human B-cell maturation antigen (BCMA) immunoglobulin G1 (IgG1) antibody conjugated via the noncleavable linker 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (MCC), to the cytotoxic maytansine-derivative, DM1, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AMG 224 selectively binds to BCMA expressed on the surface of tumor cells. Upon internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of tumor cells that express BCMA. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF)and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.	Pharmacologic Substance
C170915	Anti-BCMA Antibody-drug Conjugate CC-99712	Anti-BCMA ADC CC-99712 || Anti-BCMA Antibody Drug Conjugate CC-99712 || Anti-BCMA Antibody-drug Conjugate CC-99712 || Anti-BCMA Antibody-drug Conjugate CC-99712 || CC 99712 || CC-99712 || CC99712	An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17), linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-BCMA ADC CC-99712, the antibody moiety targets and binds to the cell surface antigen BCMA expressed on certain cancer cells. Upon binding and internalization, the cytotoxic agent is released and kills the BCMA-expressing cancer cells through an as of yet unknown mechanism of action. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival. It is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.	Pharmacologic Substance
C184309	Anti-BCMA CAR-NK Cells	Anti-BCMA CAR-NK Cells || Anti-BCMA CAR-NKs || Anti-BCMA CAR-Natural Killer Cells	A preparation of umbilical cord blood (CB)-derived natural killer cells (NKs) expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunomodulating and antineoplastic activities. Upon transfusion, the anti-BCMA CAR-NK cells recognize, bind to and induce selective cytotoxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival.	Pharmacologic Substance
C167337	Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA	ARC-T Plus Anti-BCMA SparX || Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA || Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA || Anti-TAG ARC-T Cells Directed by BCMA Bi-valent/TAG SparX Protein || Immunotherapeutic Combination Agent SparX Protein Plus CART-ddBCMA || TAG-containing SparX /Bivalent BCMA-targeted ARC-T Cells	An immunotherapeutic combination agent composed of antigen receptor complex T cells (ARC-T cells) which contain a proprietary binding domain specific for a universal TAG instead of a single chain variable fragment (scFv) binding domain, and a tumor-targeting antigen protein, soluble protein antigen-receptor X-linker (sparX) protein, containing a TAG moiety fused to two B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) binding domains, with potential antineoplastic activities. Upon administration of the anti-BCMA sparX protein plus BCMA-directed ARC T-cells CART-ddBCMA, the sparX protein, with its two BCMA binding domains, specifically targets and binds to two BCMA expressed on tumor cells. In turn, the ARC-T cells, with their anti-TAG domain, target and bind to the TAG domain on the sparX protein. This directly links the ARC-T cells to the BCMA-expressing tumor cells, through the ARC-T cell- sparX -tumor cell complex formation, thereby causing direct tumor cell killing. BCMA, a tumor-associated antigen (TAA), is found on the surfaces of plasma cells and is overexpressed on a variety of tumor cell types. Compared to anti-BCMA CAR-T cells, CART-ddBCMA, containing ARC-T cells that are re-programmed in vivo by the TAG sparX protein, shows enhanced efficiency and an improved safety profile. As ARC-T activity is dependent on the sparX dose administered, the rate of tumor cell killing, and related toxicities are also dependent on the sparX dose administered.	Pharmacologic Substance
C179409	Anti-BCMA/Alpha-amanitin Antibody-drug Conjugate HDP-101	ADC HDP-101 || Anti-BCMA Antibody-drug Conjugate HDP-101 || Anti-BCMA/Alpha-amanitin ADC HDP-101 || Anti-BCMA/Alpha-amanitin Antibody-drug Conjugate HDP-101 || Anti-BCMA/Alpha-amanitin Antibody-drug Conjugate HDP-101 || HDP 101 || HDP-101 || HDP101	An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) conjugated, via a cleavable linker, to the cytotoxic, RNA polymerase II inhibitor alpha-amanitin, with potential antineoplastic activity. Upon administration of anti-BCMA/alpha-amanitin ADC HDP-101, the antibody moiety targets and binds to the cell surface antigen BCMA expressed on certain cancer cells. Upon antibody/antigen binding, internalization and cleavage, the cytotoxic alpha-amanitin is released. Alpha-amanitin binds to and inhibits RNA polymerase II, prevents RNA synthesis, induces apoptosis, and inhibits the proliferation of BCMA-overexpressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival; it is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.	Pharmacologic Substance
C179632	Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06	Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06 || Anti-BCMA/Anti-CD3 FIT-Ig Bispecific Antibody EMB-06 || Anti-BCMA/CD3 Bispecific Antibody EMB-06 || BCMAxCD3 Bispecific Antibody EMB-06 || EMB 06 || EMB-06 || EMB06 || Fabs-In-Tandem Immunoglobulin Bispecific Antibody EMB-06	A tetravalent, bispecific antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-BCMA/anti-CD3 bispecific antibody EMB-06 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. In EMB-06, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites.	Pharmacologic Substance
C165656	Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459	Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459 || Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459 || Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459 || Anti-BCMA/CD3 Bispecific Antibody REGN5459 || Anti-CD3/Anti-BCMA Bispecific Antibody REGN5459 || REGN 5459 || REGN-5459 || REGN5459	A human bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-BCMA/anti-CD3 bispecific antibody REGN5459 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Pharmacologic Substance
C181676	Anti-BCMA/Anti-CD3 Bispecific Antibody WVT078	Anti-BCMA/Anti-CD3 Bispecific Antibody WVT078 || Anti-BCMA/Anti-CD3 Bispecific Antibody WVT078 || Anti-BCMA/CD3 Bispecific Antibody WVT078 || BCMA x CD3 Bispecific Antibody WVT078 || WVT 078 || WVT-078 || WVT078	A bispecific antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-BCMA/anti-CD3 bispecific antibody WVT078 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.	Pharmacologic Substance
C187125	Anti-BCMA/Anti-GPRC5D CAR-T Cells OriC321	Anti-BCMA/Anti-GPRC5D CAR-T Cells OriC321 || BCMA/GPRC5D Dual Target CAR-T Cells OriC321 || BCMA/GPRC5D-targeted CAR T-cells OriC321 || Bispecific BCMA/GPRC5D-targeted CAR T Cells OriC321 || OriC 321 || OriC-321 || OriC321	A preparation of T-lymphocytes engineered to express chimeric antigen receptor(s) (CAR) targeting the human tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and G-protein coupled receptor family C group 5 member D (GPRC5D) and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-BCMA/anti-GPRC5D CAR-T cells OriC321 specifically and simultaneously target and bind to tumor cells expressing BCMA and/or GPRC5D. This induces selective toxicity in tumor cells that express BCMA and/or GPRC5D. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation.	Pharmacologic Substance
C150127	Anti-BCMA/PBD ADC MEDI2228	ADC MEDI2228 || Anti-BCMA ADC MEDI2228 || Anti-BCMA/PBD ADC MEDI2228 || Anti-BCMA/PBD ADC MEDI2228 || Anti-BCMA/PBD MEDI2228 || Antibody-drug Conjugate MEDI2228 || MEDI 2228 || MEDI-2228 || MEDI-2228 || MEDI2228	An antibody-drug conjugate (ADC) consisting of a fully human monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) that is site-specifically conjugated, via a protease-cleavable linker, to a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-BCMA/PBD ADC MEDI2228, the antibody moiety targets the cell surface antigen BCMA expressed on certain cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of BCMA-overexpressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival; it is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.	Pharmacologic Substance
C185129	Antibody STING Drug Conjugate TAK-500	ADC  STING Agonist TAK-500 || ADC TAK-500 || Antibody STING Drug Conjugate TAK-500 || Antibody STING Drug Conjugate TAK-500 || Antibody-drug Conjugate TAK-500 || STING ADC TAK-500 || Stimulator of Interferon Genes Agonist TAK-500 || TAK 500 || TAK-500 || TAK500	An antibody-drug conjugate (ADC) composed of an as of yet undisclosed antibody conjugated to TAK-676, an agonist for the stimulator of interferon genes (STING; transmembrane protein 173; TMEM173), with potential immuno-activating and antineoplastic activities. Upon intravenous administration, antibody STING drug conjugate TAK-500 targets and binds to the undisclosed target, thereby allowing TAK-676 to bind to STING. This activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system. The conjugation of the antibody to TAK-676 improves targeted delivery of the STNG agonist and increases tumor exposure to TAK-676 and enhances the STING-mediated anti-tumor immune responses.	Pharmacologic Substance
C161599	Antibody-drug Conjugate ABBV-011	ABBV 011 || ABBV-011 || ABBV011 || Antibody-drug Conjugate ABBV-011 || Antibody-drug Conjugate ABBV-011 || SC 011 || SC-011 || SC011	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against an as of yet undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ABBV-011 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills tumor cells expressing this particular TAA through an as of yet undisclosed mechanism.	Pharmacologic Substance
C129401	Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014	ADC Anti-TIM-1-vcMMAE CDX-014 || ADC CDX-014 || Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014 || Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014 || Antibody-drug Conjugate CDX-014 || CDX-014 || CDX-014 || CR014-vc-MMAE || CR014-vcMMAE	A monoclonal antibody-drug conjugate (ADC) comprised of human immunoglobulin G1 (IgG1) clone CR014, which targets the extracellular domain of T-cell immunoglobulin mucin-1 (TIM-1; HAVCR1), that is linked, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of ADC anti-TIM-1-vcMMAE CDX-014, the monoclonal antibody moiety targets and binds to TIM-1. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of TIM-1-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. TIM-1 is upregulated in a variety of cancer cell types while only minimally expressed in healthy tissue. The linkage system in CDX-014 is highly stable in plasma, resulting in increased specificity and cytotoxic efficacy towards TIM-1-positive cells.	Pharmacologic Substance
C106256	Antibody-Drug Conjugate DFRF4539A	ADC DFRF4539A || Antibody-Drug Conjugate DFRF4539A || Antibody-Drug Conjugate DFRF4539A || DFRF4539A	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against a specific myeloma antigen and conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DFRF4539A selectively binds to a specific protein expressed on the surface of myeloma cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C137821	Antibody-drug Conjugate MEDI7247	ADC MEDI7247 || Antibody-drug Conjugate MEDI7247 || Antibody-drug Conjugate MEDI7247 || MEDI 7247 || MEDI-7247 || MEDI7247	An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of MEDI7247 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Pharmacologic Substance
C118572	Antibody-drug Conjugate PF-06647263	Antibody-drug Conjugate PF-06647263 || Antibody-drug Conjugate PF-06647263 || PF-06647263		Pharmacologic Substance
C118570	Antibody-drug Conjugate PF-06664178	Antibody-drug Conjugate PF-06664178 || Antibody-drug Conjugate PF-06664178 || PF-06664178		Pharmacologic Substance
C180906	Antibody-drug Conjugate RC118	ADC RC118 || Antibody-drug Conjugate RC118 || RC 118 || RC-118 || RC118	An antibody-drug conjugate (ADC) composed of an as of yet undisclosed monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of ADC RC118 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Pharmacologic Substance
C123284	Antibody-drug Conjugate SC-002	ADC SC-002 || Antibody-drug Conjugate SC-002 || Antibody-drug Conjugate SC-002 || SC-002	An antibody-drug conjugate (ADC) composed of an as of yet publicly unknown monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-002 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Pharmacologic Substance
C136807	Antibody-drug Conjugate SC-004	ADC SC-004 || Antibody-drug Conjugate SC-004 || Antibody-drug Conjugate SC-004 || SC 004 || SC-004 || SC-004 || SC004	An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-004 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.	Pharmacologic Substance
C154558	Antibody-drug Conjugate SC-005	Antibody-drug Conjugate SC-005 || SC 005 || SC 005 || SC-005 || SC-005	An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-005 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.	Pharmacologic Substance
C136779	Antibody-drug Conjugate SC-006	ADC SC-006 || Antibody-drug Conjugate SC-006 || Antibody-drug Conjugate SC-006 || SC 006 || SC-006 || SC-006 || SC006	An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-006 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Pharmacologic Substance
C147029	Antibody-drug Conjugate SC-007	ADC SC-007 || Antibody-drug Conjugate SC-007 || Antibody-drug Conjugate SC-007 || SC-007 || SC-007	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against an undisclosed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-007 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Pharmacologic Substance
C181025	Antibody-drug Conjugate SHR-A1904	ADC SHR-A1904 || Antibody-drug Conjugate SHR-A1904 || Antibody-drug Conjugate SHR-A1904 || SHR A1904 || SHR-A1904 || SHRA1904	An antibody-drug conjugate (ADC) composed of an as of yet undisclosed monoclonal antibody against a tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of ADC SHR-A1904 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Pharmacologic Substance
C185413	Antibody-drug Conjugate SHR-A1912	ADC SHR-A1912 || Antibody-drug Conjugate SHR-A1912 || SHR A1912 || SHR-A1912 || SHRA1912	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SHR-A1912 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Pharmacologic Substance
C185430	Antibody-drug Conjugate TORL-1-23	ADC TORL-1-23 || Antibody-drug Conjugate TORL-1-23 || Antibody-drug Conjugate TORL-1-23 || TORL 1-23 || TORL-1-23 || TORL1-23	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of TORL-1-23 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Pharmacologic Substance
C185565	Antibody-drug Conjugate TORL-2-307-ADC	ADC TORL-2-307-ADC || Antibody-drug Conjugate TORL-2-307-ADC || Antibody-drug Conjugate TORL-2-307-ADC || TORL 2-307-ADC || TORL-2-307-ADC || TORL2-307-ADC	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of TORL-2-307-ADC targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Pharmacologic Substance
C175508	Anti-BTN3A Agonistic Monoclonal Antibody ICT01	Anti-BTN3A Agonist Monoclonal Antibody ICT01 || Anti-BTN3A Agonistic Monoclonal Antibody ICT01 || Anti-BTN3A Agonistic Monoclonal Antibody ICT01 || ICT 01 || ICT-01 || ICT01	A humanized agonistic monoclonal antibody directed against butyrophilin subfamily 3 member A (BTN3A; CD277), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-BTN3A agonistic monoclonal antibody ICT01 targets and binds to BTN3A present on epithelial and tumor cells. BTN3A binding may sensitize tumor cells to gamma 9 delta 2 (Vg9Vd2) T cell killing. The Vg9Vd2 T cells secrete effector cytokines and exert a cytolytic effect on tumor cells. This may abrogate BTN3A-mediated tumor immunity and may enhance anti-tumor immune response. BTN3A, a member of the butyrophilin superfamily of immunomodulators, is upregulated in tumor cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C177110	Anti-C5aR1 Monoclonal Antibody TJ210	Anti-C5aR Monoclonal Antibody TJ210 || Anti-C5aR1 Monoclonal Antibody TJ210 || Anti-C5aR1 Monoclonal Antibody TJ210 || MOR 210 || MOR-210 || MOR044254 || MOR210 || TJ 210 || TJ-210 || TJ210 || TJ210001 || WBP2191	A differentiated human monoclonal antibody targeting the complement component fragment 5a receptor (C5aR1, CD88), with potential immunomodulating and antineoplastic activities.  Upon administration, the anti-C5aR1 monoclonal antibody TJ210 specifically targets and binds to the N-terminus of C5aR1 expressed on subsets of tumor-promoting cells, such as myeloid-derived suppressor cells (MDSCs), neutrophils and M2 macrophages. This prevents the binding of its ligand complement factor 5a (C5a) to C5aR1 and prevents the C5aR1-mediated activation, migration and accumulation of the C5aR1-expressing cells in the tumor microenvironment (TME). This abrogates the secretion of inflammatory and angiogenic factors by these cells and restores the activation of T- and natural killer (NK) cells. This results in the induction of anti-tumor immune responses and inhibits tumor cell proliferation. C5a, a factor in the complement cascade, is often overexpressed in the TME, where it attracts and activates C5aR1-expressing tumor-promoting immune cells, and contributes to tumor immune suppression.	Amino Acid, Peptide, or Protein || Immunologic Factor
C125900	Anti-CA19-9 Monoclonal Antibody 5B1	5B1 || Anti-CA19-9 Monoclonal Antibody 5B1 || Anti-CA19-9 Monoclonal Antibody 5B1 || HuMab 5B1 || HuMab-5B1 || MVT-5873 || MVT-5873	A human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9), with potential antineoplastic activity. Upon administration, monoclonal antibody 5B1 binds to CA19-9 and kills CA19-9-expressing tumor cells, possibly through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). CA19-9 is overexpressed on a number of different tumor cell types, and plays a key role in tumor cell survival and metastasis.	Immunologic Factor || Pharmacologic Substance
C95764	Anti-CA6-DM4 Immunoconjugate SAR566658	Anti-CA6-DM4 Immunoconjugate SAR566658 || SAR-566658 || SAR-566658 || SAR566658 || huDs6-DM4	An immunoconjugate consisting of a humanized monoclonal antibody against the tumor-associated sialoglycotope CA6 (huDS6) conjugated to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-CA6 monoclonal antibody moiety of SAR566658 targets and binds to the cell surface antigen CA6. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CA6-expressing tumor cells. The CA6 epitope is found on a variety of solid tumors, including breast, ovarian, cervical, lung and pancreatic tumors.	Pharmacologic Substance
C181752	Anti-CAIX CAR T Cells	Anti-CAIX CAR T Cells || CAIX-targeted CAR-T Cells	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) carbonic anhydrase IX (CAIX; carbonic anhydrase 9; CA9; G250), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CAIX CAR T-cells target and bind to CAIX-expressing tumor cells, thereby inducing selective toxicity in CAIX-expressing tumor cells. CAIX is a member of the carbonic anhydrase family that is found in a majority of renal cell carcinomas while absent in most normal tissues.	Pharmacologic Substance
C163950	Anti-CCR4 Monoclonal Antibody	Anti-CCR4 Monoclonal Antibody	Any monoclonal antibody that targets C-C chemokine receptor 4 (CCR4; CCR-4).	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C175477	Anti-CCR7 Antibody-drug Conjugate JBH492	Anti-CCR7 ADC JBH492 || Anti-CCR7 Antibody-drug Conjugate JBH492 || Anti-CCR7 Antibody-drug Conjugate JBH492 || Anti-CCR7-DM4 Antibody-drug Conjugate JBH492 || JBH 492 || JBH-492 || JBH492	An antibody-drug conjugate (ADC) composed of an antibody targeting CC chemokine receptor 7 (CCR7) and conjugated to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-CCR7 ADC JBH492, the antibody moiety targets and binds to CCR7 on tumor cells. Upon antibody/antigen binding and internalization, the ADC releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics. This results in the inhibition of cell division and cell growth of CCR7-expressing tumor cells. CCR7, a G-protein coupled receptor, is normally expressed by subsets of immune cells and overexpressed by various types of cancer cells. Its overexpression has been associated with lymph node metastasis and poor survival.	Pharmacologic Substance
C179626	Anti-CCR7 Monoclonal Antibody CAP-100	Anti-CCR7 Monoclonal Antibody CAP-100 || CAP 100 || CAP-100 || CAP100	A humanized immunoglobulin G1 (IgG1) monoclonal antibody against C-C-chemokine receptor 7 (CCR7), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR7 monoclonal antibody CAP-100 targets and binds to CCR7 on tumor cells, and neutralizes ligand-mediated signaling through both ligands CCL19 and CCL21. This prevents the activity of CCR7 on tumor cells. CAP-100 is expected to prevent the migration of tumor cells to and their survival in lymphoid niches. In addition, CAP-100 eliminates CCR7-positive tumor cells via the induction of Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). CCR7, a G-protein coupled receptor involved in trafficking of cells to lymph nodes, is normally expressed by subsets of immune cells and overexpressed in various types of cancer cells, such as in many hematological malignancies. Its overexpression has been associated with lymph node metastasis and poor survival.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C179913	Anti-CCR8 Monoclonal Antibody BMS-986340	Anti-CCR8 Monoclonal Antibody BMS-986340 || Anti-CCR8 Monoclonal Antibody BMS-986340 || BMS 986340 || BMS-986340 || BMS986340	A human immunoglobulin G1 (IgG1) nonfucosylated (NF) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody BMS-986340 targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. BMS-986340 eliminates CCR8-positive Tregs via the induction of Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC), thereby depleting CCR8-positive Tregs. This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.	Pharmacologic Substance
C183159	Anti-CCR8 Monoclonal Antibody GS-1811	Anti-C-C-chemokine Receptor 8 Monoclonal Antibody GS-1811 || Anti-CCR8 Monoclonal Antibody GS-1811 || GS 1811 || GS-1811 || GS1811 || JTX 1811 || JTX-1811 || JTX1811	A humanized immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody GS-1811 targets and binds to CCR8 on CCR8-positive, immunosuppressive tumor-infiltrating T regulatory (TITR) cells in the tumor microenvironment (TME), and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. GS-1811 depletes CCR8-positive TITR cells via antibody-dependent cell-mediated cytotoxicity (ADCC), which may reactivate antitumor immune responses. CCR8 is specifically expressed by TITR cells in multiple types of cancer and plays a key role in immunosuppression.	Pharmacologic Substance
C186374	Anti-CCR8 Monoclonal Antibody LM-108	Anti-CCR8 Monoclonal Antibody LM-108 || LM 108 || LM-108 || LM108	A monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody LM-108 targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.	Pharmacologic Substance
C185418	Anti-CCR8 Monoclonal Antibody S-531011	Anti-C-C-chemokine Receptor 8 Monoclonal Antibody S-531011 || Anti-CCR8 Monoclonal Antibody S-531011 || S 531011 || S-531011 || S531011	A human immunoglobulin G1 (IgG1) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody S-531011 targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. S-531011 eliminates CCR8-positive Tregs via the induction of Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC), thereby depleting CCR8-positive Tregs. This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.	Pharmacologic Substance
C174050	Anti-CD117 Monoclonal Antibody JSP191	AMG 191 || AMG-191 || AMG191 || Anti-CD117 Monoclonal Antibody JSP191 || Anti-CD117 Monoclonal Antibody JSP191 || Anti-c-Kit Monoclonal Antibody JSP191 || JSP 191 || JSP-191 || JSP191	A humanized monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), that can potentially be used to deplete hematopoietic stem cells (HSCs). Upon administration, the anti-CD117 monoclonal antibody JSP191 targets and binds to CD117. This prevents the binding of stem cell factor (SCF) to its receptor CD117 on HSCs.  As CD117 binding to SCF is critical for survival and maintenance of blood forming stem cells, blocking this interaction causes the HSCs that are present in the bone marrow niches to be depleted. JSP191 can potentially be used as a conditioning regimen to prepare patients for hematopoietic stem cell transplantation.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C186516	Anti-CD117/Amanitin Antibody-drug Conjugate MGTA-117	ADC MGTA-117 || Anti-CD117 ADC MGTA-117 || Anti-CD117/Amanitin Antibody-drug Conjugate MGTA-117 || Anti-CD117/Amanitin Antibody-drug Conjugate MGTA-117 || Anti-c-Kit/Amanitin ADC MGTA-117 || MGTA 117 || MGTA-117 || MGTA117	An antibody-drug conjugate (ADC) consisting of a human monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), conjugated, via a cleavable linker, to the cytotoxic RNA polymerase II inhibitor amanitin, with potential antineoplastic activity and that can potentially be used as a conditioning agent to selectively deplete hematopoietic stem cells (HSCs) prior to allogeneic HSC transplants or other treatments for which HSCs need to be depleted. Upon administration of the anti-CD117/amanitin ADC MGTA-117, the antibody moiety targets and binds to the cell surface antigen CD117. Upon internalization and cleavage, the cytotoxic amanitin is released, binds to and inhibits RNA polymerase II. This prevents RNA synthesis and induces apoptosis of CD117-overexpressing HSCs and leukemic blasts. CD117, a transmembrane protein and receptor tyrosine kinase, is highly expressed on HSCs, progenitor cells and on leukemia cells. MGTA-117 is engineered to have a short half-life.	Pharmacologic Substance
C121231	Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1	Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1 || Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1 || Hu-Mik-Beta-1 || Hu-Mik-beta1 || Hu-Mikb1 || HuMikBeta1 || Humanized Mik-beta-1	A humanized version of the immunoglobulin (Ig) G1 monoclonal antibody Mik-Beta-1 (Hu-Mik-Beta-1) directed against CD122, the beta-subunit shared by the interleukin-2 (IL-2) and IL-15 receptor (IL-2/IL-15Rbeta). Upon intravenous infusion, Hu-Mik-Beta-1 binds to CD122 expressed on certain tumor cells. This blocks the binding of the inflammatory cytokines IL-2 and IL-15 to IL-2R and IL-15R, respectively, and prevents IL-2/IL-2R- and IL-15/IL-15R-mediated signaling. This may inhibit the proliferation of CD122-expressing tumor cells. In addition, blocking CD122 on T-lymphocytes prevents the over-activation of T-lymphocytes in various T-cell mediated autoimmune diseases, which is predominantly mediated by IL-15/IL-15R signaling. CD122, involved in both IL-2 and IL-15 signaling, is overexpressed on certain cancer cells, such as those found in T-cell large granular lymphocyte (T-LGL) leukemia.	Pharmacologic Substance
C143251	Anti-CD123 ADC IMGN632	Anti-CD123 ADC IMGN632 || Anti-CD123 ADC IMGN632 || Antibody-drug Conjugate IMGN632 || CD123-targeted ADC IMGN632 || IMGN 632 || IMGN-632 || IMGN632	An antibody-drug conjugate (ADC) consisting of a humanized anti-CD123 (interleukin-3 (IL-3) receptor alpha chain; IL3RA) immunoglobulin G1 (IgG1) monoclonal antibody conjugated, via a cleavable linker, to a cytotoxic, DNA-alkylating payload, which is an indolino-benzodiazepine dimer containing an imine moiety, with potential antineoplastic activity. Upon administration of anti-CD123 ADC IMGN632, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic moiety is released, and covalently binds to and alkylates DNA with its imine moiety. This results in cell cycle arrest in S-phase, which leads to apoptosis and inhibition of cell growth in cells overexpressing CD123. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers.	Pharmacologic Substance
C91093	Anti-CD123 Monoclonal Antibody CSL360	Anti-CD123 Monoclonal Antibody CSL360 || CSL360	A chimeric IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain) with potential antineoplastic activity. Derived from mouse monoclonal antibody 7G3, anti-CD123 monoclonal antibody CSL360 binds to and neutralizes CD123 which is upregulated on leukemic stem cells (LSC) in acute myeloid leukemia (AML). This may inhibit IL-3-dependent signalling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C123380	Anti-CD123 Monoclonal Antibody KHK2823	Anti-CD123 Monoclonal Antibody KHK2823 || KHK2823	A fully human monoclonal antibody against CD123 (interleukin-3 receptor alpha chain) with potential antineoplastic activity. Anti-CD123 monoclonal antibody KHK2823 binds to and neutralizes CD123, which is upregulated on leukemic stem cells (LSC) found in myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). This agent may inhibit IL-3-dependent signaling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C187654	Anti-CD123/Anti-CD3 Bispecific DART Molecule MGD024	Anti-CD123/Anti-CD3 Bispecific DART Molecule MGD024 || Anti-CD123/CD3 Bispecific DART Molecule MGD024 || CD123 x CD3 Bispecific DART Molecule MGD024 || Dual-Affinity Re-Targeting Protein MGD024 || MGD 024 || MGD-024 || MGD024	An Fc-bearing, bispecific antibody-like protein directed against the tumor-associated antigen (TAA) CD123 and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD123/anti-CD3 bispecific DART molecule MGD024 simultaneously binds to both CD123-expressing cancer cells and CD3-expressing T-cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain prolongs the half-life of the agent, and a reduced affinity of CD3-binding results in less cytokine release.	Pharmacologic Substance
C157257	Anti-CD123/CD3 Bispecific Antibody APVO436	APVO 436 || APVO-436 || APVO-436 || APVO436 || Anti-CD123 x Anti-CD3 Bispecific Antibody APVO436 || Anti-CD123/CD3 Bispecific Antibody APVO436 || Anti-CD123/CD3 Bispecific Antibody APVO436 || Bispecific Anti-CD123 x Anti-CD3 Antibody APVO436 || CD123 x CD3 Targeting Bispecific Antibody APVO436	An immunoglobulin Fc-modified bispecific monoclonal antibody against the tumor-associated antigen (TAA) CD123 and the human T-cell surface antigen CD3 bispecific monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD123/CD3 monoclonal antibody APVO436 simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody. Compared to some other CD123 x CD3 targeting bispecific antibodies, APVO436 causes less cytokine release upon T-cell stimulation.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C128486	Anti-CD123/CD3 Bispecific Antibody JNJ-63709178	Anti-CD123/CD3 Bispecific Antibody JNJ-63709178 || Anti-CD123/CD3 Bispecific Antibody JNJ-63709178 || Humanized CD123 x CD3 DuoBody JNJ-63709178 || JNJ-63709178	A humanized anti-CD123/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-CD123/CD3 bispecific antibody JNJ-63709178 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of JNJ-63709178, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of cancers; its expression is low or absent in normal, healthy cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C160348	Anti-CD123/CD3 BiTE Antibody SAR440234	Anti-CD123/CD3 BiTE Antibody SAR440234 || Anti-CD123/CD3 BiTE Antibody SAR440234 || Bispecific T-cell Engager Antibody SAR440234 || CD123xCD3 Bispecific T-cell Engager SAR440234 || SAR 440234 || SAR-440234 || SAR440234	A bispecific T-cell engager (BiTE) antibody comprised of a humanized Fc-silenced immunoglobulin G1 (IgG1) backbone and two single-chain variable fragments (scFvs): one directed against the CD3 antigen expressed on T-lymphocytes and another directed against the alpha-chain of the interleukin-3 receptor (IL-3RA; CD123), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion, anti-CD123/CD3 BiTE antibody SAR440234 binds to both CD3 expressed on T-cells and CD123 expressed on tumor cells. This activates and redirects cytotoxic T-lymphocytes (CTLs) to CD123-expressing tumor cells, leading to enhanced CTL-mediated elimination of CD123-expressing tumor cells. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.	Amino Acid, Peptide, or Protein
C129457	Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A	ADC SGN-CD123A || Anti-CD123 ADC SGN-CD123A || Anti-CD123-PBD ADC SGN-CD123A || Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A || Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A || Antibody-drug Conjugate SGN-CD123A || SGN CD123A || SGN-CD123A || SGN-CD123A	An antibody-drug conjugate (ADC) consisting of an anti-CD123 humanized monoclonal antibody conjugated, via a stable maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD123 ADC SGN-CD123A, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD123-overexpressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers, including myeloid leukemia, and increased expression of CD123 on leukemic stem cells is associated with poor prognosis. Cysteine engineering of the monoclonal antibody (EC-mAb) allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C124132	Anti-CD133-CAR Vector-transduced Allogeneic T Lymphocytes	Allogeneic Anti-CD133 CAR T Cells || Allogeneic CART133 || Anti-CD133-CAR Vector-transduced Allogeneic T Lymphocytes	A preparation of allogeneic peripheral blood T-lymphocytes (PBTL) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the chimeric CD (cluster of differentiation) 133 antigen receptor, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD133-CAR vector-transduced allogeneic T-lymphocytes specifically recognize and kill CD133-expressing tumor cells. CD133, a tumor associated antigen (TAA), is overexpressed on a variety of tumor cell types.	Cell || Pharmacologic Substance
C131828	Anti-CD133-PE38-KDEL Fusion Protein	Anti-CD133-Deimmunized Pseudomonas Exotoxin A-KDEL Fusion Protein || Anti-CD133-PE38-KDEL Fusion Protein || Deimmunized CD133KDEL || Deimmunized CD133KDEL Toxin || dCD133KDEL	A fusion protein consisting of an anti-single-chain variable fragment (scFv) peptide sequence targeting the extracellular domain of human CD133 (prominin-1) (anti-CD133scFV) and a deimmunized truncated form of Pseudomonas exotoxin A (38-kDa derivative of PE; PE38) where the five C-terminal amino acid residues have been replaced with the endoplasmic reticulum (ER) retention signal, KDEL, with potential antineoplastic activity. Upon administration of the anti-CD133-PE38-KDEL fusion protein, the anti-CD133 scFV moiety targets and binds to CD133, which is expressed on a variety of tumor cells. Upon internalization of the receptor-fusion protein complex, the KDEL sequence targets the fusion protein to the ER, where the PE38 exotoxin portion then inhibits protein synthesis, which results in a reduction of proliferation of CD133-expressing tumor cells. CD133, a glycoprotein expressed by a variety of cancers and especially by cancer stem cells (CSCs), plays a key role in tumor initiation, proliferation and progression.	Pharmacologic Substance
C160715	Anti-CD137 Agonistic Monoclonal Antibody ADG106	4-1BB-directed Agonistic Monoclonal Antibody ADG106 || ADG 106 || ADG-106 || ADG-106 || ADG106 || Anti-4-1BB Agonistic Monoclonal Antibody ADG106 || Anti-CD137 Agonistic Monoclonal Antibody ADG106 || Anti-CD137 Agonistic Monoclonal Antibody ADG106 || CD137-directed Agonistic Monoclonal Antibody ADG106	A human agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating activity. Upon administration, anti-CD137 agonistic monoclonal antibody ADG106 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C168522	Anti-CD137 Agonistic Monoclonal Antibody AGEN2373	AGEN 2373 || AGEN-2373 || AGEN2373 || Anti-4-1BB Agonistic Monoclonal Antibody AGEN2373 || Anti-CD137 Agonist Monoclonal Antibody AGEN2373 || Anti-CD137 Agonistic Monoclonal Antibody AGEN2373 || Anti-CD137 Agonistic Monoclonal Antibody AGEN2373 || Anti-CD137 Monoclonal Antibody AGEN2373	A conditionally-active, fully human immunoglobulin G1 (IgG1) agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody AGEN2373 targets and binds to a non-ligand blocking epitope on CD137, thereby activating CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. In addition, as AGEN2373 engages with CD137 only in the presence of CD137 ligand and/or Fc gamma receptor-expressing antigen-presenting cells (APCs), this agent may have a decreased toxicity profile and improved tolerability compared to other agents that activate CD137 signaling beyond the tumor site in humans.	Amino Acid, Peptide, or Protein || Immunologic Factor
C173548	Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017	ATOR 1017 || ATOR-1017 || ATOR1017 || Anti-4-1BB Monoclonal Antibody ATOR-1017 || Anti-CD137 Agonist Monoclonal Antibody ATOR-1017 || Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017 || Anti-CD137 Monoclonal Antibody ATOR-1017	A humanized agonistic immunoglobulin G4 (IgG4) monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody ATOR-1017 targets and binds to CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells, and CD137 is activated upon crosslinking to Fc-gamma receptors (FcgRs) on macrophages. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. 4-1BB and FcgRs are both highly expressed in the tumor environment (TME) while their co-expression in non-tumor tissues is low. This may prevent systemic adverse effects.	Pharmacologic Substance
C162039	Anti-CD137 Agonistic Monoclonal Antibody CTX-471	Anti-4-1BB Agonistic Monoclonal Antibody CTX-471 || Anti-CD137 Agonistic Monoclonal Antibody CTX-471 || Anti-CD137 Agonistic Monoclonal Antibody CTX-471 || CTX 471 || CTX-471 || CTX471	A fully human immunoglobulin G4 (IgG4) agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody CTX-471 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Amino Acid, Peptide, or Protein || Immunologic Factor
C180831	Anti-CD137 Agonistic Monoclonal Antibody EU101	Agonistic Anti-4-1BB Monoclonal Antibody EU101 || Anti-CD137 Agonist Monoclonal Antibody EU101 || Anti-CD137 Agonistic Monoclonal Antibody EU101 || Anti-CD137 Monoclonal Antibody EU101 || EU 101 || EU-101 || EU101	A humanized agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody EU101 targets and binds to CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T-cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Pharmacologic Substance
C171541	Anti-CD137 Agonistic Monoclonal Antibody LVGN6051	Anti-4-1BB Agonistic Monoclonal Antibody LVGN6051 || Anti-CD137 Agonist Monoclonal Antibody LVGN6051 || Anti-CD137 Agonistic Monoclonal Antibody LVGN6051 || Anti-CD137 Agonistic Monoclonal Antibody LVGN6051 || Anti-CD137 Monoclonal Antibody LVGN6051 || LVGN 6051 || LVGN-6051 || LVGN6051	A humanized agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody LVGN6051 targets and binds to CD137, thereby activating CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Amino Acid, Peptide, or Protein || Immunologic Factor
C184376	Anti-CD137 Agonistic Monoclonal Antibody YH004	Anti-4-1BB Monoclonal Antibody YH004 || Anti-CD137 Agonistic Monoclonal Antibody YH004 || YH 004 || YH-004 || YH004	A humanized immunoglobulin G1 (IgG1) agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody YH004 targets and binds to CD137, thereby activating CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Pharmacologic Substance
C179635	Anti-CD137/PD-L1 Bispecific Antibody FS222	Anti-CD137/Anti-PD-L1 Bispecific Antibody FS222 || Anti-CD137/PD-L1 Bispecific Antibody FS222 || Anti-PD-L1/Anti-4-1BB Bispecific Antibody FS222 || CD137xPD-L1 Bispecific Antibody FS222 || FS 222 || FS-222 || FS222	A tetravalent immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-CD137/PD-L1 bispecific antibody FS222 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells, thereby crosslinking PD-L1-expressing tumor cells and T-lymphocytes. Through CD137 binding, FS222 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, FS222 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor cells and activated T-lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing tumor cells.	Pharmacologic Substance
C120317	Anti-CD157 Monoclonal Antibody MEN1112	Anti-CD157 Monoclonal Antibody MEN1112 || MEN1112	A humanized, Fc engineered, de-fucosylated monoclonal immunoglobulin G1 (IgG1) antibody directed against the bone marrow stromal cell antigen 1 (BST1/CD157), with potential antineoplastic activity. Upon intravenous infusion, anti-CD157 monoclonal antibody MEN1112 specifically binds to and induces an antibody dependent cell cytotoxic (ADCC) response against CD157-expressing tumor cells. CD157, also known as ADP-ribosyl cyclase 2, is a glycosyl-phosphatidylinositol (GPI)-anchored transmembrane protein belonging to the ADP-ribosyl-cyclase family and is overexpressed on certain cancer cell types. Fc-optimization of MEN1112, which involves the removal of fucose residues from its Fc domain, allows for enhanced Fc-gamma receptor binding on effector cells, such as natural killer (NK) cells, and further enhances tumor cell lysis.	Amino Acid, Peptide, or Protein || Immunologic Factor
C185133	Anti-CD163 Monoclonal Antibody OR2805	Anti-CD163 Monoclonal Antibody OR2805 || OR 2805 || OR-2805 || OR2805	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive receptor CD163 (scavenger receptor cysteine-rich type 1 protein M130), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD163 monoclonal antibody OR2805 targets and binds to CD163 expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), and prevents the binding of CD163 to its ligands. This inhibits CD163-mediated immunosuppression, including the secretion of immunosuppressive cytokines and the inhibition of T-cell activation. This enhances T-cell activation and proliferation and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. CD163, an immunosuppressive receptor highly expressed on TAMs, plays an important role in immunosuppression and the inhibition of anti-tumor T-cell immune responses.	Pharmacologic Substance
C187655	Anti-CD19 Antibody-drug Conjugate IKS03	Anti-CD19 ADC IKS03 || Anti-CD19 Antibody-drug Conjugate IKS03 || Anti-CD19/PBD ADC IKS03 || IKS 03 || IKS-03 || IKS03 || LCB 73 || LCB-73 || LCB73	An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19), that is site-specifically conjugated with a tumor-cleavable beta-glucuronide linker to a tumor-cleavable prodrug of pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-CD19 ADC IKS03 targets and binds to CD19 expressed on tumor cells. Upon binding and internalization, both the linker and prodrug are selectively cleaved by lysosomal b-glucuronidase overexpressed in tumor cells. Free PBD is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing CD19-expressing cancer cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.	Pharmacologic Substance
C126377	Anti-CD19 Antibody-drug Conjugate SGN-CD19B	ADC SGN-CD19B || Anti-CD19 Antibody-drug Conjugate SGN-CD19B || Anti-CD19 Antibody-drug Conjugate SGN-CD19B || SGN CD19B || SGN-CD19B	An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody (hBU12ec) with engineered cysteines (EC-mAb) conjugated, via a maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer (SGD-1882), with potential antineoplastic activity. Upon administration of anti-CD19 ADC SGN-CD19B, the antibody moiety targets the cell surface antigen CD19, which is found on B-cell-derived cancers. Upon antibody/antigen binding, internalization and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor belonging to the immunoglobulin superfamily and a B-cell specific antigen, is expressed on B-cell-derived cancers. The cysteine engineering of the EC-mAb allows for a site-specific and stable conjugation of PBD to the antibody.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C172202	Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003	Anti-CD19 AbTCR-expressing T-cells ET019003 || Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003 || Anti-CD19 T-cells ET019003 || Anti-CD19-TCR T-cells ET019003 || CD19-targeted T-cells ET019003 || ET 019003 || ET-019003 || ET019003 || ET019003-T Cells	A preparation of T-lymphocytes that have been engineered by incorporating an as of yet undisclosed co-stimulatory molecule into T-cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) structure (ET190L1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 AbTCR-expressing T-cells ET019003 targets and binds to CD19-expressing tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. The binding to CD19-expressing tumor cells may also activate the undisclosed costimulatory domain, leading to further T-cell proliferation. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. ET019003 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells, while they are less likely to stimulate cytokine release syndrome (CRS) and less likely to cause cytokine-related toxicities.	Cell || Pharmacologic Substance
C187300	Anti-CD19 CAR T Cells AT101	AT 101 || AT-101 || AT101 || Anti-CD19 CAR T Cells AT101 || Anti-CD19 CAR T-cells AT101 || Anti-CD19 CAR-T Cells AT101	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 CAR T cells AT101 recognize and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Cell || Pharmacologic Substance
C165551	Anti-CD19 CAR T-cells XLCART001	Anti-CD19 CAR T-cells XLCART001 || Autologous C7R-GD2.CART Cells || CD19-specific CAR T-cells XLCART001 || XLCART001	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 CAR T-cells XLCART001 targets and binds to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Cell || Pharmacologic Substance
C170903	Anti-CD19 iCAR NK Cells	Anti-CD19 Inhibitory Chimeric Antigen Receptor-Natural Killer Cells || Anti-CD19 iCAR NK Cells || Anti-CD19 iCAR Natural Killer Cells || Anti-CD19 iCAR-NK Cells	A preparation of natural killer (NK) cells engineered to express an inhibitory chimeric antigen receptor (iCAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 iCAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCAR is designed to spare normal cells from NK cell actions by including an inhibitory receptor that is activated upon binding to antigens that are present on normal cells only. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Cell || Pharmacologic Substance
C105805	Anti-CD19 Monoclonal Antibody DI-B4	Anti-CD19 Monoclonal Antibody DI-B4 || DI-B4 || anti-CD19 MoAb DI-B4	A low-fucosylated, humanized, IgG1 isotype, monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Anti-CD19 monoclonal antibody DI-B4 binds to CD19, which may result in a strong antibody-dependent cellular cytotoxicity (ADCC) directed at CD19-expressing B-cells but with minimal complement dependent cytotoxicity. DI-B4 contains low levels of fucose, which contributes to its enhanced ADCC activity. CD19 is a B-cell specific membrane antigen that is widely expressed during B-cell development and in all B-cell lineage malignancies.	Pharmacologic Substance
C74003	Anti-CD19 Monoclonal Antibody MDX-1342	Anti-CD19 Monoclonal Antibody MDX-1342 || Anti-CD19 Monoclonal Antibody MDX-1342 || MDX-1342	A fully human anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential antineoplastic activity. Anti-CD19 monoclonal antibody MDX-1342 binds to CD19, depleting and eliminating CD19-expressing B-cells. CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.	Pharmacologic Substance
C187129	Anti-CD19/Anti-CD20/Anti-CD22 CAR-T Cells LCAR-AIO	Anti-CD19/Anti-CD20/Anti-CD22 CAR-T Cells LCAR-AIO || Anti-CD19/CD20/CD22 CAR T Cells LCAR-AIO || Anti-CD19/CD20/CD22 CAR T-cells LCAR-AIO || LCAR-AIO || Tri-specific CD19xCD20xCD22 CAR-T Cells LCAR-AIO	A preparation of human T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20 and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/anti-CD20/anti-CD22 CAR-T cells LCAR-AIO target and bind to CD19, CD20 and CD22 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.	Cell || Pharmacologic Substance
C82375	Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL	Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL || Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL || Anti-CD19/CD22 BLT DT2219ARL || DT2219ARL || DT2219ARL immunotoxin	An immunotoxin consisting of two scFv ligands recognizing human CD19 and CD22 linked to the first 389 amino acids of diphtheria toxin (DT), DT 390, with potential antineoplastic activity. The VH and VL regions of anti-CD22 (sFv) and anti-CD19 are reversed and linked by an aggregration stabilizing linker (ARL) consisting of a 20 amino acid segment of human muscle aldolase (hma) and an Xho1-compatible restriction site; the CDR3 region of the VH of anti-CD22 sFv is mutated to enhance its affinity. The anti-CD19 and anti CD-22 portions of the immunotoxin specifically bind to CD19 and CD22 receptors on tumor B cells. Upon internalization, DT catalyzes ADP ribosylation of elongation factor 2 (EF-2) which may result in the irreversible inhibition of protein synthesis and cell death in CD19- and CD22-expressing tumor cells. CD19 and CD22 are transmembrane proteins upregulated on malignant B cells.	Amino Acid, Peptide, or Protein || Immunologic Factor
C186728	Anti-CD19/CD20/CD22 CAR T-Cells	Anti-CD19/20/22 Chimeric Antigen Receptor T-Cells || Anti-CD19/CD20/CD22 CAR T-Cells || Anti-CD19/CD20/CD22 CAR T-Cells || CD19/CD20/CD22-targeted CAR-T Cells	A preparation of human T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20 and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD20/CD22 CAR-T cells target and bind to CD19, CD20 and CD22 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.	Cell || Pharmacologic Substance
C170904	Anti-CD19/CD22 CAR NK Cells	Anti-CD19/Anti-CD22 CAR Natural Killer Cells || Anti-CD19/CD22 CAR NK Cells || Anti-CD19/CD22 CAR-NK Cells || Anti-CD19/CD22 CAR-Natural Killer Cells || Anti-CD19/CD22 Chimeric Antigen Receptor-Natural Killer Cells	A preparation of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD22 CAR-NK cells target and bind to CD19 and CD22 expressed on the surface of tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.	Cell || Pharmacologic Substance
C178589	Anti-CD19/CD3 Bispecific Antibody GNR-084	Anti-CD19/Anti-CD3 Bispecific Antibody GNR-084 || Anti-CD19/CD3 Bispecific Antibody GNR-084 || Anti-CD19/CD3 Bispecific T-cell Engager Antibody GNR-084 || CD19 x CD3 Bispecific Antibody GNR-084 || GNR 084 || GNR-084 || GNR084	A bispecific antibody and a T-cell engager targeting both the tumor-associated antigen (TAA) CD19, and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 bispecific antibody GNR-084 binds to both the CD3 antigen on T-cells and the CD19 antigen expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.	Pharmacologic Substance
C178577	Anti-CD19/CD3 Bispecific Antibody TNB-486	Anti-CD19/CD3 Bispecific Antibody TNB-486 || Anti-CD19/CD3 T-cell Engaging Bispecific Antibody TNB-486 || Bispecific Antibody TNB-486 || CD19 x CD3 T-BsAb TNB-486 || TNB 486 || TNB-486 || TNB-486 || TNB486	A human bispecific T-cell engager antibody composed of a fixed-light-chain (FLC) arm targeting the CD3 antigen found on T-lymphocytes and a heavy-chain-only (HCO) arm targeting the B-cell-specific membrane protein CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 bispecific antibody TNB-486 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD19 antigen expressed on malignant B-cells. This activates and redirects CTLs to CD19-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages. The FLC arm weakly activates CD3. The HCO arm has a high affinity anti-CD19 moiety.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C153215	Anti-CD19/CD3 BiTE Antibody AMG 562	AMG 562 || AMG-562 || AMG562 || Anti-CD19/CD3 BiTE Antibody AMG 562 || Anti-CD19/CD3 BiTE Antibody AMG 562 || BiTE Antibody AMG 562 || Bispecific T-cell Engager Antibody AMG 562 || CD19/CD3-directed Bispecific T-cell Engager Antibody AMG 562	A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 BiTE antibody AMG 562 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD19 antigen expressed on malignant B-cells. This activates and redirects CTLs to CD19-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.	Amino Acid, Peptide, or Protein || Immunologic Factor
C115101	Anti-CD19/CD3 Tetravalent Antibody AFM11	AFM-11 || AFM11 || Anti-CD19/CD3 Tetravalent Antibody AFM11	An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth.	Cell || Pharmacologic Substance
C178448	Anti-CD19/CD3/PD-L1/4-1BB Tetra-specific Antibody GNC-038	Anti-CD19/CD3/PD-L1/4-1BB Tetra-specific Antibody GNC-038 || CD19 x CD3 x PD-L1 x 4-1BB Tetra-specific Antibody GNC-038 || GNC 038 || GNC-038 || GNC038	An anti-CD19/anti-CD3/anti-PD-L1/anti-4-1BB tetra-specific antibody, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD19/CD3/PD-L1/4-1BB tetra-specific antibody GNC-038 targets and binds to the tumor-associated antigen (TAA) CD19 overexpressed on the surface of B-cells, the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) expressed on tumor cells, the T-cell surface antigen CD3 and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9) expressed on a variety of leukocyte subsets including activated T-lymphocytes. This may crosslink CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs) and result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. In addition, 4-1BB binding results in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, GNC-038 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances CTL-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. CD19, a B-cell specific membrane antigen, is expressed during normal B-cell development and on B-cell malignancies.	Pharmacologic Substance
C187649	Anti-CD19-CAR CMV-specific T-lymphocytes	Anti-CD19-CAR CMV-specific T-cells || Anti-CD19-CAR CMV-specific T-lymphocytes || Anti-CD19-CAR CMV-specific T-lymphocytes || CMV-specific CD19 CAR-T Cells || CMV-specific CD19-CAR T Cells	A preparation of human cytomegalovirus (CMV)-specific T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19-CAR CMV-specific T-lymphocytes recognize, bind to, and induce selective toxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. The anti-CD19-CAR CMV-specific T-lymphocytes may potentially be expanded in vivo through CMV vaccination.	Cell || Pharmacologic Substance
C111041	Anti-CD19-CAR FMC63-28Z Retroviral Vector-transduced Allogeneic T-lymphocytes	Anti-CD19-CAR FMC63-28Z Retroviral Vector-transduced Allogeneic T-lymphocytes || Anti-CD19-CAR FMC63-28Z Retroviral Vector-transduced Allogeneic T-lymphocytes || FMC63-28Z CAR-transduced Allogeneic T-lymphocytes || MSGV1-FMC63-28Z Anti-CD19 CAR-transduced Allogeneic T-lymphocytes	Allogeneic T-lymphocytes derived from peripheral blood mononuclear cells (PBMC) transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of both the light and heavy chain variable regions of anti-CD19 monoclonal antibody FMC63, coupled to the molecule CD28 and the signaling domain of the zeta chain of the T-cell receptor (TCR) (FMC63-28Z), with potential immunomodulating and antineoplastic activities. Upon transfusion, the anti-CD19-CAR FMC63-28Z retroviral vector-transduced allogeneic T lymphocytes specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.	Cell || Pharmacologic Substance
C88055	Anti-CD19-CAR Retroviral Vector-Transduced Autologous T Cells	Anti-CD19-CAR Retroviral Vector-Transduced Autologous T Cells || Anti-CD19-CAR Retroviral Vector-Transduced Autologous T Cells	A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19-CAR retroviral vector-transduced autologous T cells direct the T-lymphocytes to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex, which regulates both the assembly of complete TCR complexes and their expression on the cell surface. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.	Cell || Pharmacologic Substance
C165774	Anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing Autologous T-lymphocytes Hu1928-Hu20BB	Anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing Autologous T-lymphocytes Hu1928-Hu20BB || Anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing Autologous T-lymphocytes Hu1928-Hu20BB || Autologous CAR-19/CAR-20-T Cells Hu1928-Hu20BB || Hu1928-Hu20BB || nti-CD19/CD20 CAR Autologous T-lymphocytes Hu1928-Hu20BB	A preparation of autologous human T-lymphocytes that have been genetically modified to express the CAR construct Hu1928-Hu20BB that consists of two chimeric antigen receptor (CAR) constructs: one encoding a fully-human anti-CD19 CAR with a co-stimulatory domain of CD28, Hu19-CD828, and one encoding a human anti-CD20 CAR with a co-stimulatory domain of 4-1BB (CD137), Hu20BB, with potential immunostimulating and antineoplastic activities. Upon re-infusion, the anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing autologous T-lymphocytes Hu1928-Hu20BB recognize and kill CD19- and/or CD20-expressing tumor B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19- and/or CD20-expressing tumor cells, thereby causing tumor cell lysis. Both the tumor-associated antigens (TAAs) CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.	Cell || Pharmacologic Substance
C112179	Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic Natural Killer Cells	Anti-CD19 Redirected NK Cells || Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic NK Cells || Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic Natural Killer Cells || Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Donor NK Cells || Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Donor Natural Killer Cells || Anti-CD19-CAR-CD3zeta-4-1BB-Expressing NK Cells || Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Natural Killer Cells || NKCARCD19	Allogeneic natural killer (NK) cells transduced with an mRNA expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. NK cells from haploidentical donors are expanded in culture and electroporated with the CAR mRNA. Upon transfusion of the transduced cultured cells, CD19CAR-CD3zeta-4-1BB-expressing allogeneic NK cells bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. Its inclusion may also increase antitumor activity, when compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Pharmacologic Substance || Cell
C143156	Anti-CD19-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes	Anti-CD19-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes || Anti-CD19/CD20 CAR Autologous T-lymphocytes || Autologous CAR-20/19-T Cells	Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 in tandem with an anti-CD20 scFv, and coupled to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta), and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon transfusion, anti-CD19-CD20-CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes recognize and direct T-cells to CD19- or CD20-expressing tumor B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19- or CD20-expressing tumor cells, and causes tumor cell lysis. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.	Cell || Pharmacologic Substance
C180683	Anti-CD1d/Vdelta2 Gamma Delta T-cell Engaging Bispecific Antibody LAVA-051	Anti-CD1d/Anti-Vdelta2 Gamma Delta Bispecific T-cell Engager Antibody LAVA-051 || Anti-CD1d/Vdelta2 Gamma Delta T-cell Engaging Bispecific Antibody LAVA-051 || CD1d x Vdelta2 Gamma Delta bsTCE Antibody LAVA-051 || LAVA 051 || LAVA-051 || LAVA051 || bsTCE Antibody LAVA-051	A humanized bispecific gamma delta T-cell engager (TCE) antibody directed against both CD1d and Vdelta2, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD1d gamma delta T-cell engaging bispecific antibody LAVA-051 binds to both CD1d-expressing tumor cells and Vgamma9Vdelta2 T-cells. This activates and redirects the Vgamma9Vdelta2 T-cells to CD1d-expressing tumor cells, and the Vgamma9Vdelta2 T-cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. The Vgamma9Vdelta2 T-cells also activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. In addition, this activates invariant natural killer T-cells (iNKTs). The iNKTs secrete large amounts of various cytokines, which may activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells. CD1d, an antigen-presenting glycoprotein, plays an important role in the presentation of glycolipid antigens to iNKTs; it is also expressed by various hematologic malignancies.	Pharmacologic Substance
C185870	Anti-CD20 Antibody-drug Conjugate MRG001	ADC MRG001 || Anti-CD20 ADC MRG001 || Anti-CD20 Antibody-drug Conjugate MRG001 || Anti-CD20/MMAE ADC MRG001 || MRG 001 || MRG-001 || MRG001	An antibody-drug conjugate (ADC) composed of a chimeric anti-CD20 monoclonal antibody conjugated via a valine citrulline linker to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of anti-CD20 ADC MRG001, the monoclonal antibody moiety of MRG001 targets and binds to CD20 on the surfaces of tumor B-cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CD20-expressing tumor cells. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B-cells during most stages of B-cell development. It is often overexpressed in B-cell malignancies.	Pharmacologic Substance
C188178	Anti-CD20 Antibody-drug Conjugate TRS005	ADC TRS005 || Anti-CD20 ADC TRS005 || Anti-CD20 Antibody-drug Conjugate TRS005 || Anti-CD20/MMAE ADC TRS005 || TRS 005 || TRS-005 || TRS005	An antibody-drug conjugate (ADC) composed of an anti-CD20 monoclonal antibody conjugated via a valine-citrulline linker to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of anti-CD20 ADC TRS005 targets and binds to CD20 on the surfaces of tumor B-cells. Upon internalization and cleavage, MMAE is released. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CD20-expressing tumor cells. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B-cells during most stages of B-cell development. It is often overexpressed in B-cell malignancies.	Pharmacologic Substance
C121167	Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein	Anti-CD20 B9E9 scFv-SA Fusion Protein || Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein || Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein || Anti-CD20 B9E9-SA Fusion Protein || B9E9 scFvSA Fusion Protein || Recombinant Anti-CD20 B9E9 scFvSA Fusion Protein || scFv B9E9-streptavidin Fusion Protein	An Escherichia coli periplasm-expressed tetrameric fusion protein composed of four single-chain variable regions (scFv) of the murine immunoglobulin (Ig) G2a anti-CD20 monoclonal antibody B9E9 fused to the streptavidin (SA) gene of Streptomyces avidinii (scFv-SA), with potential use in pretargeted radioimmunotherapy (PRIT). Upon intravenous administration of the anti-CD20 B9E9 scFv-SA fusion protein, this agent targets and binds to CD20-expressing tumor cells. Subsequently, a biotinylated N-acetylgalactosamine-containing clearing agent is administered, which binds to the streptavidin moiety of the unbound fusion protein and promotes its hepatic excretion. In turn, radiolabeled DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-biotin is administered and, due to its small size, quickly distributes. The biotin moiety efficiently binds to the SA moiety of the bound fusion protein, which localizes the biotin-conjugated radionuclide to the tumor site. CD20, a tumor-associated antigen (TAA), is overexpressed on B-cell malignancies. PRIT increases both tumor uptake and renal elimination of the radionuclide conjugate as compared to conventional radioimmunotherapy (RIT), where the radioisotope is bound to the antibody before administration; this increases the dose of radionuclide delivered to the tumor while limiting radiation exposure for normal, healthy tissues.	Pharmacologic Substance
C155899	Anti-CD20 Monoclonal Antibody B001	Anti-CD20 Monoclonal Antibody B001 || B 001 || B001	A recombinant humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Upon intravenous administration, anti-CD20 monoclonal antibody B001 specifically binds to CD20 on the surfaces of B-cells. Although the exact mechanisms through which B001 exert its effects have not been elucidated, B001 may induce a B-cell directed cell-mediated immune response against CD20-expressing B-cells and/or prevent CD20-medaited signaling. This induces tumor cell apoptosis and inhibits proliferation. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B-cells during most stages of B-cell development and which is often overexpressed in B-cell malignancies.	Immunologic Factor || Pharmacologic Substance
C173955	Anti-CD20 Monoclonal Antibody BAT4306F	Anti-CD20 Monoclonal Antibody BAT4306F || BAT 4306F || BAT-4306F || BAT4306F	A recombinant, glycosylation-modified monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody BAT4306F, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The complete defucosylation of BAT4306F may result in enhanced ADCC.	Pharmacologic Substance
C166140	Anti-CD20 Monoclonal Antibody MIL62	Anti-CD20 Monoclonal Antibody MIL62 || MIL 62 || MIL-62 || MIL62	A glyco-engineered recombinant humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody MIL62, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, MIL62 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.	Immunologic Factor || Pharmacologic Substance
C90590	Anti-CD20 Monoclonal Antibody PRO131921	Anti-CD20 Monoclonal Antibody PRO131921 || Anti-CD20 Monoclonal Antibody PRO131921 || PRO131921	A third-generation, humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody PRO131921 specifically binds to the B cell-specific cell surface antigen CD20. This may result in the induction of a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B cells during most stages of B cell development and which is often overexpressed in B-cell malignancies.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C94206	Anti-CD20 Monoclonal Antibody TL011	Anti-CD20 Monoclonal Antibody TL011 || TL011	A monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody TL011 specifically binds to the B cell-specific cell surface antigen CD20 antigen (MS4A1; membrane-spanning 4-domains, subfamily A, member 1), thereby potentially triggering an immune response against CD20-positive B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies.	Immunologic Factor || Pharmacologic Substance
C186366	Anti-CD20/anti-CD3 Bispecific Antibody CM355	Anti-CD20/CD3 Bispecific Antibody CM355 || Anti-CD20/anti-CD3 Bispecific Antibody CM355 || CD20/CD3 Bispecific Antibody CM355 || CD20xCD3 Bispecific Antibody CM355 || CM 355 || CM-355 || CM355	A bispecific antibody and novel T cell engager1 (nTCE) targeting both the tumor-associated antigen (TAA) CD20 and the CD3, a T-cell surface antigen, with potential immunomodulating and antineoplastic activities. Upon administration, anti-cd20/anti-cd3 bispecific antibody CM355 binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.	Pharmacologic Substance
C186674	Anti-CD200R1 Monoclonal Antibody 23ME-00610	23ME 00610 || 23ME-00610 || 23ME00610 || Anti-CD200R1 Monoclonal Antibody 23ME-00610	A humanized monoclonal antibody directed against the immune checkpoint cell surface transmembrane glycoprotein CD200 receptor 1 (CD200R1; CD200R; HCRTR2; MOX2R; OX2R; CD200 receptor 1), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-CD200R1 monoclonal antibody 23ME-00610 targets and binds to CD200R1, thereby preventing the interaction of CD200R1 with its ligand CD200, which is highly expressed on certain tumor cell types, and preventing its activity. This inhibits CD200R1-mediated signaling pathways and may re-activate tumor-exhausted T-cells and myeloid cells. This may lead to a T-cell mediated anti-tumor immune response and may kill cancer cells. CD200R1 is an inhibitory receptor expressed on T-cells and myeloid cells and plays a key role in the maintenance of immune tolerance and immunosuppression.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C165598	Anti-CD205 Antibody-drug Conjugate OBT076	Anti-CD205 ADC OBT076 || Anti-CD205 Antibody-drug Conjugate OBT076 || Anti-CD205 Antibody-drug Conjugate OBT076 || MEN 1309 || MEN-1309 || MEN1309 || OBT 076 || OBT-076 || OBT076	An antibody-drug conjugate (ADC) comprised of an anti-CD205 (lymphocyte antigen 75; Ly75) humanized immunoglobin G1 (IgG1) monoclonal antibody conjugated to DM4, a maytansinoid microtubule disruptor, via a cleavable N-succinimidyl-4-(2-pyridyldithio) butanoate (SPDB) linker, with potential antineoplastic activity. Upon intravenous administration, anti-CD205 ADC OBT076 specifically targets and binds to CD205, a receptor involved in antigen capture and endocytosis, expressed on tumor cells. Following rapid internalization of the ADC/CD205 complex, OBT076 releases its DM4 payload due to cleavage of the SPDB linker by intracellular proteases. Then the DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of both cell division and cell growth of CD205-expressing tumor cells. CD205, a type I transmembrane surface glycoprotein belonging to the C-type lectin receptor family, is normally expressed on various antigen-presenting cells (APCs) and some leukocyte sub-populations but it is overexpressed in multiple cancer types where it plays a key role in facilitating metastatic invasion.	Pharmacologic Substance
C104006	Anti-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocyte Cells	Anti-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocyte Cells	A preparation of autologous blood T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of an anti-CD20 scFv (single chain variable fragment); the cytoplasmic portion of the human TCR-[zeta] molecule; and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon transfusion, anti-CD20-CAR-CD3zeta-4-1BB-expressing autologous T-lymphocyte cells direct T-cells to CD20-expressing tumor cells. This results in cytotoxic T lymphocyte (CTL) and antibody responses against CD20-expressing tumor cells, causing tumor cell lysis. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the T-cell receptor (TCR)/CD3 complex and regulates the assembly of complete TCR complexes and their expression on the cell surface. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD20; the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone.	Pharmacologic Substance
C120546	Anti-CD20-engineered Toxin Body MT-3724	Anti-CD20-engineered Toxin Body MT-3724 || Anti-CD20-engineered Toxin Body MT-3724 || MT-3724 || MT-3724	An engineered toxin body (ETB) composed of the single-chain variable fragment (ScFv) from an antibody targeting CD20 that is linked to a modified form of the ribosome-inactivating alpha subunit of Shiga-like toxin 1 (Shiga-like Toxin-1 A or SLT-1A), with antineoplastic activity. Upon administration, the ScFv moiety of anti-CD20-engineered toxin body MT-3724 targets and binds to the CD20 antigen expressed on tumor cells. Upon internalization, the SLT-1A moiety is released and acts as an N-glycosidase, which binds to and cleaves an adenine nucleobase in the 28S RNA component of the 60S subunit of ribosomes and prevents ribosome activity. This inhibits protein synthesis and eventually leads to apoptosis of CD20-expressing tumor cells. CD20, a B-cell specific transmembrane protein and tumor-associated antigen (TAA), is expressed during most stages of B-cell development and is often overexpressed in B-cell malignancies.	Pharmacologic Substance
C156882	Anti-CD22 ADC TRPH-222	Anti-CD22 ADC TRPH-222 || Anti-CD22 ADC TRPH-222 || Anti-CD22 Antibody-drug Conjugate TRPH-222 || Anti-CD22-4AP ADC TRPH-222 || CAT-02-106 || TRPH 222 || TRPH-222 || TRPH-222 || TRPH222	An antibody-drug conjugate (ADC) composed of an anti-CD22 humanized monoclonal antibody site-specifically conjugated to, via formylglycine (FG) residues and a protease insensitive 4AP linker, a cytotoxic microtubule-targeting maytansinoid payload, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of TRPH-222 binds to B-cell-specific CD22 receptors and is rapidly internalized, thereby delivering the payload intracellularly. Upon proteolytic cleavage, the maytansinoid payload binds to tubulin, disrupting microtubule assembly/disassembly dynamics, inhibiting both cell division and tumor cell proliferation. CD22, a cell surface sialoglycoprotein, is expressed on mature B-cells and on most malignant B-cells. The site specific and stable conjugation to the payload allows for a higher drug-to-antibody ratio (DAR) and an enhanced therapeutic index.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C124656	Anti-CD22 scFv TCRz:41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes	Anti-CD22 scFv TCRz:41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes || Anti-CD22 scFv TCRz:41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes || Autologous T-lymphocytes-expressing CD22 CARs-expressing Tandem TCR-zeta/4-1BB || TCRzeta/4-1BB CART22 Cells	Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric T-cell receptor consisting of an anti-CD22 single chain variable fragment (scFv) and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Autologous peripheral blood lymphocytes (PBLs) from a patient with CD22-positive cancer are transduced with this lentiviral vector that encodes the CAR gene specific for CD22. After isolation, transduction, expansion in culture and reintroduction into the patient, the anti-CD22 scFv TCRz:41BB-CAR lentiviral vector-transduced autologous T-lymphocytes express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing tumor cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.	Cell || Pharmacologic Substance
C178408	Anti-CD22/CD3 Bispecific Antibody JNJ-75348780	Anti-CD22/CD3 Bispecific Antibody JNJ-75348780 || CD22 x CD3 Bispecific Antibody JNJ-75348780 || JNJ 75348780 || JNJ-75348780 || JNJ75348780	A human bispecific antibody, with potential antineoplastic activity. Anti-CD22/CD3 bispecific antibody JNJ-75348780 contains two binding sites, one for the tumor-associated antigen (TAA) CD22, and one for the T-cell surface antigen CD3. Upon administration, JNJ-75348780 binds to both CD3 on T-cells and CD22-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor B-cells. CD22 is exclusively expressed on B-cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.	Immunologic Factor || Pharmacologic Substance
C180889	Anti-CD226 Agonist Antibody LY3435151	Anti-CD226 Agonist Antibody LY3435151 || Anti-CD226 Agonist Antibody LY3435151 || Anti-CD226 Agonistic Antibody LY3435151 || Anti-DNAM-1 Agonist Antibody LY3435151 || LY 3435151 || LY-3435151 || LY3435151	An agonistic antibody targeting the human cell surface glycoprotein CD226 (DNAX accessory molecule-1; DNAM-1), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD226 agonist antibody LY3435151 targets and binds to CD226 on a variety of immune cell types, including T-cells, natural killer (NK) cells, B-cells and monocytes. This induces CD226-dependent signaling pathways, which may trigger the activation of antigen-presenting cells (APCs) and activate T-cells and NK cells. This may result in an enhanced cytotoxic T-lymphocyte (CTL)-mediated and NK cell-mediated immune response against tumor cells. CD226, a cell surface glycoprotein that functions as an adhesion molecule, is expressed on various immune cells and plays an important role in the co-activation of T-cells and NK cells upon interaction with its ligands CD155 and CD112.	Pharmacologic Substance
C168772	Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A	Anti-CD228 Antibody-drug Conjugate SGN-CD228A || Anti-CD228-MMAE ADC SGN-CD228A || Anti-CD228/MMAE ADC SGN-CD228A || Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A || Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A || Anti-melanotransferrin ADC SGN-CD228A || SGN CD228A || SGN-CD228A || SGNCD228A	An antibody-drug conjugate (ADC) composed of a humanized antibody targeting the cell surface antigen cluster of differentiation (CD228; melanotransferrin; MFI2; MELTF) that is conjugated, via a beta-glucuronidase-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-CD228/MMAE ADC SGN-CD228A targets and binds to CD228 on the surface of tumor cells. Following internalization of SGN-CD228A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CD228-expressing tumor cells. CD228, a cell-surfaced, glycosylphosphatidylinoitol (GPI)-anchored glycoprotein, belongs to the transferrin family of iron-binding proteins.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C120035	Anti-CD22-CAR m971-BBz Lentiviral Vector-transduced Autologous T Lymphocytes	Anti-CD22-CAR m971-BBz Cells || Anti-CD22-CAR m971-BBz Lentiviral Vector-transduced Autologous T Lymphocytes || Anti-CD22-CAR m971-BBz Lentiviral Vector-transduced Autologous T Lymphocytes	Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of an anti-CD22 single chain variable fragment (scFv) derived from the monoclonal antibody (moAb) 971 (m971), and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Autologous peripheral blood lymphocytes (PBLs) from a patient with CD22-positive cancer are transduced with this lentiviral vector that encodes the CAR gene specific for CD22. After expansion in culture and reintroduction into the patient, the anti-CD22-CAR m971-BBz lentiviral vector-transduced autologous T-lymphocytes express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing tumor cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells. m971 binds to a membrane proximal epitope on CD22 and has a higher binding affinity compared to other anti-CD22 moAb.	Cell || Pharmacologic Substance
C173969	Anti-CD25 Monoclonal Antibody RO7296682	Anti-CD25 Monoclonal Antibody RG6292 || Anti-CD25 Monoclonal Antibody RO7296682 || Anti-CD25 Monoclonal Antibody RO7296682 || RG 6292 || RG-6292 || RG6292 || RO 7296682 || RO-7296682 || RO-7296682 || RO7296682 || T-regulatory Cell-depleting Antibody RO7296682	A monoclonal antibody against CD25 (IL-2R alpha), with potential antineoplastic activity. Upon administration, the anti-CD25 monoclonal antibody RO7296682 targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells and prevent immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the interleukin (IL)-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.	Pharmacologic Substance
C187110	Anti-CD25-IL-2 Monoclonal Antibody AU-007	AU 007 || AU-007 || AU007 || Anti-CD25-IL-2 Monoclonal Antibody AU-007	A human immunoglobulin (Ig) G1 monoclonal antibody directed against the CD25 subunit-interacting domain of the cytokine interleukin-2 (IL-2; IL2), with potential immunomodulatory activity. Upon administration, anti-CD25-IL2 monoclonal antibody AU-007 targets, binds to and blocks the CD25 subunit-interacting domain of IL-2, thereby blocking the binding of IL-2 to the CD25 subunit (IL-2 receptor subunit alpha; IL-2Ralpha) of the human trimeric IL-2 receptor (IL-2R) expressed on the surface of regulatory T-lymphocytes (Tregs), thereby inhibiting IL-2Ralpha-mediated Tregs activation. This may prevent Treg-mediated immunosuppression. As the ability of IL-2 to bind to dimeric CD122 (IL-2Rbeta)/CD132 receptor is preserved, AU-007 promotes immune effector activation by IL-2 via IL-2-mediated signaling through the dimeric IL-2R. This may active an anti-tumor immune response against tumor cells through activation of T-lymphocytes, natural killer (NK) cells, and NK T-cells, thereby killing cancer cells. In addition, by blocking the binding of IL-2 to CD25 expressed on vascular endothelium and smooth muscle cells and subsequent activation, exacerbation of vascular leak syndrome (VLS) is prevented. IL-2 binds to the IL-2R dimeric receptor expressed on CD8 T effector cells, memory T cells, NK cells and NKT cells and is composed of CD122 and CD132. The IL-2R trimeric receptor expressed on Tregs and vascular endothelium is composed of CD25, CD122 and CD132.	Pharmacologic Substance
C150677	Anti-CD26 Monoclonal Antibody YS110	Anti-CD26 Monoclonal Antibody YS110 || YS110	A humanized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the extracellular domain of dipeptidyl peptidase 4 (CD26; DPP4; DPP IV), with potential antineoplastic activity. Upon administration of anti-CD26 monoclonal antibody YS110, this antibody targets and binds to CD26 expressed on tumor cells. This inhibits CD26 activity and causes internalization of CD26-YS110. This leads to cell cycle arrest, lysis and inhibition of growth in CD26-positive tumor cells. YS110 also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD26-expressing tumor cells. CD26, a 110-kDa, type II transmembrane glycoprotein, is overexpressed in a variety of cancer cell types while absent in normal, healthy cells and plays a key role in tumor cell growth, migration, invasion and survival. It also plays a major role in the regulation of T-cell activity.	Amino Acid, Peptide, or Protein || Immunologic Factor
C106266	Anti-CD27L Antibody-Drug Conjugate AMG 172	AMG 172 || AMG-172 || AMG-172 || Anti-CD27L Antibody-Drug Conjugate AMG 172 || Anti-CD27L Antibody-Drug Conjugate AMG 172	An immunoconjugate consisting of a human IgG1 monoclonal antibody directed against CD27L conjugated, via a non-cleavable linker, to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to CD27L on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of cancer cells that express CD27L. CD27L, a type II transmembrane protein and member of the tumor necrosis factor family, is a co-stimulatory molecule constitutively expressed on a subset of activated T-cells, B-cells, and dendritic cells, which is overexpressed in certain tumor cell types.	Pharmacologic Substance
C74004	Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1)	A-dmDT390-bisFv(UCHT1) || Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1) || Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1) || RESIMMUNE || Resimmune	A bivalent recombinant fusion protein immunotoxin derived from the anti-CD3 monoclonal antibody UCHT1 with potential antineoplastic activity. Anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1) consists of 1-390 amino acid residues of chain A diphtheria toxin (DT) joined via a spacer to the Fv fragment of UCHT1, which is connected to a second UCHT1 Fv fragment via a disulfide bond (hence the "bisFv" designation); the addition of the second Fv fragment overcomes the steric hindrance of immunotoxin binding due to the large N-terminal DT domain. Once inside target T cells, the DT moiety catalyzes the transfer of the ADP-ribose moiety of NAD to diphthamide, a posttranslationally modified histidine residue found in elongation factor 2 (EF-2); inactivation of EF-2, disruption of polypeptide chain elongation, and cell death ensue. CD3 is a complex of five cell-surface polypeptides associated with the T cell receptor (TCR) complex.	Pharmacologic Substance
C116330	Anti-CD3 OKT3/Humanized Anti-GD2 3F8 Bispecific Antibody-activated T Lymphocytes	Anti-CD3 OKT3/Humanized Anti-GD2 3F8 Bispecific Antibody-activated T Lymphocytes || Anti-CD3 x hu3F8 Bispecific Antibody Armed ATC || GD2Bi-aATC || Hu3F8Bi Armed ATC || OKT3/Humanized 3F8 Bispecific Antibody-activated T Lymphocytes	Autologous activated T cells that have been coated with bispecific antibodies (BiAb) comprised of anti-CD3 murine monoclonal antibody OKT3 heteroconjugated to anti-GD2 humanized monoclonal antibody 3F8 (hu3F8), with potential antineoplastic and immunomodulating activities. In vitro, T cells are exposed to OKT3, which binds to the T cell receptor-CD3 complex on the T cell surface, crosslinks the CD3 receptors and leads to T cell activation. In turn, the hu3F8 monoclonal antibody is heteroconjugated to OKT3. Upon administration, anti-CD3 x anti-GD2 bispecific antibody-armed activated T cells attach to GD2-expressing tumor cells, thereby selectively cross-linking T cells and tumor cells. This results in selective cytotoxicity towards the GD2-expressing tumor cells. In addition, cytokine and chemokine secretion by the T cells further activates the immune system, which leads to the recruitment and activation of cytotoxic T lymphocytes (CTLs), and additional CTL-mediated tumor-specific cell lysis. GD2, a disialoganglioside and tumor-associated antigen, is overexpressed in a variety of tumor cell types. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.	Cell || Pharmacologic Substance
C95751	Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells	Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells || Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells || Anti-CD3 x CD20Bi-Armed ATC	Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities. In vitro, T cells are activated through exposure to the anti-CD3 murine monoclonal antibody OKT3 and low-dose interleukin 2 (Il-2) for 6-14 days and then armed with anti-CD3 x anti-CD20 bispecific antibody (CD20Bi). Upon administration, anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (AATC) attach to CD3-expressing T cells and CD20-expressing tumor cells, selectively cross-linking T cells and tumor cells. This may result in the recruitment and activation of cytotoxic T lymphocyte (CTLs), CTL-mediated specific tumor cell lysis, and the secretion of antitumor cytokines and chemokines. CD20, a cell surface phosphoprotein, is found on normal B cells and most B-cell tumors.	Cell || Pharmacologic Substance
C173369	Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044	Anti-CD3/5T4 Bispecific Antibody GEN1044 || Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044 || Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044 || DuoBody-CD3x5T4 || GEN 1044 || GEN-1044 || GEN1044	A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD3/anti-5T4 bispecific antibody GEN1044 simultaneously targets and binds to CD3 expressed on T-cells and 5T4 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the 5T4-expressing tumor cells. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.	Pharmacologic Substance
C95760	Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05	Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05 || FBTA05	A trifunctional bispecific monoclonal antibody with potential antineoplastic activity. FBTA05 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen; and one for human CD20, a tumor-associated antigen that is exclusively expressed on B cells during most stages of B cell development and often overexpressed in B-cell malignancies. In addition, the modified Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). FBTA05 brings T cells, CD20-expressing tumor B-cells and APCs together into tricellular complexes, which may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells. Fc-mediated binding of APCs in the tricellular complex potentiates CD20 antigen presentation to T cells and the activation of anti-tumor cytotoxic T cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C185602	Anti-CD3/Anti-Claudin18.2 Bispecific Antibody IBI389	Anti-CD3/Anti-CLDN18.2 Bispecific Antibody IBI389 || Anti-CD3/Anti-Claudin18.2 Bispecific Antibody IBI389 || Anti-CLDN18.2/Anti-CD3 Bispecific Antibody IBI389 || Anti-Claudin18.2/CD3 Bispecific Antibody IBI389 || CLDN18.2 x CD3 Bispecific Antibody IBI389 || IBI 389 || IBI-389 || IBI389	A bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD3/anti-CLDN18.2 bispecific antibody IBI389 simultaneously binds to both CD3-expressing T-cells and CLDN18.2-expressing cancer cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C125185	Anti-CD3/Anti-EGFR-bispecific Monoclonal Antibody-armed Activated Autologous T-lymphocytes	Anti-CD3 x Anti-EGFR AATCs || Anti-CD3 x Anti-EGFR BATs || Anti-CD3 x Anti-EGFR-bispecific Antibody Armed Activated Autologous T-cells || Anti-CD3/Anti-EGFR-bispecific Monoclonal Antibody-armed Activated Autologous T-lymphocytes	Autologous activated T-cells that have been coated with bispecific antibodies (BiAb) comprised of an anti-CD3 monoclonal antibody heteroconjugated to an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, with potential antineoplastic and immunomodulating activities. Upon administration, anti-CD3 x anti-EGFR bispecific antibody-armed activated T-cells (AATC) attach to and selectively cross-link CD3-expressing T-cells and EGFR-expressing tumor cells. This results in the activation of cytotoxic T-lymphocytes (CTLs) and selective cytotoxicity towards the EGFR-expressing tumor cells. In addition, cytokine and chemokine secretion by the T-cells further activates the immune system, which leads to the recruitment and activation of CTLs, and additional CTL-mediated tumor-specific cell lysis. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T-cells, and is required for signal transduction. EGFR, a receptor tyrosine kinase, is overexpressed on the surfaces of various tumor cell types.	Cell || Pharmacologic Substance
C166258	Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119	Anti-CD3 x Anti-GUCY2C Bispecific Antibody PF-07062119 || Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119 || Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119 || Anti-GUCY2C/Anti-CD3 Bispecific Antibody PF-07062119 || PF 07062119 || PF-07062119 || PF07062119 || T-cell Bispecific Antibody PF-07062119	A bispecific antibody against human CD3, a T-cell surface antigen, and human guanylate cyclase 2C (GUCY2C; GCC; guanylyl cyclase C; heat-stable enterotoxin receptor; hSTAR), with potential antineoplastic activity. Upon administration, anti-CD3/anti-GUCY2C bispecific antibody PF-07062119 targets and binds to both CD3 on T-cells and GUCY2C expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against GUCY2C-expressing tumor cells. GUCY2C, a transmembrane receptor expressed on intestinal epithelial cells, is overexpressed on certain tumors of the gastrointestinal (GI) tract.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C153147	Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424	AMG 424 || AMG-424 || AMG424 || Anti-CD3 x Anti-CD38 Bispecific Monoclonal Antibody AMG 424 || Anti-CD3/Anti-CD38 Bispecific Monoclonal Antibody AMG 424 || Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424 || Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424 || CD3xCD38 BsAb AMG 424	A humanized, bispecific monoclonal antibody (BsAb) targeting CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody AMG 424 binds to both CD3 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.	Pharmacologic Substance
C165583	Anti-CD3/CD7-Ricin Toxin A Immunotoxin	Anti-CD3/CD7-RTA Immunotoxin || Anti-CD3/CD7-Ricin Toxin A Immunotoxin || Anti-CD3/CD7-Ricin Toxin A Immunotoxin || CD3/CD7-Ricin A IT || T-Guard	An immunotoxin (IT) combination composed of two antibody-drug conjugates (ADCs), one containing a monoclonal antibody against CD3 and one against the CD7 antigen on activated T-cells and natural killer (NK) cells, and both conjugated to ricin toxin A (RTA), the A-chain form of the potent plant toxin ricin, that can potentially be used to destroy activated T- and NK cells. Upon administration of the anti-CD3/CD7-RTA immunotoxin, the anti-CD3 antibody moiety targets and binds to activated T-cells; the anti-CD7 antibody moiety targets and binds to CD7 on activated T-cells and NK cells. Upon internalization and cleavage, the RTA moiety irreversibly inhibits protein synthesis and induces apoptosis in the activated T-cells. This may eliminate activated T-cells and may improve conditions such as graft-versus-host-disease (GvHD). In addition, the binding and blocking of the anti-CD3 antibody to the T-cell receptor/CD3 complex (TCR/CD3) results in activation-induced cell death (AICD) and immunosuppression.	Pharmacologic Substance
C148543	Anti-CD3/MUC1 Antibody-armed PD-1 Inhibitor-induced Cytokine-induced Killer Cells	Anti-CD3/MUC1 Antibody-armed PD-1 Inhibitor-induced Cytokine-induced Killer Cells || Anti-CD3/MUC1-armed PD-1 Inhibitor-induced CIK Cells || PD-1 Activated CIK Armed With Anti-CD3/Anti-MUC1 Bispecific Antibody	A preparation of cytokine-induced killer cells (CIKs), which have been exposed, ex vivo, to a specific set of cytokines and a programmed cell death protein 1 (PD-1) inhibitor, mixed with a bispecific anti-cluster of differentiation 3 (CD3)/anti-mucin-1 (MUC1) antibody, with potential anti-tumor cytotoxic activity. Upon administration of the anti-CD3/MUC1 antibody-armed PD-1 inhibitor-induced CIKs, the antibody moiety binds to both CD3 on the CIKs and MUC1 on cancer cells. This crosslinks the CIKs and tumor cells, which allows the CIKs to target and lyse MUC1-expressing cancer cells. PD-1 blockade activates the CIKs. The cytokines used, usually interferon-gamma (IFNg), interleukin 1 (IL-1), and IL-2, stimulate the proliferation and maturation of peripheral blood mononuclear cells (PBMCs) into CIK cells. Anti-CD3 stimulation allows for the CIKs' improved lytic activity.	Cell || Pharmacologic Substance
C77886	Anti-CD30 Monoclonal Antibody MDX-1401	Anti-CD30 Monoclonal Antibody MDX-1401 || Anti-CD30 Monoclonal Antibody MDX-1401 || MDX-1401	A fully human, second-generation, nonfucosylated monoclonal antibody directed against the cell surface receptor CD30 with potential immunomodulating and antineoplastic activities. Anti-CD30 monoclonal antibody MDX-1401 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas. Compared to conventional antibodies, deletion of fucose molecules on the antibody backbone, as is done in MDX-1401, may result in an increased affinity for Fc receptors and an enhanced antibody-dependent cellular cytotoxicity (ADCC).	Amino Acid, Peptide, or Protein || Immunologic Factor
C74005	Anti-CD30 Monoclonal Antibody XmAb2513	Anti-CD30 Monoclonal Antibody XmAb2513 || Anti-CD30 Monoclonal Antibody XmAb2513 || XMAB-2513 || XmAb2513	A humanized monoclonal antibody directed against the cell surface receptor CD30 with potential immunotherapeutic activity. Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas.	Pharmacologic Substance
C94219	Anti-CD30/CD16A Monoclonal Antibody AFM13	AFM13 || Anti-CD30/CD16A Monoclonal Antibody AFM13 || Anti-CD30/CD16A Monoclonal Antibody AFM13	A tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Anti-CD30/CD16A monoclonal antibody AFM13 binds to the CD16A expressed on natural killer (NK) cells with two of its binding sites and to CD30 on CD30-expressing tumor cells with the other two binding sites, thereby selectively cross-linking tumor and NK cells. This may result in NK cell activation, antibody-dependent cellular cytotoxicity (ADCC) and eventually tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is overexpressed in hematologic malignancies; CD16A is specifically expressed on the surface of NK cells.	Immunologic Factor || Pharmacologic Substance
C172064	Anti-CD30/DM1 Antibody-drug Conjugate F0002	ADC F0002 || Anti-CD30/DM1 ADC F0002 || Anti-CD30/DM1 Antibody-drug Conjugate F0002 || F 0002 || F-0002 || F0002 || F0002-ADC	An antibody drug conjugate (ADC) consisting of a monoclonal antibody directed against the tumor necrosis factor (TNF) receptor CD30 conjugated, via a nonreducible thioether linker (succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate or SMCC), to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of F0002 targets and binds to CD30-expressing tumor cells. Upon cellular uptake and internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly and disassembly dynamics. This inhibits both cell division and the proliferation of tumor cells that express CD30. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8; TNFRSF8) may be constitutively expressed in some hematologic malignancies.	Pharmacologic Substance
C156458	Anti-CD32B Monoclonal Antibody BI-1206	Anti-CD32B Monoclonal Antibody BI-1206 || Anti-CD32B Monoclonal Antibody BI-1206 || Anti-hFcgRIIB Monoclonal Antibody BI-1206 || Anti-hFcgammaRIIB mAb BI-1206 || BI 1206 || BI-1206 || BI-1206 || BI1206	A fully human monoclonal antibody targeting the Fc gamma receptor IIB (FcgRIIB; CD32B) with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, anti-CD32B monoclonal antibody BI-1206 selectively binds to CD32B, a receptor expressed on the surface of B-cells. This prevents CD32B-mediated internalization of anti-CD20 monoclonal antibodies, such as rituximab, which abrogates tumor cell resistance caused by CD32B-mediated monoclonal antibody internalization and degradation of CD32B-expressing B-cells. By blocking CD32B, BI-1206 may recover and enhance the activity of rituximab and other anti CD20 monoclonal antibodies. In addition, BI-1206 itself activates the immune system to exert an immune-mediated tumor cell death of B-cells. CD32B, an inhibitory member of the FcgammaR family, is implicated in immune cell desensitization and tumor cell resistance.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C125717	Anti-CD33 Antibody-drug Conjugate IMGN779	ADC IMGN779 || Anti-CD33 ADC IMGN779 || Anti-CD33 Antibody-drug Conjugate IMGN779 || Anti-CD33 Antibody-drug Conjugate IMGN779 || IMGN-779 || IMGN779	An antibody-drug conjugate (ADC) consisting of the humanized monoclonal antibody Z4681A conjugated, via a cleavable disulfide linker, to the cytotoxic DNA alkylating agent DGN462, which is an indolino-benzodiazepine dimer containing a mono-imine moiety, with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DGN462 conjugate IMGN779 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DGN462 moiety is released, and covalently binds to and alkylates DNA, thereby causing cell cycle arrest, apoptosis and inhibition of cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and myeloid leukemia cells.	Pharmacologic Substance
C116737	Anti-CD33 Monoclonal Antibody BI 836858	Anti-CD33 Monoclonal Antibody BI 836858 || Anti-CD33 Monoclonal Antibody BI 836858 || BI 836858 || BI-836858	An engineered, fully human, immunoglobulin (Ig) G1 anti-CD33 monoclonal antibody, with potential antineoplastic activity. Upon administration, anti-CD33 monoclonal antibody BI 836858 induces an antibody-dependent cellular cytotoxicity (ADCC) against CD33-expressing tumor cells, leading to cell death. CD33, a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells, is overexpressed on myeloid leukemia cells.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C71523	Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633	Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633	An immunoconjugate consisting of the humanized monoclonal antibody huMy9-6 conjugated to the cytotoxic maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DM4 conjugate AVE9633 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DM4 moiety is released, binds tubulin, and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of cell division and cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells as well as on myeloid leukemia cells.	Immunologic Factor || Pharmacologic Substance
C155970	Anti-CD33/CD3 Bispecific Antibody GEM 333	Anti-CD33 Bispecific Antibody GEM 333 || Anti-CD33/Anti-CD3 Bispecific Antibody GEM 333 || Anti-CD33/CD3 Antibody GEM 333 || Anti-CD33/CD3 Bispecific Antibody GEM 333 || GEM 333 || GEM-333 || GEM333	A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon administration of anti-CD33/CD3 bispecific antibody GEM 333, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C162296	Anti-CD33/CD3 Bispecific Antibody JNJ-67571244	Anti-CD33/CD3 Bispecific Antibody JNJ-67571244 || Anti-CD33/CD3 Bispecific Antibody JNJ-67571244 || JNJ 67571244 || JNJ-67571244 || JNJ67571244	A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CD33/CD3 bispecific antibody JNJ-67571244 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen expressed on certain tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in CTL-mediated killing of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.	Pharmacologic Substance
C131174	Anti-CD352 Antibody-drug Conjugate SGN-CD352A	ADC SGN-CD352A || Anti-CD352 Antibody-drug Conjugate SGN-CD352A || Anti-CD352 Antibody-drug Conjugate SGN-CD352A || PBD Dimer ADC SGN-CD352A || PBD-based Anti-CD352 ADC SGN-CD352A || PBD-based Anti-CD352 Antibody-drug Conjugate SGN-CD352A || SGN-CD352A || SGN-CD352A	An antibody-drug conjugate (ADC) consisting of an engineered cysteine humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) that is conjugated to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD352 ADC SGN-CD352A, the antibody moiety targets the cell surface antigen CD352. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD352-overexpressing tumor cells. CD352, a tumor-associated antigen (TAA), is overexpressed on a variety of cancers. Cysteine engineering of the monoclonal antibody allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.	Pharmacologic Substance
C172443	Anti-CD37 Bispecific Monoclonal Antibody GEN3009	Anti-CD37 Bispecific Monoclonal Antibody GEN3009 || Anti-CD37 Bispecific Monoclonal Antibody GEN3009 || DuoHexaBody-CD37 || DuoHexaBody-CD37 GEN3009 || GEN 3009 || GEN-3009 || GEN3009	An Fc-engineered, humanized, bispecific hexamer formation-enhanced immunoglobulin (Ig) G1 monoclonal antibody that targets two separate epitopes on the tumor-associated antigen (TAA) CD37, with the E430G hexamerization-enhancing mutation, with potential immunomodulating and antineoplastic activities. Upon administration, the anti-CD37 bispecific monoclonal antibody GEN3009 specifically targets and binds to two non-overlapping CD37 epitopes, thereby inducing an assembly of antibody hexamers through intermolecular Fc-Fc interactions at the cell surface of CD37-overexpressing tumor cells. These hexamers recruit and activate C1, the first component of complement, thereby triggering the complement cascade which activates the immune system to induce complement-dependent cytotoxicity (CDC). In addition, GEN3009 binding to the CD37-overexpressing tumor cells also causes antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). CD37, a member of the tetraspanin superfamily of cell surface antigens, is expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. The E430G mutation in the Fc domains enhances Fc-mediated IgG hexamerization upon cellular target binding, and enhances CDC.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C119700	Anti-CD37 MMAE Antibody-drug Conjugate AGS67E	AGS67E || Anti-CD37 MMAE ADC AGS67E || Anti-CD37 MMAE Antibody-drug Conjugate AGS67E || Anti-CD37 MMAE Antibody-drug Conjugate AGS67E	An antibody-drug conjugate (ADC) composed of AGS67C, a human anti-CD37 monoclonal antibody covalently linked, via reduced cysteines and a protease cleavable linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AGS67E binds to CD37 antigens on tumor B-cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.	Pharmacologic Substance
C122833	Anti-CD37 Monoclonal Antibody BI 836826	Anti-CD37 Monoclonal Antibody BI 836826 || Anti-CD37 Monoclonal Antibody BI 836826 || BI 836826 || BI-836826 || MAb 37.1	An Fc-engineered, chimeric immunoglobulin (Ig) G1 monoclonal antibody against the tumor-associated antigen (TAA) CD37, with potential antineoplastic activity. Upon administration, the anti-CD37 monoclonal antibody BI 836826 both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. BI 836826 is Fc-engineered to improve ADCC activity and enhance affinity for the receptor Fc-gamma-RIIIa, which is expressed on human natural killer (NK) cells. CD37, a member of the tetraspanin superfamily of cell surface antigens, is overexpressed on a variety of cancer cell types and plays a key role in tumor cell proliferation.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C171034	Anti-CD37-CAR-expressing T-lymphocytes	Anti-CD37-CAR T-cells || Anti-CD37-CAR-T Cells || Anti-CD37-CAR-expressing T-lymphocytes || Anti-CD37-CAR-expressing T-lymphocytes || CAR-37 T Cells	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD37 (cluster of differentiation 37), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD37-CAR T-cells specifically recognize and kill CD37-expressing tumor cells. CD37, a member of the tetraspanin superfamily of cell surface antigens, is expressed in B-cell non-Hodgkin lymphomas (NHL), in chronic lymphocytic leukemia (CLL), and in some cases of cutaneous and peripheral T-cell lymphomas. It plays a key role in tumor cell proliferation.	Cell || Pharmacologic Substance
C174057	Anti-CD38 Antibody-drug Conjugate STI-6129	ADC STI-6129 || Anti-CD38 ADC STI-6129 || Anti-CD38 Antibody-drug Conjugate STI-6129 || Anti-CD38 Antibody-drug Conjugate STI-6129 || Anti-CD38-Duostatin 5.2 ADC STI-6129 || CD38-077 || LNDS1001 || STI 6129 || STI-6129 || STI6129	An antibody-drug conjugate (ADC) composed of STI-5171, a fully human monoclonal antibody targeting human cell surface glycoprotein and tumor-associated antigen (TAA) CD38, site-specifically conjugated, via a non-polyethylene glycol linker, to a monomethyl auristatin F (MMAF)-derived cytotoxic payload, with potential antineoplastic activity. Upon administration of anti-CD38 ADC STI-6129, the antibody moiety targets and binds to CD38 on tumor cells. Upon antibody/antigen binding and internalization, the MMAF derivative binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.	Pharmacologic Substance
C179660	Anti-CD38 Monoclonal Antibody CID-103	Anti-CD38 Monoclonal Antibody CID-103 || CID 103 || CID-103 || CID103 || TSK011010	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), with potential antineoplastic activity. Upon administration, anti-CD38 monoclonal antibody CID-103 specifically targets and binds to CD38 expressed on tumor cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), cell lysis and depletion of CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.	Pharmacologic Substance
C180505	Anti-CD38 Monoclonal Antibody CM313	Anti-CD38 Monoclonal Antibody CM313 || CM 313 || CM-313 || CM313	A monoclonal antibody directed against the human cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), with potential antineoplastic activity. Upon administration, anti-CD38 monoclonal antibody CM313 specifically targets and binds to CD38 expressed on tumor cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) and apoptosis, resulting in cell lysis and depletion of CD38-expressing tumor cells. In addition, CM313 inhibits the extracellular enzyme activity of CD38. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies. It plays an important role in the regulation of migration and receptor-mediated adhesion, as well as various cell functions through its multiple ecto- and endo-enzymatic activities.	Pharmacologic Substance
C179514	Anti-CD38 Monoclonal Antibody GEN3014	Anti-CD38 Monoclonal Antibody GEN3014 || Anti-CD38 Monoclonal Antibody GEN3014 || GEN 3014 || GEN-3014 || GEN-3014 || GEN3014 || HexaBody-CD38	A hexamerization-enhanced human immunoglobulin G1 (IgG1) monoclonal antibody that targets the cell surface glycoprotein CD-38 and carries the E430G mutation, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD38 monoclonal antibody GEN3014 targets and binds to CD38 on CD38-positive tumor cells, thereby forming antibody hexamers through increased intermolecular Fc-Fc interactions upon antigen binding. This may trigger direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by GEN3014 induces downmodulation of CD38, inhibits CD38 cyclase activity, and may abrogate immune suppression in the tumor microenvironment (TME). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.	Pharmacologic Substance
C166376	Anti-CD38 Monoclonal Antibody SAR442085	Anti-CD38 Monoclonal Antibody SAR442085 || Anti-CD38 Monoclonal Antibody SAR442085 || SAR 442085 || SAR-442085 || SAR442085	A preparation of Fc-engineered monoclonal antibody that targets the cell surface glycoprotein CD-38 with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, anti-CD38 monoclonal antibody SAR442085 targets and binds to CD38 on CD38-positive tumor cells. This may trigger, in addition to other possible responses, antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.	Pharmacologic Substance
C179569	Anti-CD38 Monoclonal Antibody SG301	Anti-CD38 Monoclonal Antibody SG301 || SG 301 || SG-301 || SG301	A human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that targets the cell surface glycoprotein CD38, with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, anti-CD38 monoclonal antibody SG301 targets and binds to CD38 on CD38-positive tumor cells. This may trigger, in addition to other possible responses, antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.	Pharmacologic Substance
C158087	Anti-CD38/BCMA CAR T-lymphocytes	Anti-CD38/Anti-BCMA CAR T-cells || Anti-CD38/Anti-BCMA CAR T-lymphocytes || Anti-CD38/BCMA CAR T-cells || Anti-CD38/BCMA CAR T-lymphocytes	A preparation of T-lymphocytes that have been genetically modified to express a dual-targeted chimeric antigen receptor (CAR) recognizing the tumor-associated antigens (TAAs), cluster of differentiation 38 (CD38) and B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the anti-CD38/BCMA CAR T-cells are directed to and induce selective toxicity in both CD38- and BCMA-expressing cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. BCMA is found on the surfaces of plasma cells and is and overexpressed on malignant plasma cells.	Cell || Pharmacologic Substance
C173645	Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257	Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257 || Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257 || SAR 442257 || SAR-442257 || SAR442257 || Tri-specific T-cell Engager SAR442257	A tri-specific T-cell engager and monoclonal antibody targeting CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), CD3, a T-cell surface antigen, and CD28, a T-cell specific surface glycoprotein and co-stimulatory molecule, with potential antineoplastic activity. Upon intravenous administration, anti-CD38/CD3/CD28 tri-specific monoclonal antibody SAR442257 targets and binds to CD3 and CD28 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. In addition, SAR442257 can also directly target CD28 expressed on tumor cells, such as multiple myeloma cells, thereby enhancing the anti-tumor activity of this agent and allowing it to bind to tumor cells when CD38 is occupied by other antibodies. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.	Pharmacologic Substance
C147563	Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342	Anti-CD38 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1342 || Anti-CD38/Anti-CD3 Bispecific Monoclonal Antibody GBR 1342 || Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342 || Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342 || BEAT GBR 1342 || CD38xCD3 BsAb GBR 1342 || GBR 1342 || GBR-1342 || GBR-1342 || GBR1342	A humanized, bispecific monoclonal antibody (BsAb) against human CD3, a T-cell surface antigen, and the human cell surface glycoprotein CD38, a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, anti-CD38/anti-CD3 bispecific monoclonal antibody GBR 1342 binds to both CD3 on T-cells and CD38 expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis. GBR 1342 uses the proprietary bispecific engagement by antibodies based on the T-cell receptor (BEAT) platform.	Pharmacologic Substance
C184369	Anti-CD38/CD3 Bispecific Monoclonal Antibody XmAb18968	Anti-CD3/CD38 Bispecific Monoclonal Antibody XmAb18968 || Anti-CD38/CD3 Bispecific Monoclonal Antibody XmAb18968 || CD3 x CD38 Bispecific Monoclonal Antibody XmAb18968 || XmAb 18968 || XmAb-18968 || XmAb18968	A bispecific monoclonal antibody targeting CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, anti-CD3/CD38 bispecific monoclonal antibody XmAb18968 binds to both CD3 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.	Pharmacologic Substance
C188121	Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014	Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014 || Anti-CD39 Antibody/TGFb-Trap ES014 || Anti-CD39/TGF-b RII Bifunctional Fusion Protein ES014 || Bifunctional Antibody-Ligand Trap ES014 || Bifunctional Fusion Protein ES014 || ES 014 || ES-014 || ES014	A fusion protein composed of a monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1) and fused to the transforming growth factor-beta receptor type II (TGF-beta RII) ectodomain, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39/TGF-beta RII ectodomain fusion protein ES014 specifically and simultaneously targets and binds to the CD39 antigen and TGF-beta in the tumor microenvironment (TME), thereby preventing CD39- and TGF-beta-mediated signaling. By preventing CD39 activation, the conversion and degradation of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) is abrogated as CD39 is the rate-limiting enzyme in the ATP-adenosine pathway. This leads to an increase in the extracellular levels of immunogenic ATP and a decrease in the levels of immunosuppressive adenosine within the TME. A high level of ATP increases pro-inflammatory cytokine levels and promotes both T-cell proliferation and the stimulation of dendritic and other myeloid-derived cells that are necessary for innate and adaptive immunity. The binding to TGF-beta prevents the activation of TGF-beta RII-mediated signaling pathways and also prevents the activation of CD39. This further reverses the immunosuppressive nature of the TME. This may further stimulate a T-cell-mediated anti-tumor immune response and may inhibit tumor cell proliferation. CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy; blocking its action may improve anti-tumor immune responses. TGF-beta is expressed by a number of cancer cell types and is involved in cancer cell proliferation, tumor progression, and immunosuppression. It suppresses T-cell activation and induces CD39 expression.	Pharmacologic Substance
C185121	Anti-CD39 Monoclonal Antibody ES002023	Anti-CD39 Monoclonal Antibody ES002023 || ES 002023 || ES-002023 || ES002023 || ES2023	A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody ES002023 specifically targets and binds to the CD39 antigen, thereby preventing the conversion and degradation of adenosine triphosphate (ATP) to adenosine monophosphate (AMP). This leads to an increase in the extracellular levels of immunogenic ATP and a decrease in the levels of immunosuppressive adenosine within the tumor microenvironment (TME). A high level of ATP increases pro-inflammatory cytokine levels and promotes both T-cell proliferation and the stimulation of dendritic and other myeloid-derived cells that are necessary for innate and adaptive immunity. CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy; blocking its action may improve anti-tumor immune responses.	Pharmacologic Substance
C175591	Anti-CD39 Monoclonal Antibody IPH5201	Anti-CD39 Monoclonal Antibody IPH5201 || IPH 5201 || IPH-5201 || IPH5201	A monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody IPH5201 specifically targets and binds to the CD39 antigen, thereby preventing the conversion and degradation of the immune-stimulatory adenosine triphosphate (ATP) to adenosine monophosphate (AMP). This leads to an increase in the extracellular levels of ATP and a decrease in the levels of immunosuppressive adenosine within the tumor microenvironment (TME). A high level of ATP increases pro-inflammatory cytokine levels and promotes both T-cell proliferation and the stimulation of dendritic cells (DCs) and other myeloid-derived cells that are necessary for innate and adaptive immunity. CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy. Blocking its action may improve anti-tumor immune responses.	Amino Acid, Peptide, or Protein || Immunologic Factor
C187256	Anti-CD39 Monoclonal Antibody PUR001	Anti-CD39 Monoclonal Antibody PUR001 || Anti-CD39 Monoclonal Antibody PUR001 || PUR 001 || PUR-001 || PUR001	A monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody PUR001 specifically targets and binds to the CD39 antigen, thereby preventing the conversion and degradation of adenosine triphosphate (ATP) to adenosine monophosphate (AMP). This leads to an increase in the extracellular levels of immunogenic ATP and a decrease in the levels of immunosuppressive adenosine within the tumor microenvironment (TME). A high level of ATP increases pro-inflammatory cytokine levels and promotes both T-cell proliferation and the stimulation of dendritic and other myeloid-derived cells that are necessary for innate and adaptive immunity. CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy; blocking its action may improve anti-tumor immune responses.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C171450	Anti-CD39 Monoclonal Antibody SRF617	Anti-CD39 Monoclonal Antibody SRF617 || Anti-CD39 Monoclonal Antibody SRF617 || SRF 617 || SRF-617 || SRF617	A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody SRF617 specifically binds to the CD39 antigen, thereby preventing the conversion and degradation of adenosine triphosphate (ATP) to adenosine monophosphate (AMP). This leads to an increase in the extracellular levels of immunogenic ATP and a decrease in the levels of immunosuppressive adenosine within the tumor microenvironment (TME). A high level of ATP increases pro-inflammatory cytokine levels and promotes both T-cell proliferation and the stimulation of dendritic and other myeloid-derived cells that are necessary for innate and adaptive immunity. CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy. Blocking its action may improve anti-tumor immune responses.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C162693	Anti-CD39 Monoclonal Antibody TTX-030	Anti-CD39 Monoclonal Antibody TTX-030 || Anti-CD39 Monoclonal Antibody TTX-030 || TTX 030 || TTX-030 || TTX030	A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1) with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody TTX-030 specifically binds to the CD39 antigen, which may inhibit both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy; blocking its action may promote the stimulation of dendritic and other myeloid-derived cells that are necessary for both innate and adaptive immunity.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C174420	Anti-CD4 CAR T-cells	Anti-CD4 CAR T-cells || CD4 CAR T Cells || CD4-specific CAR T Cells	A preparation of T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD4 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD4 CAR T-cells target and bind to CD4-expressing tumor cells, thereby inducing selective toxicity in CD4-expressing tumor cells. CD4 antigen is expressed in CD4-positive T cell lymphomas.	Cell || Pharmacologic Substance
C178347	Anti-CD40 Agonist Antibody YH003	Anti-CD40 Agonist Antibody YH003 || YH 003 || YH-003 || YH003	A humanized agonistic antibody targeting the immune checkpoint human B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD40 agonist antibody YH003 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.	Immunologic Factor || Pharmacologic Substance
C150558	Anti-CD40 Agonist Monoclonal Antibody CDX-1140	Agonist CD40 Antibody CDX-1140 || Anti-CD40 Agonist Monoclonal Antibody CDX-1140 || Anti-CD40 Agonist Monoclonal Antibody CDX-1140 || Anti-CD40 Agonistic Monoclonal Antibody CDX-1140 || CDX 1140 || CDX-1140 || CDX-1140	A fully human immunoglobulin G2 (IgG2) agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, CDX-1140 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.	Immunologic Factor || Pharmacologic Substance
C178278	Anti-CD40 Agonist Monoclonal Antibody LVGN7409	Anti-CD40 Agonist Monoclonal Antibody LVGN7409 || Anti-CD40 Agonist Monoclonal Antibody LVGN7409 || LVGN 7409 || LVGN-7409 || LVGN7409	A humanized, agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD40 agonist monoclonal antibody LVGN7409 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.	Pharmacologic Substance
C181768	Anti-CD40 Agonist Monoclonal Antibody MIL97	Anti-CD40 Agonist Antibody 2141-V11 || Anti-CD40 Agonist Monoclonal Antibody MIL97 || MIL 97 || MIL-97 || MIL97	A recombinant, humanized, agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CD40 agonist monoclonal antibody MIL97 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.	Immunologic Factor || Pharmacologic Substance
C101366	Anti-CD40 Monoclonal Antibody Chi Lob 7/4	Anti-CD40 Monoclonal Antibody Chi Lob 7/4 || Chi Lob 7/4	An IgG1 chimeric monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-CD40 monoclonal antibody Chi Lob 7/4 binds to CD40 on a variety of immune cell types, triggering the cellular proliferation and activation of antigen-presenting cells (APCs), activating B cells and T cells, and enhancing the immune response; in addition, this agent binds to the CD40 antigen present on the surfaces of some solid tumor cells, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) eventually resulting in decreased tumor growth. CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, many B-cell malignancies, and many solid tumors, mediating both indirect tumor cell death through the activation of the immune system and direct tumor cell apoptosis.	Immunologic Factor || Pharmacologic Substance
C121217	Anti-CD40 Monoclonal Antibody SEA-CD40	Anti-CD40 Monoclonal Antibody SEA-CD40 || Anti-CD40 Monoclonal Antibody SEA-CD40 || SEA-CD40	A proprietary, non-fucosylated monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-CD40 monoclonal antibody SEA-CD40 binds to CD40 on a variety of immune cell types, triggering both cellular proliferation and activation of antigen-presenting cells (APCs), which activates B-cells and T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC), and eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system. The non-fucosylated antibody shows increased efficacy as compared to its fucosylated counterpart.	Immunologic Factor || Pharmacologic Substance
C168604	Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042	Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042 || Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042 || Anti-CD40/Anti-CD137 Bispecific Agonist Monoclonal Antibody GEN1042 || BNT 312 || BNT-312 || BNT312 || DuoBody-CD40x4-1BB GEN1042 || GEN 1042 || GEN-1042 || GEN1042	A humanized immunoglobulin (Ig) G1, Fc-silenced, bispecific, agonistic monoclonal antibody targeting both CD40 and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulatory and antineoplastic activity. Upon administration, anti-CD40/anti-4-1BB bispecific agonist monoclonal antibody GEN1042 simultaneously binds to CD40 and 4-1BB, crosslinks CD40 and 4-1BB positive cells, induces conditional stimulation, and activates both CD40- and 4-1BB-medicated signaling. The activation of CD40-mediated signaling triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The activation of 4-1BB-mediated signaling induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system. 4-1BB, a surface glycoprotein of the TNFRSF, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Pharmacologic Substance || Immunologic Factor
C132681	Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428	ABBV 428 || ABBV-428 || Anti-CD40 x Anti-TAA Bispecific Monoclonal Antibody ABBV-428 || Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428 || Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428	A bispecific monoclonal antibody composed of a binding domain for an epitope found on the cell-surface receptor CD40 linked to a binding domain directed to an as of yet undisclosed tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. Upon administration of anti-CD40/anti-TAA bispecific monoclonal antibody ABBV-428, the anti-TAA moiety targets and binds to the TAA expressed on the tumor cells. The agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells. This leads to the activation and proliferation of effector and memory T-cells, and enhances the immune response against tumor cells, which kills and inhibits the proliferation of the TAA-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as macrophages, B-lymphocytes, and dendritic cells (DCs); it plays a key role in the activation of the immune system.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C116881	Anti-CD44 Monoclonal Antibody RO5429083	Anti-CD44 Monoclonal Antibody RO5429083 || Anti-CD44 Monoclonal Antibody RO5429083 || RG 7356 || RO-5429083 || RO5429083	A recombinant, humanized monoclonal antibody targeting the cancer stem cell (CSC) antigen CD44, with potential immunomodulating and antineoplastic activities. Upon administration, RO5429083 binds to the constant region of the extracellular domain of CD44, thereby preventing the activation of various CD44-mediated signal transduction pathways. This may lead to a reduction in the proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in tumor cell proliferation, migration and survival.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C88287	Anti-CD45 BC8 Monoclonal Antibody-Streptavidin Conjugate	Anti-CD45 BC8 Antibody-Streptavidin Fusion Protein || Anti-CD45 BC8 Monoclonal Antibody-Streptavidin Conjugate || BC8 scFv4SA Fusion Protein	An immunoconjugate containing a monoclonal antibody directed against the CD45 antigen BC8, conjugated to streptavidin, a nonglycosylated homotetrameric protein that has four high affinity binding sites for biotin. Anti-CD45 BC8 antibody-streptavidin conjugate binds to CD45, a transmembrane protein tyrosine phosphatase that is expressed on the surface of normal and malignant hematopoietic cells. Upon administration of a biotin-based radioconjugate, the biotin moiety of the radioconjugate binds to the streptavidin moiety of anti-CD45 BC8 antibody-streptavidin conjugate and, upon cellular internalization, specifically delivers cytotoxic radiation to CD45-expressing tumor cells.	Pharmacologic Substance
C74009	Anti-CD45 Monoclonal Antibody AHN-12	AHN-12 || Anti-CD45 Monoclonal Antibody AHN-12 || Anti-CD45 Monoclonal Antibody AHN-12	A high affinity IgG1 monoclonal antibody with potential immunotherapeutic activity. Anti-CD45 monoclonal antibody AHN-12 recognizes CD45, a transmembrane protein tyrosine phosphatase that is expressed on the surface of normal and malignant hematopoietic cells.	Pharmacologic Substance
C156416	Anti-CD46 Antibody-drug Conjugate FOR46	ADC FOR46 || Anti-CD46 ADC FOR46 || Anti-CD46 Antibody-drug Conjugate FOR46 || Anti-CD46 Antibody-drug Conjugate FOR46 || Antibody-drug Conjugate FOR46 || CD46-ADC FOR46 || FOR 46 || FOR-46 || FOR46	An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cluster of differentiation 46 (CD46; membrane cofactor protein; MCP) and conjugated to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon administration, anti-CD46 ADC FOR46 specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. Upon binding and internalization, the cytotoxic payload kills the CD46-expressing tumor cells. The conformational epitope of CD46 is highly expressed in multiple tumor cell types while minimally expressed or absent in normal, healthy tissues.  FOR46 does not interfere with other CD46-mediated pathways that naturally occur in normal, healthy tissues.	Pharmacologic Substance
C173421	Anti-CD47 ADC SGN-CD47M	ADC SGN-CD47M || Anti-CD47 ADC SGN-CD47M || Anti-CD47 ADC SGN-CD47M || Anti-CD47 Antibody-drug Conjugate SGN-CD47M || SGN CD47M || SGN-CD47M || SGNCD47M	An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against human cell surface antigen CD47 conjugated to an as of yet not fully elucidated toxin, with potential antineoplastic activity. Upon administration of SGN-CD47M, the anti-CD47 monoclonal antibody moiety targets and binds to CD47 on tumor cell surfaces; upon internalization, the toxin moiety kills tumor cells through a mechanism of action that has not been elucidated. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells.	Pharmacologic Substance
C159583	Anti-CD47 Monoclonal Antibody	Anti-CD47 Monoclonal Antibody	Any monoclonal antibody that targets the CD47 antigen.	Amino Acid, Peptide, or Protein
C159600	Anti-CD47 Monoclonal Antibody AO-176	AO 176 || AO-176 || AO176 || Anti-CD47 Monoclonal Antibody AO-176 || Anti-CD47 Monoclonal Antibody AO-176	A humanized immunoglobulin G2 (IgG2) monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody AO-176 preferentially binds to CD47 on tumor cells because it exhibits enhanced binding at the acidic pH found in the tumor microenvironment (TME). This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. In addition, AO-176 induces immunogenic cell death (ICD) and releases damage-associated molecular patterns (DAMPs) from tumor cells, thereby further stimulating immune responses. AO-176 is also able to induce direct cytotoxic cell death by a cell autonomous mechanism. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Amino Acid, Peptide, or Protein || Immunologic Factor
C121211	Anti-CD47 Monoclonal Antibody CC-90002	Anti-CD47 Mab CC-90002 || Anti-CD47 Monoclonal Antibody CC-90002 || Anti-CD47 Monoclonal Antibody CC-90002 || CC 90002 || CC-90002	A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody CC-90002 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Amino Acid, Peptide, or Protein || Immunologic Factor
C174192	Anti-CD47 Monoclonal Antibody IMC-002	Anti-CD47 Monoclonal Antibody IMC-002 || Anti-CD47 Monoclonal Antibody IMC-002 || IMC 002 || IMC-002 || IMC002	A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody IMC-002 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. IMC-002 does not bind to red blood cells (RBCs). This may prevent adverse effects such as anemia that can result from the blockade of CD47 expressed on RBCs.	Pharmacologic Substance
C179331	Anti-CD47 Monoclonal Antibody MIL95	Anti-CD47 Monoclonal Antibody MIL95 || CM 312 || CM-312 || CM312 || MIL 95 || MIL-95 || MIL95	A humanized monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody MIL95 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.	Pharmacologic Substance
C160202	Anti-CD47 Monoclonal Antibody SHR-1603	Anti-CD47 Monoclonal Antibody SHR-1603 || SHR 1603 || SHR-1603 || SHR1603	A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody SHR-1603 preferentially binds to CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Amino Acid, Peptide, or Protein || Immunologic Factor
C180830	Anti-CD47 Monoclonal Antibody STI-6643	Anti-CD47 Monoclonal Antibody STI-6643 || STI 6643 || STI-6643 || STI-6643 || STI6643	A human monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody STI-6643 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) but is overexpressed on the surface of a variety of cancer cells and contributes to poor prognosis. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate. Compared to other anti-CD47 monoclonal antibodies, STI-6643 shows decreased binding to red blood cells (RBCs). This may prevent adverse effects such as anemia that can result from the blockade of CD47 expressed on RBCs. In addition, STI-6643 has a minimal effect on T-, B- or natural killer (NK) cell depletion which may further improve its efficacy by preserving infiltrating anti-tumor immune cells.	Amino Acid, Peptide, or Protein || Immunologic Factor
C175603	Anti-CD47 Monoclonal Antibody ZL-1201	Anti-CD47 Monoclonal Antibody ZL-1201 || Anti-CD47 Monoclonal Antibody ZL-1201 || ZL 1201 || ZL-1201 || ZL1201	A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody ZL-1201 targets and binds to CD47 expressed on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha (SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.	Pharmacologic Substance
C185132	Anti-CD47/Anti-HER2 Bispecific Antibody IMM2902	Anti-CD47/Anti-HER2 Bispecific Antibody IMM2902 || Anti-CD47/Anti-HER2 Bispecific Monoclonal Antibody IMM2902 || Anti-CD47/HER2 Bispecific Antibody IMM2902 || CD47 x HER2 Bispecific Antibody IMM2902 || IMM 2902 || IMM-2902 || IMM2902	A bispecific antibody directed against both the human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-CD47/anti-HER2 bispecific antibody IMM2902, the anti-HER2 moiety selectively targets and binds to the tumor-associated antigen (TAA) HER2 on HER2-expressing tumor cells, thereby improving the binding of the anti-CD47 moiety to the HER2-expressing tumor cells. The CD47 binding by IMM2902 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the HER2-expressing tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of HER2-expressing tumor cells. IMM2902 may also induce an anti-tumor activity through the induction of antibody-dependent cellular cytotoxicity (ADCC). CD47, also called integrin-associated protein (IAP), is widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. HER-2, overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation, differentiation and survival. Co-targeting CD47 and HER2 may limit the binding of IMM2902 to CD47 on healthy hematopoietic stem cells (HSCs) and may minimize any associated adverse effects.	Pharmacologic Substance
C184379	Anti-CD47/Anti-PD-L1 Bispecific Antibody 6MW3211	6MW3211 || Anti-CD47/Anti-PD-L1 Bispecific Antibody 6MW3211 || Anti-CD47/PD-L1 Bispecific Antibody 6MW3211 || CD47 x PD-L1 Bispecific Antibody 6MW3211	A humanized bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47/anti-PD-L1 bispecific antibody 6MW3211 targets and binds to both CD47 and PD-L1 expressed on tumor cells. The CD47 binding by 6MW3211 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of 6MW3211 to PD-L1 blocks its binding to and activation of its receptor, programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows proliferation of cancer cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) that is expressed on activated T-cells, suppresses the immune system and results in immune evasion. By co-targeting CD47 and PD-L1, 6MW3211 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs).	Pharmacologic Substance
C176744	Anti-CD47/Anti-PD-L1 Bispecific Antibody IBI322	Anti-CD47/Anti-PD-L1 Bispecific Antibody IBI322 || Anti-CD47/PD-L1 Bispecific Antibody IBI322 || IBI 322 || IBI-322 || IBI322	A recombinant bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47/anti-PD-L1 bispecific antibody IBI322 targets and binds to both CD47 and PD-L1 expressed on tumor cells, with a higher binding affinity to PD-L1 and a lower binding affinity to CD47. The CD47 binding by IBI322 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of IBI322 to PD-L1 blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. By co-targeting CD47 and PD-L1 with a higher binding affinity to PD-L1, IBI322 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs). PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Pharmacologic Substance
C180866	Anti-CD47/Anti-PD-L1 Bispecific Antibody PF-07257876	Anti-CD47/Anti-PD-L1 Bispecific Antibody PF-07257876 || Anti-CD47/Anti-PD-L1 Bispecific Antibody PF-07257876 || Anti-CD47/PD-L1 Bispecific Antibody PF-07257876 || CD47 x PD-L1 Bispecific Antibody PF-07257876 || CD47-PD-L1 Bispecific Antibody PF-07257876 || PF 07257876 || PF-07257876 || PF07257876	A bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47/anti-PD-L1 bispecific antibody PF-07257876 targets and binds to both CD47 and PD-L1 expressed on tumor cells. The CD47 binding by PF-07257876 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of PF-07257876 to PD-L1 blocks its binding to and activation of its receptor, programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows proliferation of cancer cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) that is expressed on activated T-cells, suppresses the immune system and results in immune evasion. By co-targeting CD47 and PD-L1, PF-07257876 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs).	Pharmacologic Substance
C166137	Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801	Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801 || Bispecific Monoclonal Antibody TG-1801 || TG 1801 || TG-1801 || TG-1801 || TG1801	A bispecific monoclonal antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-CD47/CD19 bispecific monoclonal antibody TG-1801, the anti-CD19 moiety selectively targets and binds to CD19 on CD19-positive B-cells, thereby improving binding of the anti-CD47 moiety to the CD19+ malignant B-cells. The CD47 binding by TG-1801 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD19/CD47-expressing tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD19/CD47-expressing tumor cells. In addition, TG-1801 induces an anti-tumor activity through the induction of antibody dependent cellular cytotoxicity (ADCC). CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. CD19 is a membrane antigen that is widely expressed during B-cell development and in B-cell malignancies. By co-targeting CD47 and CD19, TG-1801 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs) which causes unwanted macrophage-mediated phagocytosis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C179653	Anti-CD47/CD20 Bispecific Antibody IMM0306	Anti-CD20/CD47 Antibody Receptor Recombinant Protein IMM0306 || Anti-CD20/CD47 mAb-Trap IMM0306 || Anti-CD47/CD20 Bispecific Antibody IMM0306 || IMM 0306 || IMM-0306 || IMM-0306 || IMM0306	A bispecific antibody directed against both the B-cell-specific membrane protein and tumor-associated antigen (TAA) CD20, and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-CD47/CD20 bispecific antibody IMM0306, the anti-CD20 moiety selectively targets and binds to CD20 on CD20-positive B-cells, thereby improving the binding of the anti-CD47 moiety to the CD20-positive malignant B-cells. The CD47 binding by IMM0306 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD20/CD47-expressing tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD20/CD47-expressing tumor cells. In addition, IMM0306 may induce an anti-tumor activity through the induction of antibody dependent cellular cytotoxicity (ADCC). CD47, also called integrin-associated protein (IAP), is widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. CD20 is a membrane antigen that is overexpressed in B-cell malignancies. By co-targeting CD47 and CD20, IMM0306 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs) which causes unwanted macrophage-mediated phagocytosis.	Pharmacologic Substance
C148103	Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A	Anti-CD48 ADC SGN-CD48A || Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A || Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A || SGN CD48A || SGN-CD48A || SGNCD48A	An antibody-drug conjugate (ADC) composed of an antibody targeting the cell surface antigen CD48 that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary next-generation PEGylated glucuronide linker, with potential antineoplastic activity. Following intravenous administration, the antibody moiety of anti-CD48 ADC SGN-CD48A binds to CD48 on the surface of tumor cells. Following internalization of the ADC, the MMAE binds to tubulin and inhibits microtubule polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in CD48-expressing tumor cells. CD48, a member of the signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, is involved in T-cell activation and leukocyte trafficking. Additionally, CD48 is expressed on the surface of multiple myeloma cells at significantly higher levels than it is expressed on normal lymphocytes and monocytes. The linkage system in SGN-CD48A improves stability, reduces off-target uptake, and enables conjugation of larger numbers of MMAE/antibody than other systems, resulting in increased specificity against CD48-positive cells.	Pharmacologic Substance
C160787	Anti-CD52 Monoclonal Antibody ALLO-647	ALLO 647 || ALLO-647 || ALLO647 || Anti-CD52 Monoclonal Antibody ALLO-647 || Anti-CD52 Monoclonal Antibody ALLO-647	A monoclonal antibody directed against the cell surface glycoprotein CD52 (CAMPATH-1 antigen; Cambridge pathology 1 antigen), with potential immunodepleting activity. Upon administration, anti-CD52 monoclonal antibody ALLO-647 selectively targets and binds to CD52, thereby triggering a host immune response that results in the lysis of CD52-positive lymphocytes. This leads to immunodepletion and may prevent graft-versus-host disease (GvHD). CD52 is a glycoprotein expressed on the surface of many immune cells, including essentially all B- and T-lymphocytes.	Amino Acid, Peptide, or Protein || Immunologic Factor
C181024	Anti-CD7 CAR T Cells SenL-T7	Anti-CD7 CAR T Cells SenL-T7 || Anti-CD7 CAR T-cells SenL-T7 || Anti-CD7 CAR-T Cells SenL-T7 || SenL T7 || SenL-T7 || SenLT7	A preparation of T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD7 CAR T cells SenL-T7 specifically recognize and bind to CD7-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD7 is a transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.	Pharmacologic Substance
C172817	Anti-CD7 CAR T-cells	Anti-CD7 CAR T-cells || Anti-CD7 CAR T-lymphocytes || CD7 CAR T-cells	A preparation of T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD7 CAR T-cells specifically recognize and bind to CD7-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD7 is a transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.	Cell || Pharmacologic Substance
C84855	Anti-CD70 Antibody-Drug Conjugate MDX-1203	Anti-CD70 ADC MDX-1203 || Anti-CD70 Antibody-Drug Conjugate MDX-1203 || Anti-CD70 Antibody-Drug Conjugate MDX-1203 || MDX-1203	An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody, directed against the extracellular domain of the human CD70 molecule, conjugated to a prodrug of a CC-1065 (rachelmycin) analogue via a stable peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate MDX-1203 selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the prodrug moiety is released and activated and binds to double-stranded B-DNA within the minor groove, thereby alkylating the -3 position of adenine, which may result in the inhibition of cellular proliferation of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The antitumor antibiotic CC-1065, a DNA minor-groove-binding alkylating agent, was originally isolated from the bacterium Streptomyces zelensis.	Pharmacologic Substance
C117732	Anti-CD70 Antibody-drug Conjugate SGN-CD70A	Anti-CD70 Antibody-drug Conjugate SGN-CD70A || SGN-CD70A || SGN-CD70A	An antibody-drug conjugate (ADC) containing an engineered cysteine monoclonal antibody (EC-mAb), directed against the extracellular domain of the human CD70 molecule, conjugated to the synthetic, cytotoxic, DNA minor-groove crosslinking agent, pyrrolobenzodiazepine (PBD) dimer, via a stable, protease-cleavable, peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate SGN-CD70A selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the PBD dimer moiety is released and covalently binds, through its imine moieties, to the N2 positions of guanines on opposite strands of DNA. This induces DNA double strand breaks and inhibits DNA replication, which lead to the inhibition of cell growth of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The cysteine moiety of the EC-mAb allows for the stable conjugation of the PBD to the antibody.	Immunologic Factor || Pharmacologic Substance
C162699	Anti-CD70 CAR-expressing T Lymphocytes	Anti-CD70 CAR-expressing T Lymphocytes || Anti-CD70 CAR-expressing T Lymphocytes || Anti-CD70 CAR-expressing T-cells || CD70 CAR T-cells || CD70 CAR T-lymphocytes	A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7) fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD70 CAR-expressing T-lymphocytes, express anti-CD70-CAR on their cell surfaces and bind to the CD70 antigen on tumor cell surfaces thereby neutralizing the activity of CD70. This may induce antibody-dependent cellular cytotoxicity (ADCC) against CD70-expressing tumor cells. CD70, a cytokine belonging to the tumor necrosis superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance.	Cell || Pharmacologic Substance
C78187	Anti-CD70 Monoclonal Antibody MDX-1411	Anti-CD70 Monoclonal Antibody MDX-1411 || Anti-CD70 Monoclonal Antibody MDX-1411 || MDX-1411	A glycoengineered, fully human IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Anti-CD70 fully human monoclonal antibody MDX-1411 selectivity binds to the extracellular domain of CD70, which may induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on renal cell carcinoma (RCC) cells among other cancer cell types.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C177902	Anti-CD70 Monoclonal Antibody SEA-CD70	Anti-CD70 Monoclonal Antibody SEA-CD70 || Anti-CD70 Monoclonal Antibody SEA-CD70 || SEA CD70 || SEA-CD70 || SEACD70 || Sugar-engineered Antibody CD70	A humanized, nonfucosylated monoclonal antibody directed against the human CD70 antigen, with potential immunomodulatory and antineoplastic activities. Upon administration, anti-CD70 monoclonal antibody sugar-engineered antibody (SEA)-CD70 selectivity targets and binds to the extracellular domain of CD70, which blocks CD70-mediated signaling. This may inhibit cellular proliferation and survival of CD70-expressing tumor cells, and may modulate the immune system to inhibit inflammatory signals and increase antigen-specific T-cell responses in the tumor microenvironment (TME). In addition, SEA-CD70 induces antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) against CD70-expressing tumor cells. CD70, a member of the tumor necrosis factor (TNF) family, is aberrantly expressed on malignant myeloid blasts while absent from healthy hematopoietic progenitor cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C153287	Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029	Anti-CD71 Probody/vcMMAE Drug Conjugate CX-2029 || Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029 || Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029 || Antibody Prodrug-drug Conjugate CX-2029 || CD71-Directed Probody Therapeutic CX-2029 || CD71-directed PDC CX-2029 || CX 2029 || CX-2029 || CX2029 || PBC CX-2029 || PDC-targeting CD71 CX-2029	A probody-drug conjugate (PDC) composed of a monoclonal antibody directed against the transferrin receptor 1 (TFR1;TRP1; CD71), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, and conjugated, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of the anti-CD71/vcMMAE PDC CX-2029, the anti-CD71 moiety is unable to bind to CD71 antigen, which is highly expressed on both tumor and healthy dividing cells, until the masking peptide that is attached to the anti-CD71 probody is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Local protease-mediated removal of the linker and masking peptide enables specific binding of the unmasked anti-CD71 moiety to CD71 expressed on tumor cells. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of CD71-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. CD71, a transmembrane glycoprotein, is a highly expressed protein present in a number of solid and hematologic cancers, but is also expressed on normal, healthy tissues. The peptide masking of CX-2029 minimizes binding of the anti-CD71 antibody moiety to normal, healthy cells and may minimize systemic toxicity, when compared to other anti-CD71 antibody-drug conjugates (ADCs). Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C132266	Anti-CD73 Monoclonal Antibody BMS-986179	Anti-CD73 Monoclonal Antibody BMS-986179 || Anti-CD73 Monoclonal Antibody BMS-986179 || BMS 986179 || BMS-986179 || BMS-986179	A monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody BMS-986179 targets and binds to CD73, leading to clustering and internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C180375	Anti-CD73 Monoclonal Antibody HLX23	Anti-CD73 Monoclonal Antibody HLX23 || HLX 23 || HLX-23 || HLX23	A recombinant, humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody HLX23 targets and binds to CD73 on tumor cells, thereby inhibiting the activity of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and the adenosine-mediated suppression of lymphocyte activity and trafficking. This increases the activity of cytotoxic T-lymphocytes (CTLs), activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment (TME).	Amino Acid, Peptide, or Protein || Immunologic Factor
C185394	Anti-CD73 Monoclonal Antibody IBI325	Anti-CD73 Monoclonal Antibody IBI325 || IBI 325 || IBI-325 || IBI325	A monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody IBI325 targets and binds to CD73 on tumor cells, thereby inhibiting the activity of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and the adenosine-mediated suppression of lymphocyte activity and trafficking. This attenuates the adenosine-induced immunosuppression in tumor microenvironment (TME), increases the activity of cytotoxic T-lymphocytes (CTLs), activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME.	Pharmacologic Substance
C182010	Anti-CD73 Monoclonal Antibody INCA00186	Anti-CD73 Monoclonal Antibody INCA00186 || Anti-CD73 Monoclonal Antibody INCA00186 || INCA 00186 || INCA-00186 || INCA00186	A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody INCA00186 targets and binds to CD73 on tumor cells, thereby inhibiting the activity of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and the adenosine-mediated suppression of lymphocyte activity and trafficking. This attenuates the adenosine-induced immunosuppression in tumor microenvironment (TME), increases the activity of cytotoxic T-lymphocytes (CTLs), activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C186370	Anti-CD73 Monoclonal Antibody JAB-BX102	Anti-CD73 Monoclonal Antibody JAB-BX102 || JAB BX102 || JAB-BX102 || JABBX102	A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody JAB-BX102 targets and binds to CD73 on tumor cells, thereby inhibiting the activity of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and the adenosine-mediated suppression of lymphocyte activity and trafficking. This attenuates the adenosine-induced immunosuppression in the tumor microenvironment (TME), increases the activity of cytotoxic T-lymphocytes (CTLs), activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME.	Pharmacologic Substance
C158132	Anti-CD73 Monoclonal Antibody NZV930	Anti-CD73 Monoclonal Antibody NZV930 || Anti-CD73 Monoclonal Antibody NZV930 || NZV 930 || NZV-930 || NZV-930 || NZV930 || SRF 373 || SRF-373 || SRF373	A fully human monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-CD73 monoclonal antibody NZV930 targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated in many cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C176987	Anti-CD73 Monoclonal Antibody Sym024	Anti-CD73 Monoclonal Antibody Sym024 || Anti-CD73 Monoclonal Antibody Sym024 || Sym 024 || Sym-024 || Sym024	A monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody Sym024 targets and binds to CD73 on tumor cells, thereby inhibiting CD73 activity. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment (TME).	Amino Acid, Peptide, or Protein || Immunologic Factor
C148066	Anti-CD74 Antibody-drug Conjugate STRO-001	ADC STRO-001 || Anti-CD74 ADC STRO-001 || Anti-CD74 Antibody-drug Conjugate STRO-001 || Anti-CD74 Antibody-drug Conjugate STRO-001 || SP7675 || STRO-001 || STRO-001	An antibody-drug conjugate (ADC) comprised of an aglycosylated human anti-CD74 IgG1 antibody (SP7219) that has been genetically modified to incorporate the non-natural amino acid (nnAA) para-azidomethyl-L-phenylalanine (pAMF), which is site-specifically conjugated to a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead, with potential antineoplastic activity. The antibody moiety of anti-CD74 ADC STRO-001 targets and binds to the CD74 expressed on tumor cells; upon internalization, the maytansinoid linker-warhead moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of CD74-expressing tumor cells. CD74, a transmembrane glycoprotein and tumor-associated antigen (TAA) involved in major histocompatibility complex (MHC) class II protein formation and localization, is a receptor for macrophage migration inhibitory factor (MIF; MMIF). MIF binding induces intramembrane cleavage of CD74, which liberates the cytosolic intracellular domain (ICD) of CD74 and regulates the expression of genes involved in promoting cell survival. CD74 is overexpressed on cells from hematologic B-lineage malignancies.	Pharmacologic Substance
C179270	Anti-CD79b CAR T Cells	Anti-CD79b CAR T Cells || CD79b CAR-T Cells	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD79b CAR T cells target and bind to CD79b-expressing tumor cells, thereby inducing selective toxicity in CD79b-expressing tumor cells. CD79b, a critical receptor for successful B cell development and part of the B cell receptor (BCR) signaling complex, is widely expressed in certain subtypes of B cell lymphomas.	Pharmacologic Substance
C176029	Anti-CD96 Monoclonal Antibody GSK6097608	Anti-CD96 Monoclonal Antibody GSK6097608 || Anti-CD96 Monoclonal Antibody GSK6097608 || GSK 6097608 || GSK-6097608 || GSK6097608	A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor CD96 (Tactile; T cell activation increased late expression), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CD96 monoclonal antibody GSK6097608 targets, binds to and inhibits CD96 expressed primarily on T-cells and natural killer (NK) cells, thereby preventing its downstream signaling pathways. This may abrogate CD96-mediated inhibition of T-cell and NK cell effector function and may restore immune function and anti-tumor immune responses through the activation of T-cells and NKs. This may kill and inhibit growth of tumor cells. CD96, a type I transmembrane glycoprotein of the immunoglobulin superfamily and immunological checkpoint for CD8+ T-cells and NK cells, negatively regulates T-cell and NK cell activation and is overexpressed in a variety of cancer settings.	Pharmacologic Substance
C113659	Anti-CD98 Monoclonal Antibody IGN523	Anti-CD98 Monoclonal Antibody IGN523 || IGN-523 || IGN523	A humanized, monoclonal antibody targeting the CD98 (gp125) antigen, with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, IGN523 binds to CD98 expressed on the tumor cell surface and elicits both natural killer (NK)-cell mediated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity towards CD98-expressing tumor cells. In addition, IGN523 inhibits essential amino acid uptake by rapidly proliferating tumor cells. CD98, a type II transmembrane glycoprotein, is involved in both integrin signaling and amino acid transport processes; it is overexpressed in certain cancer cells and plays a key role in the proliferation, survival and metastasis of tumor cells.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C179214	Anti-CDH6 Antibody-drug Conjugate DS-6000a	Anti-CDH-6 ADC DS-6000a || Anti-CDH6 ADC DS-6000a || Anti-CDH6 Antibody-drug Conjugate DS-6000a || Anti-CDH6 Antibody-drug Conjugate DS-6000a || Anti-CDH6/DXd ADC DS-6000a || DS 6000a || DS-6000 || DS-6000a || DS6000a	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-CDH6 ADC DS-6000a, the anti-CDH6 antibody targets and binds to CDH6-expressing tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation.	Pharmacologic Substance
C131439	Anti-CDH6 Antibody-drug Conjugate HKT288	Anti-CDH6 ADC HKT288 || Anti-CDH6 Antibody-drug Conjugate HKT288 || Anti-CDH6 Antibody-drug Conjugate HKT288 || HKT 288 || HKT-288 || HKT-288 || HKT288 || Maytansine-based ADC HKT-288	An immunoconjugate consisting of a human monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) conjugated to a maytansine-based cytotoxic agent, with potential antineoplastic activity. The monoclonal antibody moiety of HKT288 targets and binds to CDH6 located on tumor cell surfaces. After internalization, the maytansine moiety binds to tubulin, which disrupts microtubule assembly/disassembly dynamics and inhibits both division and proliferation of CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation.	Pharmacologic Substance
C95728	Anti-CEA BiTE Monoclonal Antibody AMG211	AMG211 || Anti-CEA BiTE Monoclonal Antibody AMG211 || Anti-CEA BiTE Monoclonal Antibody AMG211 || MEDI-565 || MT111	A recombinant, proprietary bispecific T-cell engagers (BiTE) antibody directed against human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Anti-CEA BiTE monoclonal antibody AMG211 possesses two antigen-recognition sites, one for CEA and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings CEA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CEA-expressing cells. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.	Immunologic Factor || Pharmacologic Substance
C77865	Anti-CEA IgCD28TCR-Transduced Autologous T Cells	Anti-CEA IgCD28TCR-Transduced Autologous T Cells	A population of autologous tumor infiltrating lymphocytes (TIL) transduced with a retroviral vector encoding the chimeric gene IgCD28TCR with potential immunostimulating and antineoplastic activities. The chimeric IgCD28TCR gene consists of portions of CD28, the zeta chain of the T-cell receptor (TCRzeta), and a single chain antibody domain (sFv) specific for the tumor-associated antigen CEA.  Upon administration, these gene-modified TIL bind to tumor cells expressing CEA, which may result in activation and proliferation of TIL and an enhanced cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA may be overexpressed in various gastrointestinal and breast cancers. CD28, a T-cell surface-associated co-stimulatory molecule, is required for full T-cell activation, proliferation, and survival; expression of the CD28 fragment in this chimeric gene construct may impede activation-induced cell death (AICD) of TIL.	Cell || Pharmacologic Substance
C79842	Anti-CEA TCR Retroviral Vector-Transduced Autologous Peripheral Blood Lymphocytes	Anti-CEA TCR Retroviral Vector-Transduced Autologous PBLs || Anti-CEA TCR Retroviral Vector-Transduced Autologous Peripheral Blood Lymphocytes || Anti-CEA TCR-Gene Engineered Autologous Lymphocytes	Autologous human peripheral blood lymphocytes (PBLs), transduced with a retroviral vector encoding both the alpha and beta chains of a T cell receptor (TCR) specific for the carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, anti-CEA TCR retroviral vector-transduced autologous lymphocytes bind to tumor cells expressing CEA, which may result in cytokine expression, activation and proliferation of T-cells, and a specific cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. The tumor-associated antigen (TAA) CEA is overexpressed by a variety of cancer cell types, including those of the gastrointestinal tract, lung, and breast.	Cell || Pharmacologic Substance
C68927	Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody	Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody || F6-734 BsMAb	A bispecific monoclonal antibody (BsMAb) consisting of the Fab fragment of an anti-CEA monoclonal antibody (F6) coupled to the Fab fragment of an anti-DTPA-In monoclonal antibody (734) with potential radioimmunotherapeutic activity. In a two-step pretargeted radioimmunotherapeutic approach, this BsMAb, localizing to CEA-expressing tumor cells via the F6 Fab fragment, is introduced into patient first, followed by injection of indium 131-radiolabeled DTPA, which is recognized by the 734 Fab fragment of the BsMAb. Accordingly, a potentially lethal dose of indium 131 is delivered specifically to CEA-expressing tumor cells while minimizing radiotoxicity to normal tissues. CEA (carcinoembryonic antigen) is a tumor antigen overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers. DTPA (diethylenetriaminepentaacetic acid) is a bivalent hapten.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C82355	Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2	Anti-CEA x Anti-Histamine-Succinyl-Glycine Bispecific Monoclonal Antibody TF2 || Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2 || TF2	A tri-Fab bispecific monoclonal antibody (BiMoAb) divalent for the carcinoembryonic antigen (CEA) and monovalent for histamine-succinyl-glycine (HSG) peptide-hapten. Anti-CEA/anti-HSG bispecific monoclonal antibody TF2 binds to the tumor associated antigen (TAA) CEA on CEA-expressing tumor cells. Subsequently, an HSG peptide-hapten carrying a radionuclide is administered, binding to the anti-HSG binding fragment on the BiMoAb. Depending on the characteristics of the radionuclide used, CEA-expressing tumor cells may then be radioimaged and/or treated radioimmunotherapeutically.	Amino Acid, Peptide, or Protein || Immunologic Factor
C120305	Anti-CEACAM1 Monoclonal Antibody CM-24	Anti-CEACAM1 Monoclonal Antibody CM-24 || Anti-CEACAM1 Monoclonal Antibody CM-24 || CM-24 || CM-24	A humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting the anti-carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1; CD66a), with potential immunomodulating and antineoplastic activities. Upon administration of anti-CEACAM1 monoclonal antibody CM-24, this agent binds to CEACAM1 on cancer cells and certain immune cells. This blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. This enhances the activation of cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells and increases CTL- and NK-mediated killing of CEACAM1-overexpressing cancer cells. CEACAM1, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types. Its overexpression is correlated with both immunosuppression and poor prognosis.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C120068	Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47	Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47 || Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47 || L-DOS47 || L-DOS47	A lyophilized formulation of DOS47, an immunoconjugate composed of AFAIKL2, a recombinant camelid single-domain antibody which recognizes carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), and the enzyme urease derived from the plant Canavalia ensiformis (Jack bean), with potential antineoplastic activity. Upon intravenous administration, the AFAIKL2 antibody fragment moiety of L-DOS47 specifically targets and binds to CEACAM6 expressed on certain tumor cells. In turn, the urease moiety of L-DOS47 catalyzes the hydrolysis of urea into ammonia, which is further hydrolyzed to produce hydroxyl ions, and causes a locally increased concentration of the toxic waste product ammonia, which under normal conditions is converted into the nontoxic substance urea via the urea cycle. This increases the pH of the tumor microenvironment and alkalinizes the highly acidic environment that is needed for cancer cell survival and proliferation. In addition, the ammonia diffuses into cancer cells and exerts a cytotoxic effect. Altogether, this leads to cell death of CEACAM6-expressing cancer cells. The naturally-occurring enzyme urease catalyzes the hydrolysis of urea into ammonia and carbon dioxide. CEACAM6, a tumor-associated antigen and CEA family member, is overexpressed in a variety of tumor cells and plays a key role in tumor initiation, progression, metastasis and survival.	Pharmacologic Substance
C121784	Anti-CEA-CAR Autologous T Lymphocytes	Anti-CEA-CAR Autologous T Lymphocytes || Anti-CEA-CAR Autologous T Lymphocytes || Autologous Anti-CEA CAR-T Cells	Autologous lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CEA-CAR autologous T-lymphocytes target and bind to tumor cells expressing CEA, which results in the cytotoxic T-lymphocyte (CTL)-mediated cell killing of CEA-expressing tumor cells. CEA is overexpressed in various tumor cell types.	Pharmacologic Substance
C176771	Anti-CFH Monoclonal Antibody GT103	Anti-CFH Monoclonal Antibody GT103 || Anti-CFH Monoclonal Antibody GT103 || GT 103 || GT-103 || GT103	A recombinant human-derived monoclonal antibody targeting the tumor cell-protective protein complement factor H (CFH), with potential immunomodulatory and antineoplastic activities. Upon administration, the anti-CFH monoclonal antibody GT103 targets and binds specifically to a conformationally distinct epitope within a specific crucial functional domain of CFH bound on tumor cells. This activates the complement cascade, triggers complement dependent cytotoxicity and leads to the destruction of the tumor cells. In addition, GT103 modulates the adaptive anti-tumor immune response, thereby reducing the number of immune suppressive T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor. This may potentially provide long-term anti-tumor immunity and protection.  CFH, the major regulator of the central complement protein C3b in the alternative pathway of complement activation, normally prevents cells from destruction by the immune system. CFH may play a key role in protection against complement-mediated lysis in various cancer cells.	Amino Acid, Peptide, or Protein || Immunologic Factor
C98295	Anti-c-fms Monoclonal Antibody AMG 820	AMG 820 || AMG-820 || Anti-c-fms Monoclonal Antibody AMG 820	A fully human IgG2 monoclonal antibody against the colony-stimulating factor-1 (CSF-1 or M-CSF) receptor c-fms (or CSFR1), with potential antineoplastic activity. Upon administration, anti-c-fms monoclonal antibody AMG 820 binds to and blocks c-fms, thereby blocking CSF-1 binding to its receptor and suppressing CSF-1-induced c-fms signaling. This results in the suppression of recruitment and activation of tumor associated macrophages (TAM) within the tumor microenvironment. This eventually leads to a decrease in tumor growth. c-fms, a transmembrane protein belonging to the tyrosine kinase family, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation and regulation of cell proliferation. The presence of TAM is correlated with tumor proliferation, invasion and a poor prognosis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C125620	Anti-c-KIT Monoclonal Antibody CDX 0158	Anti-c-KIT Monoclonal Antibody CDX 0158 || Anti-c-KIT Monoclonal Antibody KTN0158 || CDX 0158 || CDX-0158 || CDX-0158 || CDX0158 || KTN 0158 || KTN-0158 || KTN0158	A humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. Upon administration, the anti-c-KIT monoclonal antibody CDX 0158 binds to and inhibits the activation of the cell surface antigen c-Kit. This leads to an inhibition of the activation of c-KIT-mediated signal transduction pathways and inhibits cell proliferation in cancer cells expressing c-Kit. In mast cells, inhibition of c-KIT and c-KIT-mediated signaling prevents mast cell activation, degranulation and subsequent cytokine release. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in various cell types, including certain cancer cells and mast cells; it plays a key role in the regulation of cell differentiation and proliferation.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C184377	Anti-claudin 18.2 Antibody-drug Conjugate CPO102	Anti-CLDN18.2 ADC CPO102 || Anti-claudin 18.2 ADC CPO102 || Anti-claudin 18.2 Antibody-drug Conjugate CPO102 || CPO 102 || CPO-102 || CPO102	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) conjugated via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, anti-CLDN18.2 ADC CPO102 specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C185853	Anti-claudin 18.2 Antibody-drug Conjugate LM-302	Anti-CLDN18.2 ADC LM-302 || Anti-claudin 18.2 ADC LM-302 || Anti-claudin 18.2 Antibody-drug Conjugate LM-302 || Anti-claudin 18.2 Antibody-drug Conjugate LM-302 || LM 302 || LM-302 || LM302	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) conjugated via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, anti-CLDN18.2 ADC LM-302 specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C187690	Anti-Claudin 18.2 Antibody-drug Conjugate SKB315	Anti-CLDN18.2 ADC SKB315 || Anti-Claudin 18.2 ADC SKB315 || Anti-Claudin 18.2 Antibody-drug Conjugate SKB315 || SKB 315 || SKB-315 || SKB315	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) that is site-specifically conjugated, via a stable linker, to a cytotoxic DNA topoisomerase I (Top I) inhibitor, with potential antineoplastic activity. Upon administration of anti-CLDN18.2 ADC SKB315, the antibody moiety specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization and the release of the Top I inhibitor, the Top I inhibitor targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C180828	Anti-claudin 18.2 Monoclonal Antibody M108	Anti-CLDN18.2 Monoclonal Antibody M108 || Anti-claudin 18.2 Monoclonal Antibody M108 || M 108 || M-108 || M108 || TERALLETHRIN	A monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 monoclonal antibody M108 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. The binding induces antibody-dependent cellular cytotoxicity (ADCC) and may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C179602	Anti-claudin 18.2 Monoclonal Antibody MIL93	Anti-CLDN18.2 Monoclonal Antibody MIL93 || Anti-claudin 18.2 Monoclonal Antibody MIL93 || MIL 93 || MIL-93 || MIL93	A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 monoclonal antibody MIL93 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C180413	Anti-Claudin18.2 ADC CMG901	Anti-CLDN18.2 ADC CMG901 || Anti-Claudin18.2 ADC CMG901 || CM G901 || CM-G901 || CMG901	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) conjugated via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, anti-CLDN18.2 ADC CMG901 specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C185607	Anti-Claudin18.2 CAR T Cells IBI345	Anti-CLDN18.2 CAR T Cells IBI345 || Anti-Claudin18.2 CAR T Cells IBI345 || IBI 345 || IBI-345 || IBI345	A preparation of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 CAR T cells IBI345 specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C178335	Anti-Claudin18.2 CAR T Cells LCAR-C18S	Anti-Claudin18.2 CAR T Cells LCAR-C18S || Anti-Claudin18.2-CAR-transduced T Lymphocytes LCAR-C18S || LCAR C18S || LCAR-C18S || LCARC18S	A preparation of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-Claudin18.2 CAR T cells LCAR-C18S specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Cell || Pharmacologic Substance
C187104	Anti-Claudin18.2 CAR-T Cells IM92	Anti-CLDN18.2 CAR T Cells IM92 || Anti-CLDN18.2 CAR-T Cells IM92 || Anti-Claudin18.2 CAR-T Cells IM92 || IM 92 || IM-92 || IM92	A preparation of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 CAR-T cells IM92 specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C173724	Anti-claudin18.2 Monoclonal Antibody AB011	AB 011 || AB-011 || AB011 || Anti-CLDN18.2 Monoclonal Antibody AB011 || Anti-claudin18.2 Monoclonal Antibody AB011	A recombinant humanized monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-claudin18.2 monoclonal antibody AB011 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C179328	Anti-claudin18.2 Monoclonal Antibody ASKB589	ASKB 589 || ASKB-589 || ASKB589 || Anti-claudin 18.2 Monoclonal Antibody ASKB589 || Anti-claudin18.2 Monoclonal Antibody ASKB589	A monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-claudin18.2 monoclonal antibody ASKB589 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C183147	Anti-claudin18.2 Monoclonal Antibody LM-102	Anti-CLDN18.2 Monoclonal Antibody LM-102 || Anti-claudin18.2 Monoclonal Antibody LM-102 || Anti-claudin18.2 Monoclonal Antibody LM-102 || LM 102 || LM-102 || LM102	A recombinant humanized monoclonal antibody directed against the tumor-associated antigen (TAA) claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 monoclonal antibody LM-102 specifically targets and binds to CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells and inhibit tumor cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C185861	Anti-Claudin-18.2 Monoclonal Antibody NBL-015	Anti-CLDN18.2 Monoclonal Antibody NBL-015 || Anti-Claudin-18.2 Monoclonal Antibody NBL-015 || NBL 015 || NBL-015 || NBL015	A human monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 monoclonal antibody NBL-015 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC). This may kill CLDN18.2-expressing tumor cells and inhibit cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C173726	Anti-Claudin18.2 Monoclonal Antibody TST001	Anti-Claudin18.2 Monoclonal Antibody TST001 || Anti-Claudin18.2 Monoclonal Antibody TST001 || TST 001 || TST-001 || TST001	A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, anti-claudin18.2 monoclonal antibody TST001 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell proliferation.  CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa. TST001 is produced with reduced fucosylation.	Amino Acid, Peptide, or Protein || Immunologic Factor
C180884	Anti-claudin18.2/Anti-4-1BB Bispecific Antibody TJ-CD4B	ABL111 || Anti-CLDN18.2/Anti-4-1BB Bispecific Antibody TJ-CD4B || Anti-claudin18.2/4-1BB Bispecific Antibody TJ-CD4B || Anti-claudin18.2/Anti-4-1BB Bispecific Antibody TJ-CD4B || Anti-claudin18.2/Anti-4-1BB Bispecific Antibody TJ-CD4B || CLDN18.2 x 4-1BB BsAb TJ-CD4B || CLDN18.2-4-1BB Bispecific Antibody TJ-CD4B || TJ-CD4B || TJ033721	A bispecific antibody composed of a human, Fc-silenced immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) fused with a single chain variable fragment (scFv) targeting 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2/anti-4-1BB bispecific antibody TJ-CD4B simultaneously targets and binds to CLDN18.2 expressed on tumor cells and 4-1BB expressed on a variety of leukocyte subsets including activated T-lymphocytes. Upon CLDN18.2 binding, the 4-1BB activation signal is induced and TJ-CD4B acts as a conditional 4-1BB agonist in the tumor microenvironment (TME), resulting in T-cell co-stimulation and T-lymphocyte-mediated anti-tumor activity. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Pharmacologic Substance
C187103	Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905	Anti-CLDN18.2/Anti-CD3 Bispecific Antibody QLS31905 || Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 || CLDN18.2xCD3 Bispecific Antibody QLS31905 || QLS 31905 || QLS-31905 || QLS31905	A bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CLDN18.2/anti-CD3 bispecific antibody QLS31905 simultaneously binds to both CLDN18.2-expressing tumor cells and CD3-expressing T-cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C181995	Anti-CLDN18.2 CAR T Cells LY011	Anti-CLDN18.2 CAR T Cells LY011 || LY 011 || LY-011 || LY011	A preparation of allogeneic T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CLDN18.2 CAR T-cells LY011 specifically recognize and bind to CLDN18.2-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Cell || Pharmacologic Substance
C187658	Anti-CLDN18.2/Anti-CD3 Bispecific Antibody ASP2138	ASP 2138 || ASP-2138 || ASP2138 || Anti-CLDN18.2/Anti-CD3 Bispecific Antibody ASP2138 || Anti-Claudin18.2/Anti-CD3 Bispecific Antibody ASP2138 || Anti-Claudin18.2/CD3 Bispecific Antibody ASP2138 || Claudin18.2 x CD3 Bispecific Antibody ASP2138	A bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CLDN18.2/anti-CD3 bispecific antibody ASP2138 simultaneously binds to both CLDN18.2-expressing tumor cells and CD3-expressing T-cells, thereby crosslinking CLDN18.2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C178332	Anti-CLDN6 CAR T-cells	Anti-CLDN6 CAR T-cells || Anti-Claudin-6 CAR-T Cells || CLDN6-targeting CAR-T Cells || Claudin 6-targeting CAR T Cells	A preparation of T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the cell surface protein claudin 6 (CLDN6), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CLDN6 CAR T-cells specifically target and bind to CLDN6-expressing tumor cells, thereby selectively lysing CLDN6-expressing tumor cells. CLDN-6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.	Pharmacologic Substance
C114286	Anti-CLDN6 Monoclonal Antibody ASP1650	ASP 1650 || ASP-1650 || ASP1650 || Anti-CLDN6 Monoclonal Antibody ASP1650 || Anti-CLDN6 Monoclonal Antibody ASP1650 || Anti-Claudin 6 Monoclonal Antibody ASP1650 || IMAB027	A monoclonal antibody directed against the cell surface protein claudin 6 (CLDN6), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CLDN6 monoclonal antibody ASP1650 binds to CLDN-6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (ADCC) and a complement-dependent cytotoxicity (CDC) mediated immune response against CLDN-6-expressing tumor cells. This may inhibit tumor cell growth. CLDN-6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C187347	Anti-CLDN6/CD3 BiTE Antibody AMG 794	AMG 794 || AMG-794 || AMG794 || Anti-CLDN6/CD3 BiTE Antibody AMG 794 || CLDN6/CD3 Bispecific T-cell Engager AMG 794 || CLDN6xCD3 Bispecific T-cell Engager AMG 794	A half-life extended (HLE) human bispecific T-cell engager (BiTE) antibody targeting the CD3 antigen expressed on T-lymphocytes and the cell surface protein claudin 6 (CLDN6; CLDN-6), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CLDN6/CD3 BiTE antibody AMG 794 targets and binds to both CD3 expressed on T-cells and CLDN6 expressed on tumor cells. This activates and redirects cytotoxic T-lymphocytes (CTLs) to CLDN6-expressing tumor cells, produces cytokines and leads to enhanced CTL-mediated elimination of CLDN6-expressing tumor cells. CLDN6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.	Pharmacologic Substance
C180614	Anti-CLL1-PBD ADC DCLL9718S	ADC DCLL9718S || Anti-CLL-1 ADC DCLL9718S || Anti-CLL1-PBD ADC DCLL9718S || Anti-CLL1-PBD ADC DCLL9718S || Anti-CLL1/PBD ADC DCLL9718S || DCLL 9718S || DCLL-9718S || DCLL9718S || RG 6109 || RG-6109 || RG6109 || TDC DCLL9718S || THIOMAB ADC DCLL9718S	An antibody-drug conjugate (ADC) consisting of MCLL0517A , an anti-C-type lectin-like molecule-1 (CLL-1; CLL1; C-type lectin domain family 12 member A; CLEC12A) humanized immunoglobulin G1 (IgG1) monoclonal antibody, conjugated, via a cleavable disulfide linker, to two cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimers, with potential antineoplastic activity. Upon administration of anti-CLL1-PBD ADC DCLL9718S, the antibody moiety targets the cell surface tumor-associated antigen (TAA) CLL1. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety covalently bind to the N2 positions of guanines on opposite strands in the minor groove of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CLL1-overexpressing tumor cells. CLL1, a transmembrane glycoprotein and member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) while absent on normal hematopoietic stem cells (HSCs). It plays an important role in disease progression and relapse of myeloid malignancies.	Pharmacologic Substance
C184368	Anti-c-Met ADC ABBV-400	ABBV 400 || ABBV-400 || ABBV400 || ADC ABBV-400 || Anti-c-Met ADC ABBV-400 || Anti-c-Met ADC ABBV-400 || Anti-c-Met Antibody-drug Conjugate ABBV-400 || c-Met ADC ABBV-400	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an undisclosed topoisomerase inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-c-Met ADC ABBV-400, the monoclonal antibody moiety targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the topoisomerase inhibitor is released, which binds to and inhibits topoisomerase, thereby inhibiting DNA replication and killing the c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.	Pharmacologic Substance
C187340	Anti-c-Met Antibody-drug Conjugate BYON3521	ADC BYON3521 || Anti-c-Met ADC BYON3521 || Anti-c-Met Antibody-drug Conjugate BYON3521 || Anti-c-Met/Duocarmycin Antibody-drug Conjugate BYON3521 || BYON 3521 || BYON-3521 || BYON3521	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) site-specifically conjugated to a linker-duocarmycin payload, with potential antineoplastic activity. Upon intravenous administration of anti-c-Met ADC BYON3521, the monoclonal antibody moiety targets and binds to c-Met expressed on tumor cells. Upon binding, the linker is cleaved inside the tumor thereby releasing the duocarmycin payload. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death in c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.	Pharmacologic Substance
C146667	Anti-c-Met Antibody-drug Conjugate HTI-1066	ADC HTI-1066 || Anti-c-Met Antibody-drug Conjugate HTI-1066 || Anti-c-Met Antibody-drug Conjugate HTI-1066 || HTI 1066 || HTI-1066	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of HTI-1066 targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the c-Met-expressing cancer cells, through an as of yet unknown mechanism of action. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.	Pharmacologic Substance
C158513	Anti-c-Met Antibody-drug Conjugate TR1801	Anti-c-Met ADC TR1801 || Anti-c-Met Antibody-drug Conjugate TR1801 || Anti-c-Met Antibody-drug Conjugate TR1801 || MT 8633 || MT-8633 || TR 1801 || TR-1801 || TR1801	An antibody-drug conjugate (ADC) consisting of a non-agonizing anti-c-Met humanized monoclonal antibody that is linked in a site-specific manner to a pyrrolobenzodiazepine dimer (PBD) toxin, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety targets and binds to the c-Met protein, which is overexpressed in certain tumor types. Upon antibody/antigen binding and internalization, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of tumor cell DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of c-Met-expressing cells. c-Met, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	Amino Acid, Peptide, or Protein
C113802	Anti-c-Met Monoclonal Antibody ARGX-111	ARGX-111 || Anti-c-Met Monoclonal Antibody ARGX-111	A human monoclonal antibody targeting c-Met, with potential antineoplastic activity. Anti-c-Met monoclonal antibody ARGX-111 binds to c-Met, and blocks both ligand-dependent and -independent activation of c-Met-mediated signaling pathways. In addition, this agent enhances antibody dependent cellular cytotoxicity (ADCC). This leads to a reduction in cell proliferation of c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors. Compared to other c-Met targeting monoclonal antibodies, ARGX-111 shows increased antibody circulation time, enhanced tissue distribution and increased efficacy. ARGX-111 is obtained through active immunization with C-met antigen in Camelids and utilizes the Camelid V-domains fused with human antibody backbones.	Amino Acid, Peptide, or Protein || Immunologic Factor
C174391	Anti-c-Met Monoclonal Antibody HLX55	Anti-c-Met Monoclonal Antibody HLX55 || HLX 55 || HLX-55 || HLX55	A humanized immunoglobulin (Ig) G2 monoclonal antibody directed against the human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-c-Met monoclonal antibody HLX55 specifically binds to the semaphorin (Sema)/Plexins-Semaphorins-Integrins (PSI) domain of c-Met, which prevents the binding of c-Met to its ligand HGF and the subsequent activation of the HGF/c-Met signaling pathway. In addition, HLX55 promotes c-Met degradation, which further inhibits c-Met-mediated signaling. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	Pharmacologic Substance
C119619	Anti-C-met Monoclonal Antibody SAIT301	Anti-C-met Monoclonal Antibody SAIT301 || SAIT301	A humanized monoclonal antibody targeting the alpha chain of the extracellular domain of human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Anti-c-Met monoclonal antibody SAIT301 binds to c-Met, thereby preventing both binding of its ligand, HGF, and the subsequent activation of the HGF/c-Met signaling pathway. In addition, SAIT301 induces c-MET internalization and subsequent degradation, which further inhibits c-Met-mediated signaling. This leads to a reduction in the proliferation of c-Met-expressing cancer cells. c-Met, a proto-oncogene receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in various tumors.	Amino Acid, Peptide, or Protein || Immunologic Factor
C179288	Anti-c-Met/MMAE ADC RC108	ADC RC108 || Anti-c-Met/MMAE ADC RC108 || Anti-c-Met/MMAE Antibody-drug Conjugate RC108 || Anti-c-met ADC RC108 || RC 108 || RC-108 || RC108 || c-Met-targeted ADC RC108 || c-Met-targeted Antibody-drug Conjugate RC108	An antibody-drug conjugate (ADC) consisting of an anti-c-Met monoclonal antibody that is conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of anti-c-Met/MMAE ADC RC108, the monoclonal antibody moiety targets and binds to the c-Met protein, which is overexpressed in certain tumor types. After internalization of the agent, the MMAE moiety is released and binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. This inhibits the proliferation of c-Met-expressing tumor cells. c-Met, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. Its expression is associated with poor prognosis in many solid tumor types.	Pharmacologic Substance
C131301	Anti-CSF1 Monoclonal Antibody PD-0360324	Anti-CSF1 Monoclonal Antibody PD-0360324 || Anti-CSF1 Monoclonal Antibody PD-0360324 || Anti-M-CSF mAb PD-0360324 || PD 0360324 || PD 360324 || PD-0360324 || PD-0360324 || PD-360,324	A humanized immunoglobulin (Ig) G2 monoclonal antibody (mAb) directed against the cytokine colony stimulating factor 1 (CSF1; CSF-1; macrophage colony-stimulating factor; M-CSF), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CSF1 monoclonal antibody PD-0360324 targets, binds to and neutralizes CSF1. This prevents the binding of CSF1 to its receptor CSF1R (CD115; M-CSFR), which is expressed on various immune cells, such as monocytes and macrophages. This prevents CSF1R activation and CSF1R-mediated signaling in these cells; this inhibits monocyte differentiation, blocks the activity of macrophages, and reduces their production of inflammatory mediators, which reduces inflammation. By blocking the activity and proliferation of CSF1R-dependent tumor-associated macrophages (TAMs) in the tumor microenvironment, PD-0360324 reduces TAM-mediated immune suppression, decreases regulatory T-cells (Tregs), re-activates the immune system, and improves anti-tumor cell responses mediated by increasing infiltration by cytotoxic T-cells. TAMs play key roles in immune suppression, and tumor cell proliferation and survival. CSF-1 plays a key role in the regulation of the proliferation, differentiation and survival of monocytes and macrophages.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C179168	Anti-CSF1R Monoclonal Antibody AMB-05X	AMB 05X || AMB-05X || AMB05X || Anti-CSF1R Monoclonal Antibody AMB-05X || Anti-CSF1R Monoclonal Antibody AMB-05X	A human immunoglobulin G2 (IgG2) monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; M-CSFR; c-fms), also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), with potential antineoplastic, anti-inflammatory, immunomodulating and anti-fibrotic activities. Upon administration, anti-CSF1R monoclonal antibody AMB-05X targets and binds to CSF1R expressed on tumor cells, monocytes and macrophages, and inhibits the binding of the CSF1R ligands and cytokines colony-stimulating factor-1 (CSF-1; CSF1) and interleukin-34 (IL-34) to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks tumor cell proliferation and the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment (TME) and activity of CSF1R-dependent tumor-associated macrophages (TAMs), AMB-05X enhances T-cell infiltration and antitumor T-cell immune responses, which further inhibits the proliferation of tumor cells. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival. In fibrosis, preventing CSF1R-mediated macrophage differentiation and fibroblast activation may prevent fibrosis. CSF1R, a cell-surface receptor overexpressed or mutated in certain tumor cell types, plays major roles in tumor cell proliferation, metastasis, inflammation, and idiopathic pulmonary fibrosis (IPF). CSF1 is overproduced in certain types of tumors.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C96801	Anti-CSF1R Monoclonal Antibody IMC-CS4	Anti-CSF1R Monoclonal Antibody IMC-CS4 || Anti-CSF1R Monoclonal Antibody IMC-CS4 || IMC-CS4 || LY3022855	A monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. CSF1R monoclonal antibody IMC-CS4 binds to CSF1R which may trigger antitumoral antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells overexpressing CSF1R. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (Cluster of Differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1); this receptor is overexpressed or mutated in certain tumor cell types and plays major roles in tumor cell proliferation and metastasis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C173422	Anti-CTLA4 Antibody Fc Fusion Protein KN044	Anti-CTLA4 Antibody Fc Fusion Protein KN044 || Anti-CTLA4 Antibody Fusion Protein KN044 || KN 044 || KN-044 || KN044	A recombinant, humanized fusion protein consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) single domain antibody linked to a Fc domain, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 antibody Fc fusion protein KN044 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Pharmacologic Substance
C94218	Anti-CTLA4 MoAb RNA/GITRL RNA-transfected Autologous Dendritic Cell Vaccine	Anti-CTLA4 MoAb RNA/GITRL RNA-transfected Autologous Dendritic Cell Vaccine || Anti-CTLA4 MoAb RNA/GITRL RNA-transfected Autologous Dendritic Cell Vaccine || GITRL/antiCTLA4 RNA DC || anti-CTLA-4 mAb Heavy and Light Chain RNA/GITRL RNA-transfected Autologous DC	An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses.	Cell || Pharmacologic Substance
C94217	Anti-CTLA4 MoAb RNA-transfected Autologous Dendritic Cell Vaccine	Anti-CTLA4 MoAb RNA-transfected Autologous Dendritic Cell Vaccine || Anti-CTLA4 MoAb RNA-transfected Autologous Dendritic Cell Vaccine || anti-CTLA-4 mAb Heavy and Light Chain RNA-transfected Autologous DC || antiCTLA4 RNA DC	An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses.	Cell || Pharmacologic Substance
C166139	Anti-CTLA-4 Monoclonal Antibody ADG116	ADG 116 || ADG-116 || ADG116 || Anti-CTLA-4 Monoclonal Antibody ADG116 || Anti-CTLA-4 Monoclonal Antibody ADG116	A human monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody ADG116 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Immunologic Factor || Pharmacologic Substance
C179276	Anti-CTLA-4 Monoclonal Antibody ADG126	ADG 126 || ADG-126 || ADG126 || Anti-CTLA-4 Monoclonal Antibody ADG126 || Anti-CTLA-4 Monoclonal Antibody ADG126 || Anti-CTLA-4 SAFEbody ADG126	A human monoclonal antibody with a masked antibody binding site directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration and the activation of the antibody binding site in the tumor microenvironment (TME), anti-CTLA-4 monoclonal antibody ADG126 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Pharmacologic Substance
C162505	Anti-CTLA-4 Monoclonal Antibody ADU-1604	ADU 1604 || ADU-1604 || ADU1604 || Anti-CTLA-4 Monoclonal Antibody ADU-1604	A humanized immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody ADU-1604 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Immunologic Factor || Pharmacologic Substance
C186372	Anti-CTLA-4 Monoclonal Antibody BA3071	Anti-CTLA-4 Monoclonal Antibody BA3071 || BA 3071 || BA-3071 || BA3071	A conditionally active biologic (CAB) and monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration and specific activation in the tumor microenvironment (TME) due to the unique microphysical conditions that are present in the TME, anti-CTLA-4 monoclonal antibody BA3071 targets and binds to CTLA-4 expressed on T-cells within the TME and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system. By using a CAB anti-CTLA-4 antibody, systemic toxicity may be reduced.	Pharmacologic Substance
C135633	Anti-CTLA4 Monoclonal Antibody BMS-986218	Anti-CTLA4 Monoclonal Antibody BMS-986218 || Anti-CTLA4 Monoclonal Antibody BMS-986218 || BMS 986218 || BMS-986218 || Monoclonal Antibody BMS-986218	A Fc-modified monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 monoclonal antibody BMS-986218 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. Removal of the fucose sugar units from the antibody's Fc region, enhances its activity and decreases the toxicity of BMS-986218.	Amino Acid, Peptide, or Protein
C173540	Anti-CTLA-4 Monoclonal Antibody HBM4003	Anti-CTLA-4 Monoclonal Antibody HBM4003 || Anti-CTLA-4 Monoclonal Antibody HBM4003 || Anti-CTLA4 Monoclonal Antibody HBM4003 || Anti-CTLA4/Anti-PD1 Monoclonal Antibody Combination BCD-217 || HBM 4003 || HBM-4003 || HBM4003	A recombinant human heavy chain only antibody (HCAb) directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody HBM4003 targets and binds to CTLA-4 expressed on T-cells, and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. In addition, HBM4003 induces an antibody-dependent cell cytotoxicity (ADCC). CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system. HBM4003, being a HCAb, is smaller than conventional antibodies which may allow for increased tissue penetration.	Pharmacologic Substance
C175970	Anti-CTLA-4 Monoclonal Antibody IBI310	Anti-CTLA-4 Monoclonal Antibody IBI310 || IBI 310 || IBI-310 || IBI310	A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody IBI310 targets and binds to CTLA-4 expressed on T-cells, and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Immunologic Factor || Pharmacologic Substance
C173547	Anti-CTLA-4 Monoclonal Antibody ONC-392	Anti-CTLA-4 Monoclonal Antibody ONC-392 || Anti-CTLA-4 Monoclonal Antibody ONC-392 || Anti-CTLA4 Monoclonal Antibody ONC-392 || ONC 392 || ONC-392 || ONC-392 || ONC392	A humanized, pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody ONC-392 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. As ONC-392 is dissociated from CTLA-4 under low pH, it does not cause lysosomal degradation of CTLA-4, preserving CTLA-4 and allowing the recycling of CTLA-4. This may result in more efficient and selective CTLA-4-targeted regulatory T-cell (Treg) depletion within the tumor microenvironment (TME) while preserving CTLA-4 functions outside the TME, thereby reducing toxicities. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Pharmacologic Substance
C159764	Anti-CTLA-4 Monoclonal Antibody REGN4659	Anti-CTLA-4 Monoclonal Antibody REGN4659 || Anti-CTLA-4 Monoclonal Antibody REGN4659 || REGN 4659 || REGN-4659 || REGN-4659 || REGN4659	A fully human immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody REGN4659 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C180687	Anti-CTLA-4 Monoclonal Antibody XTX101	Anti-CTLA-4 Monoclonal Antibody XTX101 || Anti-CTLA-4 Monoclonal Antibody XTX101 || XTX 101 || XTX-101 || XTX101	A fully humanized, Fc-engineered monoclonal antibody with masked antigen-binding regions directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration and the activation of the antigen-binding regions via cleavage by proteases that are upregulated in the tumor microenvironment (TME), anti-CTLA-4 monoclonal antibody XTX101 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Pharmacologic Substance
C176873	Anti-CTLA-4 Monoclonal Antibody YH001	Anti-CTLA-4 Monoclonal Antibody YH001 || YH 001 || YH-001 || YH001	A recombinant, humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody YH001 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Pharmacologic Substance
C173435	Anti-CTLA-4 Probody BMS-986288	Anti-CTLA-4 Probody BMS-986288 || Anti-CTLA-4 Probody BMS-986288 || BMS 986288 || BMS-986288 || BMS986288 || Probody BMS-986288	A probody composed of a modified version of ipilimumab, a recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of anti-CTLA-4 probody BMS-986288, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986288 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.	Pharmacologic Substance
C172196	Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217	Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217 || Anti-CTLA-4/PD-1 Monoclonal Antibody Combination BCD-217 || Anti-CTLA4/Anti-PD1 Monoclonal Antibody Combination BCD-217 || BCD 217 || BCD-217 || BCD217	A fixed dose combination of two monoclonal antibodies of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4/anti-PD-1 monoclonal antibody combination BCD-217 targets and binds to both PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA-4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.	Pharmacologic Substance
C157494	Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015	ADC 1015 || ADC-1015 || ADC1015 || ATOR 1015 || ATOR-1015 || ATOR1015 || Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015 || CTLA-4 x OX40 Bispecific Antibody ATOR-1015	A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T-lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T-cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T-cells, thereby enhancing the immune-mediated anti-tumor response.	Pharmacologic Substance || Amino Acid, Peptide, or Protein
C131572	Anti-CXCR4 Monoclonal Antibody PF-06747143	Anti-CXCR4 IgG1 Antibody PF-06747143 || Anti-CXCR4 Monoclonal Antibody PF-06747143 || Anti-CXCR4 Monoclonal Antibody PF-06747143 || PF 06747143 || PF-06747143 || PF-06747143	A humanized immunoglobulin (Ig) G1 monoclonal antibody (mAb) against C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, anti-CXCR4 mAb PF-06747143 binds to CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation. This results in decreased proliferation and migration of CXCR4-expressing tumor cells. In addition, PF-06747143 promotes cell death through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, is upregulated in several tumor cell types and plays an important role in cancer cell proliferation, survival, and chemotaxis, and in tumor angiogenesis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C71749	Anti-Denatured Collagen Monoclonal Antibody TRC093	Anti-Denatured Collagen Monoclonal Antibody TRC093 || D93 || MT293 || TRC093	A humanized, affinity-matured IgG1k antibody directed against denatured collagens (I-IV) with potential antiangiogenic and antineoplastic activities. Anti-denatured collagen recombinant monoclonal antibody TRC093 binds to multiple epitopes on denatured collagens, inhibiting proteolytic collagen-mediated signaling in the extracellular matrix (ECM) that is important to tumor angiogenesis, tumor growth, and metastasis. The epitopes on denatured collagen bound by this antibody are considered cryptic because, in vivo, they are accessible only on the subendothelial basement membrane of tumors or in normal tissues undergoing neovascularization.	Amino Acid, Peptide, or Protein || Immunologic Factor
C80040	Anti-DKK1 Monoclonal Antibody BHQ880	Anti-DKK1 Monoclonal Antibody BHQ880 || Anti-DKK1 Monoclonal Antibody BHQ880 || BHQ-880 || BHQ-880 || BHQ880	A humanized monoclonal antibody directed against Wnt antagonist Dickkopf-1 (DKK1) with potential anti-osteolytic activity. Anti-DKK1 monoclonal antibody BHQ880 binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1 is a potent Wnt signaling pathway antagonist.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C177765	Anti-DLL3/CD3 Bispecific Antibody BI 764532	Anti-DLL3/CD3 Bispecific Antibody BI 764532 || Anti-DLL3/CD3 Bispecific Antibody BI 764532 || BI 764532 || BI-764532 || BI764532 || DLL3/CD3 Bispecific Antibody BI 764532 || T-cell Engager BI 764532	A bispecific T-cell engager antibody directed against both the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-DLL3/CD3 bispecific antibody BI 764532 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the DLL3 antigen on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.	Pharmacologic Substance
C101521	Anti-DLL4 Monoclonal Antibody MEDI0639	Anti-DLL4 Monoclonal Antibody MEDI0639 || Anti-DLL4 Monoclonal Antibody MEDI0639 || MEDI-0639 || MEDI0639	An immunoglobulin G1 lambda monoclonal antibody directed against the Notch ligand delta-like 4 (DLL4) with potential antineoplastic activity. Anti-DLL4 monoclonal antibody MEDI0639 specifically binds to DLL4 and prevents its interaction with Notch receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may block tumor angiogenesis and eventually the inhibition of tumor cell growth. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels.	Immunologic Factor || Pharmacologic Substance
C185865	Anti-DLL4/Anti-VEGF-A Bispecific Antibody CTX-009	ABL 001 || ABL-001 || ABL001 || Anti-DLL4/Anti-VEGF-A Bispecific Antibody CTX-009 || Anti-DLL4/Anti-VEGF-A Bispecific Antibody ES104 || CTX 009 || CTX-009 || CTX009 || ES 104 || ES-104 || ES104 || NOV1501 || TR 009	A bispecific antibody targeting Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), with potential anti-angiogenic  and antineoplastic activities. Upon administration, anti-DLL4/anti-VEGF-A bispecific antibody CTX-009 simultaneously targets, binds to and blocks DLL4 and VEGF-A. This prevents the activation of DLL-4/Notch- and VEGF-A/VEGF receptor (VEGFR)-mediated signaling pathways, which play key roles in angiogenesis and tumor vascularization. This prevents angiogenesis and may halt tumor cell proliferation. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. VEGF-A is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.	Pharmacologic Substance
C78826	Anti-DR5 Agonist Monoclonal Antibody TRA-8	Anti-DR5 Agonist Monoclonal Antibody TRA-8 || Anti-death Receptor 5 Agonist Monoclonal Antibody TRA-8 || TRA-8	An agonist mouse monoclonal antibody directed against TRAIL death receptor type 5 (DR5) with potential antineoplastic activity. Anti-DR5 agonist monoclonal antibody TRA-8 binds DR5, which may induce apoptosis in DR5-expressing tumor cells. DR5 is a tumor cell surface ligand that crosslinks with death receptor type 4 (DR4) when bound by TRAIL [Tumor necrosis (TNF)-related apoptosis-inducing ligand], triggering apoptosis via a death receptor signaling pathway. The apoptotic activity of this antibody may not require DR4/DR5 crosslinking.	Pharmacologic Substance
C121158	Anti-DR5 Agonistic Antibody DS-8273a	Anti-DR5 Agonistic Antibody DS-8273a || Anti-DR5 Agonistic Antibody DS-8273a || DS 8273 || DS-8273A || DS-8273a	An agonistic monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2, with potential pro-apoptotic and antitumor activities. Upon administration, anti-DR5 agonistic antibody DS-8273a mimics the natural receptor ligand TRAIL and binds to DR5. This activates DR5 and leads to the activation of the death receptor signal pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. DR5, a member of the TNF receptor superfamily, is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.	Immunologic Factor || Pharmacologic Substance
C176625	Anti-DR5 Agonistic Monoclonal Antibody IGM-8444	Anti-DR5 Agonistic Monoclonal Antibody IGM-8444 || Anti-DR5 Agonistic Monoclonal Antibody IGM-8444 || Anti-DR5 Monoclonal Antibody IGM-8444 || DR5 Agonist Antibody IGM-8444 || IGM 8444 || IGM-8444 || IGM-8444 || IGM8444	A recombinant agonistic pentameric immunoglobulin M (IgM) monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, anti-DR5 agonistic monoclonal antibody IGM-8444, containing ten binding sites specific for DR5, specifically targets and binds to DR5, which mimics the interaction of DR5 with its natural ligand TRAIL. This cross-links and activates DR5 receptors, and activates the death receptor signaling pathway. This results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.	Immunologic Factor || Pharmacologic Substance
C157062	Anti-DR5 Agonistic Monoclonal Antibody INBRX-109	Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 || Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 || INBRX 109 || INBRX-109 || INBRX109	A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, INBRX-109 specifically binds to exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent monoclonal antibody may overcome the challenge of generating effective DR5 clustering while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.	Immunologic Factor || Pharmacologic Substance
C180585	Anti-EGFR Antibody-drug Conjugate MRG003	Anti-EGFR ADC MRG003 || Anti-EGFR Antibody-drug Conjugate MRG003 || Anti-EGFR/MMAE Antibody-drug Conjugate MRG003 || MRG 003 || MRG-003 || MRG003	An antibody-drug conjugate (ADC) consisting of a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of anti-EGFR ADC MRG003, the monoclonal antibody moiety binds to EGFR on tumor cell surfaces. Following receptor internalization, the MMAE moiety is released and binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. This inhibits the proliferation of EGFR-expressing tumor cells. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.	Pharmacologic Substance
C158602	Anti-EGFR CAR-transduced IL-12-expressing T-lymphocytes	Anti-EGFR CAR-transduced IL-12-expressing T-lymphocytes || EGFR-IL12-CAR T-cells	A preparation of human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) gene coupled to the signaling domains from CD28, 4-1BB (CD137) and CD3 zeta, and modified to express the cytokine interleukin-12 (IL-12), with potential immunostimulatory and antineoplastic activities. Upon administration, the anti-EGFR CAR-transduced IL-12-expressing T-lymphocytes target and bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFNg), activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death for the EGFR-overexpressing tumor cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.	Cell || Pharmacologic Substance
C155876	Anti-EGFR Monoclonal Antibody CPGJ 602	Anti-EGFR Monoclonal Antibody CPGJ 602 || CPGJ 602 || CPGJ-602 || CPGJ602	A recombinant, human-mouse chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, anti-EGFR monoclonal antibody CPGJ 602 targets and binds to EGFR, which prevents receptor dimerization and activation. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.	Amino Acid, Peptide, or Protein || Immunologic Factor
C2714	Anti-EGFR Monoclonal Antibody EMD 55900	Anti-EGFR Monoclonal Antibody EMD 55900 || EMD 55 900 || EMD 55900 || Mab 425 || Monoclonal Antibody 425	A murine monoclonal antibody targeting the epidermal growth factor receptor (EGFR) exhibiting anti-tumor activity. EMD 55900 antibody binds to the extracellular domain of EGFR close to the EGF binding domain and does not induce any tyrosine kinase activity on its own. As a result, EMD 55900 binding inhibits receptor activation by natural ligands thereby interrupting activation of downstream signaling cascade, required for tumor cell growth and proliferation.	Amino Acid, Peptide, or Protein || Immunologic Factor
C120316	Anti-EGFR Monoclonal Antibody GC1118	Anti-EGFR Monoclonal Antibody GC1118 || GC1118	A recombinant, human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, GC1118 binds to and blocks the ligand binding site of EGFR, which prevents receptor dimerization and activation. This may lead to an inhibition of both EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.	Amino Acid, Peptide, or Protein || Immunologic Factor
C94221	Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX	Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX || CetuGEX	A glycoengineered form of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Anti-EGFR monoclonal antibody GT-MAB 5.2-GEX specifically binds to the extracellular domain of EGFR, thereby potentially inducing an antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells, eventually leading to tumor cell apoptosis and an inhibition of tumor cell growth. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, is overexpressed on the cell surfaces of various solid tumors. This antibody has a specific glycosylation profile that may enhance its ADCC response against EGFR-expressing tumor cells.	Immunologic Factor || Pharmacologic Substance
C178313	Anti-EGFR Monoclonal Antibody JMT101	Anti-EGFR Monoclonal Antibody JMT101 || JMT 101 || JMT-101 || JMT-101 || JMT101	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody JMT101 targets, binds to and prevents the activation of EGFR. This inhibits EGFR-mediated signaling and proliferation of EGFR-expressing tumor cells. In addition, JMT101 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on various tumor cell types.	Immunologic Factor || Pharmacologic Substance
C99899	Anti-EGFR Monoclonal Antibody Mixture MM-151	Anti-EGFR Monoclonal Antibody Mixture MM-151 || Anti-EGFR Monoclonal Antibody Mixture MM-151 || MM-151	An oligoclonal therapeutic composed of three fully human monoclonal antibodies targeting epidermal growth factor receptor (EGFR or ErbB1), with potential antineoplastic activity. Upon administration of MM-151, the three antibodies bind to distinct, non-overlapping epitopes of EGFR, thereby preventing the binding of a full range of both high and low affinity EGFR ligands and inhibiting EGFR-ERK-mediated signaling. This eventually inhibits tumor cell proliferation in EGFR-overexpressing tumor cells. Furthermore, multi antibody-antigen bindings cause crosslinking of EGFR and downregulate receptor signalings that are mediated via heterodimerization of EGFR with other members of the EGFR family. EGFR, a receptor tyrosine kinase overexpressed in a variety of cancer cell types, is a key regulator of cancer cell proliferation, apoptosis, invasion, and metastasis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C117726	Anti-EGFR Monoclonal Antibody SCT200	Anti-EGFR Monoclonal Antibody SCT200 || SCT200	A recombinant monoclonal antibody against human epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SCT200 targets EGFR, prevents the activation and subsequent dimerization of this receptor and inhibits both EGFR-mediated signal transduction and cellular proliferation of EGFR-expressing tumor cells. In addition, SCT200 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on the cell surfaces of various solid tumors.	Amino Acid, Peptide, or Protein || Immunologic Factor
C121550	Anti-EGFR Monoclonal Antibody SYN004	Anti-EGFR Monoclonal Antibody SYN004 || Anti-EGFR Monoclonal Antibody SYN004 || SYN004	A glyco-engineered monoclonal antibody directed against the receptor tyrosine kinase epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SYN004 binds to the extracellular domain of EGFR, which prevents ligand binding and the subsequent activation and dimerization of the receptor. This inhibits the activation of EGFR-mediated signaling pathways and inhibits EGFR-dependent tumor cell proliferation. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor cell types.	Amino Acid, Peptide, or Protein || Immunologic Factor
C177418	Anti-EGFR Monoclonal Antibody ZZ06	Anti-EGFR Monoclonal Antibody ZZ06 || Anti-EGFR Monoclonal Antibody ZZ06 || ZZ 06 || ZZ-06 || ZZ06	A monoclonal antibody directed against human epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody ZZ06 targets, binds and prevents the activation of EGFR. This inhibits EGFR-mediated signaling and proliferation of EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on various tumor cell types.	Amino Acid, Peptide, or Protein || Immunologic Factor
C187697	Anti-EGFR/Anti-4-1BB Bispecific Antibody HLX35	Anti-EGFR/4-1BB Bispecific Antibody HLX35 || Anti-EGFR/Anti-4-1BB Bispecific Antibody HLX35 || BNA 035 || BNA-035 || BNA035 || EGFR × 4-1BB Bispecific Antibody HLX35 || HLX 35 || HLX-35 || HLX35	A recombinant human bispecific antibody targeting both the tumor-associated antigen (TAA) epidermal growth factor receptor (EGFR) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-EGFR/anti-4-1BB bispecific antibody HLX35 simultaneously targets and binds to the extracellular domain of EGFR, which is expressed on a variety of tumor cells and 4-1BB, which is expressed on activated T-lymphocytes, natural killer (NK) cells and NK-T-cells. This crosslinks EGFR-expressing tumor cells and 4-1BB-expressing T-cells. The binding to EGFR inactivates EGFR and prevents EGFR-mediated signaling. Through 4-1BB binding, HLX35 acts as a conditional 4-1BB agonist, resulting in cytotoxic T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. It also activates memory T-cells, NK cells and dendritic cells (DCs) in the tumor microenvironment (TME). This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated lysis in EGFR-expressing tumor cells. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. EGFR, belonging to the receptor tyrosine kinases family and upregulated or mutated in a variety of tumor cell types, plays a key role in tumor cell proliferation.	Pharmacologic Substance
C187337	Anti-EGFR/Anti-B7-H3 CAR-T Cells	Anti-EGFR/Anti-B7-H3 CAR-T Cells || Anti-EGFR/Anti-B7H3 CAR T Cells || Anti-EGFR/Anti-CD276 CAR T-cells || EGFR/B7-H3-targeted CAR T Cells	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the epidermal growth factor receptor (EGFR) and the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-EGFR/anti-B7-H3 CAR-T cells target and bind to EGFR-expressing tumor cells and B7-H3-expressing immune and tumor cells, thereby inducing selective toxicity in these cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.	Cell || Pharmacologic Substance
C186670	Anti-EGFR/anti-HER3 Antibody-drug Conjugate BL-B01D1	ADC BL-B01D1 || Anti-EGFR/HER3 ADC BL-B01D1 || Anti-EGFR/anti-HER3 ADC BL-B01D1 || Anti-EGFR/anti-HER3 Antibody-drug Conjugate BL-B01D1 || BL B01D1 || BL-B01D1 || BLB01D1 || Dual Antibody ADC BL-B01D1 || Dual Target ADC BL-B01D1	A dual-targeted antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) and conjugated to an as of yet not elucidated cytotoxic payload, with potential antineoplastic activity. Upon administration of anti-EGFR/anti-HER3 ADC BL-B01D1, the monoclonal antibody moieties simultaneously target and bind to EGFR and HER3 expressed on cancer cells. Following receptor internalization, the cytotoxic moiety is released and kills EGFR/HER3-expressing tumor cells through an as of yet unknown mechanism of action (MoA). EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. Simultaneously targeting both EGFR and HER3 may enhance the anti-tumor activity of BL-B01D1.	Pharmacologic Substance
C171163	Anti-EGFR/CD16A Bispecific Antibody AFM24	AFM 24 || AFM-24 || AFM24 || Anti-EGFR/Anti-CD16A Bispecific Antibody AFM24 || Anti-EGFR/CD16A Bispecific Antibody AFM24 || Anti-EGFR/CD16A Bispecific Antibody AFM24 || Anti-EGFR/CD16A Tetravalent Bispecific Antibody AFM24 || Bispecific EGFR/CD16A Innate Cell Engager AFM24	A human, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor (EGFR) and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-EGFR/CD16A bispecific antibody AFM24 simultaneously targets and binds to the CD16A expressed on natural killer (NK) cells and macrophages, and to EGFR on EGFR-expressing tumor cells, thereby selectively cross-linking EGFR-expressing tumor cells with NK cells and macrophages. This may result in NK cell and macrophage activation, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and eventually tumor cell lysis. EGFR, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. CD16A is specifically expressed on the surface of NK cells and macrophages.	Immunologic Factor || Pharmacologic Substance
C178284	Anti-EGFR/CD28 Bispecific Antibody REGN7075	Anti-EGFR/CD28 Bispecific Antibody REGN7075 || Anti-EGFR/CD28 Bispecific Antibody REGN7075 || EGFR x CD28 Bispecific Antibody REGN7075 || REGN 7075 || REGN-7075 || REGN7075 || bsAb7075	A bispecific antibody directed against both human epidermal growth factor receptor (EGFR) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of anti-EGFR/CD28 bispecific antibody REGN7075, this bispecific antibody binds to both CD28 on cytotoxic T-lymphocytes (CTLs) and EGFR found on EGFR-expressing tumor cells. This activates and redirects CTLs to EGFR-expressing tumor cells, which may result in the CTL-mediated cell death of EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on various tumor cell types.	Pharmacologic Substance
C178446	Anti-EGFR/c-Met Bispecific Antibody CKD-702	Anti-EGFR/Anti-c-Met Bispecific Antibody CKD-702 || Anti-EGFR/c-Met Bispecific Antibody CKD-702 || CKD 702 || CKD-702 || CKD702 || EGFR x c-Met Bispecific Antibody CKD-702	A tetravalent, bispecific antibody composed of a single-chain variable fragment (scFv) targeting epidermal growth factor receptor (EGFR) fused to the c-terminus of an immunoglobulin G1 (IgG1) antibody targeting hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met bispecific antibody CKD-702 simultaneously targets and binds to the extracellular domains of wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and c-Met-mediated signaling, thereby inhibiting tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.	Pharmacologic Substance
C179831	Anti-EGFR/c-Met Bispecific Antibody MCLA-129	Anti-EGFR/c-Met Bispecific Antibody MCLA-129 || Anti-EGFR/c-Met Bispecific Antibody MCLA-129 || Bispecific EGFR-c-Met Antibody MCLA-129 || MCLA 129 || MCLA-129 || MCLA129	A human bispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met bispecific antibody MCLA-129 simultaneously targets and binds to the extracellular domains of both EGFR and c-Met expressed on cancer cells. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways. The binding results in antibody-dependent cellular cytotoxicity (ADCC), thereby inhibiting tumor cell proliferation and survival. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.	Amino Acid, Peptide, or Protein || Immunologic Factor
C187344	Anti-EGFR/c-MET/c-MET Trispecific Antibody GB263T	Anti-EGFR/c-MET/c-MET Trispecific Antibody GB263T || EGFR x cMET x cMET Trispecific Antibody GB263T || GB 263T || GB-263T || GB263T || Trispecific EGFR/cMET/cMET Antibody GB263T	A Fc-enhanced trispecific antibody targeting epidermal growth factor receptor (EGFR) and two different epitopes of hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met/c-met trispecific antibody GB263T simultaneously targets and binds to the extracellular domain of both EGFR and two different epitopes on c-Met expressed on tumor cells, thereby preventing receptor phosphorylation and inducing internalization of EGFR and c-Met. This downregulates the expression levels of both EGFR and c-Met proteins and prevents the activation of both EGFR- and c-Met-mediated signaling pathways. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.	Pharmacologic Substance
C148507	Anti-EGFR/DM1 Antibody-drug Conjugate AVID100	ADC AVID100 || AVID-100 || AVID100 || Anti-EGFR/DM1 Antibody-drug Conjugate AVID100 || Anti-EGFR/DM1 Antibody-drug Conjugate AVID100 || Antibody-drug Conjugate AVID100	A targeted antibody drug conjugate (ADC) consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of AVID100 binds to  EGFR on tumor cell surfaces. Following receptor internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.	Pharmacologic Substance
C131175	Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013	Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013 || Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013 || Pan-HER mAb Mixture Sym013 || Sym-013 || Sym013 || pan-HER Antibody Mixture Sym013	An antibody mixture composed of six humanized, immunoglobulin G1 (IgG1) monoclonal antibodies directed against three members of the human epidermal growth factor receptor (EGFR; HER) family: EGFR (HER1; ErbB1), HER2 (ErbB2) and HER3 (ErbB3), with potential antineoplastic activity. Upon administration of anti-EGFR/HER2/HER3 monoclonal antibody mixture Sym013, the six antibodies bind to non-overlapping epitopes on EGFR, HER2 and HER3, which prevents both ligand binding and receptor activation, and induce simultaneous down-modulation of EGFR, HER2 and HER3.  This inhibits the activation of HER-dependent signaling pathways and HER-dependent tumor cell proliferation. Overexpression of the HER family plays a key role in many cancers; targeting multiple HER family members simultaneously may increase therapeutic efficacy.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C178396	Anti-EGFR/HER3 Bispecific Antibody SI-B001	Anti-EGFR/HER3 Bispecific Antibody SI-B001 || Anti-EGFR/anti-HER3 Bi-specific Monoclonal Antibody SI-B001 || EGFR/HER3 Bispecific Antibody SI-B001 || HER3 x EGFR SI-B001 || SI B001 || SI-B001 || SIB001	An immunoglobulin G (IgG) bispecific antibody targeting both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon administration, anti-EGFR/HER3 bispecific antibody SI-B001 simultaneously targets and binds to EGFR and HER3 expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and HER3-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.	Pharmacologic Substance
C179196	Anti-EGFR/LGR5 Bispecific Antibody MCLA-158	Anti-EGFR/Anti-LGR5 Bispecific Antibody MCLA-158 || Anti-EGFR/LGR5 Bispecific Antibody MCLA-158 || Anti-EGFR/LGR5 Bispecific Antibody MCLA-158 || EGFR x LGR5 Bispecific Antibody MCLA-158 || MCLA 158 || MCLA-158 || MCLA158	An immunoglobulin G1 (IgG1) bispecific antibody targeting both epidermal growth factor receptor (EGFR; HER1; ErbB1) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential antineoplastic activity. Upon administration, anti-EGFR/LGR5 bispecific antibody MCLA-158 simultaneously targets and binds to both EGFR and LGR5, thereby inhibiting the activation of both EGFR- and LGR5-mediated signaling pathways. This results in the inhibition of tumor cell proliferation. EGFR, a receptor tyrosine kinase (RTK) upregulated and/or mutated in a variety of tumor cell types, plays an important role in tumor cell proliferation. LGR5, a member of the Wnt signaling pathway, is a cancer stem cell (CSC) receptor overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival.	Pharmacologic Substance
C99222	Anti-EGFRvIII Antibody Drug Conjugate AMG 595	AMG 595 || Anti-EGFRvIII Antibody Drug Conjugate AMG 595 || Anti-EGFRvIII Antibody Drug Conjugate AMG 595 || Anti-EGFRvIII-DM1 Immunoconjugate AMG 595	An immunoconjugate consisting of a human monoclonal antibody directed against the deletion-mutant of epidermal growth factor receptor, EGFRvIII, conjugated via a non-cleavable linker to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to EGFRvIII on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that express the EGFRvIII mutant. EGFRvIII, a deletion mutation of exons 2-7 in the epidermal growth factor receptor gene, is overexpressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma.	Pharmacologic Substance
C111565	Anti-EGFRvIII CAR-transduced Allogeneic T-lymphocytes	Anti-EGFRvIII CAR PG13-139-CD8-CD28BBZ- transduced T-lymphocytes || Anti-EGFRvIII CAR-transduced Allogeneic T-lymphocytes || Anti-EGFRvIII CAR-transduced Allogeneic T-lymphocytes	Allogeneic human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) variant III (EGFRvIII) mutant chimeric T cell receptor (chimeric antigen receptor or CAR) gene coupled to the signaling domains from CD8, CD28, 4-1BB (CD137) and CD3 zeta, with potential immunostimulatory and antineoplastic activities. Upon administration, the anti-EGFRvIII CAR-transduced allogeneic T lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces; subsequently, EGFRvIII-expressing tumor cells may be lysed. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and absent in normal, healthy cells; it plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.	Cell || Pharmacologic Substance
C88307	Anti-EGFRvIII Immunotoxin MR1-1	Anti-EGFRvIII Immunotoxin MR1-1 || Anti-EGFRvIII Immunotoxin MR1-1 || MR1-1 || MR1-1KDEL || MR1scFvPE38KDEL	A recombinant immunotoxin consisting of single-chain variable domain fragment antibody directed against the tumor-specific antigen EGFRvIII (MR1scFv) fused to domains II and III of the Pseudomonas exotoxin (PE38KDEL), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-EGFRvIII immunotoxin MR1-1 binds to EGFRvIII; upon internalization, the exotoxin portion inhibits protein synthesis, resulting in a reduction in tumor cell proliferation of EGFRvIII- expressing tumor cells. EGFRvIII, a type III in-frame deletion mutation of the epidermal growth factor receptor (EGFR) gene, is expressed by a variety of cancers, including glioblastoma multiforme, non-small lung carcinoma, and breast carcinoma. Compared to intact IgG antibodies, single-chain antibodies such as MR1scFv are smaller and may penetrate tumors better. Pseudomonas exotoxin PE38KDEL was modified to remove the natural cell binding domain.	Pharmacologic Substance
C180836	Anti-EGFRvIII/CD3 Bispecific Antibody hEGFRvIII:CD3 bi-scFv	Anti-EGFRvIII/CD3 Bispecific Antibody hEGFRvIII:CD3 bi-scFv || BRiTE || hEGFRvIII-CD3-bi-scFv Bispecific T-cell Engager || hEGFRvIII:CD3 bi-scFv	A bispecific antibody and T-cell engager composed of two single chain variable fragments (bi-scFvs) directed against both a mutant form of the human epidermal growth factor receptor (EGFR), EGFR variant III (EGFRvIII), and the epsilon subunit of the human T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-EGFRvIII/CD3 bispecific antibody hEGFRvIII:CD3 bi-scFv specifically binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and hEGFRvIII on hEGFRvIII-expressing tumor cells. This crosslinks T-cells and tumor cells, and activates and redirects CTLs to hEGFRvIII-expressing tumor cells. This leads to CTL-mediated killing of hEGFRvIII-expressing tumor cells. hEGFRvIII, a mutant form of EGFR expressed in certain tumor cell types and frequently seen in malignant glioma, plays a key role in tumor cell proliferation and survival.	Pharmacologic Substance
C186377	Anti-EGFRvIII/CD3 Bispecific Antibody RO7428731	Anti-EGFRvIII/Anti-CD3 Bispecific Antibody RO7428731 || Anti-EGFRvIII/CD3 Bispecific Antibody RO7428731 || EGFRvIII x CD3 Bispecific Antibody RO7428731 || RO 7428731 || RO-7428731 || RO7428731	A bispecific antibody directed against both a mutant form of the human epidermal growth factor receptor (EGFR), EGFR variant III (EGFRvIII), and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-EGFRvIII/CD3 bispecific antibody RO7428731 specifically binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and EGFRvIII on EGFRvIII-expressing tumor cells. This crosslinks T-cells and tumor cells, and activates and redirects CTLs to EGFRvIII-expressing tumor cells. This leads to CTL-mediated killing of EGFRvIII-expressing tumor cells. EGFRvIII, a mutant form of EGFR expressed in certain tumor cell types and frequently seen in malignant glioma, plays a key role in tumor cell proliferation and survival.	Pharmacologic Substance
C90551	Anti-EGP-2 Immunotoxin MOC31-PE	Anti-EGP-2 Immunotoxin MOC31-PE || Anti-Epithelial Glycoprotein-2 Immunotoxin MOC31-PE || MOC31-PE	An immunotoxin consisting of a monoclonal antibody directed against epithelial glycoprotein-2 (EP-2, or epithelial cell adhesion molecule (EpCAM)) conjugated to the bacterial toxin Pseudomonas exotoxin A (PE) with potential antineoplastic activity. Upon administration of anti-EGP-2 immunotoxin MOC31-PE, the monoclonal antibody moiety targets and binds to EP-2. Upon internalization, the Pseudomonas exotoxin A moiety then inactivates elongation factor 2 (EF-2) through ADP ribosylation, resulting in inhibition of protein synthesis in EP-2-expressing cells. EP-2, a tumor-associated antigen, is overexpressed in a variety of cancer cell types.	Pharmacologic Substance
C102980	Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F	ADC AGS-16C3F || AGS-16C3F || AGS-16C3F || Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F || Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F	An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody (AGS-16C) directed to the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3), conjugated via a non-cleavable linker to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, that has potential antineoplastic activity. Upon intravenous administration of ADC AGS-16C3F, the monoclonal antibody moiety of this conjugate selectively binds to ENPP3 then is internalized and undergoes proteolytic cleavage to release MMAF. MMAF binds to and inhibits tubulin polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 has been found to be overexpressed in renal neoplasms.	Pharmacologic Substance
C116626	Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F	AGS-16M8F || Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F || Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F	An antibody-drug conjugate (ADC) containing a human immunoglobulin (Ig) G2k monoclonal antibody (AGS-16C) directed against the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3, NPP3, B10, PDNP3 CD203c, or PD-IBETA ), conjugated, via the non-cleavable maleimidocaproyl (mc) linker, to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-ENPP3/MMAF ADC AGS-16M8F, the monoclonal antibody moiety selectively binds to ENPP3 expressed on tumor cells; upon internalization, the ADC is degraded by lysosomal proteases and MMAF is released. In turn, MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 is overexpressed in most renal neoplasms and some liver cancers.	Pharmacologic Substance
C133022	Anti-Ep-CAM Monoclonal Antibody ING-1	Anti-Ep-CAM Monoclonal Antibody ING-1 || ING 1 || ING-1	An engineered monoclonal antibody (MAb) directed against the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326), with potential antitumor activity. Upon administration, anti-Ep-CAM monoclonal antibody ING-1 binds to Ep-CAM, which may result in a cytotoxic T-lymphocyte (CTL)-mediated immune response against Ep-CAM-expressing tumor cells. Ep-CAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.	Pharmacologic Substance
C178327	Anti-EpCAM/Anti-CD3 Bispecific Antibody M701	Anti-EpCAM/Anti-CD3 Bispecific Antibody M701 || EpCAM x CD3 Bispecific Antibody M701 || M 701 || M-701 || M701	A human-mouse chimeric bispecific antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM), with potential immunomodulating and antineoplastic activities. Upon administration, anti-EpCAM/anti-CD3 bispecific antibody M701 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and EpCAM on EpCAM-expressing tumor cells. This activates and redirects CTLs to EpCAM-expressing tumor cells, which results in the CTL-mediated cell death of EpCAM-expressing tumor cells. EpCAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.	Pharmacologic Substance
C136981	Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310	Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310 || Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310 || Anti-EphA2 Antibody-targeted Nanoliposome MM-310 || Anti-EphA2 Docetaxel-based Nanoliposome MM-310 || EphA2-targeted Docetaxel Nanoliposome MM-310 || MM 310 || MM-310 || MM310	A formulation containing nanoparticles composed of liposomes that are conjugated to scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2) and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation taxane analog, with potential antineoplastic activity. Upon intravenous administration of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2 moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site due to the unique characteristics of the tumor vasculature. In turn, docetaxel is taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth; its expression is associated with poor prognosis. Compared to free docetaxel, MM-310 increases docetaxel's half-life, and provides enhanced and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel's efficacy while lowering its systemic toxicity.	Pharmacologic Substance
C118447	Anti-EphA2 Monoclonal Antibody DS-8895a	Anti-EphA2 Monoclonal Antibody DS-8895a || DS-8895a	A monoclonal antibody directed against the ephrin receptor A2 (EphA2), with potential antineoplastic activity. Upon administration, anti-EphA2 monoclonal antibody DS-8895a selectively binds to cells expressing the EphA2 receptor. This blocks EphA2 activation and EphA2-mediated signaling. In addition, DS-8895a may activate an immune response against EphA2-expressing tumor cells. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth.	Immunologic Factor || Pharmacologic Substance
C79836	Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547	1C1-mcMMAF || Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547 || Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547 || MEDI-547 || Medi-547	An auristatin analogue immunoconjugate directed against Eph receptor A2 (EphA2)-positive cancer cells with potential antineoplastic activity. Anti-EphA2 monoclonal antibody-MMAF immunoconjugate MEDI-547 is generated by conjugating the fully human IgG1 anti-EphA2 monoclonal antibody (1C1) to the small-molecule microtubule inhibitor monomethyl auristatin phenylalanine (MMAF) via the stable linker maleimidocaproyl (mc) (1C1-mcMMAF). The monoclonal antibody moiety of this agent selectively binds to cells expressing the EphA2 receptor. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C125633	Anti-Epidermal Growth Factor Receptor 2 Antibody Expressing Pluripotent Killer T-Lymphocytes	Anti-ERBB2 Antibody Expressing Pluripotent Killer T-Cells || Anti-ERBB2 Antibody Expressing Pluripotent Killer T-Lymphocytes || Anti-Epidermal Growth Factor Receptor 2 Antibody Expressing Pluripotent Killer T-Cells || Anti-Epidermal Growth Factor Receptor 2 Antibody Expressing Pluripotent Killer T-Lymphocytes || Anti-HER2 Antibody Expressing Pluripotent Killer T-Cells || Anti-HER2 Antibody Expressing Pluripotent Killer T-Lymphocytes || PIK-HER2	A specific population of pluripotent killer (PIK) T-cells that have been induced to express high levels of antibodies against human epidermal growth factor receptor 2 (ERBB2; HER2), with potential antitumor activity. Although the exact mechanism(s) of action through which PIK-HER2 cells exert their effects has yet to be elucidated, upon infusion, these cells secrete antibodies targeting HER2 expressed on the surface of tumor cells. This may inhibit HER2-dependent signaling, which may lead to inhibition of cellular proliferation and differentiation. Additionally, these cells may stimulate the host immune system to mount both a highly-specific cytotoxic T-lymphocyte (CTL) response and antibody-dependent cell cytotoxicity (ADCC) directed against HER2-overexpressing tumors, which leads to tumor cell lysis. HER2 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases and is frequently overexpressed in solid tumors.	Cell || Pharmacologic Substance
C85486	Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111	Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111 || Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111 || MM-111 || MM-111	A bispecific monoclonal antibody directed against the human epidermal growth factor receptors ErbB2 (Her2) and ErbB3 (Her3) with potential antineoplastic activity. The anti-ErB2 targeting arm of anti-ErbB2/anti-ErbB3 bispecific monoclonal antibody MM-111 binds to ErbB2 on tumor cells with high affinity while the anti-Erb3 therapeutic arm binds to ErbB3, which may result in the inhibition of cellular proliferation and differentiation in ErbB2-overexpressing tumor cells via inhibition of ErbB3-dependent signal transduction pathways. ErbB2 and ErB3 are members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases and are frequently overexpressed in solid tumors.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C102535	Anti-ErbB3 Monoclonal Antibody AV-203	AV 203 || AV-203 || AV-203 || AV203 || Anti-ErbB3 MoAb AV-203 || Anti-ErbB3 Monoclonal Antibody AV-203 || Anti-ErbB3 Monoclonal Antibody AV-203 || CAN-017	A humanized monoclonal antibody (MoAb) directed against the human receptor tyrosine-protein kinase ErbB-3 (HER3) with potential antineoplastic activity. Anti-ErbB3 MoAb AV-203 binds to and inhibits both ligand neuregulin-1 (NRG-1)-dependent and ligand-independent ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and may lead to inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family, is frequently overexpressed in solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.	Pharmacologic Substance
C113333	Anti-ErbB3 Monoclonal Antibody CDX-3379	Anti-ErbB3 Monoclonal Antibody CDX-3379 || Anti-ErbB3 Monoclonal Antibody CDX-3379 || CDX 3379 || CDX-3379 || CDX-3379 || CDX3379 || KTN 3379 || KTN-3379 || KTN3379	A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (HER3), with potential antineoplastic activity. Upon administration, the anti-ErbB3 monoclonal antibody CDX-3379 targets and binds to a unique epitope on ErbB3, thereby preventing ErbB3 phosphorylation and both ligand-dependent and ligand-independent ErbB3 signaling. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C103859	Anti-ErbB3 Monoclonal Antibody REGN1400	Anti-ErbB3 Monoclonal Antibody REGN1400 || REGN 1400 || REGN-1400 || REGN-1400 || REGN1400	A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Upon administration, anti-ErbB3 monoclonal antibody REGN1400 binds to ErbB3 and prevents neuregulin 1 ligand binding to ErbB3, which may result in an inhibition of ErbB3-dependent phosphatidylinositol-3 kinase (PI3K)/Akt signaling. This eventually leads to the inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance.	Pharmacologic Substance
C116742	Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A	ADC DEDN6526A || Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A || Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A || DEDN6526A	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal antibody against anti-endothelin B receptor (ETBR) and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DEDN6526A binds to ETBR-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. ETBR, a G-protein coupled receptor that can activate RAF/MEK signaling, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis.	Pharmacologic Substance
C123829	Anti-FGFR3 Antibody-drug Conjugate LY3076226	ADC LY3076226 || Anti-FGFR3 ADC LY3076226 || Anti-FGFR3 Antibody-drug Conjugate LY3076226 || Anti-FGFR3 Antibody-drug Conjugate LY3076226 || Anti-fibroblast Growth Factor Receptor 3 Antibody-Drug Conjugate LY3076226 || LY-3076226 || LY3076226	An antibody-drug conjugate (ADC) composed of a human monoclonal antibody against the fibroblast growth factor receptor type 3 (FGFR3) that is conjugated to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, the antibody moiety of anti-FGFR3 ADC LY3076226 binds to FGFR3. Upon internalization, the cytotoxic moiety causes cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.	Pharmacologic Substance
C126334	Anti-FGFR4 Monoclonal Antibody U3-1784	Anti-FGFR4 Monoclonal Antibody U3-1784 || U3 1784 || U3-1784	A human monoclonal antibody against human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, U3-1784 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival.	Pharmacologic Substance
C158099	Anti-FL(FITC-E2) CAR T Cells	Anti-FL(FITC-E2) CAR T Cells || Anti-FL(FITC-E2) CAR T Cells || Anti-FL(FITC-E2) CAR T-lymphocytes || Anti-FL(FITCE2) CAR Expressing T Cells || AntiFL(FITCE2) CAR Expressing T Cells || Fluorescein-specific (FITC-E2)-CAR T Cells	A preparation of genetically modified T-cells transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a second generation chimeric antigen receptor (CAR) consisting of an anti-fluorescein (anti-FL) fluorescein isothiocyanate (FITC)-E2 single chain variable fragment (scFv), that is coupled, via an immunoglobulin G4 (IgG4) hinge-CH2(L295D)-CH3 spacer, to the costimulatory signaling molecules CD28, CD137 (4-1BB), and CD3 zeta, and linked to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Prior to the administration of anti-FL(FITC-E2) CAR T-cells, the CAR-T adaptor molecule (CAM) EC17 is administered. EC17 is a bispecific molecule that is composed of folic acid conjugated to FITC (folate-FITC). EC17 targets and binds with its folate moiety with high affinity to folate receptor (FR)-expressing tumor cells. Upon administration of the anti-FL(FITC-E2) CAR T-cells, these cells are attracted by and bind to the FITC antigen moiety of EC17. Upon binding to EC17, the T-cells induce specific tumor cell lysis, cytokine secretion, and proliferation, and activate a robust immune response against the EC17-bound, FR-expressing tumor cells. FR is overexpressed in various tumor cell types and is associated with increased leukemic cell proliferation and aggressiveness. The co-stimulatory molecules are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity. EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The reactivity of the anti-FL(FITC-E2) CAR T-cells is dependent on dosing of EC17, and therefore allows CAR T-cell activity to be controlled by dosing of EC17.	Cell || Pharmacologic Substance
C129937	Anti-FLT3 Antibody-drug Conjugate AGS62P1	ADC AGS62P1 || AGS62P1 || AGS62P1 || Anti-FLT3 Antibody-drug Conjugate AGS62P1 || Anti-FLT3 Antibody-drug Conjugate AGS62P1	An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the extracellular domain of receptor-type tyrosine-protein kinase FLT3 (FLT-3; FMS-like tyrosine kinase 3; CD135; fetal-liver kinase 2; FLK2) and conjugated, via an oxime linker and the site-directed non-natural amino acid linker para-acetyl-phenylalanine (pAcF), to a microtubule-disrupting cytotoxic agent, with potential antineoplastic activity. Upon administration of ADC AGS62P1, the antibody moiety targets and binds to FLT3. Upon antibody/antigen binding and internalization, the microtubule-targeting agent binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. The site-specific conjugation of the cytotoxic agent to the antibody, through pAcF, improves the biophysical properties of AGS62P1, increases payload distribution and stability, and optimizes its efficacy. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage, acute lymphoblastic leukemias and acute myeloid leukemias.	Pharmacologic Substance
C129376	Anti-FLT3 Monoclonal Antibody 4G8-SDIEM	4G8-SDIEM || Anti-FLT3 Monoclonal Antibody 4G8-SDIEM || FLYSYN	A human, Fc-optimized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135), with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody 4G8-SDIEM blocks FLT3 ligand binding to FLT3 and subsequent phosphorylation of FLT3, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may lead to the inhibition of cellular proliferation and decreased survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C85453	Anti-FLT3 Monoclonal Antibody IMC-EB10	Anti-FLT3 Monoclonal Antibody IMC-EB10 || Anti-FLT3 Monoclonal Antibody IMC-EB10 || IMC-EB10	A fully human, IgG1 monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135) with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody IMC-EB10 blocks FLT3 ligand binding to FLT3 and subsequent FLT3 phosphorylation, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may result in the inhibition of cellular proliferation and survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C185677	Anti-FLT3/CD3 Bispecific Antibody CLN-049	Anti-FLT3/Anti-CD3 Bispecific Antibody CLN-049 || Anti-FLT3/CD3 Bispecific Antibody CLN-049 || Anti-FLT3/CD3 Bispecific Antibody CLN-049 || CLN 049 || CLN-049 || CLN049 || FLT3 x CD3 Bispecific Antibody CLN-049 || FLT3 x CD3 Bispecific T Cell Engager CLN-049	A T-cell-engaging, humanized, Fc-silenced immunoglobulin G1 (IgG1)-based bispecific antibody directed against both the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2) and the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-FLT3/CD3 bispecific antibody CLN-049 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and FLT3 found on FLT3-expressing tumor cells. This activates and redirects CTLs to FLT3-expressing tumor cells, which results in the CTL-mediated cell death of FLT3-expressing tumor cells. FLT3, a cytokine receptor belonging to the class III tyrosine kinase receptors, is overexpressed or mutated in most B-lineage and acute myeloid leukemias (AMLs).	Pharmacologic Substance
C158067	Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002	Anti-FolRa ADC STRO-002 || Anti-FolRalpha ADC STRO-002 || Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002 || Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002 || STRO 002 || STRO-002 || STRO002	An antibody drug conjugate (ADC) composed of SP8166 (H01), an anti-folate receptor alpha (FolRa; FOLR1) human immunoglobulin G1 (IgG1) antibody, conjugated to a proprietary cleavable drug linker, SC239, containing a tubulin-targeting 3-aminophenyl hemiasterlin warhead, SC209, with potential antineoplastic activity. Upon intravenous administration, the SP8166 antibody moiety targets and binds to FolRa expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic SC209 moiety induces tumor cell death in FolRa-expressing cells. FolRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, FolRa expression is limited in normal tissues.	Pharmacologic Substance
C178282	Anti-FOXP3 Antisense Oligonucleotide AZD8701	AZD 8701 || AZD-8701 || AZD8701 || Anti-FOXP3 ASO AZD8701 || Anti-FOXP3 Antisense Oligonucleotide AZD8701 || Anti-FOXP3 Antisense Oligonucleotide AZD8701 || FOXP3-targeting Antisense Oligonucleotide AZD8701 || ION 736 || ION-736 || ION736 || IONIS-AZ7-2.5Rx	An antisense oligonucleotide (ASO) targeting the Forkhead Box P3 (FOXP3) mRNA, with potential immunomodulating and antineoplastic activities. Upon administration, anti-FOXP3 ASO AZD8701 blocks the translation of the FOXP3 protein. Reduction of FOXP3 levels may lessen the immunosuppressive functions of regulatory T-cells (Tregs). This may lead to an enhanced immune response and antitumor activity. FOXP3, a transcription factor, plays an important role in the functioning of immunosuppressive Tregs. Tregs are overexpressed in various cancers and are associated with poor response to immune checkpoint inhibitors and poor survival.	Pharmacologic Substance
C118443	Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012	Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012 || Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012 || BMS-986012 || BMS-986012	A monoclonal antibody directed against the ganglioside fucosyl-GM1, with potential antineoplastic and immunomodulating activities. Upon administration, anti-fucosyl-GM1 monoclonal antibody BMS-986012 binds to fucosyl-GM1 on cancer cells and may activate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against the bound tumor cells. This may inhibit the proliferation of GM1-expressing tumor cells. Fucosyl-GM1, a sphingolipid monosialoganglioside and tumor associated antigen (TAA), is overexpressed on the surface of many cancer cells while its expression is minimal or non-existent in normal tissues.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C177412	Anti-galectin-9 Monoclonal Antibody LYT-200	Anti-Gal-9 Monoclonal Antibody LYT-200 || Anti-galectin-9 Monoclonal Antibody LYT-200 || Anti-galectin-9 Monoclonal Antibody LYT-200 || LYT 200 || LYT-200 || LYT200	A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive protein galectin-9, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-galectin-9 monoclonal antibody LYT-200 targets, binds to and blocks galectin-9 on tumor cells which prevents galectin-9-mediated signaling. This may abrogate activation of immunosuppressive signaling pathways in the tumor microenvironment (TME) and may activate a cytotoxic T-lymphocyte (CTL)-mediated immune response against the galectin-9-expressing tumor cells. Galectin-9, overexpressed on a variety of tumor cells, plays a key role in cancer cell proliferation and evasion of immune responses. Its expression is correlated with decreased patient survival.	Pharmacologic Substance
C79795	Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962	Anti-GM2 Monoclonal Antibody BIW-8962 || Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962 || Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962 || BIW-8962	A humanized anti-ganglioside GM2 (GM2) monoclonal antibody with potential antineoplastic and immunomodulating activities. Upon administration, anti-ganglioside GM2 monoclonal antibody BIW-8962 may activate an antibody dependent cellular cytotoxicity (ADCC) against GM2-expressing tumor cells. GM2 is a tumor associated antigen (TAA) overexpressed on the surface of many cancer cells, such as multiple myeloma (MM) cells and neuroblastoma cells.	Amino Acid, Peptide, or Protein || Immunologic Factor
C181077	Anti-GARP Monoclonal Antibody DS-1055a	Anti-GARP Monoclonal Antibody DS-1055a || Anti-GARP Monoclonal Antibody DS-1055a || Anti-glycoprotein A Repetitions Predominant Monoclonal Antibody DS-1055a || DS 1055a || DS-1055a || DS1055a	An afucosylated human monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GARP monoclonal antibody DS-1055a selectively targets and binds to GARP and depletes GARP-positive regulatory T-cells (Tregs). This leads to a reversal of immunosuppression mediated by GARP-positive Tregs and enhances the immune response to tumor cells. GARP, a transmembrane protein highly expressed on activated, immunosuppressive Tregs in the tumor microenvironment (TME), is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function and the immunosuppressive nature of Tregs.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C156707	Anti-GCC Antibody-Drug Conjugate TAK-164	Anti-GCC ADC TAK-164 || Anti-GCC Antibody-Drug Conjugate TAK-164 || Anti-GCC Antibody-Drug Conjugate TAK-164 || TAK 164 || TAK-164 || TAK-164 || TAK164	An antibody-drug conjugate (ADC) comprised of a full-length, fully-human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the extracellular domain of guanylyl cyclase C (GCC; GUCY2C), conjugated using the peptide-linked indolino-benzodiazepine DNA alkylator DGN549 (IGN-P1), with potential antineoplastic activity. Upon intravenous administration of TAK-164, the antibody moiety selectively binds to GCC-expressing cells. Upon antibody/antigen binding and internalization, the cytotoxic DGN549 payload is released and binds to guanine residues on opposing strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of GCC-expressing cells. GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, is overexpressed on the surface of certain tumor cells.	Pharmacologic Substance
C80042	Anti-GD2 Monoclonal Antibody hu14.18K322A	Anti-GD2 Monoclonal Antibody hu14.18K322A || Anti-GD2 Monoclonal Antibody hu14.18K322A || hu14.18K322A	A monoclonal antibody directed against human glycosphingolipid GD2 with potential antineoplastic activity. Upon binding to the GD2 antigen, anti-GD2 monoclonal antibody hu14.18K322A triggers a host immune response against GD2-expressing tumor cells, which may result in tumor cell death. GD2, an O-acetylated disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas.	Amino Acid, Peptide, or Protein || Immunologic Factor
C91383	Anti-GD2 Monoclonal Antibody MORAb-028	Anti-GD2 Monoclonal Antibody MORAb-028 || MORAb-028	A human IgM monoclonal antibody directed against disialoganglioside GD2 with potential immunomodulating activity. Upon administration, anti-GD2 monoclonal antibody MORAb-028 may stimulate the immune system to exert a complement-mediated cytotoxic response against GD2-expressing tumor cells. The glycosphingolipid GD2 is a tumor associated antigen (TAA) overexpressed on the surface of many cancer cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C179257	Anti-GD2/PSMA/CD276 4SCAR-expressing T-cells	Anti-GD2/Anti-PSMA/Anti-CD276 4SCAR T Cells || Anti-GD2/PSMA/CD276 4SCAR-expressing T-cells || GD2/PSMA/CD276 4SCAR-T Cells || Multi-4SCAR-T Cells	A preparation of  T-cells that are genetically engineered to express fourth generation chimeric antigen receptors (4SCARs) targeting the three tumor-associated antigens (TAAs) prostate-specific membrane antigen (PSMA), disialoganglioside (GD2), and the immune checkpoint molecule protein B7-homologue 3 (B7-H3, CD276), coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (CD3zeta; CD3z), and fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-GD2/PSMA/CD276-4SCAR-expressing T-cells are directed to and induce selective toxicity in GD2-, PSMA- and CD276-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. PSMA, a type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors, including brain tumor, neuroblastoma (NB) and some lymphoma tumor tissues. CD276, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is highly expressed on many solid tumors including NB. It is a negative regulator of the T-cell activation and plays a key role in tumor evasion. GD2 is overexpressed on the surface of NB cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.	Cell || Pharmacologic Substance
C136426	Anti-GD3 Antibody-drug Conjugate PF-06688992	Anti-GD3 ADC PF-06688992 || Anti-GD3 Antibody-drug Conjugate PF-06688992 || Anti-GD3 Antibody-drug Conjugate PF-06688992 || GD3 ADC PF-06688992 || PF 06688992 || PF-06688992 || PF-06688992	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells, and linked to an as of yet not fully elucidated chemotherapeutic agent, with potential antineoplastic activity. Upon administration of the ADC PF-06688992, the antibody moiety targets and binds to GD3 expressed on melanoma cells. Upon internalization, the chemotherapeutic agent specifically kills the GD3-positive cells. GD3 represents a major surface marker on most human melanoma cells and is not expressed on most other types of normal, healthy cells.	Pharmacologic Substance
C179558	Anti-GDF-15 Monoclonal Antibody CTL-002	Anti-GDF-15 Monoclonal Antibody CTL-002 || CTL 002 || CTL-002 || CTL002	A humanized, hinge-stabilized immunoglobulin G4 (IgG4) monoclonal antibody directed against growth/differentiation factor 15 (GDF-15; macrophage inhibitory cytokine-1; MIC-1; non-steroidal anti-inflammatory drug-inducible gene-1; NAG-1; placental transforming growth factor-beta; pTGFB; prostate-derived factor; PDF; placental bone morphogenetic protein; PLAB), with potential antineoplastic activity. Upon administration, anti-GDF-15 monoclonal antibody CTL-002 specifically targets, binds to and inhibits the activity of GDF-15, which may include its inhibition of lymphocyte function-associated antigen 1 (LFA-1) activation on CD8+ T-cells. This may restore immune cell infiltration into the tumor, leading to tumor cell killing and inhibition of tumor cell proliferation. GDF-15, a divergent member of the transforming growth factor-beta (TGF-beta) superfamily of cytokines, is upregulated in tissue injuries and also secreted by various tumors. It has been linked to immunosuppression in the tumor microenvironment (TME) and is associated with drug resistance and poor prognosis.	Pharmacologic Substance
C165256	Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV	APCs Expressing HPV16 E6/E7 SQZ-PBMC-HPV || Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV || Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV || SQZ PBMC HPV || SQZ-PBMC-HPV	A preparation of antigen presenting cells (APCs) specific for human papillomavirus (HPV) type 16 E6 and E7 proteins, with potential immunomodulating and antineoplastic activities. Autologous peripheral blood mononuclear cells (PBMCs) were ex vivo manipulated, using a technique involving membrane disruption to get the HPV16 E6 and E7 proteins into the cells; the resulting APCs present the antigens in a major histocompatibility type I (MHC-I) manner.  Upon administration of the APCs-expressing HPV16 E6/E7 SQZ-PBMC-HPV, these cells activate the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing HPV16 E6 and E7.  HPV16 E6 and E7 play an important role in the development of certain types of cancer.	Pharmacologic Substance
C120039	Antigen-targeted Personalized Breast Cancer Vaccine	Antigen-targeted Personalized Breast Cancer Vaccine || IVAC_W_bre1_uID	An individualized, therapeutic cancer vaccine (IVAC) composed of liposomes containing RNA encoding two or three tumor associated antigens (TAAs) that are specifically expressed in the patient's individual cancer selected from a warehouse ("off the shelf") and p53 RNA, with potential immunostimulatory and antineoplastic activities. Upon administration, the antigen-targeted personalized breast cancer vaccines are translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the TAAs. The RNAs in the vaccine are specifically selected for an individual patient after RNA profiling of the patient's tumor.	Pharmacologic Substance
C159411	Anti-GITR Agonistic Monoclonal Antibody ASP1951	ASP 1951 || ASP-1951 || ASP-1951 || ASP1951 || Anti-GITR Agonistic Monoclonal Antibody ASP1951 || Anti-GITR Agonistic Monoclonal Antibody ASP1951 || Anti-GITR Agonistic Monoclonal Antibody PTZ-522 || PTZ 522 || PTZ-522 || PTZ522	A human, high-affinity, tetravalent monospecific agonistic monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357), with potential immune checkpoint modulating activity. Upon administration, anti-GITR agonistic monoclonal antibody ASP1951 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-lymphocytes. This induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs), which may promote the elimination of tumor cells. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C132267	Anti-GITR Agonistic Monoclonal Antibody BMS-986156	Anti-GITR Agonistic Monoclonal Antibody BMS-986156 || Anti-GITR Agonistic Monoclonal Antibody BMS-986156 || Anti-GITR MoAb BMS-986156 || BMS 986156 || BMS-986156 || BMS-986156 || GITR Agonist BMS-986156 || TNFRSF18 Agonist BMS-986156	An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody BMS-986156 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C178331	Anti-GITR AgonisticMonoclonal Antibody REGN6569	Anti-GITR AgonisticMonoclonal Antibody REGN6569 || REGN 6569 || REGN-6569 || REGN6569	An agonistic monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357), with potential immune checkpoint modulating and antineoplastic activities. Upon administration, anti-GITR agonistic monoclonal antibody REGN6569 targets, binds to and activates GITR, which is expressed on the cell surface of multiple types of T-lymphocytes and other immune cells. This induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs), which may promote the elimination of tumor cells. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.	Pharmacologic Substance
C128028	Anti-GITR Monoclonal Antibody GWN 323	Anti-GITR Monoclonal Antibody GWN 323 || Anti-GITR Monoclonal Antibody GWN 323 || GWN 323 || GWN-323 || GWN323	An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody GWN 323 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.	Pharmacologic Substance
C116065	Anti-GITR Monoclonal Antibody MK-4166	Anti-GITR Monoclonal Antibody MK-4166 || MK-4166	An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody (MoAb) with potential immunomodulating activity. Anti-GITR monoclonal antibody MK-4166 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system and induces both the activation and proliferation of tumor-antigen-specific T effector cells, and suppresses the function of activated T regulatory cells. This leads to tumor cell eradication. Also, this agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including regulatory T-cells, effector T-cells, B-cells, and natural killer (NK) cells.	Pharmacologic Substance
C153261	Anti-Globo H Monoclonal Antibody OBI-888	Anti-Globo H Monoclonal Antibody OBI-888 || Anti-Globo H Monoclonal Antibody OBI-888 || OBI 888 || OBI-888 || OBI-888 || OBI888	A monoclonal antibody targeting the hexasaccharide glycosphingolipid antigen Globo H with potential immunostimulating, anti-angiogenic and antineoplastic activities. Upon infusion, anti-Globo H monoclonal antibody OBI-888 may induce tumor cell destruction via the activation of antibody dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), and may reduce immunosuppression. Globo H is a tumor-associated antigen (TAA) expressed on the surface of various types of cancer cells.	Pharmacologic Substance
C165657	Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999	ADC OBI 999 || Anti-Globo H/MMAE ADC OBI 999 || Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999 || Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999 || OBI 999 || OBI-888/MMAE ADC OBI-999 || OBI-999 || OBI999	An antibody-drug conjugate (ADC) composed of OBI-888 (OBI 888), a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) globohexaosylceramide (globo H), covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of anti-globo H/MMAE ADC OBI 999, the antibody moiety of OBI 999, OBI 888, targets and binds to globo H on tumor cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE targets and binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in globo H-expressing tumor cells. Globo H, a hexasaccharide glycosphingolipid, is (over)expressed on the surface of many types of tumor cells. Globo H is minimally or not expressed on healthy, normal cells; its expression on cancer cells is associated with increased proliferation and poor prognosis.	Pharmacologic Substance
C129936	Anti-Glypican 3/CD3 Bispecific Antibody ERY974	Anti-GPC3/CD3 BiAb ERY974 || Anti-GPC3/CD3 Bispecific Antibody ERY974 || Anti-Glypican 3/CD3 Bispecific Antibody ERY974 || Anti-Glypican 3/CD3 Bispecific Antibody ERY974 || ERY-974 || ERY974	An anti-glypican 3 (GPC3; GPC-3)/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-GPC3/CD3 bispecific antibody ERY974 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for GPC3, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of ERY974, this bispecific antibody simultaneously binds to both CD3-expressing and GPC3-expressing cells, thereby crosslinking GPC3-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and an oncofetal antigen protein, is overexpressed in a variety of cancers; it plays a role in cell division and growth regulation.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C132989	Anti-Glypican 3-scFvGC33-CAR-expressing T Lymphocytes	Anti-GPC3-scFvGC33-CAR Autologous T Lymphocytes || Anti-Glypican 3-scFvGC33-CAR-expressing T Lymphocytes || Anti-Glypican 3-scFvGC33-CAR-expressing T Lymphocytes || Autologous GAP T Cells || Autologous GPC3-CAR T Cells || GPC3-CAR Transduced Autologous T Cells || Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells || Glypican 3-specific Chimeric Antigen Receptor-expressing Autologous T Cells	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from the anti-glypican-3 (GPC3) monoclonal antibody GC33 (scFvGC33), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3-scFvGC33-CAR autologous T-lymphocytes specifically target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells.. GPC3 plays an important role in cellular proliferation and differentiation.	Pharmacologic Substance
C85464	Anti-GnRH Vaccine PEP223	Anti-GnRH Vaccine PEP223 || PEP223	A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C118442	Anti-gpA33/CD3 Monoclonal Antibody MGD007	Anti-gpA33/CD3 Monoclonal Antibody MGD007 || Anti-gpA33/CD3 Monoclonal Antibody MGD007 || Humanized gpA33 x CD3 DART (TM) Protein MGD007 || MGD-007 || MGD007	An anti-glycoprotein A33 (gpA33)/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-gpA33/CD3 monoclonal antibody MGD007 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for gpA33, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of MGD007, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and gpA33-expressing cancer cells, thereby crosslinking cytotoxic T-lymphocytes (CTLs) to gpA33-expressing tumor cells. This may result in CTL-mediated cell lysis of the crosslinked tumor cells. The gpA33 antigen, a member of the immunoglobulin superfamily, is expressed in certain malignancies, including colon and gastrointestinal cancers.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C187109	Anti-GPC3/Anti-CD3 Bispecific Antibody CM350	Anti-GPC3/Anti-CD3 Bispecific Antibody CM350 || Anti-GPC3/CD3 Bispecific Antibody CM350 || CM 350 || CM-350 || CM350 || GPC3 x CD3 Bispecific Antibody CM350	A bispecific antibody directed against the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3/anti-CD3 bispecific antibody CM350 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and GPC3 on GPC3-expressing tumor cells. This activates and redirects CTLs to GPC3-expressing tumor cells, leading to CTL-mediated killing of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells. GPC3 plays an important role in tumor cell proliferation in various tumor cell types.	Pharmacologic Substance
C121638	Anti-GPC3-CAR Autologous T Lymphocytes	Anti-GPC3 CAR Autologous T Cells || Anti-GPC3-CAR Autologous T Lymphocytes || Anti-GPC3-CAR Autologous T Lymphocytes || CAR-GPC3 T Cells || GPC3-targeted CAR Autologous T Cells || Glypican-3-specific CAR T Cells	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3-CAR autologous T-lymphocytes specifically target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation.	Cell || Pharmacologic Substance
C173713	Anti-GPC3-CAR T-lymphocytes TAK-102	Anti-GPC3 CAR T Cells TAK-102 || Anti-GPC3-CAR T-lymphocytes TAK-102 || CAR T Cells TAK-102 || Glypican-3-specific CAR T Cells TAK-102 || TAK 102 || TAK-102 || TAK102	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3-CAR T-lymphocytes TAK-102 specifically targets and binds to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed on normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation.	Cell || Pharmacologic Substance
C172987	Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a	ADC DS-6157a || Anti-GPR20 ADC DS-6157a || Anti-GPR20/DXd ADC DS-6157a || Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a || Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a || DS 6157a || DS-6157a || DS6157a	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the G protein-coupled receptor 20 (GPR20) conjugated to the cytotoxic DNA topoisomerase I inhibitor and exatecan derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the anti-GPR20/DXd ADC DS-6157a, the anti-GPR20 antibody targets and binds to GPR20-expressing tumor cells. Upon cellular uptake, the DXd moiety targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits the proliferation of GPR20-expressing tumor cells. GPR20 is overexpressed on certain tumor cell types.	Pharmacologic Substance
C103857	Anti-GRP78 Monoclonal Antibody PAT-SM6	Anti-GRP78 Monoclonal Antibody PAT-SM6 || PAT-SM6	A IgM monoclonal antibody (MoAb) against 78-kDa glucose-regulated protein (GRP78; also called BiP or HSPA5), with potential proapoptotic and antineoplastic activities. Upon intravenous administration of the anti-GRP78 monoclonal antibody PAT-SM6, the MoAb strongly binds to GRP78, thereby preventing the activation of multiple GRP78-mediated pathways and blocking the GRP78-induced suppression of apoptotic pathways. This eventually leads to the induction of tumor cell apoptosis and a reduction in tumor cell proliferation. GRP78, the endoplasmic reticulum (ER) chaperone and unfolded protein response (UPR) regulator, is overexpressed on the surface of a variety of cancer cell types; its expression is associated with increased tumor cell survival and proliferation, as well as angiogenesis and resistance to chemotherapy.	Amino Acid, Peptide, or Protein || Immunologic Factor
C179261	Anti-GUCY2C CAR-T Cells	Anti-GUCY2C CAR-T Cells || Anti-guanylate Cyclase 2C CAR T Cells || GUCY2C-targeting CAR T-cells	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting human guanylate cyclase 2C (GUCY2C; GCC; guanylyl cyclase C; heat-stable enterotoxin receptor; hSTAR), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GUCY2C CAR-T cells target and bind to GUCY2C-expressing tumor cells, thereby inducing selective toxicity in GUCY2C-expressing tumor cells. GUCY2C, a transmembrane receptor expressed on intestinal epithelial cells, is overexpressed on certain tumors of the gastrointestinal (GI) tract.	Pharmacologic Substance
C131295	Anti-HA Epitope Monoclonal Antibody MEDI8852	Anti-HA Epitope Monoclonal Antibody MEDI8852 || Anti-HA Epitope Monoclonal Antibody MEDI8852 || Anti-Influenza A Hemagglutinin Epitope mAb MEDI8852 || MEDI 8852 || MEDI-8852 || MEDI-8852 || MEDI8852 || pan-Influenza A mAb MEDI8852	A human immunoglobulin (Ig) G1 kappa monoclonal antibody (mAb) targeting a unique epitope in the stalk of the influenza A hemagglutinin (HA) protein, with broad influenza A virus neutralization activity. MEDI8852 was derived from an antibody isolated from human memory B-cells from patients previously infected with influenza caused by type A strains that was further optimized to increase neutralization potential. Upon infusion, MEDI8852 targets and binds to a region within the stalk of the HA protein that is highly conserved amongst all influenza A virus subtypes. This neutralizes and prevents essential steps of the viral lifecycle, thereby blocking infectivity of all influenza A virus subtypes. HA, a glycoprotein found on the surface of the influenza virus, plays a key role in viral attachment and cell entry.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C95721	Anti-HB-EGF Monoclonal Antibody KHK2866	Anti-HB-EGF MoAb KHK2866 || Anti-HB-EGF Monoclonal Antibody KHK2866 || Anti-HB-EGF Monoclonal Antibody KHK2866 || KHK-2866 || KHK2866	A proprietary fucose-free monoclonal antibody directed against human heparin-binding EGF-like growth factor (HBEGF) with potential antineoplastic activity. Anti-HB-EGF Monoclonal Antibody KHK2866 binds to HBEGF, thereby blocking its binding to the EGF receptors. This prevents EGF receptor activation and the subsequent induction of cell growth signaling. HBEGF is mitogenic for fibroblasts and smooth muscle and may be involved in macrophage-mediated cellular proliferation. The fucose-free monoclonal antibodies enhance antigen dependent cellular cytotoxicity (ADCC), and increase binding affinity to the Fc Receptor to overcome genetic polymorphism.	Immunologic Factor || Pharmacologic Substance
C95736	Anti-HBEGF Monoclonal Antibody U3-1565	Anti-HBEGF Monoclonal Antibody U3-1565 || Anti-HBEGF Monoclonal Antibody U3-1565 || U3-1565	A humanized monoclonal antibody directed against human heparin-binding EGF-like growth factor (HBEGF) with potential antineoplastic activity. Anti-HBEGF monoclonal antibody U3-1565 binds to HBEGF and blocks the binding of HBEGF to the EGF receptors. This prevents EGF receptor activation and the subsequent induction of cell growth signaling. HBEGF is mitogenic for fibroblasts and smooth muscle and may be involved in macrophage-mediated cellular proliferation.	Immunologic Factor || Pharmacologic Substance
C129593	Anti-hCD70-CAR Retroviral Vector-transduced Autologous PBLs	Anti-hCD70 Autologous CAR-transduced T Cells || Anti-hCD70 CAR autologous PBLs || Anti-hCD70-CAR Retroviral Vector-transduced Autologous PBLs || Anti-hCD70-CAR Retroviral Vector-transduced Autologous PBLs || Anti-hCD70-CAR Retroviral Vector-transduced Autologous Peripheral Blood Lymphocytes	A preparation of autologous human peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding for a T-cell chimeric antigen receptor (CAR) gene specific for the human cluster of differentiation 70 (CD70), with potential immunostimulatory and antineoplastic activities. Autologous PBLs from a patient with CD70-positive cancer are transduced with a retroviral vector that encodes the CAR gene specific for CD70. After expansion in culture and reintroduction into the patient, anti-hCD70-CAR retroviral vector-transduced autologous PBLs bind to the CD70 antigen on tumor cell surfaces; subsequently, CD70-expressing tumor cells are lysed. CD70, the ligand for the costimulatory receptor CD27, is overexpressed on the surfaces of various cancer cell types.	Pharmacologic Substance
C116630	Anti-hepcidin Monoclonal Antibody LY2787106	Anti-hepcidin Monoclonal Antibody LY2787106 || Anti-hepcidin Monoclonal Antibody LY2787106 || LY-2787106 || LY2787106	A humanized monoclonal antibody (MoAb) targeting the peptide hormone hepcidin, with potential anti-anemic activity. Upon intravenous administration, anti-hepcidin MoAb LY2787106 binds to hepcidin and prevents it from binding to the iron exporting protein ferroportin, which is expressed on both the basolateral surface of gastrointestinal (GI) enterocytes and the plasma membrane of macrophages. This prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export, thus increasing iron export from macrophages and iron absorption by enterocytes. This normalizes plasma iron levels, increases erythropoiesis and may inhibit anemia. Hepcidin, produced in hepatocytes, plays a key role in the homeostasis of systemic iron; it is upregulated during acute and chronic inflammation in response to cytokines and, in certain cancers, may contribute to cancer-associated anemia.	Pharmacologic Substance
C173076	Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702	ACE 1702 || ACE-1702 || ACE1702 || Anti-HER2 Antibody Conjugated NK Cells ACE1702 || Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702 || Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702 || Anti-HER2 Antibody Natural Killer Cell Conjugate ACE1702 || Anti-HER2 Conjugated NK Cells ACE1702 || Anti-HER2 NK Cells ACE1702 || Anti-HER2 oNK Cells	An off-the-shelf preparation of natural killer (NK) cells conjugated to a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential antineoplastic activity. Upon administration of anti-HER2 antibody conjugated natural killer cells ACE1702, the antibody moiety targets and binds to HER2 on tumor cells, which may lead to cell lysis of HER2-expressing tumor cells by the NK cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Pharmacologic Substance
C155712	Anti-HER2 Antibody-drug Conjugate	Anti-ErbB2 ADC || Anti-HER-2 ADC || Anti-HER2 ADC || Anti-HER2 Antibody-drug Conjugate	Any antibody-drug conjugate (ADC) that is directed against the human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).	Pharmacologic Substance
C156480	Anti-HER2 Antibody-drug Conjugate A166	A 166 || A-166 || A166 || ADC A166 || Anti-HER2 ADC A166 || Anti-HER2 Antibody-drug Conjugate A166 || Anti-HER2 Antibody-drug Conjugate A166	An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC A166, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Pharmacologic Substance
C123917	Anti-HER2 Antibody-drug Conjugate ARX788	ADC ARX788 || ARX-788 || ARX788 || Anti-HER2 ADC ARX788 || Anti-HER2 Antibody-drug Conjugate ARX788 || Anti-HER2 Antibody-drug Conjugate ARX788	An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated, via the non-natural amino acid linker para-acetyl-phenylalanine (pAcF), to the auristatin analog and potent microtubule inhibitor monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of anti-HER2 ADC ARX788, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of ARX788, increases payload stability and optimizes its efficacy.	Pharmacologic Substance
C173966	Anti-HER2 Antibody-drug Conjugate BAT8001	ADC BAT8001 || Anti-HER2 ADC BAT8001 || Anti-HER2 Antibody-drug Conjugate BAT8001 || BAT 8001 || BAT-8001 || BAT8001	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated via an uncleavable linker to an as of yet undisclosed maytansine derivative, with potential antineoplastic activity. Upon administration of the anti-HER2 ADC BAT8001, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the cytotoxic maytansine derivative binds to tubulin, thereby affecting microtubule assembly and disassembly dynamics. This inhibits tumor cell proliferation and induces apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C173962	Anti-HER2 Antibody-drug Conjugate DP303c	ADC DP303c || Anti-HER2 Antibody-drug Conjugate DP303c || Antibody-drug Conjugate DP303c || DP 303c || DP-303c || DP303c	An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC DP303c, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C126355	Anti-HER2 Antibody-drug Conjugate MEDI4276	ADC MEDI4276 || Anti-HER2 Antibody-drug Conjugate MEDI4276 || Anti-HER2 Antibody-drug Conjugate MEDI4276 || MEDI-4276 || MEDI-4276 || MEDI4276	An antibody-drug conjugate (ADC) composed of a bispecific antibody against the extracellular domain of human epidermal growth factor receptor 2 (HER2; ERBB2) comprised of the single-chain variable fragment (scFv) of the anti- HER2 monoclonal antibody trastuzumab, which binds to domain IV of HER2, fused to the heavy chains of the anti-HER2 monoclonal antibody 39S, which binds to domain II of HER2, and conjugated, via a cleavable linker, to the cytotoxic anti-microtubule agent tubulysin, with potential antineoplastic activity. Upon administration of ADC MEDI4276, the anti-HER2 bispecific antibody specifically targets and binds to HER2 on the surface of certain cancer cells. Upon binding, crosslinking and internalization of antibody-HER2 complexes occurs and MEDI4276 is transported to the lysosome where the linker is cleaved, thereby delivering tubulysin inside HER2-expressing cancer cells. Tubulysin binds to tubulin and inhibits microtubule polymerization, which blocks cell division. This results in G2/M phase arrest, tumor cell apoptosis, and decreased proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Pharmacologic Substance
C178312	Anti-HER2 Antibody-drug Conjugate SHR-A1811	ADC SHR-A1811 || Anti-HER2 ADC BAT8001 || Anti-HER2 ADC SHR-A1811 || Anti-HER2 Antibody-drug Conjugate SHR-A1811 || SHR A1811 || SHR-A1811 || SHRA1811	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to an as of yet undisclosed payload, with potential antineoplastic activity. Upon administration of the anti-HER2 ADC SHR-A1811, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the payload exerts cytotoxic activity, which inhibits tumor cell proliferation and induces apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C187291	Anti-HER2 Bispecific Antibody KM257	Anti-HER-2 Bispecific Antibody KM257 || Anti-HER2 Bispecific Antibody KM257 || KM 257 || KM-257 || KM257	A bispecific antibody directed against two distinct domains of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, anti-HER2 bispecific antibody KM257 simultaneously targets and binds to two different domains of HER2. This prevents the activation of HER2 signaling pathways. In addition, by binding to HER2, KM257 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that express HER2. This results in tumor cell apoptosis and inhibits the proliferation of HER2-expressing tumor cells. HER2, overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation, differentiation and survival.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C188118	Anti-HER2 Bispecific Antibody TQB2930	Anti-HER2 Bispecific Antibody TQB2930 || TQB 2930 || TQB-2930 || TQB2930	A bispecific antibody directed against two distinct domains of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, anti-HER2 bispecific antibody TQB2930 simultaneously targets and binds to two different domains of HER2. This prevents the activation of HER2 signaling pathways, resulting in tumor cell apoptosis and growth inhibition of HER2-expressing tumor cells. HER2, overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation, differentiation and survival.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C162115	Anti-HER2 Bispecific Antibody-drug Conjugate ZW49	ADC ZW49 || Anti-HER2 Bispecific ADC ZW49 || Anti-HER2 Bispecific Antibody-drug Conjugate ZW49 || Anti-HER2 Bispecific Antibody-drug Conjugate ZW49 || ZW-49 || ZW49	An antibody-drug conjugate (ADC) consisting of a bispecific monoclonal antibody (ZW25) directed against two different epitopes of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2, receptor tyrosine-protein kinase erbB-2) linked to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon intravenous administration, anti-HER2 bispecific ADC ZW49 targets and binds to HER2 expressed on tumor cells. Following receptor internalization, the cytotoxic payload is released and induces tumor cell death through an as of yet unknown mechanism of action. Additionally, binding of HER2 may inhibit HER2 activation, HER2 signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Pharmacologic Substance
C160349	Anti-HER2 Immune Stimulator-antibody Conjugate NJH395	Anti-HER2 ISAC NJH395 || Anti-HER2 Immune Stimulator-antibody Conjugate NJH395 || Anti-HER2 Immune Stimulator-antibody Conjugate NJH395 || NJH 395 || NJH-395 || NJH-395 || NJH395	An immune stimulator-antibody conjugate (ISAC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a not yet disclosed immune stimulator, with potential antineoplastic and immunostimulating activities. Upon administration of the anti-HER2 immune stimulator-antibody conjugate NJH395, the antibody moiety targets and binds to HER2 expressed on tumor cells. Upon antibody/antigen binding, the immune-stimulating moiety may, through an as of yet undisclosed mechanism, enhance the immune-mediated killing of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed in many cancer types and plays a key role in tumor cell proliferation and tumor vascularization.	Pharmacologic Substance
C178336	Anti-HER2 Molecule AIP-303	AIP 303 || AIP-303 || AIP303 || Anti-HER2 Molecule AIP-303	A molecule targeting the tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2, EGFR2, ERBB2), with potential antineoplastic activity. Upon administration, the anti-HER2 molecule AIP-303 targets and binds to HER2-expressing cells. This may inhibit HER2-mediated signaling and inhibit growth in HER2-overexpressing tumor cells. HER2, a tyrosine kinase, is overexpressed on the cell surfaces of various tumor cell types.	Pharmacologic Substance
C155711	Anti-HER2 Monoclonal Antibody	Anti-ErbB2 Monoclonal Antibody || Anti-HER-2 Monoclonal Antibody || Anti-HER2 Monoclonal Antibody || Anti-HER2 Monoclonal Antibody	Any monoclonal antibody that is directed against human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C174121	Anti-HER2 Monoclonal Antibody B002	Anti-HER2 Monoclonal Antibody B002 || B 002 || B-002 || B002	A humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody B002 targets and binds to HER2 on HER2-expressing tumor cells. This prevents HER2-mediated signaling and may lead to antitumor activity. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Pharmacologic Substance
C177912	Anti-HER2 Monoclonal Antibody BAY2701438	Anti-HER2 Monoclonal Antibody BAY2701438 || Anti-HER2 Monoclonal Antibody BAY2701438 || BAY 2701438 || BAY-2701438 || BAY2701438	A monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential antineoplastic activity. Upon administration, the anti-HER2 monoclonal antibody BAY2701438 targets and specifically binds to HER2 on tumor cells, thereby blocking HER2-mediated signaling. This may inhibit proliferation of HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.	Pharmacologic Substance
C90579	Anti-HER2 Monoclonal Antibody CT-P6	Anti-HER2 Monoclonal Antibody CT-P6 || CT-P06 || CT-P6	A monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activity. After binding to HER2 on the tumor cell surface, anti-HER2 monoclonal antibody CT-P6 may induce a cytotoxic T-lymphocyte (CTL) as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C172198	Anti-HER2 Monoclonal Antibody HLX22	Anti-HER2 Monoclonal Antibody HLX22 || HLX 22 || HLX-22 || HLX22	A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), with potential immunomodulating and antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody HLX22 targets and binds to HER2 on tumor cell surface. This may induce a cytotoxic T-lymphocyte (CTL) response as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C179287	Anti-HER2 Monoclonal Antibody QL1209	Anti-HER2 Monoclonal Antibody QL1209 || QL 1209 || QL-1209 || QL1209	A humanized monoclonal antibody directed against the domain II of the extracellular domain of human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody QL1209 targets and binds to HER2 on HER2-expressing tumor cells. This prevents HER2-mediated signaling and may lead to an inhibition of proliferation in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Pharmacologic Substance
C178328	Anti-HER2/Anti-CD3 Bispecific Antibody M802	Anti-HER2/Anti-CD3 Bispecific Antibody M802 || HER2 x CD3 Bispecific Antibody M802 || M 802 || M-802 || M802	A humanized bispecific antibody composed of a monovalent unit directed against the tumor-associated antigen (TAA) human epidermal growth factor 2 (HER2; ErbB2; HER-2) and a single chain unit directed against CD3 found on T-lymphocytes, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-HER2/anti-CD3 bispecific antibody M802 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and HER2 on HER2-expressing tumor cells. This activates and redirects CTLs to HER2-expressing tumor cells, which results in the CTL-mediated cell death of HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.	Pharmacologic Substance
C142889	Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302	Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1302 || Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302 || Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302 || GBR 1302 || GBR-1302	An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 bispecific monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-HER2/Anti-CD3 bispecific monoclonal antibody GBR 1302 possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of GBR 1302, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.	Amino Acid, Peptide, or Protein
C185600	Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705	Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705 || Anti-HER2/PD-1 Bispecific Antibody SSGJ-705 || HER2 x PD-1 Bispecific Antibody SSGJ-705 || SSGJ 705 || SSGJ-705 || SSGJ705	A bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-HER2/anti-PD-1 bispecific antibody SSGJ-705 simultaneously targets, binds to and inhibits HER2 and PD-1 and their downstream signaling pathways, and bridges PD-1-expressing T-cells to HER2-expressing tumor cells. This may inhibit tumor cell proliferation of HER2-overexpressing cells. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses against the HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C132112	Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522	ADC XMT-1522 || Anti-HER2 ADC XMT-1522 || Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522 || Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522 || XMT-1522	An antibody-drug conjugate (ADC) composed of HT-19, a monoclonal antibody directed against the human epidermal growth factor receptor 2 (ERBB2; HER2), conjugated, via a proprietary biodegradable, hydrophilic polymer backbone and various linkers, to proprietary auristatin-derived payload molecules (about 15 per antibody), with potential antineoplastic activity. Upon administration of anti-HER2/auristatin payload ADC XMT-1522, the antibody moiety targets and binds to a unique epitope in the extracellular domain (ECD) of HER2. Upon internalization, cleavage and release of the cytotoxic molecules, the auristatin-derived molecules bind to tubulin and inhibit its polymerization, which results in G2/M phase arrest and induces apoptosis of HER2-expressing tumor cells. The attachment of multiple auristatin molecules to the backbone enables XMT-1522 to effectively kill tumors that express relatively low amounts of the HER2 protein; therefore, this agent shows increased therapeutic potential in tumors with low HER2 expression compared to other anti-HER2 antibody-based therapies. The polymer-based proprietary platform optimizes delivery of the cytotoxic drug payload and improves drug solubility.	Pharmacologic Substance
C181934	Anti-HER2/CD3/CD28 Tri-specific Antibody SAR443216	Anti-CD3xCD28xHER2 Trispecific Antibody SAR443216 || Anti-HER2/CD3/CD28 Tri-specific Antibody SAR443216 || Anti-HER2/CD3/CD28 Tri-specific Antibody SAR443216 || CD3xCD28xHER2 Trispecific T-cell Engager SAR443216 || SAR 443216 || SAR-443216 || SAR443216 || Tri-specific T-cell Engager SAR443216	A tri-specific T-cell engager and monoclonal antibody targeting the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), CD3, a T-cell surface antigen, and CD28, a T-cell specific surface glycoprotein and co-stimulatory molecule, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-HER2/CD3/CD28 tri-specific antibody SAR443216 targets and binds to CD3 and CD28 on T-cells and HER2 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C187696	Anti-HER2/CD3/XTEN Protease-activated T-cell Engager AMX-818	AMX 818 || AMX-818 || AMX818 || Anti-HER2/CD3/XTEN Protease-activated T-cell Engager AMX-818 || HER2-XPAT AMX-818 || Masked HER2 TCE AMX-818 || Prodrug HER2-XPAT T-cell Engager AMX-818 || Prodrug TCE AMX-818 || TCE AMX-818 || XTENylated Protease-activated T Cell Engager AMX-818 || Xtenylated Protease-activated TCE AMX-818	A protease-activated prodrug T-cell engager (TCE) composed of two tandem single chain variable fragments (scFvs) targeting the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and CD3, a T-cell surface antigen, and conjugated, via a protease-cleavable linker, to two unstructured polypeptides (XTEN), with potential immunomodulating and antineoplastic activities. Double XTEN masking allows for universal masks that sterically hinder target binding of AMX-818 until cleaved by proteases; it also prolongs half-life. Upon intravenous administration of anti-HER2/CD3/XTEN protease-activated TCE AMX-818, the XTEN masks are proteolytically cleaved in the tumor microenvironment (TME) by dysregulated proteases at the base of the XTEN masks which releases the active TCE. The anti-HER2 scFv moiety targets and binds to HER2 expressed on tumor cells. The CD3 scFv moiety targets and binds to T-cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. The XTEN masks allows specific activation of AMX-818 in the TME and limits systemic unmasking; this minimizes systemic toxicity and increases efficacy. In healthy tissues, where protease activity is tightly regulated, the HER2-XTENylated protease-activated T cell engager (XPAT) AMX-818 remains predominantly inactive.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C170932	Anti-HER2/HER3 Dendritic Cell Vaccine	Anti-HER2/3 DC Vaccine || Anti-HER2/3 Dendritic Cell Vaccine || Anti-HER2/HER3 Dendritic Cell Vaccine || Anti-HER2/HER3 Dendritic Cell Vaccine	A dendritic cell (DC)-based cancer vaccine against the tumor-associated antigens (TAAs) human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and 3 (HER3; ErbB3), with potential immunomodulatory and antineoplastic activities. Upon administration of the anti-HER2/HER3 DC vaccine, the immune system gets exposed to HER2 and HER3, which may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2/3-positive tumor cells. This may result in tumor cell death and decreased tumor growth. HER-2/3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are overexpressed by a variety of cancers.	Cell || Pharmacologic Substance
C174205	Anti-HER2/MMAE Antibody-drug Conjugate MRG002	ADC MRG002 || Anti-HER2/MMAE ADC MRG002 || Anti-HER2/MMAE Antibody-drug Conjugate MRG002 || Anti-HER2/MMAE Antibody-drug Conjugate MRG002 || MRG 002 || MRG-002 || MRG002	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-HER2/MMAE ADC MRG002 targets and binds to HER2 on the surface of tumor cells. Following internalization of MRG002, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C155940	Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A	ADC DHES0815A || Anti-HER2/PBD-MA ADC DHES0815A || Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A || Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A || Anti-HER2/PBD-Monoamide ADC DHES0815A || DHES-0815A || DHES0815A	An antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) linked to a DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA), with potential antineoplastic activity. Upon intravenous administration of ADC DHES0815A, the monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Following receptor internalization and lysosome-mediated cleavage, the cytotoxic PBD-MA moiety is released. In turn, the imine groups of the PBD-MA moiety bind to and crosslink specific sites of DNA, resulting in DNA strand breaks, cell cycle arrest, and cell death in HER2 expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Pharmacologic Substance
C91091	Anti-HER2-CAR Autologous CMV-Specific Cytotoxic T-Lymphocytes	Anti-HER2-CAR Autologous CMV-Specific Cytotoxic T-Lymphocytes || Anti-HER2-CAR Autologous CMV-Specific Cytotoxic T-Lymphocytes	Autologous human cytomegalovirus (CMV)-specific human cytotoxic T-lymphocytes (CTLs) transduced with a retroviral vector encoding a human anti-Her-2 (epidermal growth factor receptor 2) chimeric T cell receptor (CAR) gene with potential immunostimulatory and antineoplastic activities. Autologous CTLs from a patient with Her-2- and CMV-positive glioblastoma multiforme (GBM) are genetically modified to express CAR gene specific for Her-2 on their cell surfaces. After expansion in culture and reintroduction into the patient, the anti-HER2-CAR autologous CMV-specific CTLs bind to Her-2 antigen on tumor cell surfaces; subsequently, Her-2-positive tumor cells and stem cells may be lysed. Her-2 (ErbB-2), a receptor tyrosine kinase (RTK) overexpressed by a variety of cancer cell types, plays key roles in tumor cell proliferation and tumor angiogenesis. CMV is present in the majority of GBM tumors.	Cell || Pharmacologic Substance
C79834	Anti-Her-2-CAR Retroviral Vector-Transduced Autologous Peripheral Blood Lymphocytes	Anti-Her-2-CAR Retroviral Vector-Transduced Autologous Peripheral Blood Lymphocytes || Anti-Her-2-CAR-Engineered Autologous PBLs || Anti-Her-2-CAR-Engineered Autologous Peripheral Blood Lymphocytes || Anti-Her-2-Chimeric Antigen Receptor-Engineered Autologous Peripheral Blood Lymphocytes	Autologous human peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding an anti-Her-2 (epidermal growth factor receptor 2) chimeric T cell receptor (chimeric antigen receptor or CAR) gene with potential immunostimulatory and antineoplastic activities. Autologous PBLs from a patient with Her-2-positive cancer are pulsed with a retroviral vector that encodes the CAR gene specific for Her-2. After expansion in culture and reintroduction into the patient, anti-Her-2-CAR retroviral vector-transduced autologous peripheral blood lymphocytes, which express anti-Her-2-CAR on their cell surfaces, bind to Her-2 antigen on tumor cell surfaces. Subsequently, Her-2-expressing tumor cells may be lysed. Her-2 (ErbB-2), a receptor tyrosine kinase (RTK) overexpressed by a variety of cancer cell types, belongs to the EGFR superfamily and plays key roles in both tumor cell proliferation and tumor angiogenesis.	Cell || Pharmacologic Substance
C173420	Anti-HER2-DM1 ADC B003	ADC B003 || Anti-HER2-DM1 ADC B003 || Anti-HER2-DM1 Antibody-drug Conjugate B003 || B 003 || B-003 || B003 || Recombinant Humanized Anti-HER2 Monoclonal Antibody-MCC-DM1 B003	An antibody-drug conjugate (ADC) consisting of a recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC), with potential antineoplastic activity. Upon administration of B003, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics, inhibiting cell division and the proliferation of cancer cells that overexpress HER2.	Pharmacologic Substance
C173827	Anti-HER2-DM1 Antibody-drug Conjugate GQ1001	ADC GQ1001 || Anti-HER2-DM1 ADC GQ1001 || Anti-HER2-DM1 Antibody-drug Conjugate GQ1001 || Anti-HER2-DM1 Antibody-drug Conjugate GQ1001 || GQ 1001 || GQ-1001 || GQ1001	An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated, via a site-specific linker, to the cytotoxic maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon administration of anti-HER2-DM1 ADC GQ1001, the antibody moiety targets and binds to HER2 on tumor cell surfaces. Upon cellular uptake and internalization, DM1 binds to tubulin and interferes with microtubule assembly and disassembly dynamics. This inhibits cell division and the proliferation of tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Pharmacologic Substance
C141420	Anti-HER2-vc0101 ADC PF-06804103	Anti-HER2-vc0101 ADC PF-06804103 || Anti-HER2-vc0101 ADC PF-06804103 || Anti-HER2-vcAur0101 ADC PF-06804103 || Anti-NG-HER2 ADC PF-06804103 || Anti-NG-Her2-vc0101 ADC PF-06804103 || Antibody-drug Conjugate PF-06804103 || PF 06804103 || PF-06804103 || PF06804103	A proprietary antibody-drug conjugate (ADC) composed of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) site-specifically linked, via a protease cleavable linker, to an analog of dolastatin 10, Auristatin-0101, with potential antineoplastic activity. Upon administration, anti-HER2-vc0101 ADC PF-06804103 targets HER2 expressed on tumor cells. Upon binding, internalization and cleavage, Auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.	Pharmacologic Substance
C111997	Anti-HER3 Monoclonal Antibody GSK2849330	Anti-HER3 Monoclonal Antibody GSK2849330 || Anti-HER3 Monoclonal Antibody GSK2849330 || GSK2849330	A monoclonal antibody directed against the human epidermal growth factor receptor 3 (HER3; ERBB3) with potential antineoplastic activity. Anti-HER3 monoclonal antibody GSK2849330 binds to HER3 and inhibits its activation. This may prevent HER3-mediated signaling and inhibit HER3-dependent tumor cell proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors and is associated with poor prognosis and drug resistance; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.	Amino Acid, Peptide, or Protein || Immunologic Factor
C186673	Anti-HER3 Monoclonal Antibody SIBP-03	Anti-HER3 Monoclonal Antibody SIBP-03 || SIBP 03 || SIBP-03 || SIBP03	A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 3 (HER3; ERBB3), with potential antineoplastic activity. Upon administration, anti-HER3 monoclonal antibody SIBP-03 targets and binds to HER3 and inhibits its activation. This may prevent HER3-mediated signaling and inhibit HER3-dependent tumor cell proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors and is associated with poor prognosis and drug resistance; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C81939	Anti-HGF Monoclonal Antibody TAK-701	Anti-HGF MoAb TAK-701 || Anti-HGF Monoclonal Antibody TAK-701 || TAK-701	A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody TAK-701 binds to the soluble ligand HGF, preventing HGF binding to and activation of the HGF receptor c-Met and so the activation of the c-Met signaling pathway; this may result in the induction of cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in a variety of tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	Pharmacologic Substance
C176875	Anti-HGF Monoclonal Antibody YYB101	Anti-HGF Monoclonal Antibody YYB101 || Anti-hepatocyte Growth Factor Monoclonal Antibody YYB101 || YYB 101 || YYB-101 || YYB101	A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF), with potential antineoplastic activity. Upon administration, anti-HGF monoclonal antibody YYB101 targets and binds to HGF, preventing the binding of HGF to the HGF receptor c-Met and the activation of the c-Met signaling pathway. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	Pharmacologic Substance
C68930	Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968	Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968 || Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968 || EZN-2968 || RO7070179 || anti-HIF-1alpha LNA AS-ODN	A synthetic antisense oligodeoxynucleotide (AS ODN) targeting hypoxia-inducible factor-1alpha (HIF-1alpha) with potential antineoplastic activity. Anti-HIF-1alpha LNA antisense oligonucleotide EZN-2968 hybridizes with HIF-1alpha mRNA and blocks t HIF-1 alpha protein expression, which may result in the inhibition of angiogenesis, the inhibition of tumor cell proliferation, and apoptosis. HIF-1alpha, normally activated in response to hypoxia-induced stress, is a key transcription regulator of a large number of genes important in cellular adaptation to low-oxygen conditions, including angiogenesis, cell proliferation, apoptosis, and cell invasion.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C165547	Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1	Anti-HIV-1 LV-expressing sh5/C46 Cal-1 || Anti-HIV-1 LVsh5/C46 || Anti-HIV-1 Lentiviral Vector sh5/C46 || Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1 || Cal-1 || Cal-1 Vector || LVsh5/C46 || LVsh5/C46 Vector	A gene transfer construct composed of a self-inactivating (SIN) lentiviral vector (LV) expressing a short hairpin RNA (shRNA) that targets the human C-C chemokine receptor type 5 (CCR5) mRNA (sh5) and expressing the HIV entry inhibitor C46, with potential anti-human immunodeficiency virus (HIV) type 1 (HIV-1) activity. Upon transduction of the anti-HIV-1 LVsh5/C46 Cal-1 in specified blood cell populations, such as peripheral blood mononuclear cells (PBMCs), hematopoietic stem/progenitor cells (HSPCs) and CD4+ T-lymphocytes, the cells express shCCR5 and C46. shCCR5 targets and binds to CCR5 mRNA, which inhibits the expression of CCR5 and prevents binding of the virus to the cellular CCR5 co-receptor. The cell surface expression of the cell membrane-anchored C46  peptide blocks HIV-1 fusion to the cellular membrane. The removal of CCR5 from and the production of C46 in the bone marrow and white blood cells, make the transduced cells resistant to and protect them from HIV-1 entry, infection and replication. HIV-resistant HSPCs could provide long-term protection against latent HIV infection and against HIV-associated cancers. C46 is a membrane-anchored 46-amino acid sequence found in HIV-1 gp41. CCR5 is a HIV-1 co-receptor that mediates HIV attachment and cell entry.	Pharmacologic Substance
C122679	Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes	Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes || Anti-HLA-A2/NY-ESO1 TCR-transduced Autologous T cells || Autologous Anti-HLA-A2/NY-ESO1 TCR-transduced T Lymphocytes || Autologous HLA-A2/NY-ESO-1-specific TCR Gene-transduced T-lymphocytes	Autologous human peripheral blood T-lymphocytes transduced with a lentiviral or retroviral vector encoding a human leukocyte antigen A2 (HLA-A2) restricted anti-cancer-testis antigen 1 (NY-ESO-1) T-cell receptor (TCR) gene, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the anti-HLA-A2/NY-ESO-1 TCR-transduced autologous T lymphocytes recognize and bind to NY-ESO-1/HLA-A2-positive tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.	Cell || Pharmacologic Substance
C103860	Anti-HLA-DR Monoclonal Antibody IMMU-114	Anti-HLA-DR MoAb L243 || Anti-HLA-DR Monoclonal Antibody IMMU-114 || Anti-HLA-DR Monoclonal Antibody IMMU-114 || IMMU-114 || hL243gamma4P	A humanized IgG4 monoclonal antibody that targets the human leukocyte antigen HLA-DR, with potential antineoplastic activity. Upon administration, anti-HLA-DR monoclonal antibody IMMU-114 binds to HLA-DR on HLA-DR-expressing tumor cells and, although the exact mechanism has yet to be fully elucidated, appears to induce hyperactivation of ERK- and JNK-dependent mitogen activated protein kinase signaling pathways. This may lead to mitochondrial membrane depolarization and reactive oxygen species (ROS) generation. This eventually leads to an induction of tumor cell apoptosis and a reduction in tumor cell proliferation. IMMU-14 may be beneficial in the treatment of graft versus host disease (GVHD) as it appears to suppress T-lymphocyte proliferation and natural killer (NK) cell activation. As the Fc region of the orgnial IgG1 MoAb was replaced with the IgG4 isotype, IMMU-114 does not induce a complement cytotoxicity (CDC) or an antibody-dependent cell-mediated cytotoxicity (ADCC). HLA-DR, a MHC class II molecule, is found on various b-cell hematologic malignancies and in autoimmune diseases as well as on normal cells.	Pharmacologic Substance
C175374	Anti-HLA-G Antibody TTX-080	Anti-HLA-G Antibody TTX-080 || Anti-HLA-G Antibody TTX-080 || HLA-G Antagonist TTX-080 || TTX 080 || TTX-080 || TTX080	An antibody targeting HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G), with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G antibody TTX-080 targets and binds to HLA-G, thereby preventing the binding of HLA-G to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes, and dendritic cells (DCs). This may prevent the HLA-G-mediated immune suppression, thereby activating both innate and adaptive immune responses. This may activate anti-tumor immune responses. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion.	Pharmacologic Substance
C182073	Anti-HLA-G/CD3 Bispecific Antibody JNJ-78306358	Anti-HLA-G/CD3 Bispecific Antibody JNJ-78306358 || JNJ 78306358 || JNJ-78306358 || JNJ78306358 || T Cell Redirecting Bispecific Antibody JNJ-78306358	A bispecific antibody targeting the tumor-associated antigen (TAA) HLA-G histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G) and the CD3 antigen found on T-lymphocytes, with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G/CD3 bispecific antibody JNJ-78306358 targets and binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and HLA-G found on HLA-G-expressing tumor cells. This activates and redirects CTLs to HLA-G-expressing tumor cells, which results in the CTL-mediated cell death of HLA-G-expressing tumor cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion. It inhibits immune responses by binding to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T- and B-lymphocytes, and dendritic cells (DCs).	Pharmacologic Substance
C185397	Anti-HPV16 TCR-engineered T-cells CRTE7A2-01	Anti-HPV16 TCR T Cells CRTE7A2-01 || Anti-HPV16 TCR-T Cells CRTE7A2-01 || Anti-HPV16 TCR-engineered T-cells CRTE7A2-01 || CRTE7A2 01 || CRTE7A2-01 || CRTE7A201	A preparation of T-lymphocytes that has been genetically modified to express a T-cell receptor (TCR) specific for an as of yet not identified viral oncoprotein(s) of human papillomavirus type 16 (HPV16), with potential antineoplastic activity. Upon intravenous administration, the anti-HPV16 TCR-engineered T-cells CRTE7A2-01 specifically recognize and bind to the HPV16 oncoprotein(s) expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the HPV16 oncoprotein(s).	Pharmacologic Substance
C129694	Anti-human GITR Monoclonal Antibody AMG 228	AMG 228 || AMG-228 || AMG228 || Agonistic GITR Antibody AMG 228 || Anti-human GITR Monoclonal Antibody AMG 228 || Anti-human GITR Monoclonal Antibody AMG 228	An agonistic anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor receptor superfamily, member 18; TNFRSF18; GITR; CD357) humanized monoclonal antibody, with potential immune checkpoint modulating activity. Anti-human GITR monoclonal antibody AMG 228 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teffs), and suppresses the function of activated T regulatory cells (Tregs). This leads to immune-mediated tumor cell eradication though a cytotoxic T-lymphocyte (CTL) response. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.	Pharmacologic Substance
C95023	Anti-human GITR Monoclonal Antibody TRX518	Anti-huGITR MoAb TRX518 || Anti-human GITR Monoclonal Antibody TRX518 || Anti-human GITR Monoclonal Antibody TRX518 || TRX518	A humanized, Fc disabled anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody (MoAb) with immunomodulating activity. Anti-human GITR MoAb TRX518 blocks the interaction of GITR, found on multiple types of T cells, with its ligand, thereby inducing both the activation of tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. This agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models.	Immunologic Factor || Pharmacologic Substance
C146762	Anti-ICOS Agonist Monoclonal Antibody BMS-986226	Anti-ICOS Agonist Monoclonal Antibody BMS-986226 || Anti-ICOS Agonist Monoclonal Antibody BMS-986226 || Anti-ICOS BMS-986226 || Anti-inducible T-cell Co-stimulator BMS-986226 || BMS 986226 || BMS-986226 || BMS986226	An agonistic monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ICOS agonist monoclonal antibody BMS-986226 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.	Amino Acid, Peptide, or Protein
C123267	Anti-ICOS Monoclonal Antibody MEDI-570	Anti-ICOS Monoclonal Antibody MEDI-570 || Anti-ICOS Monoclonal Antibody MEDI-570 || MEDI-570 || MEDI-570	An Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-ICOS MoAb MEDI-570 targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Fc optimization enhances antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C79798	Anti-IGF-1R Monoclonal Antibody AVE1642	AVE-1642 || AVE-1642 || AVE1642 || Anti-IGF-1R Monoclonal Antibody AVE1642 || anti-CD122 monoclonal antibody AVE1642	A humanized monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R/CD221) with potential antineoplastic activity. Anti-IGF-1R monoclonal antibody AVE1642 specifically binds to and blocks membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signal transduction, which may result in the induction of apoptosis and a decrease in cellular proliferation. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C71530	Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022	Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022 || Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022 || BIIB-022 || BIIB022	A recombinant, human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R recombinant monoclonal antibody BIIB022 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C124227	Anti-IL-8 Monoclonal Antibody BMS-986253	Anti-IL-8 Monoclonal Antibody BMS-986253 || Anti-IL-8 Monoclonal Antibody BMS-986253 || BMS 986253 || BMS-986253 || BMS986253 || HUMAX-IL8 || HuMax-IL-8 || HuMax-IL8 || MDX 018 || MDX-018	A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, BMS-986253 directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, BMS-986253 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.	Immunologic Factor || Pharmacologic Substance || Amino Acid, Peptide, or Protein
C188044	Anti-ILT2 Monoclonal Antibody AGEN1571	AGEN 1571 || AGEN-1571 || AGEN1571 || Anti-ILT2 Monoclonal Antibody AGEN1571	A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory immune checkpoint receptor Ig-like transcript 2 (ILT2; leukocyte immunoglobulin-like receptor subfamily B member 1; LILRB1; leukocyte immunoglobulin-like receptor 1; LIR1; monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD85j), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-ILT2 monoclonal antibody AGEN1571 targets and binds to ILT2. This prevents the binding of ILT2 ligands, including the immunosuppressive MHC molecule HLA class I histocompatibility antigen, alpha chain G (HLA-G; human leukocyte antigen G), to the ILT2 receptor and prevents ILT2-mediated signaling. This inhibits ILT2-mediated immune suppression, thereby promoting both innate and adaptive immune responses and may result in the activation of anti-tumor immune responses. ILT2, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed on both innate and adaptive immune cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion.	Pharmacologic Substance
C179566	Anti-ILT2 Monoclonal Antibody BND-22	Anti-ILT2 Monoclonal Antibody BND-22 || Anti-ILT2 Monoclonal Antibody BND-22 || BND 22 || BND-22 || BND22	A humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory immune checkpoint receptor Ig-like transcript 2 (ILT2; leukocyte immunoglobulin-like receptor subfamily B member 1; LILRB1; leukocyte immunoglobulin-like receptor 1; LIR1; monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD85j), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT2 monoclonal antibody BND-22 targets and binds to ILT2. This prevents the binding of ILT2 ligands, including the immunosuppressive MHC molecule HLA class I histocompatibility antigen, alpha chain G (HLA-G; human leukocyte antigen G), to the ILT2 receptor and prevents ILT2-mediated signaling. This inhibits ILT2-mediated immune suppression, thereby activating both innate and adaptive immune responses. This may activate anti-tumor immune responses. ILT2, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed on both innate and adaptive immune cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor types and plays a key role in cancer immune evasion.	Pharmacologic Substance
C180904	Anti-ILT2/Anti-ILT4 Monoclonal Antibody NGM707	Anti-ILT2/Anti-ILT4 Monoclonal Antibody NGM707 || Anti-ILT2/Anti-ILT4 Monoclonal Antibody NGM707 || Anti-ILT2/ILT4 Monoclonal Antibody NGM707 || ILT2/ILT4 Dual Antagonist Monoclonal Antibody NGM707 || NGM 707 || NGM-707 || NGM707	A humanized, dual antagonist monoclonal antibody directed against the inhibitory immune checkpoint receptors immunoglobulin (Ig)-like transcript 2 (ILT2; leukocyte immunoglobulin-like receptor subfamily B member 1; LILRB1; leukocyte immunoglobulin-like receptor 1; LIR1; monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD85j) and ILT4 (LILRB2; LIR2; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT2/anti-ILT4 monoclonal antibody NGM707 targets and binds to both ILT2 and ILT4. This prevents the binding of ILT2 and ILT4 ligands, including the major histocompatibility complex class I (MHC I) molecules human leukocyte antigen (HLA)-A, HLA-B, HLA-C and HLA-G, to the ILT2 and ILT4 receptors and prevents ILT2- and ILT4-mediated signaling. This inhibits ILT2- and ILT4-mediated immune suppression and may activate both innate and adaptive immune responses, including natural killer (NK) and CD8+ T-cell tumor cell killing, and macrophage phagocytosis of tumor cells. ILT2 and ILT4, expressed on myeloid cells in the tumor microenvironment (TME), are upregulated in various cancer types and play an important role in tumor immune evasion. ILT2 is also expressed on various innate and adaptive immune cells including NK cells, B-cells and a subset of cytolytic T-cells.	Pharmacologic Substance
C160204	Anti-ILT4 Monoclonal Antibody MK-4830	Anti-ILT4 Monoclonal Antibody MK-4830 || Anti-ILT4 Monoclonal Antibody MK-4830 || Anti-LIR2 Monoclonal Antibody MK-4830 || Anti-leukocyte Immunoglobulin-like Receptor 2 Monoclonal Antibody MK-4830 || MK 4830 || MK-4830 || MK4830	A human monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; LILRB2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT4 monoclonal antibody MK-4830 targets and binds to ILT4. This prevents the binding of ILT4 ligands to their receptor and prevents ILT4-mediated signaling. This abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. ILT4, plays a key role in tumor immune evasion. ILT4, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells.	Pharmacologic Substance
C187298	Anti-Immunoglobulin-beta CAR T Cells	Anti-Immunoglobulin-beta CAR T Cells || shRNA-IL-6-modified Anti-CD19 CAR-T Cells	A preparation of T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting immunoglobulin-beta (Igb), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-Igb CAR T cells are directed to, specifically bind to, and induce selective toxicity in Igb antigen-expressing tumor cells.	Pharmacologic Substance
C176038	Anti-integrin Beta-1 Monoclonal Antibody OS2966	Anti-CD29 Monoclonal Antibody OS2966 || Anti-integrin Beta-1 Monoclonal Antibody OS2966 || Anti-integrin Beta-1 Monoclonal Antibody OS2966  || Anti-integrin Beta1 Monoclonal Antibody OS2966  || OS 2966 || OS-2966  || OS2966 	A humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. Upon administration, anti-integrin beta-1 monoclonal antibody OS2966 targets and binds to integrin beta-1 on the surface of tumor cells and macrophages in the tumor microenvironment (TME), thereby preventing integrin beta-1-mediated activation of downstream signaling pathways. This may include the blockade of the binding of integrin beta-1 to the effector kinase focal adhesion kinase (FAK), preventing FAK-mediated activation of Stat1 and Akt. This may inhibit tumor cell proliferation, invasion and migration in integrin beta-1-overexpressing tumor cells. Integrin beta-1, the dominant subunit in all four classes of integrin receptors, plays an important role in tumor cell proliferation, invasion, and drug resistance.	Pharmacologic Substance
C172391	Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A	Anti-integrin Beta-6 Antibody-drug Conjugate SGN-B6A || Anti-integrin Beta-6-MMAE ADC SGN-B6A || Anti-integrin Beta-6/MMAE ADC SGN-B6A || Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A || Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A || SGN B6A || SGN-B6A || SGNB6A	An antibody-drug conjugate (ADC) composed of a humanized antibody targeting integrin beta-6 and conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-integrin beta-6/MMAE ADC SGN-B6A targets and binds to integrin beta-6 on the surface of tumor cells. Following internalization of SGN-B6A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in integrin beta-6-expressing tumor cells. Integrin beta-6 is a subunit of integrin alpha-V beta-6 (aVb6). Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C78839	Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388	Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388 || IMGN388	An immunoconjugate consisting of an anti-integrin monoclonal antibody covalently attached to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Integrin-targeted immunoconjugate IMGN388 binds to tumor cell surface integrins; upon internalization, the DM4 moiety is released from the immunoconjugate, binding to tubulin and disrupting microtubule assembly/disassembly dynamics, which may result in inhibition of cell division and cell growth of integrin-expressing tumor cells. Integrins, a class of transmembrane cell surface receptors, link the extracellular matrix (ECM) to intracellular signaling pathways that control cell proliferation and differentiation.	Pharmacologic Substance
C186652	Anti-interleukin-1 Beta Monoclonal Antibody AK114	AK 114 || AK-114 || AK114 || Anti-IL-1 Beta Monoclonal Antibody AK114 || Anti-IL-1b Monoclonal Antibody AK114 || Anti-interleukin-1 Beta Monoclonal Antibody AK114 || Anti-interleukin-1beta Monoclonal Antibody AK114	A monoclonal antibody targeting the human proinflammatory cytokine interleukin-1 beta (IL-1b), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, anti-IL-1b monoclonal antibody AK114 targets and binds to IL-1b and prevents the binding of IL-1b to the IL-1 receptor. This inhibits IL-1b-mediated signaling pathways, and suppresses inflammatory responses, tumorigenesis and angiogenesis mediated by IL-1b. IL-1b plays a key role in inflammation, which is present in various disease states including cancers. IL-1b-mediated signaling pathways include MAPK, cyclooxygenase and nuclear factor kappa B (NF-kB) pathways, which may lead to macrophage activation, intra-tumoral accumulation of immunosuppressive myeloid cells, and tumor growth, invasiveness, metastasis, and angiogenesis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C179661	Anti-interleukin-1 Beta Monoclonal Antibody FL-101	Anti-IL-1 Beta Monoclonal Antibody FL-101 || Anti-IL-1b Monoclonal Antibody FL-101 || Anti-interleukin-1 Beta Monoclonal Antibody FL-101 || Anti-interleukin-1beta Monoclonal Antibody FL-101 || FL 101 || FL-101 || FL101	A monoclonal antibody targeting the human proinflammatory cytokine interleukin-1 beta (IL-1b), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, anti-IL-1b monoclonal antibody FL-101 targets and binds to IL-1b and prevents the binding of IL-1b to the IL-1 receptor. This inhibits IL-1b-mediated signaling pathways, and suppresses inflammatory responses, tumorigenesis and angiogenesis mediated by IL-1b. IL-1b plays a key role in inflammation, which is present in various disease states including cancers. IL-1b-mediated signaling pathways include MAPK, cyclooxygenase and nuclear factor kappa B (NF-kB) pathways, which may lead to macrophage activation, intra-tumoral accumulation of immunosuppressive myeloid cells, and tumor growth, invasiveness, metastasis, and angiogenesis.	Pharmacologic Substance
C181996	Anti-KAAG1 Antibody-Drug Conjugate ADCT-901	ADC ADCT-901 || ADCT 901 || ADCT-901 || ADCT901 || Anti-KAAG1 ADC ADCT-901 || Anti-KAAG1 Antibody-Drug Conjugate ADCT-901 || Anti-KAAG1 Antibody-Drug Conjugate ADCT-901 || Antibody-drug Conjugate ADCT-901	An antibody-drug conjugate (ADC) composed of 3A4, a humanized monoclonal antibody directed against human kidney associated antigen 1 (KAAG1; RU2) and conjugated, through a cathepsin-cleavable linker, to SG3199, a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-KAAG1 ADC ADCT-901, the 3A4 moiety targets and binds to KAAG1, which is expressed on the surfaces of a variety of cancer cell types. Upon endocytosis and enzymatic cleavage by cathepsin, free PBD is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing KAAG1-expressing cancer cells. KAAG1, overexpressed by certain tumor cell types, plays a key role in tumor cell proliferation. Its expression on healthy tissue is very restricted.	Pharmacologic Substance
C78464	Anti-KIR Monoclonal Antibody IPH 2101	1-7F9 || Anti-KIR Monoclonal Antibody IPH 2101 || Anti-KIR Monoclonal Antibody IPH 2101 || IPH 2101 || IPH-2101	A human monoclonal antibody directed against the human inhibitory killer IgG-like receptor (KIR) with potential immunostimulating and antineoplastic activities. Anti-KIR monoclonal antibody IPH 2101 binds to the KIR receptor expressed on human natural killer (NK) cells, which may prevent KIR-mediated inhibition of NK cells and permit NK cell-mediated anti-tumor cytotoxicity. KIRs are surface glycoproteins that bind to major histocompatibility complex (MHC)/human leukocyte antigen (HLA) class I subtypes on target cells; binding of KIRs inhibits NK cell-mediated cytotoxicity.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C183544	Anti-KLK2 CAR-T Cells JNJ-75229414	Anti-KLK2 CAR T Cells JNJ-75229414 || Anti-KLK2 CAR-T Cells JNJ-75229414 || Anti-kallikrein-2 CAR T-cells JNJ-75229414 || JNJ 75229414 || JNJ-75229414 || JNJ75229414 || KLK2 CAR-T Cells JNJ-75229414	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting human kallikrein-2 (hK2; KLK2) expressed on tumor cells, with potential immunostimulating and antineoplastic activities. Upon administration, anti-KLK2 CAR-T cells JNJ-75229414 target and bind to KLK2-expressing tumor cells, thereby inducing selective toxicity in KLK2-expressing tumor cells. KLK2 is overexpressed in certain tumors, including prostate adenocarcinoma.	Pharmacologic Substance
C180825	Anti-KLK2/CD3 Bispecific Antibody JNJ-78278343	Anti-KLK2/CD3 Bispecific Antibody JNJ-78278343 || JNJ 78278343 || JNJ-78278343 || JNJ78278343 || T-cell Redirecting Agent JNJ-78278343	A T-cell redirecting agent and humanized immunoglobulin (Ig) G1 bispecific antibody targeting both human kallikrein-2 (hK2; KLK2) expressed on tumor cells and the CD3 receptor complex expressed on T-cells, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, anti-KLK2/CD3 bispecific antibody JNJ-78278343 binds to both CD3 on T-cells and KLK2 on KLK2-expressing tumor cells. The resulting cross-linkage activates and redirects T-cells to KLK2-expressing tumor cells. This results in T-cell-mediated lysis of KLK2-expressing tumor cells. KLK2 is overexpressed in certain tumors, including prostate adenocarcinoma.	Pharmacologic Substance
C156889	Anti-K-RAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes	Anti-K-RAS G12D mTCR-transduced Autologous PBLs || Anti-K-RAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes || Anti-K-RAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes || Anti-KRAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes	Autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding for an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine (Gly, G) to aspartic acid (Asp, D) point mutation at position 12 (G12D) variant of K-RAS (KRAS), with potential immunomodulating and antineoplastic activities. HLA-A1101-positive PBLs are harvested from a K-RAS G12D-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12D mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12D mTCR-expressing PBLs target and bind to K-RAS G12D-overexpressing tumor cells, which results in both cytokine secretion, including interferon-gamma (IFN-g), and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	Cell || Pharmacologic Substance
C142888	Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes	Anti-K-RAS G12V mTCR-transduced Autologous PBLs || Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes || Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes || Anti-KRAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes	Autologous peripheral blood lymphocytes (PBLs) transduced with an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine to valine point mutation at position 12 (G12V) variant of K-RAS, with potential antineoplastic activity. HLA-A1101 positive PBLs are harvested from a K-RAS G12V-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12V mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12V mTCR-expressing PBLs target and bind to K-RAS G12V-overexpressing tumor cells, which results in both cytokine secretion and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	Cell || Pharmacologic Substance
C82391	Anti-KSP/Anti-VEGF siRNAs ALN-VSP02	ALN-VSP02 || Anti-KSP/Anti-VEGF siRNAs ALN-VSP02 || Anti-KSP/Anti-VEGF siRNAs ALN-VSP02	A lipid nanoparticle formulation containing two small interfering RNAs (siRNAs) for kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF) with potential antitumor activity. Upon intravenous administration, the siRNAs in KSP/VEGF siRNAs ALN-VSP02ALN bind to both KSP and VEGF messenger RNAs (mRNAs), preventing translation of KSP and VEGF proteins; this may result in growth inhibition of tumor cells that overexpress KSP and VEGF. VEGF and KSP are upregulated in many tumor cells and play an important role in tumor proliferation and survival.	Pharmacologic Substance
C185282	Anti-LAG-3 Monoclonal Antibody HLX26	Anti-LAG-3 Monoclonal Antibody HLX26 || Anti-LAG3 Monoclonal Antibody HLX26 || Anti-lymphocyte-activation Gene-3 Monoclonal Antibody HLX26 || HLX 26 || HLX-26 || HLX26	A recombinant monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3 monoclonal antibody HLX26 targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.	Pharmacologic Substance
C168603	Anti-LAG-3 Monoclonal Antibody IBI-110	Anti-LAG-3 Monoclonal Antibody IBI-110 || Anti-LAG-3 Monoclonal Antibody IBI110 || IBI 110 || IBI-110 || IBI110	A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3 monoclonal antibody IBI110 targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.	Amino Acid, Peptide, or Protein || Immunologic Factor
C157127	Anti-LAG-3 Monoclonal Antibody INCAGN02385	Anti-LAG-3 Monoclonal Antibody INCAGN02385 || Anti-LAG-3 Monoclonal Antibody INCAGN02385 || Anti-LAG3 Monoclonal Antibody INCAGN02385 || INCAGN 02385 || INCAGN 2385 || INCAGN-02385 || INCAGN02385 || INCAGN2385	A Fc-engineered immunoglobulin G1-kappa (IgG1k) monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, monoclonal antibody INCAGN02385 targets and binds to human LAG-3 on tumor-infiltrating  lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both proliferation and activation of T-cells. Its expression on  TILs is associated with tumor-mediated immune suppression.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C179260	Anti-LAG-3 Monoclonal Antibody LBL-007	Anti-LAG-3 Monoclonal Antibody LBL-007 || Anti-LAG3 Monoclonal Antibody LBL-007 || LBL 007 || LBL-007 || LBL007	A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3 monoclonal antibody LBL-007 targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.	Pharmacologic Substance
C156177	Anti-LAG-3 Monoclonal Antibody Sym022	Anti-LAG-3 Monoclonal Antibody Sym022 || Anti-LAG-3 Monoclonal Antibody Sym022 || SYM-022 || Sym 022 || Sym-022 || Sym022	A recombinant, human Fc-inert monoclonal antibody targeting lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, monoclonal antibody Sym022 binds to human LAG-3 and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHCII) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHCII binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Additionally, Sym022 decreases LAG-3 surface levels through internalization and shredding. LAG-3 plays a key role in the activation of T-cells and natural killer (NK) cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C181022	Anti-LAG-3/Anti-PD-L1 Bispecific Antibody IBI323	Anti-LAG-3/Anti-PD-L1 Bispecific Antibody IBI323 || Anti-LAG-3/PD-L1 Bispecific Antibody IBI323 || IBI 323 || IBI-323 || IBI323 || LAG-3 x PD-L1 Bispecific Antibody IBI323	A recombinant, bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG-3; LAG3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAG-3/anti-PD-L1 bispecific antibody IBI323 simultaneously targets and binds to LAG-3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG-3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Pharmacologic Substance
C150734	Anti-LAG-3/PD-L1 Bispecific Antibody FS118	Anti-LAG-3/PD-L1 Bispecific Antibody FS118 || Anti-LAG-3/PD-L1 Bispecific Antibody FS118 || FS118 || LAG-3/PD-L1 Bispecific Antibody FS118 || LAG-3/PD-L1 Mab2 FS118 || Mab2 FS118	A bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. FS118 is generated by incorporating an anti-LAG-3 Fc-region with antigen binding (Fcab) into a PD-L1-specific antibody. Upon administration, FS118 simultaneously targets and binds to LAG3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF) negatively regulates both proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C187128	Anti-LAIR1 Monoclonal Antibody NGM438	Anti-LAIR1 Antagonist Antibody NGM438 || Anti-LAIR1 Monoclonal Antibody NGM438 || NGM 438 || NGM-438 || NGM438	A monoclonal antibody directed against the collagen-binding immune inhibitory receptor leukocyte-associated immunoglobulin-like receptor 1 (LAIR1; LAIR-1; CD305), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LAIR1 monoclonal antibody NGM438 targets, binds to and blocks LAIR1, thereby preventing its interaction with tumor-associated and stromal-derived collagens and the formation of the stromal checkpoint LAIR1-collagen complex. This may inhibit LAIR1-collagen complex-mediated downstream signaling pathways and abrogates LAIR1-collagen complex-mediated myeloid cell immune suppression and inhibition of antitumor immunity. This may also inhibit the physical exclusion of immune cells from the tumor by the LAIR1-collagen complex and enhance T-cell infiltration of the tumor. LAIR1, an immune inhibitory receptor expressed on immune cells and upregulated in various cancers along with stromal-derived collagens, plays an important role in tumor infiltration, immunosuppression and immune tolerance.	Pharmacologic Substance
C126275	Anti-LAMP1 Antibody-drug Conjugate SAR428926	ADC SAR428926 || Anti-LAMP1 ADC SAR428926 || Anti-LAMP1 Antibody-drug Conjugate SAR428926 || SAR428926	An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) conjugated, via the disulfide-containing cleavable linker N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-LAMP1 ADC SAR428926, the anti-LAMP1 monoclonal antibody moiety targets and binds to the cell surface antigen LAMP1. After antibody-antigen interaction and internalization, the SPDB linker is selectively cleaved by proteases in the cytosol and the DM4 moiety is released. DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting both cell division and cell growth of LAMP1-expressing tumor cells. LAMP1, overexpressed on a variety of cancer cells, plays a key role in cell-cell adhesion and migration. The SPDB linker is resistant to cleavage in the bloodstream, which may increase stability and reduce toxicity.	Pharmacologic Substance
C173598	Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181	Anti-TGF-beta 1 Monoclonal Antibody SRK-181 || Anti-latent TGF-b1 Monoclonal Antibody SRK-181 || Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181 || Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181 || Anti-latent TGFb1 Monoclonal Antibody SRK-181 || SRK 181 || SRK-181 || SRK181	A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, anti-latent TGFb1 monoclonal antibody SRK-181 specifically targets, binds to, and inhibits the activation of latent TGFb1 complexes, thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the predominant isoform in many tumors.	Pharmacologic Substance
C175411	Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102	Anti-LeB/LeY Monoclonal Antibody GNX102 || Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102 || Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102 || Anti-branched Lewis B/Lewis Y Monoclonal Antibody GNX102 || GNX 102 || GNX-102 || GNX102	A humanized monoclonal antibody directed against human tumor-associated carbohydrate antigens (TACAs) Lewis B (LeB) and Lewis Y (LeY), with potential antineoplastic activity. Upon administration, anti-LeB/LeY monoclonal antibody GNX102 binds to branched LeB and LeY glycans, which may induce an antibody-dependent cellular cytotoxicity (ADCC) response against LeB- and LeY-expressing tumor cells. LeB and LeY antigens, tetrasaccharides with low to moderate expression in monomeric form in normal adult tissues, is overexpressed in branched form in multiple forms of cancers.	Pharmacologic Substance
C126794	Anti-LGR5 Monoclonal Antibody BNC101	Anti-LGR5 Monoclonal Antibody BNC101 || BNC-101 || BNC101 || ET-101	A humanized monoclonal antibody targeting leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential antineoplastic activity. Upon administration, the anti-LGR5 humanized monoclonal antibody BNC101 targets and binds to LGR5, thereby inhibiting LRG5-mediated signal transduction pathways. This prevents proliferation of LRG5-expressing tumor cells. LGR5, a member of the Wnt signaling pathway, is a cancer stem cell (CSC) receptor overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C156176	Anti-LIF Monoclonal Antibody MSC-1	Anti-LIF Monoclonal Antibody MSC-1 || Anti-LIF Monoclonal Antibody MSC-1 || MSC 1 || MSC-1 || MSC1	A humanized immunoglobulin G1 (IgG1) monoclonal antibody against leukemia inhibitory factor (LIF), with potential  immunomodulating and antineoplastic activities. Upon intravenous administration, monoclonal antibody MSC-1 binds to LIF and inhibits LIF signaling by blocking the recruitment of glycoprotein 130 (gp130) to the LIF-LIF receptor (LIFR)-gp130 signaling complex. This inhibits signal transducer and activator of transcription 3 (STAT3) signaling and inhibits tumor cell growth. In addition, the inhibition of LIF signaling abrogates the immunosuppressive tumor microenvironment  (TME) by decreasing immunosuppressive M2 macrophages and allows for the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. LIF, a member of the interleukin-6 (IL-6) family of cytokines, is involved in many physiological and pathological processes and plays an important role in both creating the TME and promoting the activity of cancer-initiating cells (CICs). LIF is overexpressed in many tumor cell types and its expression correlates with poor prognosis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C185720	Anti-LILRB2 Monoclonal Antibody IO-108	Anti-ILT4 Monoclonal Antibody IO-108 || Anti-LILRB2 Monoclonal Antibody IO-108 || Anti-LILRB2 Monoclonal Antibody IO-108 || IO 108 || IO-108 || IO108	A monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (LILRB2; ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti- LILRB2 monoclonal antibody IO-108 targets and binds to LILRB2. This prevents the binding of LILRB2 ligands to their receptor and prevents LILRB2-mediated signaling. This abrogates the immunosuppressive activities of LILRB2 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. LILRB2, plays a key role in tumor immune evasion. LILRB2, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and in certain tumors.	Pharmacologic Substance
C178281	Anti-LILRB2 Monoclonal Antibody JTX-8064	Anti-ILT4 Monoclonal Antibody JTX-8064 || Anti-LILRB2 Monoclonal Antibody JTX-8064 || Anti-LILRB2 Monoclonal Antibody JTX-8064 || JTX 8064 || JTX-8064 || JTX8064	A humanized monoclonal antibody directed against the inhibitory immune checkpoint receptor leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; immunoglobulin-like transcript 4; ILT4; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-LILRB2 monoclonal antibody JTX-8064 targets and binds to LILRB2. This prevents the binding of LILRB2 ligands, including endogenous major histocompatibility complex class I (MHC I) molecules, to their receptor and prevents LILRB2-mediated signaling. This may abrogate the immunosuppressive activities of LILRB2 in the tumor microenvironment (TME), activate the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhance a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. LILRB2, expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells, plays a key role in tumor immune evasion.	Pharmacologic Substance
C174485	Anti-LILRB4 Monoclonal Antibody IO-202	Anti-LILRB4 Monoclonal Antibody IO-202 || Anti-LILRB4 Monoclonal Antibody IO-202 || Anti-leukocyte Immunoglobulin-like Receptor B4 Monoclonal Antibody IO-202 || IO 202 || IO-202 || IO202	A monoclonal antibody directed against the immune inhibitory receptor leukocyte immunoglobulin-like receptor B4 (LILRB4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LILRB4 monoclonal antibody IO-202 targets, binds to and inhibits LILRB4 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells, and inhibit tumor infiltration. LILRB4, an immune inhibitory receptor normally expressed on monocytic cells and highly expressed on monocytic acute myeloid leukemia (AML) cells, functions as an immune checkpoint that negatively regulates T-cell activation as its extracellular domain inhibits T-cell activity. It plays an important role in tumor infiltration in leukemias through multiple signaling pathways.	Pharmacologic Substance
C186492	Anti-LILRB4 Monoclonal Antibody NGM831	Anti-ILT-3 Monoclonal Antibody NGM831 || Anti-ILT3 Monoclonal Antibody NGM831 || Anti-LILRB4 Monoclonal Antibody NGM831 || Anti-LILRB4 Monoclonal Antibody NGM831 || ILT3 Antagonist Antibody NGM831 || NGM 831 || NGM-831 || NGM831	A monoclonal antibody directed against the myeloid-enriched immune inhibitory receptor leukocyte immunoglobulin-like receptor B member 4 (LILRB4; ILT3; ILT-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-LILRB4 monoclonal antibody NGM831 targets, binds to and blocks LILRB4, thereby preventing the interaction with its ligands, such as fibronectin, in the tumor microenvironment (TME). This prevents the activation of LILRB4-mediated downstream signaling pathways. This may abrogate LILRB4-mediated promotion of myeloid cell immunosuppression and inhibition of antitumor immunity. This may restore immune function by activating dendritic cells (DCs) and T-cells, and may promote T-cell-mediated immune responses against tumor cells. LILRB4, an inhibitory immune receptor highly expressed on tumor-associated myeloid cells, primarily tolerogenic DCs, myeloid-derived suppressor cells (MDSCs) and M2 macrophages, functions as an immune checkpoint that negatively regulates DC- and T-cell activation. It is upregulated in several tumor types and plays an important role in tumor infiltration, immunosuppression and immune tolerance.	Pharmacologic Substance
C116745	Anti-Ly6E Antibody-Drug Conjugate RG 7841	ADC DLYE5953A || Anti-LY6E-VCMMAE || Anti-Ly6E Antibody-Drug Conjugate DLYE5953A || Anti-Ly6E Antibody-Drug Conjugate RG 7841 || DLYE5953A || RG 7841 || RG-7841 || RG-7841 || RG7841	An antibody-drug conjugate (ADC) composed of an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) and linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the antibody moiety of RG 7841 targets and binds to Ly6E expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills, through an as of yet unknown mechanism of action, the Ly6E-expressing cancer cells. Ly6E, an interferon (IFN)-inducible glycosylphosphatidylinositol (GPI)-linked cell membrane protein, is expressed on a variety of tumor cell types.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C162462	Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C	Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C || Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C || IMC C103C || IMC-C103C || IMCC103C || ImmTAC IMC-C103C || ImmTAC Molecule IMC-C103C || Immune Mobilizing Monoclonal TCR Against Cancer IMC-C103C || T-cell Redirecting Bi-specific Biologic IMC-C103C	A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) human melanoma-associated antigen A4 (MAGE-A4) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon intravenous administration of IMC-C103C, the TCR moiety of this agent targets and binds to MAGE-A4 on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C91092	Anti-Melanin Monoclonal Antibody PTI-6D2	Anti-Melanin Monoclonal Antibody PTI-6D2 || PTI-6D2	A monoclonal antibody (MoAb) against extracellular melanin with tumor targeting activity. Anti-melanin monoclonal antibody PTI-6D2 binds to extracellular melanin, a melanocyte pigment which is released during tumor cell turnover from dead melanoma tumor cells, while avoiding the binding of melanin in normal, healthy tissue because of melanin's normal intracellular location. Upon labeling with the beta-emitting radioisotope rhenium Re 188 (PTI-188), this MoAb may target multiple melanoma (MM) cells, thereby delivering a cytotoxic dose of radiation specifically to the targeted tumor cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C120303	Anti-mesothelin Antibody-drug Conjugate BMS-986148	Anti-mesothelin Antibody-drug Conjugate BMS-986148 || Anti-mesothelin Antibody-drug Conjugate BMS-986148 || BMS-986148	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the cell surface glycoprotein mesothelin and conjugated to an as of yet undisclosed cytotoxic drug, with potential antineoplastic activity. The monoclonal antibody moiety of anti-mesothelin ADC BMS-986148 targets and binds to the tumor associated antigen mesothelin. Upon internalization, the cytotoxic agent kills or prevents cellular proliferation of mesothelin-expressing tumor cells through an as of yet undescribed mechanism of action. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.	Pharmacologic Substance
C124650	Anti-mesothelin CAR Vector-transduced Autologous T-lymphocytes	Anti-meso-CAR Vector-transduced Autologous T Cells || Anti-mesothelin CAR Vector-transduced Autologous T-lymphocytes	Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-human tumor-associated antigen (TAA) mesothelin single chain variable fragment (scFv), the intracellular CD3 zeta T-cell receptor domain and the 4-1BB (cd137) costimulatory domain, with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the anti-mesothelin CAR vector-transduced autologous T-lymphocytes specifically target and kill mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.	Cell || Pharmacologic Substance
C187372	Anti-mesothelin CAR Vector-transduced T-lymphocytes	Anti-MSLN CAR-T Cells || Anti-mesothelin CAR Vector-transduced T-lymphocytes || Anti-mesothelin CAR Vector-transduced T-lymphocytes || HuCART-meso	A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-MSLN CAR vector-transduced T-lymphocytes specifically target and kill MSLN-expressing tumor cells. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.	Cell || Pharmacologic Substance
C97038	Anti-mesothelin CIR mRNA-electroporated Autologous T Cells	Anti-mesothelin CIR mRNA-electroporated Autologous T Cells || Anti-mesothelin CIR mRNA-electroporated Autologous T Cells || Autologous Redirected RNA Meso-CIR T cells	Autologous chimeric immune receptor (CIR) T cells transfected with anti-mesothelin chimeric T cell receptor mRNA, with potential antineoplastic activity. The anti-mesothelin mRNA encodes a single chain antibody variable fragment (ScFv), the intracellular CD 3 zeta T cell receptor domain and the 4-1BB (cd137) costimulatory domain. Upon intravenous administration, the anti-mesothelin CIR mRNA-electroporated autologous T cells may attach to cancer cells expressing mesothelin. This may stimulate the secretion of multiple cytokines and may result in cell lysis of mesothelin-expressing cancer cells. Mesothelin is a cell surface glycoprotein involved in cell adhesion and is overexpressed in many epithelial-derived cancers.	Cell || Pharmacologic Substance
C121782	Anti-mesothelin iCasp9M28z CAR-transduced Autologous T Lymphocytes	Anti-mesothelin iCasp9M28z CAR-transduced Autologous T Lymphocytes || Anti-mesothelin iCasp9M28z CAR-transduced Autologous T Lymphocytes || iCasp9M28z T Cells	Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for mesothelin linked to the signaling domains for the co-stimulatory molecules CD28 and CD3 zeta, as well as the suicide gene inducible caspase 9 (iCasp9 or iC9), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-mesothelin iCasp9M28z CAR-transduced autologous T lymphocytes specifically target and kill mesothelin-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, a dimerizing agent can be administered, which binds to the FKBP12-F36V drug-binding domain and activates caspase 9, resulting in the apoptosis of the administered T-cells. Mesothelin, a tumor-associated antigen, is overexpressed in a variety of cancer cell types.	Cell || Pharmacologic Substance
C116746	Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A	Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A || Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A || DMOT-4039A || DMOT4039A || RG 7600 || RG7600	An antibody-drug conjugate (ADC) composed of MMOT0530A, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface glycoprotein mesothelin (MSLN), and covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DMOT4039A binds to MSLN-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. MSLN, a tumor-associated antigen (TAA), is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.	Pharmacologic Substance
C174395	Anti-mesothelin/MMAE Antibody-drug Conjugate RC88	ADC RC88 || Anti-mesothelin Antibody-drug Conjugate RC88 || Anti-mesothelin/MMAE ADC RC88 || Anti-mesothelin/MMAE Antibody-drug Conjugate RC88 || RC 88 || RC-88 || RC88	An antibody-drug conjugate (ADC) composed of an antibody directed against the human cell surface glycoprotein mesothelin and conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-mesothelin/MMAE ADC RC88 targets and binds to the tumor associated antigen (TAA) mesothelin on the surface of tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.	Pharmacologic Substance
C121653	Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100	Anti-MSLN-PE24 cFP LMB-100 || Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100 || Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100 || LMB-100 || LMB-100 || RG 7787 || RG-7787 || RG7787 || RO 6927005 || RO6927005	An anti-mesothelin (MSLN) recombinant cytolytic fusion protein (cFP) composed of a humanized Fab fragment of anti-MSLN monoclonal antibody SS1 linked to a truncated and de-immunized 24 kDa fragment of the Pseudomonas exotoxin (PE) (PE24), with potential antineoplastic activity. Upon intravenous administration of anti-MSLN-PE24 cFP LMB-100, the anti-MSLN moiety targets and binds to MSLN-expressing tumor cells. Upon binding and internalization through endocytosis, the toxin moiety ADP-ribosylates and inactivates eukaryotic elongation factor 2 (eEF2), preventing the elongation step of protein synthesis and leading to both an inhibition of protein synthesis and an induction of MSLN-expressing tumor cell apoptosis. MSLN, a tumor-associated antigen overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation and migration. The engineered PE24 portion of LMB-100 does contain the targeting domain and furin cleavage site, which are needed for cytotoxicity, but most of the translocation domain II is deleted and the catalytic domain III contains point mutations, which result in the deletion and silencing of most T- and B-cell epitopes; therefore, the immunogenicity and toxicity is reduced compared to non-engineered PE toxin, which allows for the administration of larger doses of LMB-100.	Pharmacologic Substance
C127906	Anti-Met Monoclonal Antibody Mixture Sym015	Anti-Met Monoclonal Antibody Mixture Sym015 || Anti-Met Monoclonal Antibody Mixture Sym015 || Hu9006-Hu9338 || Hu9006/Hu9338 || Sym 015 || Sym-015 || Sym015	A mixture of two humanized immunoglobulin G1 (IgG1) monoclonal antibodies, Hu9006 and Hu9338, which recognize non-overlapping epitopes in the extracellular domain of the human hepatocyte growth factor receptor (MET; HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-MET monoclonal antibody mixture Sym015 targets and binds to the extracellular domain of MET, thereby preventing the binding of its ligand, hepatocyte growth factor (HGF). This may prevent activation of the receptor and MET-mediated signal transduction pathways. This inhibits MET-dependent tumor cell proliferation. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C182004	Anti-MET x MET Antibody Drug Conjugate REGN5093-M114	ADC REGN5093-M114 || Anti-MET ADC REGN5093-M114 || Anti-MET Antibody-drug Conjugate REGN5093-M114 || Anti-MET x MET ADC REGN5093-M114 || Anti-MET x MET Antibody Drug Conjugate REGN5093-M114 || Antibody-drug Conjugate REGN5093-M114 || MET x MET ADC REGN5093-M114 || REGN5093-M 114 || REGN5093-M-114 || REGN5093-M114	An antibody-drug conjugate (ADC) consisting of REGN5093, a biparatopic monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), and conjugated, via a protease cleavable linker, to the cytotoxic maytansine derivative M24, with potential antineoplastic activity. Upon administration of anti-MET x MET ADC REGN5093-M114, the REGN5093 moiety targets and binds to two different, non-overlapping epitopes on MET expressed on the tumor cell surface. After antibody-antigen interaction followed by internalization and protease cleavage, the maytansine M24 moiety binds to tubulin, inhibits microtubule assembly, and induces microtubule disassembly. This leads to a disruption of mitosis and the inhibition of cell proliferation in cancer cells expressing MET. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	Pharmacologic Substance
C118281	Anti-Met/EGFR Monoclonal Antibody LY3164530	Anti-Met/EGFR Monoclonal Antibody LY3164530 || LY-3164530 || LY3164530	A monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) and human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-Met/EGFR MoAb LY3164530 targets and prevents the activation of EGFR and c-Met. This leads to a downstream inhibition of EGFR/c-Met-mediated signal transduction pathways, and prevents cellular proliferation in tumor cells overexpressing EGFR and c-Met. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surface of various solid tumor cell types. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C125690	Antimetabolite FF-10502	Antimetabolite FF-10502 || Antimetabolite FF-10502 || FF-10502 || FF-10502-01	An antimetabolite with potential antineoplastic activity. Upon administration, FF-10502 is able to enter the nucleus where it inhibits DNA polymerases, thereby preventing DNA synthesis and halting tumor cell proliferation.	Pharmacologic Substance
C148500	Anti-minor Histocompatibility Complex Donor T-Lymphocytes	Anti-MiHA Donor T-lymphocytes || Anti-MiHA T Cells || Anti-minor Histocompatibility Complex Donor T-Lymphocytes || GLIDE || GLIDE Cells || GLIDE T-lymphocytes || Guided Lymphocyte Immunopeptide Derived Expansion Against MiHAs Cells || Guided Lymphocyte Immunopeptide Derived Expansion Cells || MiHA T-lympocytes || MiHA-specific T Cells	A preparation of allogeneic, donor-derived T-lymphocytes that are specific for a unique set of minor histocompatibility complex antigens (MiHA) exclusively found on the surface of malignant cells, with potential immunomodulating and antineoplastic activities. T-lymphocytes are derived from an allogeneic hematopoietic cell transplant (AHCT) donor. Ex vivo, these T-cells are exposed to and primed against a select set of host-specific hematopoietic tissue-restricted MiHAs that are expressed on leukemic cells. Then the cells are subsequently expanded. After AHCT and infusion of the anti-MiHA T-lymphocytes, these cells target and bind to MiHA antigens expressed on the host's leukemia cells, thereby killing these cancer cells. MiHA are small, cell-surface peptides that are associated with graft-versus-host disease (GvHD). The selected set of MiHAs is expressed mainly, or only, by hematopoietic cells, and overexpressed on leukemic cells.	Cell || Pharmacologic Substance
C178439	Anti-MSLN CAR-T Cells LCAR-M23	Anti-MSLN CAR-T Cells LCAR-M23 || Anti-mesothelin CAR T-cells LCAR-M23 || LCAR M23 || LCAR-M23 || LCARM23 || Mesothelin-targeting CAR T Cells LCAR-M23	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-MSLN CAR-T cells LCAR-M23 specifically target and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.	Pharmacologic Substance
C124646	Anti-MUC1 CAR-transduced Autologous T-lymphocytes	Anti-MUC1 Autologous CAR T Cells || Anti-MUC1 CAR-transduced Autologous T Cells || Anti-MUC1 CAR-transduced Autologous T-lymphocytes || Anti-Mucin1 Autologous CAR T Cells	Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) against the human tumor-associated epithelial antigen mucin 1 (MUC1), with potential immunomodulating and antineoplastic activities. Autologous PBLs from a patient with MUC1-positive cancer are transduced with a retroviral vector that encodes the CAR gene specific for MUC1. After expansion in culture and reintroduction into the patient, anti-MUC1 CAR-transduced autologous T-lymphocytes target and induce selective toxicity in MUC1-expressing tumor cells. MUC-1 is a human, hypoglycosylated tumor-associated antigen (TAA) overexpressed by epithelial cancer cells.	Cell || Pharmacologic Substance
C118362	Anti-MUC1 Monoclonal Antibody BTH1704	Anti-MUC1 Monoclonal Antibody BTH1704 || BTH1704	A monoclonal antibody against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, anti-MUC1 monoclonal antibody BTH1704 targets and binds to MUC1 expressed on the surface of tumor cells, which can potentially activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.	Pharmacologic Substance
C177111	Anti-MUC1/EGFR Bispecific Antibody Drug Conjugate M1231	ADC M1231 || Anti-MUC1/EGFR ADC M1231 || Anti-MUC1/EGFR Bispecific ADC M1231 || Anti-MUC1/EGFR Bispecific Antibody Drug Conjugate M1231 || Anti-MUC1/EGFR Bispecific Antibody Drug Conjugate M1231 || M 12231 || M-1231 || M1231	An antibody drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) mucin-1 (MUC1) and human epidermal growth factor receptor (EGFR), conjugated, via a cleavable valine-citruline-based linker, to the hemiasterlin-related toxic warhead, with potential antineoplastic activity. Upon intravenous administration, the antibody moiety of anti-MUC1/EGFR bispecific ADC M1231 targets and binds to MUC1 and EGFR expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic hemiasterlin moiety of M1231 binds to the vinca domain on tubulin, resulting in inhibition of tubulin polymerization and microtubule assembly, depolymerization of existing microtubules, inhibition of mitosis, and inhibition of cellular proliferation. MUC1 and EGFR, overexpressed on the surface of a variety of cancer cells, play key roles in tumor cell survival and proliferation. MUC1 and EGFR are often co-localized due to loss of membrane polarization on tumor cells while co-expression in normal cells is limited.	Pharmacologic Substance
C176028	Anti-MUC16/CD28 Bispecific Antibody REGN5668	Anti-MUC16 x Anti-CD28 Bispecific Antibody REGN5668 || Anti-MUC16/CD28 Bispecific Antibody REGN5668 || Anti-MUC16/CD28 Bispecific Antibody REGN5668 || MUC16xCD28 Bispecific Antibody REGN5668 || REGN 5668 || REGN-5668 || REGN5668	A bispecific monoclonal antibody against both the tumor-associated antigen (TAA) human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential antineoplastic and immunostimulating activities. Upon administration, anti-MUC16/CD28 bispecific antibody REGN5668 binds to both CD28 on T-cells and MUC16-expressing tumor cells, which cross-links the T-cells to the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells. MUC16, a member of the mucin family of glycoproteins, is overexpressed by several epithelial cancers, including ovarian cancer.	Amino Acid, Peptide, or Protein || Immunologic Factor
C147031	Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A	ADC DMUC4064A || Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A || Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A || DMUC-4064A || DMUC4064A || RG7882 || THIOMAB-drug Conjugate DMUC4064A	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against human mucin 16 (MUC16; cancer antigen 125; CA125; FLJ14303) conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, anti-MUC16/MMAE ADC DMUC4064A binds to MUC16 located on the tumor cell surface. After internalization of the agent, the MMAE moiety is released and binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. MUC16, a member of the mucin family glycoproteins, is overexpressed in a variety of tumor cells and plays a key role in tumor cell proliferation.	Pharmacologic Substance
C165588	Anti-MUC17/CD3 BiTE Antibody AMG 199	AMG 199 || AMG199 || Anti-MUC17 x Anti-CD3 BiTE AMG 199 || Anti-MUC17/CD3 BiTE Antibody AMG 199 || Anti-MUC17/CD3 BiTE Antibody AMG 199 || Anti-MUC17/CD3 Bispecific Antibody AMG 199 || BiTE Antibody AMG 199 || Bispecific T-cell Engager Antibody AMG 199 || MUC17/CD3-directed Bispecific T-cell Engager Antibody AMG 199 || MUC17xCD3 Bispecific T-cell Engager AMG 199	A half-life extended (HLE), human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human mucin 17 (MUC17), and one directed against human CD3, a T-cell surface antigen found on T-lymphocytes, with potential antineoplastic activity. Upon administration, anti-MUC17/CD3 BiTE antibody AMG 199 binds to both CD3 on T-cells and MUC17 expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against MUC17-expressing tumor cells. MUC17, a member of the mucin family of glycoproteins, is overexpressed in a variety of tumor cells of epithelial origin and plays a key role in tumor cell dissemination.	Pharmacologic Substance || Amino Acid, Peptide, or Protein
C178406	Anti-mucin-1/PE Immunoconjugate BM7PE	Anti-MUC1/PE BM7PE || Anti-mucin-1/PE Immunoconjugate BM7PE || BM7 PE || BM7-PE || BM7PE || Immunotoxin BM7PE	An immunoconjugate containing BM7, a murine monoclonal antibody directed against the human tumor-associated antigen (TAA) mucin-1 (MUC1; MUC-1) covalently linked to the bacterial toxin Pseudomonas exotoxin A (PE), with potential antitumor activity. Upon administration of BM7PE, the antibody moiety targets and binds to MUC1. In turn, the PE moiety inhibits protein synthesis via modifying translation elongation factor 2 (EF-2), thereby causing apoptosis and inhibiting tumor cell growth and proliferation in MUC1-overexressing cancer cells.  MUC1, a type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.	Pharmacologic Substance
C173702	Anti-NaPi2b Antibody-drug Conjugate XMT-1592	Anti-NaPi2b ADC XMT-1592 || Anti-NaPi2b Antibody-drug Conjugate XMT-1592 || Anti-NaPi2b Antibody-drug Conjugate XMT-1592 || Anti-NaPi2b/Auristatin F-HPA ADC XMT-1592 || NaPi2b-targeted Antibody-drug Conjugate XMT-1592 || XMT 1592 || XMT-1592 || XMT1592	An antibody-drug conjugate (ADC) composed of XMT-1535, a humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), that is site-specifically bioconjugated to the cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin F-hydroxypropylamide), with potential antineoplastic activity. Upon administration of anti-NaPi2b ADC XMT-1592, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Following internalization of XMT-1592 and release of AF-HPA, the AF-HPA binds to tubulin and inhibits microtubule polymerization, which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.	Pharmacologic Substance
C129821	Antineoplastic Biological Agent	Anti-cancer Biological Agent || Anticancer Biological || Antineoplastic Biological || Antineoplastic Biological Agent || Antineoplastic Biological Agent || Antineoplastic Biotherapeutic	Any agent that has a biological nature, such as agents containing living organisms, derived from living organisms, or comprised of ex vivo synthesized analogs of substances derived from living organisms, and that exerts antineoplastic activity.	Pharmacologic Substance
C129818	Antineoplastic Hormonal/Endocrine Agent	Antineoplastic Endocrinal Agent || Antineoplastic Hormonal Agent || Antineoplastic Hormonal Therapeutic || Antineoplastic Hormonal/Endocrine Agent	Any agent that affects hormone levels and exerts antineoplastic effects. Antineoplastic hormonal/endocrine agents treat either hormone-dependent or hormone-sensitive cancers by modulating hormone levels and manipulating the endocrine system.	Pharmacologic Substance
C129820	Antineoplastic Immunomodulating Agent	Anti-cancer Immunotherapeutic || Antineoplastic BRM || Antineoplastic Biological Response Modifier || Antineoplastic Immunomodulating Agent || Antineoplastic Immunomodulating Agent || Antineoplastic Immunotherapeutic	Any agent that is capable of modulating the immune system in order to exert antineoplastic effects. Antineoplastic immunomodulating agents either activate the immune system, restore certain immune system activators or abrogate immunosuppression.	Pharmacologic Substance
C129819	Antineoplastic Radiopharmaceutical Agent	Anti-cancer Radiopharmaceutical || Antineoplastic Radiopharmaceutical || Antineoplastic Radiopharmaceutical Agent	Any radiopharmaceutical agent that targets cancer cells and exerts an antineoplastic effect through radiotoxicity.	Pharmacologic Substance
C2100	Antineoplastic Vaccine GV-1301	Antineoplastic Vaccine GV-1301 || GV-1301	Antineoplastic vaccine being developed against liver cancer. (NCI)	Pharmacologic Substance
C1004	Antineoplaston A10	3-Phenylacetylamino-2, 6-piperidinedione || 3-Phenylacetylamino-2,6-piperidinedione || A10 || ANTINEOPLASTON A10 || Antineoplaston A10 || Antineoplaston A10 || Atengenal || Benzeneacetamide, N-(2,6-dioxo-3-piperidinyl)-, (S)-	A piperidinedione antineoplaston with potential antineoplastic activity.  Antineoplaston A10 was originally isolated from human urine but is now synthetically derived.  This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis.  Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. (NCI04)	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C1613	Antineoplaston AS2-1	AS2-1 || Antineoplaston AS2-1 || Antineoplaston AS2-1 || Astugenal || L-Glutamine, N2-(phenylacetyl)-, Monosodium Salt, Mixture with Sodium Benzeneacetate	A 4:1 mixture of phenylacetate and phenylacetylgluatmine, degradation products of the antineoplaston agent A10.  Antineoplaston AS2-1 inhibits the incorporation of L-glutamine into tumor-cell proteins, leading to cell cycle arrest in the G1 phase and inhibition of mitosis.  This agent may also inhibit RAS oncogene expression and activate tumor suppressor gene p53, resulting in cell differentiation and apoptosis. (NCI04)	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C179293	Anti-netrin-1 Monoclonal Antibody NP137	Anti-NTN1 MoAB NP137 || Anti-netrin-1 Monoclonal Antibody NP137 || NP 137 || NP-137 || NP137	A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the laminin-related protein netrin-1 (NTN1), with potential antineoplastic activity. Upon administration, anti-NTN1 monoclonal antibody NP137 targets, binds to and neutralizes NTN1, thereby preventing its binding to and activation of NTN1 receptors.  By blocking NTN1, NP137 is able to restore apoptosis in tumor cells. This inhibits tumor growth and metastasis. NTN1, overexpressed by a variety of cancers, plays a key role in promoting tumor initiation, progression, proliferation, adhesion, invasion, survival and modulation of tumor+F52:J54 plasticity and the tumor microenvironment (TME).	Amino Acid, Peptide, or Protein || Immunologic Factor
C124647	Anti-nf-P2X7 Antibody Ointment BIL-010t	Anti-nf-P2X7 Antibody Ointment BIL-010t || BIL-010t || BSCT 10 % Ointment	An ointment formulation composed of a purified sheep immunoglobulin G (IgG) antibody against the non-functional form of the purinergic P2X7 receptor (nf-P2X7), with potential antineoplastic activity. Upon topical application of the anti-nf-P2X7 antibody ointment BIL-010t, the antibody binds to nf-P2X7 and inhibits its antiapoptotic activity. This may induce apoptosis and inhibit the growth of nf-P2X7-overexpressing cancer cells. P2X7, an ATP-gated cation-selective channel, plays a role in the induction of apoptosis; nf-P2X7, is upregulated in a variety of cancer cell types while not expressed on normal, healthy cells and is unable to form a large transmembrane, apoptotic pore upon exposure to ATP and prevents apoptosis.	Pharmacologic Substance
C176867	Anti-NKG2A Monoclonal Antibody BMS-986315	Anti-NKG2A Monoclonal Antibody BMS-986315 || BMS 986315 || BMS-986315 || BMS986315	A human monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, anti-NKG2A monoclonal antibody BMS-986315 targets and binds to NKG2A, and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.	Amino Acid, Peptide, or Protein || Immunologic Factor
C185890	Anti-NKG2A Monoclonal Antibody Sym025	Anti-NKG2A Monoclonal Antibody Sym025 || Anti-NKG2A Monoclonal Antibody Sym025 || S 095029 || S-095029 || S095029 || Sym 025 || Sym-025 || Sym025	A monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, anti-NKG2A monoclonal antibody Sym025 targets and binds to NKG2A, and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.	Pharmacologic Substance
C156402	Anti-NRP1 Antibody ASP1948	ASP 1948 || ASP-1948 || ASP-1948 || ASP1948 || Anti-NRP1 Antibody ASP1948 || Anti-NRP1 Antibody ASP1948 || Anti-neuropilin-1 Antibody ASP1948 || PTZ 329 || PTZ-329 || PTZ329	A human immunoglobulin G4 (IgG4) monoclonal antibody directed against neuropilin-1 (NRP1; CD304; BDCA-4), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-NRP1 antibody ASP1948 specifically targets and binds to NRP1. This prevents the binding of NRP1 to its ligand and may block the immune inhibitory actions of regulatory T-cells (Tregs) mediated by the interaction of NRP1 with its ligand. This may enhance the immune response against tumor cells. NRP1 is a transmembrane co-receptor protein expressed in Tregs; it plays an important role in maintaining the stability and function of Tregs.	Amino Acid, Peptide, or Protein || Immunologic Factor
C91721	Anti-Nucleolin Aptamer AS1411	AS1411 || Anti-Nucleolin Aptamer AS1411 || Anti-Nucleolin Aptamer AS1411	A 26-base guanine-rich oligodeoxynucleotide aptamer with potential apoptotic induction activity. Upon administration, anti-nucleolin aptamer AS1411 targets and binds to nucleolin, a nucleolar phosphoprotein which is overexpressed on the surface of certain cancer cells. Via binding to cell surface nucleolin, AS1411 is internalized and may prevent nucleolin from binding to and stabilizing mRNA of the anti-apoptotic BCL2, thereby destabilizing BCL2 mRNA, leading to a reduction in BCL2 protein synthesis. This may lead to the induction of apoptosis.	Nucleic Acid, Nucleoside, or Nucleotide || Pharmacologic Substance
C116847	Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A	Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A || Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A || CTAG1A ASCI || GSK-2241658A || GSK2241658A || GSK2241658A Antigen-Specific Cancer Immunotherapeutic	An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity.	Pharmacologic Substance
C114295	Anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes	Anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes || Autologous CD62L+-derived T Lymphocytes Transduced With NY-ESO-1-specific TCR	Human autologous CD62L-positive T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T-Lymphocytes bind to NY-ESO-1-overexpressing tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. CD62L, also called L-selectin, is a lymphoid homing receptor and differentiation marker and is expressed on a subset of CD8-positive T-lymphocytes; it is involved in the migration of T-lymphocytes to lymph nodes and may improve the efficacy for ex vivo-expanded T-cells following adoptive cell therapy.	Cell || Pharmacologic Substance
C153130	Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso	Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso || Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso || Bispecific NY-ESO-1- and LAGE-1A-specific TCR/Anti-CD3 || HLA- A*0201-Restricted NY-ESO-1- and LAGE-1A-specific Soluble TCR/Anti-CD3 Bispecific Molecule || IMCNYESO || IMCnyeso	A bispecific molecule composed of a soluble, affinity-enhanced T-cell receptor (TCR) specific for human leukocyte antigen A2 (HLA-A2)-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), fused to a single-chain variable fragment (scFv) specific for the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon infusion, anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso specifically targets and binds with its TCR moiety to NY-ESO-1 and/or LAGE-1A expressed on tumor cells and with its scFv moiety to CD3 expressed on T-cells. This crosslinks tumor cells and T-cells, re-directs and activates T-cells, and results in a cytotoxic T-lymphocyte (CTL)-mediated destruction of NY-ESO-1 and/or LAGE-1A-positive tumor cells. NY-ESO-1 and LAGE-1A, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*0201 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.	Pharmacologic Substance
C118368	Anti-OFA Immunotherapeutic BB-MPI-03	Anti-OFA Immunotherapeutic BB-MPI-03 || Anti-OFA Immunotherapeutic BB-MPI-03 || BB-MPI-03 || BBMPI03	A cancer vaccine composed of 3 different cytotoxic T-cell epitopes derived from the tumor-associated antigen oncofetal antigen (OFA), with potential immunostimulating and antineoplastic activities. Upon intradermal administration, anti-OFA immunotherapeutic vaccine BB-MPI-03 activates the immune system to elicit a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing OFA. OFA, also called immature laminin receptor protein (iLRP), is expressed in fetal tissues and is overexpressed in various cancers; its expression is correlated with cancer cell survival.	Immunologic Factor || Pharmacologic Substance
C185389	Anti-OX40 Agonist Monoclonal Antibody BAT6026	Agonistic Anti-OX40 Monoclonal Antibody BAT6026 || Anti-OX40 Agonist Monoclonal Antibody BAT6026 || BAT 6026 || BAT-6026 || BAT6026	An agonistic recombinant monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory activity. Upon administration, anti-OX40 agonist monoclonal antibody BAT6026 selectively targets, binds to and activates OX40. This may induce the proliferation of memory and effector T-lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME). This enhances anti-tumor immune responses and prevents Tregs-mediated immune suppression. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation and differentiation.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C175453	Anti-OX40 Agonist Monoclonal Antibody BGB-A445	Anti-OX40 Agonist Monoclonal Antibody BGB-A445 || Anti-OX40 Agonist Monoclonal Antibody BGB-A445 || BGB A445 || BGB-A445 || BGBA445	An agonistic monoclonal antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-OX40 agonist monoclonal antibody BGB-A445 selectively binds to OX40, thereby activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.	Amino Acid, Peptide, or Protein || Immunologic Factor
C187289	Anti-OX40 Agonist Monoclonal Antibody HFB301001	Agonistic Anti-OX40 Monoclonal Antibody HFB301001 || Anti-OX40 Agonist Monoclonal Antibody HFB301001 || Anti-OX40 Agonist Monoclonal Antibody HFB301001 || HFB 301001 || HFB-301001 || HFB301001	An agonistic human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-OX40 agonist monoclonal antibody HFB301001 selectively targets and binds to a unique epitope on OX40, and activates OX40 without competing with the endogenous OX40 ligand (OX40L; tumor necrosis factor ligand superfamily member 4; TNFSF4). This may induce the proliferation of memory and effector T-lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME), thereby enhancing anti-tumor immune responses and preventing Tregs-mediated immune suppression. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation and differentiation. HFB301001 does not lead to a downregulation of OX40 following the co-stimulation of T-cells.	Amino Acid, Peptide, or Protein || Immunologic Factor || Pharmacologic Substance
C176871	Anti-OX40 Agonist Monoclonal Antibody YH-002	Agonistic Anti-OX40 Monoclonal Antibody YH-002 || Anti-OX40 Agonist Monoclonal Antibody YH-002 || YH 002 || YH-002 || YH002	An agonistic recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory activity. Upon administration, anti-OX40 agonist monoclonal antibody YH-002 selectively targets, binds to and activates OX40. This may induce the proliferation of memory and effector T-lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME). This enhances anti-tumor immune responses and prevents Tregs-mediated immune suppression. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation and differentiation.	Amino Acid, Peptide, or Protein || Immunologic Factor
C128026	Anti-OX40 Antibody BMS 986178	Anti-OX40 Antibody BMS 986178 || Anti-OX40 Antibody BMS 986178 || BMS 986178 || BMS-986178 || BMS-986178	An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, anti-OX40 monoclonal antibody BMS 986178 selectively binds to and activates the OX40 receptor, by mimicking the action of the endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor family (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C173983	Anti-OX40 Hexavalent Agonist Antibody INBRX-106	Anti-OX40 Agonistic Antibody INBRX-106 || Anti-OX40 Hexavalent Agonist Antibody INBRX-106 || Anti-OX40 Hexavalent Agonist Antibody INBRX-106 || ES 102 || ES-102 || ES102 || INBRX 106 || INBRX-106 || INBRX106	An agonistic, recombinant, humanized, hexavalent immunoglobulin G (IgG) antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, anti-OX40 hexavalent agonist antibody INBRX-106 selectively binds to six OX40 receptors per molecule, thereby clustering and activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells. Utilizing a hexavalent OX40 antibody may improve receptor clustering and downstream signaling over tetravalent or bivalent OX40 antibodies.	Pharmacologic Substance
C96040	Anti-OX40 Monoclonal Antibody	Anti-OX40 Monoclonal Antibody || anti-OX40 MoAb	An agonistic monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Mimicking the natural OX4 ligand (OX40L), anti-OX40 monoclonal antibody selectively binds to and activates the OX40 receptor. Receptor activation induces proliferation of memory and effector T lymphocytes. In the presence of tumor associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed by CD4 T cells and provides a costimulatory signal for T cell activation.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C124783	Anti-OX40 Monoclonal Antibody GSK3174998	Anti-OX40 Monoclonal Antibody GSK3174998 || Anti-OX40 Monoclonal Antibody GSK3174998 || GSK-3174998 || GSK3174998	An agonistic humanized immunoglobulin G1 (IgG1) monoclonal antibody against the cell surface receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-OX40 monoclonal antibody GSK3174998 selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.	Pharmacologic Substance || Amino Acid, Peptide, or Protein || Immunologic Factor
C178418	Anti-OX40/CD137 Bispecific Antibody FS120	Anti-OX40/Anti-CD137 Bispecific Antibody FS120 || Anti-OX40/CD137 Bispecific Antibody FS120 || Anti-OX40/CD137 Bispecific Antibody FS120 || Bispecific Antibody FS120 || FS 120 || FS-120 || FS-120 || FS120 || OX40 x CD137 Bispecific Antibody FS120	An immunoglobulin G1 (IgG1) dual-agonist, tetravalent, bispecific monoclonal antibody targeting the two human tumor necrosis factor receptor (TNFR) co-stimulatory receptors OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-OX40/CD137 bispecific antibody FS120 simultaneously targets, binds to, and activates both OX40 and CD137. This may lead to T-cell co-stimulation, induce the proliferation of memory and effector T-lymphocytes and enhance immune-mediated anti-tumor responses. OX40 and CD137, cell surface glycoproteins and members of the TNFRSF, are expressed on T-lymphocytes and natural killer (NK) cells and play an essential role in T-cell activation, differentiation, proliferation, survival and cytolytic activity.	Pharmacologic Substance
C64773	Anti-p53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes	Anti-p53 T-Cell Receptor Retroviral Vector-Transduced Peripheral Blood Lymphocytes || Anti-p53 T-Cell Receptor-Transduced Peripheral Blood Lymphocytes || Anti-p53 TCR Retroviral Vector-Transduced PBL || Anti-p53 TCR-Transduced PBL	Human autologous peripheral blood lymphocytes (PBLs) transduced with an anti-p53 T cell receptor gene with potential antineoplastic activity. PBLs are harvested from a patient and pulsed with a retroviral vector that encodes the T-cell receptor gene specific for a mutated form of p53. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these modified PBLs express the anti-p53 T cell receptor which binds to mutant p53-overexpressing tumor cells; PBL-mediated tumor growth inhibition may follow. Many tumor cell types overexpress mutant p53 proteins, which are associated with the loss of apoptosis regulation and abnormal cell proliferation.	Cell || Pharmacologic Substance
C174140	Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256	AMG 256 || AMG-256 || AMG256 || Anti-PD-1 Antibody-IL-21 Mutein Fusion Protein AMG 256 || Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256 || Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256 || PD-1-targeted IL-21 Receptor Agonist AMG 256	An antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) fused to a mutein of the cytokine interleukin-21 (IL-21), with potential immune checkpoint inhibitory, immunomodulating and antineoplastic activities. Upon administration of anti-PD-1 antibody-IL-21 mutein fusion protein AMG 256, the antibody moiety specifically targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. The IL-21 mutein moiety binds to the IL-21 receptor and activates IL-21 cytokine signaling in PD-1-expressing cells. This may modulate the proliferation and/or differentiation, promote survival, and increase the cytolytic activity of PD-1-expressing T-cells, thereby enhancing T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. IL-21 plays an important role in the regulation of cellular immune responses.	Pharmacologic Substance
C97039	Anti-PD-1 Fusion Protein AMP-224	AMP-224 || AMP-224 || Anti-PD-1 Fusion Protein AMP-224 || Anti-PD-1 Fusion Protein AMP-224	A recombinant B7-DC Fc-fusion protein composed of the extracellular domain of the PD-1 ligand programmed cell death ligand 2 (PD-L2, B7-DC) and the Fc region of human immunoglobulin (Ig) G1, with potential immune checkpoint inhibitory and antineoplastic activities. Anti-PD-1 fusion protein AMP-224 specifically binds to PD-1 on chronically stimulated T-cells and reduces their proliferation. This may restore immune function and may result in the activation of cytotoxic T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein of Ig superfamily and inhibitor receptor expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity. AMP-224 does not bind normal activated T-cells.	Pharmacologic Substance
C172820	Anti-PD-1 Monoclonal Antibody 609A	609 A || 609-A || 609A || Anti-PD-1 Monoclonal Antibody 609A	A recombinant immunoglobulin G4 (IgG4) kappa monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody 609A targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C162871	Anti-PD-1 Monoclonal Antibody BAT1306	Anti-PD-1 Monoclonal Antibody BAT1306 || Anti-PD1 Monoclonal Antibody BAT1306 || BAT 1306 || BAT-1306 || BAT1306	A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody BAT1306 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C185390	Anti-PD-1 Monoclonal Antibody BAT1308	Anti-PD-1 Monoclonal Antibody BAT1308 || Anti-PD1 Monoclonal Antibody BAT1308 || BAT 1308 || BAT-1308 || BAT1308	A humanized  immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody BAT1308 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C178405	Anti-PD-1 Monoclonal Antibody GNR-051	Anti-PD-1 Monoclonal Antibody GNR-051 || GNR 051 || GNR-051 || GNR051	A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody GNR-051 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C178280	Anti-PD-1 Monoclonal Antibody LVGN3616	Anti-PD-1 Monoclonal Antibody LVGN3616 || Anti-PD-1 Monoclonal Antibody LVGN3616 || LVGN 3616 || LVGN-3616 || LVGN3616	A humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody LVGN3616 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C153149	Anti-PD-1 Monoclonal Antibody LZM009	ANTI-PD-1 MONOCLONAL ANTIBODY LZM009 || Anti-PD-1 Monoclonal Antibody LZM009 || LZM 009 || LZM-009 || LZM009	A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, LZM009 binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways, leading to the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1 is a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells that negatively regulates T-cell activation and effector function when activated by its ligands. PD-1 plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C113332	Anti-PD-1 Monoclonal Antibody MEDI0680	AMP-514 || Anti-PD-1 Monoclonal Antibody MEDI0680 || Anti-PD-1 Monoclonal Antibody MEDI0680 || MEDI0680	A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody MEDI0680 binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Amino Acid, Peptide, or Protein || Immunologic Factor
C178345	Anti-PD-1 Monoclonal Antibody MW11	Anti-PD-1 Monoclonal Antibody MW11 || MW 11 || MW-11 || MW11	A recombinant humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody MW11 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C182009	Anti-PD-1 Monoclonal Antibody SG001	Anti-PD-1 Monoclonal Antibody SG001 || SG 001 || SG-001 || SG001	A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SG001 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C185858	Anti-PD-1 Monoclonal Antibody SHR-1901	Anti-PD-1 Monoclonal Antibody SHR-1901 || PD-1 Antibody SHR-1901 || SHR 1901 || SHR-1901 || SHR1901	A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1901 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2). PD-1 plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C142865	Anti-PD-1 Monoclonal Antibody Sym021	Anti-PD-1 Monoclonal Antibody Sym021 || Anti-PD-1 Monoclonal Antibody Sym021 || Anti-PD1 Monoclonal Antibody Sym021 || SYM-021 || Sym021	A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1 , PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody Sym021 binds to and inhibits PD-1 activation and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF), is expressed on T-cells and functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2). Activated PD-1 plays an important role in tumor evasion from host immunity.	Amino Acid, Peptide, or Protein || Pharmacologic Substance
C176874	Anti-PD-1 Monoclonal Antibody SYN125	Anti-PD-1 Monoclonal Antibody SYN125 || SYN 125 || SYN-125 || SYN125	A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SYN125 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune functions through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C178320	Anti-PD-1 Monoclonal Antibody TY101	Anti-PD-1 Monoclonal Antibody TY101 || TY 101 || TY-101 || TY101	A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody TY101 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C179633	Anti-PD-1/Anti-4-1BB Bispecific Antibody IBI-319	Anti-PD-1/Anti-4-1BB Bispecific Antibody IBI-319 || IBI 319 || IBI-319 || IBI319	A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-4-1BB bispecific antibody IBI-319 simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and 4-1BB, which is expressed on activated T-lymphocytes and natural killer (NK) cells. This crosslinks PD-1- and 4-1BB-expressing T cells. Through 4-1BB binding, IBI-319 acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, PD-1 binding prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Pharmacologic Substance
C185163	Anti-PD-1/Anti-CD3 Bispecific Antibody ONO-4685	Anti-PD-1/Anti-CD3 Bispecific Antibody ONO-4685 || Anti-PD-1/CD3 Bispecific Antibody ONO-4685 || ONO 4685 || ONO-4685 || ONO4685 || PD-1 x CD3 Bispecific Antibody ONO-4685	A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the T-cell surface antigen CD3, with potential immunomodulatory and antineoplastic activities. Upon administration, anti-PD-1/anti-CD3 bispecific antibody ONO-4685 binds to both PD-1 expressed on activated T- and B-cells and certain malignant T-cells and CD3 antigen on cytotoxic T-lymphocytes (CTLs). This may activate and redirect CTLs to PD-1-expressing cells, resulting in CTL-mediated killing of these cells. This may lead to anti-tumor activity in some T-cell lymphomas, and immunomodulatory activity in some autoimmune diseases.	Pharmacologic Substance
C162774	Anti-PD1/Anti-CTLA4 Antibody Mixture QL1706	Anti-PD-1/Anti-CTLA-4 Monoclonal Antibody Mixture PSB205 || Anti-PD-1/CTLA-4 MabPair PSB205 || Anti-PD1/Anti-CTLA4 Antibody Mixture PSB205 || Anti-PD1/Anti-CTLA4 Antibody Mixture QL1706 || Anti-PD1/Anti-CTLA4 Antibody Mixture QL1706 || Anti-PD1/CTLA4 Antibodies PSB205 || Bifunctional MabPair Product PSB205 || PSB 205 || PSB-205 || PSB205 || QL 1706 || QL-1706 || QL1706	A mixture of two engineered monoclonal antibodies produced by a single cell line of which one is directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the other one is directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD1/anti-CTLA4 antibody mixture QL1706 targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.	Pharmacologic Substance
C158505	Anti-PD-1/Anti-CTLA4 DART Protein MGD019	Anti-PD-1/Anti-CTLA4 DART Protein MGD019 || Anti-PD-1/Anti-CTLA4 DART Protein MGD019 || Bispecific DART Protein MGD019 || D-1 x CTLA4 DART Protein MGD019 || Dual-affinity Retargeting Protein MGD019 || MGD 019 || MGD-019 || MGD019 || PD-1 x CTLA4 Bispecific DART Molecule MGD019 || PD-1 x CTLA4 DART Protein MGD019	A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-PD-1/anti-CTLA4 dual-affinity re-targeting (DART) protein MGD019 specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.	Pharmacologic Substance
C173539	Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669	Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669 || Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669 || Anti-PD1/Anti-LAG3 Bispecific Antibody RO7247669 || RO 7247669 || RO-7247669 || RO7247669	A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-LAG-3 bispecific antibody RO7247669 targets and binds to both PD-1 and LAG-3 expressed on T-cells and inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.	Pharmacologic Substance
C171938	Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318	Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318 || Anti-PD-1/PD-L1 Bispecific Antibody IBI318 || Bispecific Antibody IBI318 || IBI 318 || IBI-318 || IBI318 || Recombinant Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318	A recombinant immunoglobulin G1 (IgG1) bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-PD-L1 bispecific antibody IBI318 simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1, which is expressed on tumor cells. This crosslinks PD-1-expressing T cells and PD-L1-expressing tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Amino Acid, Peptide, or Protein || Immunologic Factor
C160605	Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172	Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172 || Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172 || Anti-PD-1/PD-L1 Bispecific Antibody LY3434172 || Bispecific Antibody LY3434172 || LY 3434172 || LY-3434172 || LY3434172	A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-PD-L1 bispecific antibody LY3434172 simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Amino Acid, Peptide, or Protein || Immunologic Factor
C186661	Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868	Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 || Anti-PD-1/TGF-beta Bifunctional Fusion Protein TQB2868 || TQB 2868 || TQB-2868 || TQB2868	A bifunctional fusion protein directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and transforming growth factor beta (TGF-beta; TGFb), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TGF-beta bifunctional fusion protein TQB2868  targets and binds to PD-1 and TGF-beta and prevents the activation of PD-1 and TGF-beta-mediated signaling pathways in the tumor microenvironment (TME). This abrogates PD-1- and TGFb-mediated immunosuppression in the TME, increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities, and inhibits tumor cell proliferation in susceptible tumor cells. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands and plays an important role in tumor evasion from host immunity. TGF-beta, a pro-inflammatory mediator, is upregulated in certain types of cancers and is involved in cancer cell proliferation, tumor progression, migration and invasion, and the suppression of the immune response.	Pharmacologic Substance
C180907	Anti-PD-1/Anti-TIGIT Bispecific Antibody IBI321	Anti-PD-1/Anti-TIGIT Bispecific Antibody IBI321 || Anti-PD-1/TIGIT Bispecific Antibody IBI321 || IBI 321 || IBI-321 || IBI321 || PD-1 x TIGIT Bispecific Antibody IBI321	A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-PD-1/anti-TIGIT bispecific antibody IBI321 simultaneously targets, binds to and inhibits PD-1 and TIGIT and their downstream signaling pathways. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses. Inhibition of TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.	Pharmacologic Substance
C181016	Anti-PD-1/Anti-TIM-3 Bispecific Antibody AZD7789	AZD 7789 || AZD-7789 || AZD7789 || Anti-PD-1/Anti-TIM-3 Bispecific Antibody AZD7789 || Anti-PD-1/Anti-TIM-3 Bispecific Antibody AZD7789	A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific antibody AZD7789 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.	Pharmacologic Substance
C187980	Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410	Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410 || Anti-PD-1/TIM-3 Bispecific Antibody LB1410 || LB 1410 || LB-1410 || LB1410 || PD-1 x TIM-3 Bispecific Antibody LB1410	A recombinant humanized bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/anti-TIM-3 bispecific antibody LB1410 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.	Pharmacologic Substance
C168600	Anti-PD-1/CD47 Infusion Protein HX009	Anti-PD-1/CD47 Infusion Protein HX009 || Anti-PD1/CD47 Bi-specific Antibody Fusion Protein HX009 || HX 009 || HX-009 || HX009	A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-PD-1/CD47 infusion protein HX009, the agent simultaneously and selectively targets and binds to PD-1 expressed on T-lymphocytes and CD47 on tumor cells. The CD47 binding by HX009 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD47-expressing tumor cells. The binding of HX009 to PD-1 blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore effector T-cell functions and may further activate cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. By co-targeting CD47 and PD-1, HX009 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs), which causes unwanted macrophage-mediated phagocytosis. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.	Pharmacologic Substance
C171937	Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752	Anti-PD-1 x CTLA-4 Bispecific Antibody MEDI5752 || Anti-PD-1/Anti-CTLA-4 Bispecific Antibody MEDI5752 || Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752 || Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752 || MEDI 5752 || MEDI-5752 || MEDI5752	An engineered fragment crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD1/CTLA4 bispecific antibody MEDI5752 targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. In addition, MEDI5752 is internalized and is able to degrade PD-1. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with MEDI5752 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. It may also decrease toxicity by avoiding the binding to CTLA-4-expressing T-cells that are devoid of PD-1. The engineered Fc domain may reduce Fc effector function.	Pharmacologic Substance
C178449	Anti-PD-1/CTLA-4 Bispecific Antibody SI-B003	Anti-PD-1/Anti-CTLA-4 Bispecific Antibody SI-B003 || Anti-PD-1/CTLA-4 Bispecific Antibody SI-B003 || PD-1 x CTLA-4 Bispecific Antibody SI-B003 || SI B003 || SI-B003 || SIB003	A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD1/CTLA4 bispecific antibody SI-B003 targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with SI-B003 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.	Pharmacologic Substance
C179258	Anti-PD-1/LAG-3 Bispecific Antibody EMB-02	Anti-PD-1/LAG-3 Bispecific Antibody EMB-02 || EMB 02 || EMB-02 || EMB02	A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/LAG-3 bispecific antibody EMB-02 targets and binds to both PD-1 and LAG-3 expressed on T-cells and inhibits the PD-1- and LAG-3-mediated downregulation of T-cell activation and proliferation. This may lead to cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation and proliferation.	Pharmacologic Substance
C181027	Anti-PD-1/TGF-beta RII Bifunctional Fusion Protein JS201	Anti-PD-1/TGF-beta RII Bifunctional Fusion Protein JS201 || Anti-PD-1/TGF-beta RII Fusion Protein JS201 || JS 201 || JS-201 || JS201	A bifunctional fusion protein targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human transforming growth factor beta (TGF-beta; TGFb), with potential immune checkpoint modulating, immunomodulating and antineoplastic activities. Upon administration, anti-PD-1/TGF-beta RII bifunctional fusion protein JS201 targets and binds to PD-1 and TGF-beta and prevents the activation of PD-1 and TGF-beta-mediated signaling pathways in the tumor microenvironment (TME). This abrogates the PD-1- and TGFb-mediated immunosuppression in the TME, increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities, and inhibits tumor cell proliferation in susceptible tumor cells. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity. TGF-beta, a pro-inflammatory mediator, is upregulated in certain types of cancers and is involved in cancer cell proliferation, tumor progression and the suppression of the immune response.	Pharmacologic Substance
C185425	Anti-PD-1/TGFbRII Fusion Protein LBL-015	Anti-PD-1/TGF-beta Receptor II Bispecific Fusion Protein LBL-015 || Anti-PD-1/TGFbRII Fusion Protein LBL-015 || Bispecific Fusion Protein LBL-015 || LBL 015 || LBL-015 || LBL015	A tetravalent bispecific fusion protein targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human transforming growth factor beta (TGF-beta; TGFb), with potential immune checkpoint modulating and antineoplastic activities. Upon administration, anti-PD-1/TGF-beta receptor II (TGFbRII) fusion protein LBL-015 targets and binds to PD-1 and TGF-beta and prevents the activation of PD-1 and TGF-beta-mediated signaling pathways in the tumor microenvironment (TME). This abrogates the PD-1- and TGFb-mediated immunosuppression in the TME, increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities, and inhibits tumor cell proliferation in susceptible tumor cells. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocyte; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands and plays an important role in tumor evasion from host immunity. TGF-beta, a pro-inflammatory mediator, is upregulated in certain types of cancers and is involved in cancer cell proliferation, tumor progression, migration and invasion, and the suppression of the immune response.	Pharmacologic Substance
C160714	Anti-PD-1/TIM-3 Bispecific Antibody RO7121661	Anti-PD-1 x TIM-3 Bispecific Antibody RO7121661 || Anti-PD-1/Anti-TIM-3 Bispecific Antibody RO7121661 || Anti-PD-1/TIM-3 Bispecific Antibody RO7121661 || RO 7121661 || RO-7121661 || RO-7121661 || RO7121661	A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1/TIM-3 bispecific antibody RO7121661 simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.	Pharmacologic Substance
C170909	Anti-PD-1/VEGF Bispecific Antibody AK112	AK 112 || AK-112 || AK112 || Anti-PD-1/Anti-VEGF Bispecific Antibody AK112 || Anti-PD-1/VEGF Bispecific Antibody AK112 || PD-1/VEGF Bispecific Antibody AK112	A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration of anti-PD-1/VEGF bispecific antibody AK112, this agent simultaneously targets and binds to both PD-1 expressed on certain T-cells and VEGF. The binding of AK112 to PD-1 prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) and/or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead to a reduction in tumor growth. The binding of AK112 to VEGF prevents binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands PD-L1/ or PD-L2; it plays an important role in tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.	Pharmacologic Substance
C186368	Anti-PD-L1 Antibody-drug Conjugate SGN-PDL1V	Anti-PD-L1 ADC SGN-PDL1V || Anti-PD-L1 Antibody-drug Conjugate SGN-PDL1V || Anti-PD-L1 Vedotin ADC SGN-PDL1V || SGN PDL1V || SGN-PDL1V || SGNPDL1V	An antibody-drug conjugate (ADC) composed of an antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable peptide linker, with potential antineoplastic activity. Upon administration of the anti-PD-L1 ADC SGN-PDL1V, the anti-PD-L1 antibody specifically targets and binds to PD-L1 expressed on tumor cells. Following internalization, enzymatic cleavage and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in PD-L1-expressing tumor cells. PD-L1, a transmembrane protein, is expressed on the surface of certain immune cells and on many cancer cell types. PD-L1 binding to PD-1, a negative regulator of the immune system on activated T-cells, limits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Pharmacologic Substance
C156692	Anti-PD-L1 Monoclonal Antibody CBT-502	Anti-PD-L1 Monoclonal Antibody CBT-502 || Anti-PD-L1 Monoclonal Antibody TQB2450 || CBT 502 || CBT-502 || CBT502 || TQB 2450 || TQB-2450 || TQB2450	A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody CBT-502 specifically targets and binds to PD-L1, preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.	Pharmacologic Substance
C131537	Anti-PD-L1 Monoclonal Antibody FAZ053	Anti-PD-L1 Monoclonal Antibody FAZ053 || Anti-PD-L1 Monoclonal Antibody FAZ053 || FAZ 053 || FAZ-053 || FAZ-053 || FAZ053	A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1), with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody FAZ053 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated anti-tumor immune response and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.	Pharmacologic Substance
C159538	Anti-PD-L1 Monoclonal Antibody GR1405	Anti-PD-L1 Monoclonal Antibody GR1405 || GR 1405 || GR-1405 || GR1405	A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody GR1405 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Pharmacologic Substance
C179266	Anti-PD-L1 Monoclonal Antibody LP002	Anti-PD-L1 Monoclonal Antibody LP002 || LP 002 || LP-002 || LP002	A humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody LP002 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, by binding to PD-L1, LP002 also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Pharmacologic Substance
C78852	Anti-PD-L1 Monoclonal Antibody MDX-1105	Anti-PD-L1 Monoclonal Antibody MDX-1105 || Anti-PD-L1 Monoclonal Antibody MDX-1105 || BMS 936559 || BMS-936559 || MDX-1105	A fully human monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.	Pharmacologic Substance
C155931	Anti-PD-L1 Monoclonal Antibody MSB2311	Anti-PD-L1 Monoclonal Antibody MSB2311 || Anti-PD-L1 Monoclonal Antibody MSB2311 || Anti-PDL1 Monoclonal Antibody MSB2311 || Humanized Anti-PD-L1 Monoclonal Antibody MSB2311 || MSB 2311 || MSB-2311 || MSB2311	A second-generation, humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. The anti-PD-L1 monoclonal antibody MSB2311 contains a unique, not as of yet elucidated, pH-dependent antigen binding property allowing the antibody to only bind to PD-L1 within the acidic tumor microenvironment (TME), while it is not able to bind to PD-L1 in normal, healthy tissue. Upon administration, once able to bind to PD-L1 in the TME, MSB2311 blocks the binding of PD-L1 to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.	Pharmacologic Substance
C174520	Anti-PD-L1 Monoclonal Antibody RC98	Anti-PD-L1 Monoclonal Antibody RC98 || RC 98 || RC-98 || RC98	A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody RC98 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Pharmacologic Substance
C159978	Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105	Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105 || Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105 || Anti-PD-L1/CD137 Bispecific Antibody INBRX-105 || ES 101 || ES-101 || ES101 || INBRX 105 || INBRX-105 || INBRX105 || PDL1 x 4-1BB Bispecific Antibody INBRX-105 || PDL1 x CD137 Bispecific Antibody INBRX-105	A recombinant, humanized, bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/4-1BB bispecific antibody INBRX-105 simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, INBRX-105 acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, INBRX-105 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Pharmacologic Substance
C179637	Anti-PD-L1/Anti-4-1BB Bispecific Antibody ABL503	ABL 503 || ABL-503 || ABL503 || Anti-PD-L1/4-1BB Bispecific Antibody ABL503 || Anti-PD-L1/Anti-4-1BB Bispecific Antibody ABL503 || Anti-PD-L1/Anti-4-1BB Bispecific Antibody ABL503 || Anti-PD-L1/CD137 Bispecific Antibody ABL503 || PD-L1x4-1BB Bispecific Antibody ABL503	A bispecific antibody composed of a Fc-silenced human immunoglobulin G1 (IgG1) monoclonal antibody targeting human programmed death-ligand 1 (PD-L1) fused with a single chain variable fragment (scFv) targeting 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/anti-4-1BB bispecific antibody ABL503 simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Upon PD-L1 binding, the 4-1BB activation signal is induced and ABL503 acts as a conditional 4-1BB agonist in the tumor microenvironment (TME), resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time, ABL503 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Pharmacologic Substance
C172194	Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046	Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046 || Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046 || BNT 311 || DuoBody PD-L1 x 4-1BB GEN1046 || GEN 1046 || GEN-1046 || GEN1046	A recombinant, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/4-1BB bispecific antibody GEN1046 simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, GEN1046 acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. At the same time,GEN1046 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Amino Acid, Peptide, or Protein || Immunologic Factor
C185605	Anti-PD-L1/Anti-CD47 Bispecific Antibody BAT7104	Anti-CD47/Anti-PD-L1 Bispecific Antibody BAT7104 || Anti-PD-L1/Anti-CD47 Bispecific Antibody BAT7104 || Anti-PD-L1/CD47 Bispecific Antibody BAT7104 || Anti-PDL1/Anti-CD47 Bispecific Monoclonal Antibody BAT7104 || BAT 7104 || BAT-7104 || BAT7104 || PD-L1 x CD47 Bispecific Antibody BAT7104	A symmetric immunoglobulin G (IgG)-like bispecific antibody targeting both the human cell surface antigen CD47 and the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration, anti-PD-L1/anti-CD47 bispecific antibody BAT7104 targets and binds to both CD47 and PD-L1 expressed on tumor cells. The CD47 binding by BAT7104 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of CD47-expressing tumor cells. The binding of BAT7104 to PD-L1 blocks its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation, which protects cancer cells from phagocytosis and allows cancer cells to proliferate. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. By co-targeting CD47 and PD-L1, BAT7104 may more selectively bind to tumor cells expressing both CD47 and PD-L1, reducing the side effects caused by the blockade of CD47 expressed on healthy hematopoietic stem cells (HSCs).	Pharmacologic Substance
C185285	Anti-PD-L1/Anti-LAG-3 Bispecific Antibody ABL501	ABL 501 || ABL-501 || ABL501 || Anti-LAG-3/Anti-PD-L1 Bispecific Antibody ABL501 || Anti-PD-L1/Anti-LAG-3 Bispecific Antibody ABL501 || Anti-PD-L1/LAG-3 Bispecific Antibody ABL501 || PD-L1 x LAG-3 Bispecific Antibody ABL501	A bispecific antibody directed against two immune checkpoint proteins composed of an engineered immunoglobulin G4 (IgG4) monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG-3; LAG3) fused with a single chain variable fragment (scFv) targeting the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1/anti-LAG-3 bispecific antibody ABL501 simultaneously targets and binds to LAG-3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG-3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression.	Pharmacologic Substance
C187101	Anti-PD-L1/Anti-OX40 Bispecific Antibody EMB-09	Anti-PD-L1/Anti-OX40 Bispecific Antibody EMB-09 || Anti-PD-L1/OX40 Bispecific Antibody EMB-09 || EMB 09 || EMB-09 || EMB09 || FIT-Ig Bispecific Antibody EMB-09 || Fabs-In-Tandem Immunoglobulin Bispecific Antibody EMB-09 || PD-L1xOX40 Bispecific Antibody EMB-09	A tetravalent, bispecific antibody directed against both the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274) and the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-PD-L1/anti-OX40 bispecific antibody EMB-09 binds to PD-L1 expressed on tumor cells, and simultaneously binds to and activates OX40 on activated T-cells. The binding of EMB-09 to PD-L1 blocks its binding to and activation of its receptor, programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. The binding of EMB-09 to OX40 and the activation of OX40 induces the proliferation of memory and effector T-lymphocytes, which also enhances the anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) that is expressed on activated T-cells, suppresses the immune system and results in immune evasion. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is mainly expressed on activated T-cells and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.	Pharmacologic Substance
C185119	Anti-PD-L1/Anti-TGF-beta Bifunctional Fusion Protein TQB2858	Anti-PD-L1/Anti-TGF-beta Bifunctional Fusion Protein TQB2858 || Anti-PD-L1/TGF-beta Bifunctional Fusion Protein TQB2858 || TQB 2858 || TQB-2858 || TQB2858	A bifunctional fusion protein directed against both human programmed death ligand 1 (PD-L1) and transforming growth factor beta (TGF-beta), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, anti-PD-L1/anti-TGF-beta bifunctional fusion protein TQB2858 targets, binds to and neutralizes TGF-beta on tumor cells and simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cells. This prevents both TGF-beta- and PD-L1-mediated immunosuppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This also restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGF-beta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.	Pharmacologic Substance
C160772	Anti-PD-L1/CD137 Bispecific Antibody MCLA-145	Anti-PD-L1/4-1BB Bispecific Antibody MCLA-145 || Anti-PD-L1/Anti-CD137 Bispecific Antibody MCLA-145 || Anti-PD-L1/CD137 Bispecific Antibody MCLA-145 || Anti-PD-L1/CD137 Bispecific Antibody MCLA-145 || MCLA 145 || MCLA-145 || MCLA145	A full-length, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/CD137 bispecific antibody MCLA-145 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells, thereby crosslinking PD-L1-expressing tumor cells and T-lymphocytes. Through CD137 binding, MCLA-145 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, MCLA-145 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor cells and activated T-lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing tumor cells.	Pharmacologic Substance
C176983	Anti-PD-L1/CD27 Bispecific Antibody CDX-527	Anti-PD-L1/Anti-CD27 Bispecific Antibody CDX-527 || Anti-PD-L1/CD27 Bispecific Antibody CDX-527 || Anti-PD-L1/CD27 Bispecific Antibody CDX-527 || CDX 527 || CDX-527 || CDX527 || PD-L1xCD27 Bispecific Antibody CDX-527	A bispecific antibody directed against both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the cell surface antigen CD27, with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-PD-L1/CD27 bispecific antibody CDX-527 targets and binds to both PD-L1 expressed on tumor cells and CD27 expressed on a variety of immune cell types, including most T-lymphocytes. This prevents the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), inhibits the PD-1-mediated signaling and induces CD27-mediated signaling. This inhibits the PD-1-mediated downregulation of T-cell activation and proliferation, and enhances CD27-mediated responses, including the expansion of antigen-activated T-cells and the cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-L1, which is overexpressed in many human cancer cell types, plays an important role in the downregulation of the immune system and tumor evasion from host immunity. CD27, a co-stimulatory molecule and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes, memory B-cells and natural killer (NK) cells. It plays an important role in NK cell-mediated cytolytic activity and T- and B-lymphocyte proliferation and activation.	Pharmacologic Substance
C180675	Anti-PD-L1/Claudin18.2 Bispecific Antibody Q-1802	Anti-PD-L1/Claudin18.2 Bispecific Antibody Q-1802 || Q 1802 || Q-1802 || Q1802	A bispecific antibody directed against both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immune checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration, anti-PD-L1/Claudin18.2 bispecific antibody Q-1802 targets and simultaneously binds to both PD-L1 and CLDN18.2 expressed on certain types of tumor cells. This prevents the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), inhibits the PD-1-mediated signaling, and inhibits the PD-1-mediated downregulation of T-cell activation and proliferation. This restores and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against CLDN18.2-expressing tumor cells. PD-L1, which is overexpressed in many human cancer cell types, plays an important role in the downregulation of the immune system and tumor evasion from host immunity. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Pharmacologic Substance
C173592	Anti-PD-L1/IL-15 Fusion Protein KD033	Anti-PD-L1/IL-15 Fusion Protein KD033 || Anti-PD-L1/IL-15 Fusion Protein KD033 || KD 033 || KD-033 || KD033	A fusion protein composed of a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) fused to the immunostimulatory cytokine interleukin-15 (IL-15), with potential immunostimulatory and antineoplastic activities. Upon administration of the anti-PD-L1/IL-15 fusion protein KD033, the anti-PD-L1 antibody moiety specifically targets and binds to PD-L1 expressing cells in the tumor microenvironment (TME). In turn, IL-15 stimulates the proliferation of natural killer (NK) cells, cytotoxic T-lymphocytes (CTLs) and memory T-cells locally in the TME, which induces an anti-tumor immune response. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. PD-L1, a transmembrane protein, is expressed on the surface of antigen presenting cells (APCs) and on many cancer cell types. PD-L1 binding to PD-1, a negative regulator of the immune system on activated T-cells, limits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Pharmacologic Substance
C184375	Anti-PD-L1/TGF-beta Bispecific Antibody Y101D	Anti-PD-L1/Anti-TGF-beta Bispecific Antibody Y101D || Anti-PD-L1/TGF-beta Bispecific Antibody Y101D || PD-L1 x TGFbeta Bispecific Antibody Y101D || PD-L1/TGF-beta Bispecific Antibody Y101D || Y 101D || Y-101D || Y101D	A recombinant bispecific antibody targeting both the immunosuppressive ligand human programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the human transforming growth factor beta (TGF-beta), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the anti-PD-L1/TGF-beta bispecific antibody Y101D targets, binds to and neutralizes TGFbeta while simultaneously targets, binds to, and inhibits the activity of PD-L1 on tumor cells. This prevents both TGF-beta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGF-beta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.	Pharmacologic Substance
C185426	Anti-PD-L1/TGFbetaRII Fusion Protein BJ-005	Anti-PD-L1/TGF-beta Receptor II Bispecific Fusion Protein BJ-005 || Anti-PD-L1/TGFbetaRII Fusion Protein BJ-005 || BJ 005 || BJ-005 || BJ005 || Bispecific Fusion Protein BJ-005	A recombinant bifunctional fusion protein composed of a humanized immunoglobulin (Ig) G1 anti-programmed death ligand 1 (PD-L1) monoclonal antibody fused to the extracellular domain (ECD) of the human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration of anti-PD-L1/TGFbetaRII fusion protein BJ-005, the TGFbetaRII moiety targets, binds to and neutralizes TGFbeta while the antibody moiety simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cell. This prevents both TGFbeta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers and and play key roles in tumor immune suppression; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.	Pharmacologic Substance
C178398	Anti-PD-L1/TGF-betaRII Fusion Protein SHR 1701	Anti-PD-L1/TGF-betaRII Fusion Protein SHR 1701 || PD-L1 / TGF-b-targeting Fusion Protein SHR 1701 || PDL1 x TGFb-targeting Bifunctional Fusion Protein SHR 1701 || SHR 1701 || SHR-1701 || SHR1701	A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) monoclonal antibody bound, via the C-terminal ends of the Fc region, to the N-terminal-truncated extracellular domain (ECD) of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the TGFbetaRII moiety of SHR 1701 targets, binds to and neutralizes TGFbeta on the tumor cell while the antibody moiety simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cell. This prevents both TGFbeta- and PD-L1-mediated immuno-suppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.	Pharmacologic Substance
C157058	Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244	Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244 || Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244 || LY 3415244 || LY-3415244 || LY-3415244 || LY3415244	A bispecific antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, LY3415244 simultaneously targets and binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), and PD-L1 expressed on tumor cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Pharmacologic Substance
C179665	Anti-PD-L1/VEGFR-1 Fusion Protein HB0025	Anti-PD-L1 Monoclonal Antibody/VEGFR1 Fusion Protein HB0025 || Anti-PD-L1/VEGFR-1 Fusion Protein HB0025 || HB 0025 || HB-0025 || HB0025	A recombinant, humanized fusion protein composed of a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) fused to vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1), with potential anti-angiogenesis, immune checkpoint inhibitory and antineoplastic activities. Upon administration of the anti-PD-L1/VEGFR-1 fusion protein HB0025, the anti-PD-L1 antibody moiety specifically targets and binds to PD-L1 expressing cells in the tumor microenvironment (TME). In turn, VEGFR-1 moiety binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to the endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis and metastasis, and ultimately tumor regression. PD-L1, a transmembrane protein, is expressed on the surface of antigen presenting cells (APCs) and on many cancer cell types. PD-L1 binding to PD-1, a negative regulator of the immune system on activated T-cells, limits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Pharmacologic Substance
C84847	Anti-PKN3 siRNA Atu027	ATU-027 || Anti-PKN3 siRNA Atu027 || Atu027	A lipoplexed formulation consisting of short-interfering RNAs (siRNAs) directed against protein kinase N3 (PKN3) encapsulated in catiogenic and fusiogenic lipids with potential antineoplastic activity. Upon administration, catiogenic and fusiogenic lipids promote anti-PKN3 siRNA Atu02 uptake by tumor cells; the siRNAs moieties are subsequently released once inside the cell. The siRNAs bind to PKN3 mRNAs, which may result in the inhibition of translation and expression of the PKN3 protein and, so, growth inhibition of tumor cells that overexpress PKN3. The protein kinase C-related molecule PKN3, downstream in the phosphoinositide-3-kinase (PI3K) signaling pathway, is upregulated in many tumor cells and plays an important role in invasive cell growth and metastasis.	Pharmacologic Substance
C185127	Anti-plectin Monoclonal Antibody ZB131	Anti-CSP